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  friendship	  and	  
the	  gin.	  Thank	  you	  for	  Spain,	   lazy	  Sundays	  and	  always	  being	  there.	  A	  girl	  could	  not	  
ask	  for	  a	  better	  duo	  to	  make	  a	  trio	  with.	  Isolda	  I	  will	  be	  eternally	  grateful	  to	  you	  and	  
your	  sofa.	  I	  don’t	  know	  what	  I	  would	  have	  done	  without	  you	  both	  and	  of	  course	  the	  
arepas	  that	  changed	  my	  life!	  I	  would	  also	  like	  to	  thank	  Dr	  Luca	  Salassa	  for	  the	  coffee,	  
the	  comedy,	  the	  pasta,	  the	  hospitality	  and	  the	  words	  of	  wisdom.	  
To	   PJS	   group	  members	   past	   and	   present	   I	   would	   like	   to	   say	   thank	   you	   for	  
letting	  me	   be	   part	   of	   this	   big,	  wonderfully	   dysfunctional	   family.	  We	   have	   had	   our	  
moments	  over	  the	  years	  but	  I	  can	  honestly	  say	  that	  it	  has	  been	  an	  absolute	  pleasure	  
and	  I	  do	  not	  know	  how	  I	  would	  have	  made	  it	  through	  the	  last	  few	  years	  without	  you	  
all.	  
Dr	  Ana	  Pizarro,	  what	  do	  I	  say?	  Thank	  you	  for	  getting	  me	  in	  to	  this	  mess	  in	  the	  
first	  place,	   is	  a	  start	  I	  guess.	  I	  have	  met	  very	  few	  people	  in	  my	  life	  who,	  just	  by	  the	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way	  that	  they	  live,	  inspire	  others	  to	  be	  better	  in	  all	  that	  they	  do	  and	  you	  are	  one	  of	  
them.	  Ana,	  you	  are	  brave	  in	  all	  aspects	  of	  life	  and	  give	  hope	  to	  those	  of	  us	  who	  are	  
less	  so,	  that	  one	  day	  we	  might	  be	  too.	  Most	  importantly	  thank	  you	  for	  your	  honesty	  
and	  for	  always	  listening.	  
I	  would	  like	  to	  thank	  Dr	  Sarah	  Unterkofler	  for	  her	  seemingly	  endless	  patience	  
and	  great	  skill	  with	  optical	  equipment.	  My	  thanks	  also	  go	  to	  Dr	  Tijmen	  Euser	  and	  Prof	  
Philip	   Russell	   for	   their	   collaboration	   and	   input	   throughout	  my	   PhD.	   For	   their	   help	  
with	  all	  things	  NMR	  I	  would	  like	  to	  thank	  Dr	  Ivan	  Prokes	  and	  Mr	  Edward	  Tunnah.	  To	  
Dr	   Lijiang	   Song	   I	   will	   be	   forever	   grateful	   for	   his	   constant	   help	  with	   all	   thing	  mass	  
spectrometry	  and	  chromatography	  related.	  On	  the	  same	  note	  I	  would	  like	  to	  thank	  
Mr	  Philp	  Aston	  for	  all	  of	  his	  help	  over	  the	  years	  and	  reminding	  me	  that	  ‘it’s	  normal	  
for	  an	  analytical	  chemist	  to	  like	  things	  clean’.	  
To	  my	  dear	  friend	  and	  flatmate	  Becky,	  thank	  you	  for	  the	  late	  night	  chats	  and	  
the	  telly	  evenings.	  Our	  lovely	  little	  flat	  was	  an	  island	  of	  peace	  in	  the	  ocean	  of	  chaos	  
that	  was	  the	  past	  few	  years.	  My	  Wells	  people,	  I	  love	  you	  all!	  Thank	  you	  for	  all	  of	  the	  
welcome	   distractions	   and	   some	   of	   the	   unwelcome	   ones	   too.	   To	   Vale,	   my	   dear,	  
geographically	  we	  may	  be	  apart	  but	  I	  have	  drawn	  great	  strength	  from	  the	  knowledge	  
that	   you	   are	  with	  me	   in	   spirit.	  We	  have	  had	   some	  wonderful	   trips	   these	  past	   few	  
years,	   the	  memories	  of	  which	  have	  kept	  me	  going	  during	   the	  hard	   times.	   I	  will	   be	  
forever	  grateful	   to	  you	  and	  Antonio	   for	  our	  week	  on	   the	  magical	   island	  of	  Achill.	   I	  
look	  forward	  to	  all	  of	  the	  ones	  that	  we	  have	  yet	  to	  make.	  Thank	  you	  for	  listening	  and	  
truly	  being	  a	  friend.	  
To	  gramps,	  thank	  you	  for	  inspiring	  me	  to	  study	  what	  I	  love	  and	  nanna,	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you	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  constant	  encouragement.	  Ally	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  for	  putting	  up	  with	  my	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weird	  science	  talk	  and	  I	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  to	  you	  both	  for	  having	  to	  have	  such	  a	  massive	  geek	  
as	   a	   sister.	  Mum	   and	   dad,	   I	   was	   born	   eternally	   in	   your	   debt.	   Each	   day	   that	   debt	  
grows	  more	   and	  more.	   Thank	   you	   so	  much	   for	   everything.	   This	   would	   have	   been	  
impossible	  without	  your	  constant	  love	  and	  support.	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Abstract	  
Transition	  metal	   coordination	   complexes	   show	   great	   promise	   as	   novel	  
therapeutic	  agents	  with	  new	  mechanisms	  of	  action,	  but	  their	  characterisation,	  
and	   identification	   of	   their	   target	   sites	   present	   significant	   challenges.	   In	   this	  
thesis	  a	  variety	  of	  new	  analytical	  methods	  is	  explored	  for	  the	  study	  of	  platinum,	  
ruthenium,	  osmium	  and	  iridium	  anticancer	  complexes.	  
High	  performance	  liquid	  chromatography	  (HPLC)	  was	  used	  to	  determine	  
the	   relative	   hydrophobicity	   of	   a	   series	   of	   photoactivatable	   Pt(IV)	   diazido	  
complexes	   of	   the	   general	   type	   trans,trans,trans-­‐[Pt(N3)2(OH)2(R)(R’)].	  
Interestingly	  the	  hydrophobicities	  did	  not	  follow	  trends	  based	  on	  literature	  Log	  
P	  values	  of	   individual	   ligands	  and	  did	  not	  correlate	  with	  the	  cellular	  uptake	  or	  
antiproliferative	  activity	  of	  the	  drugs.	  Other	  factors	  such	  as	  the	  quantum	  yield	  
of	  the	  complex,	  and	  the	  type	  of	  DNA	  adducts	  appear	  to	  be	  more	  important	  for	  
their	  efficacy.	  
Chromatography	   and	   high-­‐resolution	  mass	   spectrometry	  were	   used	   to	  
study	  the	  formation	  of	  platinum	  adducts	  on	  DNA	  when	  the	  most	  active	  complex	  
trans,trans,trans-­‐[Pt(N3)2(OH)2(pyridine)2],	   8	   was	   irradiated	   in	   the	   presence	   of	  
short	  single	  strand	  oligonucleotides	  14	  bases	  in	  length.	  Complex	  8	  was	  found	  to	  
bind	   to	   the	   oligonucleotides	   as	   a	   {Pt(pyridine)2}2+	   adduct.	   Modifying	   the	  
wavelength	   of	   activation	   from	   UVA	   to	   420	   nm	   had	   no	   effect	   on	   the	   type	   of	  
adduct	   formed,	  but	   the	  higher	  energy	   irradiation	  achieved	  maximum	   levels	  of	  
DNA	   platination	   more	   quickly.	   Changing	   the	   sequence	   of	   the	   oligonucleotide	  
suggested	  that	  the	  photoactivated	  form	  of	  8	  does	  not	  favour	  the	  formation	  of	  
the	   1,2-­‐(GpG)	   bisadduct	   formed	   by	   cisplatin	   and	   other	   clinically	   approved	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platinum	  based	  drugs,	  but	  may	  form	  1,3-­‐(GpNpG)	  or	  1,3-­‐(ApNpG)	  adducts,	  as	  is	  
the	  case	  with	  other	  trans-­‐platinum	  complexes.	  
Chiral	   chromatography	   using	   cellulose-­‐	   and	   amylose-­‐based	   stationary	  
phases	   successfully	   separated	   the	   enantiomers	   of	   a	   series	   of	   organometallic	  
‘piano	   stool’	   anticancer	   complexes.	   This	   appears	   to	   be	   the	   first	   successful	  
separation	  of	   facially	   chiral	   Ru(II)	   arene	   complexes,	   the	   enantiomers	   of	  which	  
were	   stable	   in	   solution	   for	   over	   3	   h.	   In	   contrast,	   separated	   cyclopentadienyl	  
Ir(III)	  complexes	  	  with	  chiral	  metal	  centres	  epimerized	  within	  2	  h	  in	  solution	  at	  
ambient	   temperature.	   Under	   similar	   conditions	   the	   enantiomers	   of	   the	   Os(II)	  
arene	  complex	  [Os(η6-­‐p-­‐cym)(4-­‐(2-­‐pyridylazo)-­‐N,N-­‐dimethylaniline)I]+	   remained	  
stable,	   as	   did	   those	   of	   the	   ruthenium-­‐based	   complex	   [Ru(9,10-­‐
diydrophenanthrene)(en)Cl]+.	   It	   was	   shown	   that	   it	   is	   possible	   to	   separate	   the	  
diasteriomers	   of	   [Ru(η
6
-­‐para-­‐cymene)(iminopyridine)I],	   that	   can	   also	   be	  
resolved	  by	  crystallisationtechniques,	  and	  hence,	  decrease	  the	  time	  required	  to	  
separate	   the	   enantiomers.	   This	   work	   will	   therefore	   allow	   exploration	   of	   the	  
biological	  properties	  of	  some	  of	  these	  enantiomers	  
A	   novel	   technique	   for	   the	   rapid	   irradiation	   and	   detection	   of	   light-­‐
senstive	  species	  was	  developed.	  Photonic	  crystal	  fibers	  (PCFs)	  were	  coupled	  to	  a	  
mass	  spectrometer	  using	  HPLC	  tubing	  and	  fittings.	  This	  continuous	  flow	  method	  
of	   analysis	  was	   validated	  using	   the	  photaquation	  of	   cyanocobalamin.	   The	  PCF	  
system	   was	   compared	   to	   the	   conventional	   cuvette-­‐based	   approach.	   No	  
significant	  difference	  in	  the	  species	  detected	  by	  MS	  could	  be	  found,	  but	  the	  PCF	  
system	  had	  the	  advantage	  of	  requiring	  20	  times	  less	  sample	  (25	  μL),	  and	  only	  15	  
min	  of	  irradiation	  compared	  to	  10	  h	  by	  conventional	  methods.	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The	  new	  PCF-­‐MS	  system	  was	  then	  used	  to	  study	  the	   interaction	  of	   the	  
photoactivateable	  ruthenium-­‐based	  drug	  [{(η6-­‐indan)RuCl}2(μ-­‐2,3-­‐dpp)]2+	  with	  a	  
range	  of	  small	  molecules	  that	  acted	  as	  models	  for	  intracellular	  components,	  e.g.	  
5’GMP	  for	  DNA.	  The	  nucleobase	  binding	  properties	  were	  consistent	  with	  those	  
previously	   reported	  with	   plasmid	   DNA	   by	  Magennis	   et	   al:	   a	   small	   amount	   of	  
binding	   took	   place	   in	   the	   dark	   in	   view	   of	   the	   aquation	   of	   the	   mondentate	  
leaving	  groups	  but	  this	  dramatically	  increased	  upon	  photoactivation	  and	  loss	  of	  
the	   arene	   ligands.	   The	   complex	  was	   also	   found	   to	   bind	   to	   glutathione	   (GSH),	  
which	   is	   known	   to	   detoxify	   metal-­‐based	   drugs,	   an	   observation	   possibly	  
explaining	  its	  poor	  anticancer	  activity.	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  chromatography	  
SP	  stationary	  phase	  
MP	  mobile	  phase	  	  
py	  pyridine	  
LMCT	  ligand-­‐to-­‐metal	  charge	  transfer	  
PVC	  polyvinyl	  chloride	  
PTFE	  polytetrafluoroethylene	  	  
PEEK	  polyether	  ether	  ketone	  
DDW	  doubly	  deionised	  water	  
DACH	  diaminocyclohexane	  
GMP	  guanosine	  monophosphate	  
PDT	  photodynamic	  therapy	  
PCF	  photonic	  crystal	  fiber	  
ICP-­‐MS	  inductively	  coupled	  plasma	  mass	  spectrometry	  
NMR	  nuclear	  magnetic	  resonance	  
UV-­‐Vis	  ultraviolet-­‐visable	  (spectrum)	  
TFA	  trifluoroacetic	  acid	  
DDW	  doubly	  deionised	  water	  
DNA	  deoxyribonucleic	  acid	  
	   XVIII	  
HMG	  high	  mobility	  group	  (protein)	  









azpy-­‐F	  4-­‐(2-­‐	  pyridylazo)-­‐N,N-­‐fluoro	  	  
azpy-­‐NMe2	  4-­‐(2-­‐	  pyridylazo)-­‐N,N-­‐dimethylaniline)	  
tz	  thiazole	  
pycarboxphen	  3-­‐pyridinecarboxaldehyde,	  5-­‐phenyl-­‐	  
py,4-­‐(4tfmph)	  pyridine,4-­‐[4-­‐(trifluoromethyl)phenyl]-­‐	  






VWD	  variable	  wavelength	  detector	  
DEA	  diethylamine	  
TEA	  Triethylamine	  





































1.1 Metals	  in	  Medicine	  
Traditionally	   the	   pharmaceutical	   industry	   has	   focused	   on	   the	   design	   and	  
development	  of	  organic	  drugs.	  Although	  metals	  and	  metal-­‐based	  compounds	  have	  
been	  used	  for	  medicinal	  purposes	  for	  centuries,	  such	  as	  mercury	  and	  arsenic	  in	  the	  
treatment	   of	   syphilis,1	   their	   use	   has	   not	   been	   widespread.	   The	   discovery	   of	   the	  
antiproliferative	   activity	   of	   the	   platinum-­‐based	   compound	   cisplatin,	   cis-­‐
[Pt(NH3)2Cl2],	  by	  Rosenberg	  et	  al.	  in	  1968	  created	  a	  new	  wave	  of	  interest	  in	  metal-­‐
based	   therapies,2,3	   bringing	   inorganic	  medicinal	   chemistry	   to	   the	   forefront.	   Since	  
then	   the	   search	   for	   metal	   ions	   for	   medicinal	   purposes	   has	   expanded	   to	   a	   wide	  
range	  fields	  in	  therapy	  and	  diagnosis.	  
1.1.1	  Antimicrobial	  agents	  
Compounds	  of	  silver	  have	  been	  used	  as	  antimicrobial	  agents	   for	  a	  number	  
of	  years,	  often	  in	  the	  form	  of	  AgNO3.4	  Silver	  has	  the	  advantage	  of	  being	  toxic	  at	  low	  
levels	  to	  bacteria,	  but	  much	  higher	  levels	  are	  required	  to	  achieve	  toxicity	  in	  human	  
cells.	   One	   compound	   in	   clinical	   use	   for	   the	   treatment	   of	   burns	   is	   the	   polymeric	  
compound	   silver	   sulfadiazine,	   Figure	   1.1,	   which	   like	   many	   silver	   antimicrobial	  
agents	  has	  been	   incorporated	   into	  various	  materials	   such	  as	  bandages,5,6	  medical	  
instruments,7	  shoe	  insoles,	  fabrics8,9	  and	  even	  washing	  machines	  and	  food.10	  Often	  
the	   silver	   compounds	   are	   incorporated	   into	   materials	   such	   as	   functionalised	  
nanoparticles	  or	  even	  as	  dendrimers.11–13	  



















Figure	  1.1	  Structure	  of	  silver	  sulfadiazine.	  
	  
Several	   other	  metal	   compounds	   have	   also	   shown	  efficacy	   as	   antimicrobial	  
agents.	   Copper	   nanoparticles	   were	   shown	   to	   be	   inferior	   in	   activity	   to	   silver	  
nanoparticles	  by	  Ruparelia	  et	  al.	   (2008),	  but	   a	  mixed	  nanoparticle	  of	  both	  metals	  
was	   found	   to	   be	   the	  most	   effective	   against	   the	   four	   strains	   of	   bacteria	   tested.14	  
Amino	  acid-­‐based	  complexes	  of	  Co(II),	  Cu(II),	  Ni(II)	  and	  Zn(II)	  were	  tested	  for	  their	  
antibacterial	   and	  antifungal	   activity	   in	  Gram-­‐positive,	  Gram-­‐negative	  bacteria	   and	  
fungal	   strains	  by	  Chohan	  et	  al.	   	   (2006).	  They	  were	  shown	   to	  be	  active	   towards	  E.	  
coli,	  B.	  subtilis,	  S.	  flexenari,	  S.	  aureus,	  P.	  aeruginosa,	  and	  S.	  typhi	  bacteria,	  and	  for	  
antifungal	  activity	  against	  T.	  longifusus,	  C.	  albicans,	  A.	  flavus,	  M.	  canis,	  F.	  solani,	  and	  
C.	  glaberata.15	  The	  antibacterial	  properties	  of	  a	  series	  of	  Cu(II),	  V(IV)	  and	  Ni(II)	  with	  
Schiff	  bases	  obtained	  through	  the	  condensation	  of	  4-­‐amino-­‐1,5-­‐dimethyl-­‐2-­‐phenyl-­‐
1H-­‐3-­‐pyrazol-­‐3(2H)-­‐one	   (anti-­‐pyrine)	   with	   2-­‐hydroxybenzaldehyde,	   4-­‐hydroxy-­‐5-­‐
methoxyisophthalaldehyde	   and	   4,5-­‐dihydroxy	   isophalaldehyde,	   respectively,	  were	  
investigated	   by	   Rosu	   et	   al.	   (2010)	   along	   with	   their	   antiproliferative	   activity.	   The	  
complexes	   were	   found	   to	   have	   limited	   activity	   in	   both	   bacteria	   and	   cancer	   cell	  





lines.16	   The	   ruthenium-­‐based	   complexes	   [Ru(phenanthroline)2(dipyrido[3,2-­‐d:2’,3’-­‐
f]quinoxaline)]2+,	   [Ru(bipyridine)2(dipyrido[3,2-­‐a:2’,3’-­‐c](6,7,8,9-­‐tetrahydro)	  
phenazine)]2+,	  and	  [Ru(2,9-­‐Me2phenathroline)2(dipyrido[3,2-­‐	  a:2’,3’-­‐c]phenazine)]2+	  
are	   active	   towards	   both	   Gram-­‐positive	   and	   Gram-­‐negative	   bacteria.17	   Ruthenium	  
complexes	   have	   also	   shown	   promise	   in	   the	   treatment	   of	   the	   parasistic	   illness	  
Chagas’	  disease.18	  Another	  metal	  that	  has	  shown	  antiparasitic	  activity	  is	  gold;	  Au(I)	  
chloroquinoline	   complexes	   are	   active	   against	   quinolone-­‐resistant	   strains	   of	  
malaria.19	  A	  series	  of	  gold	  phosphine	  compounds	  has	  shown	  antimicrobial	  activity	  
in	   Gram-­‐positive	   bacteria,	   with	   the	   potency	   dependent	   on	   the	   structure	   of	   the	  
phosphine	  ligands.20	  
1.1.2	  Gold	  Antiarthritic	  drugs	  
Compounds	   of	   gold	   are	   also	   used	   to	   treat	   rheumatoid	   arthritis.	   There	   are	  
several	   forms	   of	   injectable	   gold	   antiarthritic	   gold	   drugs,	   including	   di-­‐sodium	  
aurothiomalate,	   aurothioglucose	   and	   sodium	   aurothiopropanol	   sulfonate.21	   The	  
orally	  active	  drug	  auranofin	  (Figure	  1.2)	  gained	  approval	  for	  use	  in	  the	  clinic	  several	  
decades	  ago.	   Its	  mechanism	  of	  action	   is	  thought	  to	   involve	  the	   induction	  of	  heme	  
oxygenase-­‐1	   and	   the	   generation	   of	   reactive	   oxygen	   species	   (ROS),	   as	   explored	   in	  
detail	   by	   Kim	   et	   al.22	   It	   is	   known	   to	   react	   readily	   with	   thiols	   such	   as	   glutathione	  
(GSH)	   and	  human	   serum	  albumin	   (HSA).23	  Using	  both	  X-­‐ray	   absorption	  near-­‐edge	  
spectroscopy	   (XANES)	   and	   extended	   X-­‐ray	   absorption	   fine	   structure	   (EXAFS),	  
Messori	   et	   al.	   studied	   the	   interaction	   of	   auranofin	   with	   bovine	   serium	   albumin	  
(BSA)	   and	   human	   serum	   apotransferrin.24	   They	   confirmed	   the	   findings	   of	   earlier	  
NMR	  studies	  performed	  by	  Sadler	  et	  al.	  that	  auranofin	  loses	  its	  thiosugar	  ligand	  and	  





subsequently	   binds	   to	   the	   Cys-­‐34	   residue	   of	   BSA,25,26	   and	   the	   loss	   of	   the	   same	  
ligand	   is	   thought	   to	   facilitate	   binding	   to	   apotransferrin.27	   In	   both	   cases	   the	   Au(I)	  












Figure	  1.2	  The	  structure	  of	  auranofin.	  
	  
Auranofin	   has	   also	   displayed	   antiparasitic	   characteristics,	   thought	   to	   be	  
derived	   from	   its	   ability	   to	   inhibit	   parasitic	   enzymes.	   The	   crystal	   structure	   of	  
auranofin	   bound	   to	   trypanothione	   reductase,	   a	   key	   enzyme	   of	   the	   parasite	  
Leishmania	   infantum,	   was	   reported	   by	   Ilari	   et	   al.28	   The	   structure	   showed	   that	  
auranofin	  was	  bound	   to	   two	   cysteine	   residues	  of	   the	  protein,	  Cys-­‐52	  and	  Cys-­‐57,	  
with	   the	   thiosugar	  moiety	   of	   auranofin	   binding	   to	   the	   trypanothione	   binding	   site	  
within	   the	  protein	   inhibiting	   the	  action	  of	   the	  enzyme.	  Auranofin	  has	   also	   shown	  
promising	  anticancer	  activity	  against	  chronic	  lymphocytic	  leukemia.29	  
1.1.3	  Bismuth	  antiulcer	  drugs	  
Bismuth	   has	   a	   long	   history	   in	   the	   treatment	   of	   ulcers.21	   These	   drugs,	  
including	  bismuth	  subsalicylate	  (BSS),	  colloidal	  bismuthcitrate	  (CBS),	  and	  ranitidine	  
bismuth	   citrate	   (RBC),	   which	   are	   often	   polymeric	   in	   structure.	   Target	   sites	   for	  





bismuth-­‐based	  drugs	  are	   thought	   to	  be	  metalloproteins	   such	  as	   transferrin	  which	  
can	  transport	  bismuth,	  and	  the	  enzyme	  urease	  in	  bacteria.30	  A	  study	  by	  Cun	  et	  al.	  
has	   shown	   that	   Bi3+	   binds	   to	   the	   histidine-­‐	   and	   cysteine-­‐rich	   domain	   at	   the	   C-­‐
terminus	  of	  the	  heat	  shock	  protein	  HspA,	  normally	  responsibly	  for	  binding	  Ni2+	  ions	  
found	  in	  Helicobacter	  pylori.31	  A	  proteomic	  study	  of	  Helicobacter	  pylori	  exposed	  to	  
bismuth	   subcitrate	   found	   that	   the	   drug	   induced	   oxidative	   stress	   in	   the	   cells,	  
suggesting	  that	  this	  may	  also	  be	  a	  key	  part	  of	  the	  mechanism	  of	  action	  of	  this	  class	  
of	   drug.32	   Tsang	   et	   al.	   monitored	   the	   bismuth	   levels	   of	   individual	   bacterial	   cells	  
exposed	  to	  antiulcer	  drugs,	  and	  found	  that	  the	  uptake	  of	  bismuth	  was	  affected	  by	  
the	  presence	  of	   ferric	   ions,33	   indicating	   that	  bismuth	   is	   taken	  up	   into	   the	  cells	  via	  
iron	  transport	  pathways.	  
	  
1.1.4	  Metal-­‐based	  insulin	  mimics	  
The	   signaling	   hormone	   insulin	   is	   essential	   for	   the	   metabolism	   of	  
carbohydrates	   and	   fat.34	   Insulin	   release	   is	   prompted	  by	   high	   blood	   glucose	   levels	  
and	   the	   subsequent	   high	   levels	   of	   insulin	   cause	   the	   liver	   and	   gut	   to	   increase	   the	  
uptake	  of	  glucose.	  It	  is	  this	  function	  of	  insulin,	  inducing	  the	  storage	  of	  glucose,	  that	  
vanadium	  and	  other	  metal	  compounds	  have	  been	  shown	  to	  mimic.	  Their	  efficacy	  is	  
believed	  to	  ascribable	  due	  to	  their	  interaction	  with	  phosphotyrosine	  phosphatases	  
(PTPases)	  and	  tyrosine	  kinases	  that	  regulate	  insulin	  receptor	  binding.35	  
The	  vanadium	  complex	  bis(maltolato)oxovanadium(IV)	   (BMOV),	  Figure	  1.3,	  
is	  an	  orally-­‐active	  insulin	  mimic	  shown	  to	  be	  effective	  at	  reducing	  glucose	  levels	  in	  
blood	   plasma.36	   To	   improve	   the	   uptake	   and	   efficacy	   of	   this	   class	   of	   drug,	   new	  
generations	   of	   vanadium	   insulin	   mimics	   have	   been	   developed.	   Some	   of	   these	  





incorporate	   vanadium	   in	  different	  oxidation	   states.	   Rehder	  et	  al.	   synthesised	  and	  
studied	  in	  detail	  22	  V(V)	  and	  V(IV)	  complexes	  containing	  –OO,	  -­‐ON,	  -­‐OS,	  -­‐NS	  and	  –
ONS	   donor	   ligands.37	   They	   found	   that	   the	   oxidation	   state	   of	   the	  metal	   had	   little	  
effect	   on	   the	   activity	   of	   the	   complexes	   since	   the	   oxidation	   states	   of	   vanadium	  
readily	   interconvert	   in	   cells.	   The	  most	   active	   compounds	   contained	   	   –ON	   ligands.	  
This	  agrees	  with	  the	  findings	  of	  Gätjens	  et	  al.	  who	  synthesised	  a	  range	  of	  vanadium	  
complexes	   derived	   from	   5-­‐carboalkoxypicolinates	   that	   were	   shown	   to	   be	   more	  









Figure	  1.3	  Structure	  of	  bis(maltolato)oxovanadium(IV)	  (BMOV).	  
	  
The	   complexes	   of	   several	   other	   metals	   have	   shown	   efficacy	   as	   insulin	  
mimics,	  such	  as	  molybdenum	  and	  tungsten.	  The	  Mo(VI)	  and	  W(VI)	  oxidation	  states	  
are	   very	   similar	   in	   configuration	   to	   V(V);	   their	   similarities	   are	   discussed	   by	  
Thompson	  et	  al.	   in	   their	   review	  of	  vanadium	  compounds	  as	   insulin	  mimics.34	  Zinc	  
complexes	   may	   also	   show	   some	   efficacy	   as	   an	   insulin	   mimic.34	   The	   naturally	  
occurring	   chromium-­‐oligopeptide	   complex	   has	   been	   found	   to	   activate	   tyrosine	  










The	   release	   of	   NO	   from	   metal	   complexes,	   usually	   by	   means	   of	  
photoactivation,	   has	   been	   shown	   to	   induce	   vasodilation.39	   The	   iron	   compound	  
sodium	   nitroprusside	   (SNP)	   has	   been	   approved	   for	   clinical	   use	   to	   control	  
hypertension.40	   The	   structure	   of	   this	   compound	   is	   shown	   in	   Figure	   1.4.	   Upon	  
irradiation	  with	   short	  wavelengths	   of	   light,	   the	  NO	   ligand	   of	   SNP	   is	   released	   first	  
and	  subsequently	  small	  amounts	  of	  the	  CN-­‐	  ligand	  can	  also	  be	  relased.41,39	  There	  are	  
also	   examples	   of	   ruthenium-­‐,42,43	   chromium-­‐,44	   nickel-­‐,45	   and	   copper-­‐based46	   NO-­‐















Figure	  1.4	  The	  structure	  of	  sodium	  nitroprusside.	  
	  
1.1.6	  MRI	  contrast	  agents	  
Advancements	  in	  other	  fields	  of	  medicine	  have	  led	  to	  new	  opportunities	  for	  
inorganic	  drugs.	  The	  use	  of	  magnetic	  resonance	  imaging	  (MRI)	  in	  medical	  diagnosis	  
has	   created	   a	   demand	   for	   contrast	   agents	   to	   improve	   the	   images	   acquired.	   	   The	  
majority	  of	  the	  contrast	  agents	  in	  use	  are	  Gd(III)-­‐based,	  though	  there	  are	  some	  iron	  
nanoparticle	   agents	   and	   the	   Mn(II)-­‐based	   agent	   Teloscan®.	   An	   example	   of	   the	  





gadolinium-­‐based	  agents	   is	   shown	   in	   Figure	  1.5.	   There	   are	   various	   agents	   for	   the	  
targeting	  of	  different	  types	  of	  tissue,	  e.g.	  liver	  and	  brain.	  The	  different	  types	  of	  MRI	  















Figure	  1.5	  The	  structure	  of	  the	  Gd(III)-­‐based	  contrast	  agent	  Dotarem®.	  
	  
1.2 Platinum-­‐based	  drugs	  
1.2.1	  Cisplatin	  
The	   serendipitous	  discovery	  of	   the	  anitproliferative	  properties	  of	   cisplatin,	  
Figure	  1.6,	  sparked	  new	  interest	  in	  metal-­‐based	  therapies	  in	  the	  late	  1960s.2,3	  In	  a	  
little	   over	   a	   decade,	   it	   had	   gained	   FDA	   approval	   and	   had	   already	   begun	   to	   save	  
lives.	   Cisplatin	   is	   highly	   effective	   in	   the	   treatment	   of	   testicular,	   ovarian,	   bladder,	  
head	   and	   neck	   cancers.49	   Platinum-­‐based	   drugs	   (cisplatin,	   carboplatin	   and	  
oxaliplatin)	  	  are	  so	  successful	  that	  sales	  are	  now	  in	  the	  order	  of	  $3	  billion	  each	  year.	  
Thier	   mechanism	   of	   action,	   metabolism	   and	   biotransformation	   have	   been	  
extensively	  studied.	  










Figure	  1.6	  The	  structure	  of	  the	  platinum-­‐based	  anticancer	  drug	  cisplatin.	  
	  
1.2.1.1 Mechanism	  of	  action	  
The	  efficacy	  of	  cisplatin	  is	  thought	  to	  be	  attributable	  to	  its	  hydrolysis	  once	  it	  
enters	  the	  cell	  and	  the	  subsequent	  binding	  of	  a	  small	  amount	  of	  the	  drug	  to	  nuclear	  
DNA.	  Many	  different	  lesions	  are	  formed	  by	  the	  hydrolysed	  cisplatin:	  monoadducts,	  
interstrand	  crosslinks,	  1,2-­‐intrastrand	  crosslinks	  and	  1,3-­‐intrastrand	  crosslinks.	  The	  
adducts	   that	   are	  believed	   to	   induce	  apoptosis	   are	   the	  1,2-­‐d(GpG)	  and	  1,2-­‐d(ApG)	  
intrastrand	   crosslinks,	   forming	   65%	   and	   25%	   of	   lesions	   (determined	   by	   high	  
performance	  liquid	  chromatography),	  respectively.50	  Cisplatin	  binds	  to	  the	  N7	  atom	  
of	   guanine	   (and	   to	   some	   extent	   adenine)	  more	   favourably	   than	   other	   nucleotide	  
binding	  sites	  since	   it	   is	   the	  most	  electron-­‐rich,	  and	   it	   forms	  the	  most	  stable	  metal	  
ion-­‐nucleobase	   complex	   at	   physiological	   pH,	   see	   Figure	   1.7.51	   In	   single-­‐stranded	  
DNA,	   the	   N3	   of	   cytidine	   and	   N1	   of	   adenine	   are	   also	   possible	   binding	   sites	   for	  
platinum.52	  
The	  1,2-­‐(GpG)	   intrastrand	  crosslink	  causes	  a	  bending	  and	  unwinding	  of	  the	  
duplex	   DNA53	   that	   is	   recognised	   by	   proteins.	   Two	   types	   of	   protein	   are	   known	   to	  
interact	  with	  cisplatin	  lesions	  on	  DNA:	  repair	  proteins	  that	  recognise	  DNA	  damage	  
and	  architectural	  proteins	  that	  are	  nuclear,	  or	  chromatin	  related	  proteins	  involved	  
in	   the	   formation	   of	   protein-­‐DNA	   or	   protein-­‐protein	   complexes.54	   Many	   of	   these	  





proteins	  contain	  the	  high	  mobility	  group	  1	  box	  (HMG1)	  motif,	  a	  sequence	  of	  around	  
80	  amino	  acids	  in	  length.	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Figure	   1.7	   Possible	   binding	   sites	   for	   transition	   metal	   ions	   in	   a	   single	   strand	  
deoxytetranulceotide	  are	  indicated	  with	  arrows.	  Adapted	  from	  ref.	  55	  
	  
Ohndorf	  et	  al.	  reported	  the	  crystal	  structure	  of	  a	  HMG1	  protein	  bound	  to	  a	  
strand	  of	  duplex	  DNA,	  of	  the	  sequence	  5’(CCT	  CTC	  TG*G*	  ACC	  TTC	  C)/5’(GGA	  GAG	  
ACC	  TGG	  AAG	  G)	   (*	   indicates	   the	  position	  of	   platinum	  binding),	   containing	   a	   1,2-­‐
c(GpG)	  cisplatin	  adduct.56	  The	  oligo-­‐cisplatin	  adduct	  created	  a	  large	  enough	  bend	  in	  
the	  duplex	  for	  a	  phenylalanine	  (Phe)	  residue	  at	  position	  37	  to	  partially	  intercalate.	  
The	  binding	  of	  HMG1	  was	  greatly	  reduced	  for	  a	  mutant	  protein	  in	  which	  Phe	  37	  was	  
substituted	   by	   alanine.	   This	   suggested	   that	   such	   intercalation	   stabilised	   this	  
modified	   DNA-­‐protein	   complex.	   The	   bound	   HMG1	   then	   interacts	   with	   mismatch	  
repair	   protein	   MutSα	   and	   with	   the	   tumour-­‐suppressor	   protein	   p53	   in	   vitro,	   and	  





enhances	  p53	  DNA-­‐binding	  activity.57	  These	  protein	   interactions	  with	  the	  cisplatin	  
bound	  DNA-­‐HMG1	  complex	  and	  other	  proteins	  initiate	  signaling	  cascades	  that	  lead	  
to	  apoptosis	  in	  cells.	  
	  
Figure	  1.8	  X-­‐ray	  crystal	  structure	  showing	  the	  interaction	  of	  the	  HMG1	  protein	  with	  
the	  duplex	  5’(CCT	  CTC	  TG*G*	  ACC	  TTC	  C)/5’(GGA	  GAG	  ACC	  TGG	  AAG	  G).	  From	  ref	  56	  
	  
1.2.1.2 Cellular	  accumulation	  
Cisplatin	   uptake	   is	   not	   entirely	   understood,	   but	   it	   is	   known	   that	   it	   enters	  
cells	   by	  passive	  diffusion.	   The	  uptake	  and	  efflux	  of	   cisplatin	   is	   also	   thought	   to	  be	  
related	  to	  the	  high-­‐affinity	  copper	  transporter	  CTR1.57	  Mutation	  or	  deletion	  of	  the	  
CTR1	  gene	  caused	  a	  reduction	  in	  the	  amount	  of	  Pt	  taken	  up	  by	  cells	  and	  an	  increase	  
in	  cisplatin	  resistance.	  Over-­‐expression	  of	  CTR1	  increases	  the	  levels	  of	  Pt	  taken	  up.58	  
Cisplatin	  was	  found	  to	  bind	  to	  the	  methionine	  residues	  of	  CTR1,	  perhaps	  allowing	  it	  
to	  enter	  the	  cell	  by	  sulphur-­‐sulphur	  ligand	  exchange.59	  Organic	  cation	  transporters	  
	  





may	  also	  play	  a	  role	  in	  cisplatin	  uptake	  and	  efflux.60	  
	  
1.2.1.3 Mechanisms	  of	  resistance	  
Some	   types	   of	   cancer	   cells	   are	   intrinsically	   resistant	   to	   cisplatin,	   whilst	  
others	   can	   develop	   resistance	   after	   prolonged	   exposure	   to	   the	   drug.	   One	   of	   the	  
main	   sources	   of	   resistance	   is	   the	   reduced	   cellular	   accumulation	   of	   cisplatin	   by	  
decreased	   influx	   and	   increased	   efflux.61	   Additionally,	   an	   increase	   in	   levels	   of	  
intracellular	  thiol	  e.g.	  GSH	  can	  detoxify	  cisplatin	  and	  increase	  efflux	  of	  platinum(II)	  
from	  the	  cell.	  Another	  means	  of	  resistance	  is	  increased	  adduct	  repair	  and	  tolerance	  
of	  Pt-­‐DNA	  lesions	  resulting	  in	  failure	  to	  induce	  apoptosis.57	  A	  diagram	  summarising	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Figure	  1.9	  A	  diagram	  of	  cisplatin	  uptake,	  efflux	  and	  DNA	  binding	  	  (adapted	  from	  
Reedijk	  et	  al.).	  55	  
	  





1.2.2 New	  generation	  platinum-­‐based	  drugs	  
Despite	   its	  great	  success,	  cisplatin	  does	  have	  some	  disadvantages.	  Patients	  
treated	   with	   cisplatin	   suffer	   from	   severe	   side-­‐effects	   such	   as	   nephrotoxicity,	  
neurotoxicity,	  ototoxicity,	  nausea	  and	  vomiting.49	  This	  along	  with	  the	   intrinsic	  and	  
acquired	   resistance	   of	   certain	   cancers	   to	   cisplatin	   has	   led	   to	   the	   development	   of	  
new	  platinum-­‐based	  alternatives.	  The	  second	  generation	  Pt-­‐based	  drug	  carboplatin,	  







Figure	  1.10	  The	  structure	  of	  the	  second	  generation	  Pt-­‐based	  drug	  Carboplatin.	  
	  
The	   hydrolysis	   of	   carboplatin	   is	   slower	   than	   that	   of	   cisplatin	   as	   the	  	  
cyclobutanedicarboxylato	   leaving	   group	   is	   not	   as	   labile	   as	   the	   chlorido	   leaving	  
groups	  of	  cisplatin.	  The	  mechanism	  of	  carboplatin	  hydrolysis	  occurs	   in	  two	  stages,	  
beginning	  with	   a	   ring	   opening	   process	  which	   is	   followed	   by	   complete	   loss	   of	   the	  
ligand.62	   This	   reduced	   rate	   of	   hydrolysis	   leads	   to	   fewer	   unwanted	   side	   reactions	  
once	   carboplatin	   has	   entered	   the	   cell,	   and	   is	   thought	   to	   be	   responsible	   for	   the	  
reduced	   side	  effects	  of	   this	  drug.60	  As	   carboplatin	  and	  cisplatin	  differ	   in	   structure	  
only	   by	   the	   leaving	   groups,	   the	   resulting	  DNA	  adducts	   formed	  by	   carboplatin	   are	  
the	  same	  as	  those	  of	  cisplatin.	  
The	  new	  generation	  platinum-­‐based	  drug	  oxaliplatin	  (Figure	  1.11),	  also	  used	  
in	   the	   clinic,	   is	   active	   in	   some	   cancers	   that	   have	   either	   acquired	   or	   intrinsic	  
resistance	  to	  cisplatin,	  e.g.	  colorectal	  cancers.63,64	  This	  different	  spectrum	  of	  activity	  





for	   oxaliplatin	   is	   thought	   to	  be	   ascribable	   to	   the	   adducts	   that	   it	   forms	  with	  DNA.	  
Although	  also	  a	  square-­‐planar	  Pt(II)	  complex,	  oxaliplatin	  does	  not	  share	  any	  of	  the	  
same	   ligands	   as	   cisplatin,	   and	   the	   lesions	   that	   it	   forms	   on	   DNA	   have	   a	   different	  










Figure	  1.11	  The	  structure	  of	  the	  new	  generation	  Pt-­‐based	  drug	  oxaliplatin.	  
	  
The	   DNA	   adducts	   of	   oxaliplatin,	   [(R,R)-­‐DACH](ethanedioato-­‐
O,O')platinum(II)	   (where	   (R,	   R)-­‐DACH	   is	   (1R,2R)-­‐cyclohexane-­‐1,2-­‐diamine),	   have	  
been	  widely	  studied	  using	  a	  range	  of	  analytical	  techniques.	  The	  crystal	  structure	  of	  
the	   1,2-­‐d(GpG)	   oxaliplatin	   adduct	  was	   reported	   by	   Spingler	  et	   al.,	  with	   the	   same	  
DNA	  duplex	   for	  which	   the	  crystal	   structure	  of	   	   the	   cisplatin	  adduct	  has	  also	  been	  
solved.65,53	   They	   found	   that	   oxaliplatin	   retains	   its	   diaminocyclohexane	   (DACH)	  
ligand	  when	  bound	  to	  DNA.	  The	  structure	  contains	  the	  enantiomerically	  pure	  (R,R)-­‐
DACH	   ligand,	   and	   it	   was	   observed	   that	   there	   is	   a	   hydrogen	   bond	   between	   the	  
pseudoequatorial	  NH	  of	  the	  (R,R)-­‐DACH	  ligand	  and	  the	  O6	  atom	  of	  the	  3ʹ′-­‐G	  of	  the	  
1,2-­‐d(GpG)	  lesion.	  This	  may	  be	  an	  indication	  of	  why	  the	  (R,R)-­‐DACH	  enantiomer	  and	  
not	  the	  (S,S)-­‐DACH	  is	  more	  clinically	  active.66	  The	  chirality	  of	  the	  DACH	  ligand	  may	  
be	   very	   important	   for	   its	   interactions	  with	  DNA	  and	   subsequently	   the	   fate	  of	   the	  
cell.	  This	  is	  an	  idea	  further	  explored	  by	  Kasparkova	  et	  al.,	  who	  found	  that	  the	  same	  
overall	  structure	  is	  formed	  by	  the	  two	  enantiomers	  upon	  binding	  to	  DNA;	  however,	  
there	  are	  small	  structural	  differences	  between	  the	  two.67	  





Kasparkova	  et	  al.	  also	  studied	  the	  differences	  between	  the	  adducts	  formed	  
by	  cisplatin	  and	  oxaliplatin	  on	  plasmid	  DNA.	  The	  DNA	  adducts	  of	  oxaliplatin	  were	  
found	  to	  unwind	  and	  bend	  the	  duplex	   to	  a	  greater	  extent	   than	  those	  of	  cisplatin,	  
reducing	   the	   ability	   of	   HMG	   proteins	   to	   bind	   to	   oxaliplatin-­‐damaged	   DNA.	  
Oxaliplatin	  also	  forms	  a	  greater	  number	  of	  interstrand	  crosslinks	  than	  cisplatin;	  this	  
type	  of	  DNA	  damage	  is	  more	  difficult	  to	  repair	  than	  intrastrand	  crosslinks.67	  As	  well	  
as	   these	  more	  qualitative	  biochemical	   experiments,	   several	   solution	   structures	  of	  
DNA	  with	   a	   1,2-­‐d(GpG)	   oxaliplatin	   have	   been	   reported.	   It	   is	   difficult	   to	   compare	  
these	   directly	   with	   those	   structures	   in	   the	   literature	   for	   the	   cisplatin	   1,2-­‐d(GpG)	  
crosslink	   in	   view	   of	   differences	   in	   the	   DNA	   sequences	   used	   and	   the	   modelling	  
programs.	  The	  study	  by	  Wu	  et	  al.	  allowed	  direct	  comparison	  between	  undamaged,	  
cisplatin-­‐bound	   and	   oxaliplatin-­‐bound	   DNA	   under	   the	   same	   conditions.68	   They	  
found	  that	  the	  overall	  bend	  of	  the	  duplex	   induced	  by	  the	  adducts	   is	  quite	  similar:	  
(22	  ±	  10)°	  for	  the	  cisplatin	  adduct,	  and	  (31	  ±	  10)°	  for	  oxaliplatin.	  This	  may	  only	  be	  a	  
small	  difference	  but	  may	  affect	  interaction	  of	  the	  two	  adducts	  with	  repair	  proteins.	  
This	  topic	  has	  been	  reviewed	  in	  detail	  by	  Chaney	  et	  al.69	  
Oxaliplatin	   and	   carboplatin	   have	   been	   approved	   for	   clinical	   use	   gobally.	  
There	  are	  three	  other	  Pt(II)	  anticancer	  drugs	  that	  have	  been	   licenced	   in	   individual	  
countries.	   They	   are	   nedaplatin,	   licensed	   in	   Japan;	   lobaplatin,	   in	   China;	   and	  
heptaplatin,	   in	  South	  Korea	   (Figure	  1.12).	  All	  of	   these	  drugs	  contain	  Pt(II)	  with	  cis	  
diam(m)ines;	   although	   there	   are	   examples	   of	   their	   activities	   against	   different	  
tumours,	  there	  are	  also	  some	  examples	  of	  their	  cross-­‐resistance	  to	  cisplatin.	  

























Figure	  1.12	  The	  structures	  of	  the	  Pt(II)	  drugs	  nedaplatin,	  lobaplatin	  and	  heptaplatin.	  
	  
There	   are	   other	   Pt(II)	   drugs	   not	   yet	   licenced	   that	   have	   shown	   promise	   in	  
clinical	  trials.	  One	  example	  is	  picoplatin,	  a	  drug	  that	  has	  not	  yet	  been	  approved	  for	  
clinical	  use	  but	  has	  reached	  phase	  III	  clinical	  trials,	  see	  Figure	  1.13.64	  Picoplatin	  has	  







Figure	  1.13	  The	  structure	  of	  picoplatin,	  a	  Pt(II)	  drug	  in	  phase	  III	  trials.	  
	  
	  





1.2.2.1	  Trans	  platinum(II)	  complexes	  
All	   of	   the	   complexes	  discussed	   above	   are	  of	   the	   cis	   configuration.	   Indeed,	  
the	   early	   discovery	   of	   the	   inactivity	   of	   the	   trans	   isomer	   of	   cisplatin,	   transplatin,	  
discouraged	   the	   synthesis	   of	   trans-­‐platinum	   complexes	   since	   it	  was	  believed	   that	  
they	  would	   have	   very	   little	   activity.71	   Transplatin	   forms	   1,3-­‐d(GpNpG)	   intrastrand	  
crosslinks	   on	   DNA	   and	   GN7−CN3	   interstrand	   crosslinks.72–74	   Some	   of	   the	   earliest	  
trans-­‐complexes	  were	   reported	   to	  have	  antiproliferative	  activity,	   Figure	  1.14,	   and	  
showed	  activity	   in	  cisplatin-­‐resistant	  cell	   lines	   (L1210	  cisplatin	   resistant	   leukaemia	  
cells)	   with	   low	   IC50	   values	   comparable	   to	   their	   cis	   analogues,	   including	   trans-­‐



















Figure	   1.14	   Structures	   of	   early	   active	   trans-­‐platinum	   complexes:	   trans-­‐
[PtCl2(pyridine)2],	  trans-­‐[PtCl2(4-­‐picoline)2]	  and	  trans-­‐[PtCl2(thiazole)2].75,76	  
	  
It	  was	  realised	  that	  trans-­‐complexes	  could	  be	  active	  and	  possibly	  offer	  new	  
mechanisms	  of	  action.	  The	  knowledge	  that	  it	  is	  sterically-­‐unfavourable	  for	  them	  to	  
form	  the	  1,2-­‐d(GpG)	  adduct	  formed	  by	  their	  cis-­‐analogues	  has	  prompted	  the	  search	  
for	   new	   active	   trans	   platinum	   complexes.	   A	   highly	   active	   trans	   complex	   that	   has	  
reached	   clinical	   trials	   is	   BBR3464	   trans,trans,trans-­‐[[PtCl(NH3)2]	   [trans-­‐
Pt(NH3)2{H2N(CH2)6NH2}2]-­‐[PtCl(NH3)2]]4+,	   the	  structure	  of	  which	   is	  shown	   in	  Figure	  
1.15.	   Atomic	   force	  microscopy	   studies	   of	   BBR3464	  with	   DNA	   have	   shown	   that	   it	  
causes	  greater	  compaction	  of	  the	  DNA	  than	  cisplatin.77	  The	  interaction	  of	  BBR3464	  





with	  DNA	  in	  cell	  free	  media,	  plasmid	  DNA	  and	  RNA	  polymerase	  II	  was	  reported	  by	  L.	  
Zerzankova	  et	  al.78	  The	  adducts	  of	  BBR3464	  form	  long	  range	  inter-­‐	  and	  intrastrand	  
crosslinks	   that	   inhibit	   RNA	   polymerase	   II	   more	   effectively	   than	   cisplatin	   adducts,	  
and	  persist	   for	   longer	  but	   induce	  a	  smaller	  overall	  bend	  of	  the	  duplex.79	  The	  DNA	  
adduct	   of	   BBR3464	   contains	   a	   large	   lesion	   in	   which	   the	   two	   ends	   bind	  
monofunctionally	   to	   the	  N7	  of	   two	  guanine	   residues	  with	   the	   linker	   sitting	   in	   the	  
minor	  grove.	  Chromatography	  and	  NMR	  spectroscopy	  were	  used	  by	  Ruhayel	  et	  al.,	  
to	  confirm	  this	   structure	  and	  reveal	   that	  BBR3464	  can	   form	  adducts	   in	   the	  3’→3’	  
direction	  as	  well	  as	  5’→5,	  this	  is	  quite	  unusual	  as	  most	  DNA	  crosslinkers	  bind	  in	  the	  

















Figure	  1.15	  Structure	  of	  the	  tri-­‐nuclear	  trans-­‐platinum	  complex	  BBR3464.	  
	  
1.2.2.2	  Delivery	  strategies	  for	  platinum	  complexes	  
As	  well	   as	   increasing	   the	   spectrum	   of	   activity	   of	   platinum-­‐based	   drugs	   by	  
altering	  their	  geometry,	  targeting	  and	  delivery	  strategies	  have	  also	  been	  employed	  
to	   help	   reduce	   their	   side-­‐effects.	   The	   subject	   of	   targeting	   platinum	   based	  
complexes	  has	  been	  recently	  reviewed	  in	  detail	  by	  Butler	  and	  Sadler81,	  but	  some	  of	  
the	  key	  methods	  used	  are	  mentioned	  here.	  There	  are	  two	  types	  of	  targeting:	  active	  
and	  passive.	  Active	   targeting	   and	  delivery	   relies	   upon	   the	   interaction	  of	   the	  drug	  





with	   biomolecules	   or	   biomarkers	   indicative	   of	   the	   cancerous	   state	   of	   the	   cell.	  
Passive	   drug	   delivery	   is	   dependent	   on	   the	   enhanced	   permeability	   and	   retention	  
effect	  of	  cancerous	  tissues.82	  
Active	  targeting	  can	  involve	  many	  different	  strategies.	  Functionalising	  a	  drug	  
molecule	  with	  hormones	  such	  as	  oestrogen	  allows	  drugs	  to	  target	  specific	  types	  of	  
cancer	   such	   as	   oestrogen-­‐positive	   breast	   cancers.	   The	   rapid	   proliferation	   rate	   of	  
cancer	  cells	  means	   that	   they	   take	  up	   large	  amounts	  of	   sugars	  and	  carbohydrates.	  
Some	  drugs	  utilise	   this	   to	   increase	   cellular	   accumulation	  of	   a	  drug	  by	  attaching	  a	  
sugar	   residue.83	   Using	   cell-­‐penetrating	   peptides	   has	   also	   proven	   effective	   in	  
increasing	  drug	  activity.84–86	  
Passive	   targeting	   and	   delivery	   takes	   advantage	   of	   the	   poor	   vasculature	  
structure	   of	   tumour	   tissue	   and	   the	   unique	   microenvironment	   that	   exists	   there.	  
These	  ‘leaky’	  cancer	  cells	  can	  allow	  larger	  molecules	  such	  as	  functionalised	  carbon	  
nanotubes	   to	   enter,	   i.e.	   would	   not	   normally	   be	   able	   to	   do	   so.87	   Functionalised	  
nanoparticles,88,89	   dendritic	   structures90	   and	   liposomal	   encapsulations91	   of	   drugs	  
have	  also	  increased	  the	  potency	  of	  some	  complexes.	  Within	  solid	  tumours	  hypoxic	  
conditions	  that	  lower	  the	  pH	  of	  the	  cells.92	  Prodrugs,	  inactive	  forms	  of	  a	  drug	  that	  
are	   activated	  within	   the	  body,	   can	  utilise	   these	   conditions	   to	   ensure	   activation	   is	  
more	  likely	  to	  occur	  within	  cancer	  cells,	  or	  in	  the	  tumour	  microenvironment.	  	  
Platinum(IV)	   complexes	   can	   also	   act	   as	   prodrugs.	   They	   are	   less	   reactive	  
towards	  substitution	  reactions	  than	  their	  Pt(II)	  analogues,	  lowering	  the	  likelihood	  of	  
unwanted	   and	   harmful	   side	   reactions.93	   Within	   the	   body,	   Pt(IV)	   prodrugs	   are	  
reduced	   to	   form	   cytotoxic	   Pt(II)	   complexes.	   The	   increased	   number	   of	   ligands	   on	  





octahedral	  Pt(IV)	  complexes	  gives	  the	  opportunity	  to	  further	  tune	  the	  properties	  of	  
the	  complex	  to	  improve	  activity,	  uptake	  and	  targeting.94	  
Many	  of	   these	  Pt(IV)	  drugs	  have	  shown	  activity	  across	  tumour	  cancer	  cells	  
(Figure	   1.16),	   but	   only	   a	   few	   have	   reached	   the	   clinic:	   tetraplatin	   (phase	   I)	   and	  
iproplatin	   (phase	   III)	   were	   abandoned	   due	   to	   severe	   side	   effects	   and	   lack	   of	  
significant	   efficacy,	   respectively,	   but	   LA-­‐12	   completed	   phase	   I	   clinical	   trials,	   and	  
satraplatin	   has	   entered	   phase	   III	   clinical	   trials;	   oxoplatin	   has	   also	   been	   tested	   in	  
clinical	   trials.95,96	   The	   majority	   of	   the	   Pt(IV)	   complexes	   in	   Figure	   1.16	   rely	   upon	  
reducing	   agents	   such	   as	   glutathione	   or	   ascorbic	   acid	   within	   the	   cell	   to	   form	   the	  
active	  Pt(II)	  drug.	  Mitaplatin	  takes	  this	  one	  step	  further	  and	  combines	  two	  known	  




















































Figure	  1.16	  Structures	  of	  Pt(IV)	  prodrugs.	  
	  





The	  majority	  of	  studies	  into	  Pt(IV)	  complexes	  and	  DNA	  are	  based	  on	  either	  
their	   reaction	   with	   free	   nucleobases	   or	   the	   binding	   properties	   of	   their	   Pt(II)	  
metabolites.97–101	   The	   emphasis	   has	   been	   more	   on	   using	   the	   metabolites	   of	   the	  
Pt(IV)	  prodrugs	   rather	   than	   the	   complexes	   themselves,	   although	   some	   studies	  on	  
Pt(IV)-­‐DNA	   complexes	   have	   been	   carried	   out,	   and	   even	   when	   starting	   with	   the	  
Pt(IV)	   drug	   the	   binding	   was	   found	   to	   be	   similar	   to	   that	   of	   their	   Pt(II)	  
counterparts.100,97,102	  	  
	  
1.2.2.3	  Photoactivation	  of	  platinum	  complexes	  
The	   Pt(IV)	   prodrug	   strategy	   may	   decrease	   adverse	   side-­‐effects,	   but	   this	  
reliance	  upon	   intracellular	   reduction	   is	  not	   the	  most	   reliable	  method	  of	   targeting	  
and	  can	  probably	  be	  improved	  upon.	  The	  use	  of	  light	  as	  a	  method	  of	  activation	  via	  
photoreduction	   offers	   spatial	   and	   temporal	   resolution	   to	   increase	   the	   targeting	  
ability	  of	  Pt(IV)	  prodrugs.	  	  
The	   first	  Pt(IV)	  photoactivatable	  complexes	   reported	  contained	   two	   iodido	  
ligands	   in	   order	   to	   achieve	   the	   reduction	   to	   Pt(II)	   by	   excitation	   of	   the	   ligand-­‐to-­‐
metal	   charge-­‐transfer	   bands.103	   An	   example	   of	   these	   compounds,	   trans,cis,cis-­‐
[Pt(OCOCH3)2(ethylenediamine)2(I)2],	   is	   shown	   in	   Figure	   1.17.	   It	   is	   essential	   for	   all	  
light-­‐activated	  drugs	  to	  show	  minimal	  or	  preferably	  no	  dark	  toxicity.	  Unfortunately,	  
diiodido	   Pt(IV)	   complexes	   only	   show	   a	   small	   difference	   between	   light	   and	   dark	  
toxicities	  as	  a	  consequence	  of	  reduction	  by	  intracellular	  thiols.104,103	  	  























Figure	  1.17	  Structures	  of	  early	  photoactivaetable	  Pt(IV)	  prodrugs.	  
	  
The	  Sadler	  group	  has	  developed	  this	  class	  of	  complex,	  replacing	  the	   iodido	  
ligands	  with	  azido	   ligands.	  The	  stability	   in	   the	  dark	  of	   these	  compounds	   is	   further	  
increased	  by	  using	  trans-­‐OH	  ligands.105	  These	  compounds	  have	  shown	  high	  activity	  
in	   human	   cancer	   cells	   upon	   photoactivation	  with	   UVA.	  With	   an	   ability	   to	   achieve	  
specific	   temporal	   and	   spatial	   activation,	   combined	  with	   tuning	   the	   activity	   of	   the	  
complexes	   by	   changing	   the	   am(m)ine	   ligands,	   Pt(IV)	   diazido	   complexes	   provide	  
interesting	  potential	  new	  anticancer	  drugs	  .106	  
There	   have	   been	   some	   previous	   studies	   on	   the	   photoreduction	   of	   Pt(IV)	  	  
azides	  and	  their	  subsequent	  interaction	  with	  both	  nucleobases	  and	  duplex	  DNA.107–
110	  The	  creation	  of	  photoproducts	  after	  irradiation	  with	  UVA	  was	  noted	  by	  the	  loss	  
of	   the	   azide-­‐to-­‐platinum	   LMCT	   band	   using	   UV-­‐Vis	   spectroscopy.	   For	   some	  
compounds,	   a	   peak	   assigned	   to	   a	  mono-­‐azido	   species	  was	   observed,	  which	   then	  
decreased	  upon	   further	   irradiation.	  NMR	  studies	   show	   that	  when	   left	   in	   the	  dark	  
these	  Pt(IV)complexes	  are	  stable	  (>	  5	  months),	  even	  in	  the	  presence	  of	  guanosine	  





monophosphate	   (GMP).111	   Irradiation	   in	   aqueous	   solution	   in	   the	   absence	   of	  
reducing	  agents	  or	  nucleobases	  can	  produce	  Pt(II)	  hydroxides	  which	  precipitate,	  but	  
in	  the	  presence	  of	  GMP,	  Pt(II)-­‐GMP	  mono-­‐	  and	  bis-­‐adducts	  are	  readily	  formed.107–
110	  The	  formation	  of	  bis-­‐adducts	  suggests	  that,	  like	  Pt(II)	  drugs,	  these	  complexes	  can	  
form	  DNA	  crosslinks,	  and	  this	  could	  be	  the	  cause	  of	  their	  cytotoxicities.	  The	  toxicity	  
of	   these	   complexes	  may	   also	   be	   increased	   by	   the	   release	   of	   azide	   radicals	   upon	  
photoactivation.112	  
	  
1.3	  Photodynamic	  therapy	  (PDT)	  
The	  use	  of	  light	  in	  the	  treatment	  of	  cancer	  is	  is	  well	  established	  in	  the	  clinic	  
in	   the	   form	   of	   photodynamic	   therapy	   (PDT).	   PDT	   uses	   photosensitisers	   such	   as	  
porphryin	  derivatives,	  e.g.	  the	  licenced	  drug	  Photofrin®.113	  Photosensitizers	  usually	  
use	  light	  to	  generate	  singlet	  oxygen	  (1O2)	  and	  radicals	  that	  cause	  cell	  damage.114,115	  
The	  mechanism	  by	  which	  photosensitisers	  generate	  free	  radicals	  and	  singlet	  oxygen	  
is	  shown	  in	  Figure	  1.18.	  The	  main	  pathway	  of	  cellular	  damage	  is	  the	  generation	  of	  
singlet	  oxygen.116	  






















Figure	   1.18	   The	  mechanism	   by	  which	   an	   excited	   photosensitiser	   induces	   cellular	  
damage	  and	  ultimately	  cell	  death.	  Adapted	  from	  Yoon	  et	  al.116	  
	  
This	  form	  of	  treatment	  uses	  red	  light	  (600	  -­‐	  850	  nm)	  to	  achieve	  penetration	  
deep	   into	   the	   tissue,	   as	   shown	   in	   Figure	   1.19.	   Photodynamic	   therapy	   does,	  
however,	   have	   its	   drawbacks	   due	   to	   its	   reliance	   on	   the	   presence	   of	   O2.	   Solid	  
tumours	   are	   often	   poorly	   vascularised	   resulting	   in	   a	   hypoxic	   tumour	  
microenvironment.92	  	  

















Figure	   1.19	  Diagram	  of	   the	  penetration	  of	   light	   into	  human	   tissue.	  Adapted	   from	  
values	  given	  by	  Balaz	  et	  al.117	  
	  
1.3.1	  Light	  delivery:	  Photonic	  crystal	  fibres	  (PCFs)	  
The	  excitation	  of	  photoactivatable	  drugs	  can	  be	  achieved	  using	  various	  light	  
sources,	  including	  LEDs	  and	  lasers	  that	  can	  then	  be	  guided	  to	  the	  tumour	  site	  using	  
fibre	   optics.	   One	   development	   in	   the	   field	   of	   fibre	   optics	   in	   the	   last	   couple	   of	  
decades	  is	  the	  introduction	  of	  photonic	  crystal	  fibres	  (PCFs).	  
Photonic	  crystal	  fibres	  are	  optical	  fibres	  that	  have	  unusual	  properties.	  They	  
contain	  a	  core	  surrounded	  by	  a	  lattice	  structure.	  The	  gaps	  within	  the	  lattice	  are	  of	  
the	  order	  of	  the	  wavelength	  of	  light	  that	  the	  fibre	  is	  intended	  to	  focus,	  and	  can	  use	  
photonic	   band	   gaps	   as	   a	   waveguide	   mechanism.118–120	   When	   light	   is	   correctly	  





focused	   into	   the	   fibre,	   the	   losses	  of	   light	  along	   the	   fibre	  as	   it	  guides	   the	   light	  are	  
very	  small.	  
There	   are	   four	   main	   types	   of	   PCF	   structure,	   see	   Figure	   1.20,	   solid	   core,	  
suspended	   core,	   hollow-­‐core	  photonic	   band	   gap	   and	  Kagmoé.121	   The	   structure	  of	  
the	   fibre	   is	   determined	   by	   stacking	   very	   high-­‐grade	   silica	   capillaries	   in	   a	  
macroscopic	   version	  of	   the	  desired	   formation.	   The	   glass	   is	   then	  heated	   to	   a	   very	  
high	  temperature	  and	  drawn	  out	  into	  fibres	  tens	  of	  micrometres	  thick.	  
Previously,	   these	   fibers	   have	   been	   used	   in	   gas	   sensing,	   fluorescence	  
detection,	  absorption	  spectroscopy	  and	  as	  vessels	  for	  catalytic	  reactions.	  A	  hollow-­‐
core	  fibre	  was	  used	  as	  a	  kind	  of	  very	  long	  pathlength	  cuvette	  allowing	  the	  detection	  
of	   species	   at	  much	   lower	   concentrations	   than	   conventional	  UV-­‐Visible	  absorption	  
spectroscopy	   and	   using	   very	   small	   sample	   volumes	   (1	   µL).122	   Reduced	   sample	  
volumes	  and	  high	  optical	  powers	  are	  the	  two	  main	  advantages	  of	  these	  fibres	  over	  
conventional	  irradiation	  methods.	  Those	  fibres	  that	  are	  of	  most	  interest	  for	  solution	  
chemistry	  are	  the	  hollow	  core,	  the	  Kagomé	  and	  the	  suspended	  core	  fibre,	  as	  they	  
allow	  for	  a	  large	  overlap	  between	  the	  sample	  and	  the	  light	  guided	  within	  the	  fibre.	  
A" B" C" D" 	  
Figure	  1.20	  Schematics	  of	  the	  structures	  of	  four	  types	  of	  PCF:	  (A)	  solid	  core,	  (B)	  
suspended	  core,	  (C)	  hollow-­‐core	  photonic	  band	  gap	  and	  (D)	  Kagmoé.121 
	  





1.4	  Organometallic	  drugs	  
The	  search	  for	  new,	  effective	  metal-­‐based	  drugs	  that	  have	  a	  different	  range	  
of	   activity	   compared	   to	   cisplatin	   and	   without	   the	   side-­‐effects	   associated	   with	  
conventional	  platinum	  drugs,	  has	  led	  to	  the	  synthesis	  of	  new	  structures.	  Several	  of	  
these	  new	  complexes	  are	  organometallic	   in	  nature	  and	  contain	  a	  metal	   ion	  other	  
than	  those	  of	  platinum.	  
1.4.1	  Ruthenium	  complexes	  
Ruthenium	  drugs	  were	  one	  of	  the	  first	  platinum	  alternatives	  to	  be	  reported,	  
since	  Ru(II)	  and	  Ru(III)	  have	  similar	  ligand	  substitution	  kinetics	  to	  those	  of	  Pt(II).123	  
The	  anticancer	  properties	  of	  Ru	  complexes,	  e.g.	  cis-­‐[Ru(NH3)4Cl2],	  were	  first	  tested	  
by	  Clarke	  et	  al.	   in	   the	   late	  1970s.124	  A	   lack	  of	   aqueous	   solubility	  prevented	   these	  
complexes	   from	   reaching	   the	   clinic.	   However,	   since	   then	   several	   Ru-­‐based	  
complexes	   have	   entered	   clinical	   trials.	   The	   complexes	   KP1019,	   indazolium	   [trans-­‐
tetrachlorobis(1H-­‐indazole)ruthenate(III)],	   and	   NAMI-­‐A,	   imidazolium	   trans-­‐
[tetrachloro-­‐(S-­‐dimethyl-­‐sulfoxide)	   1H-­‐(imidazole)ruthenate(III)],	   have	   both	  
reached	  phase	  II	  clinical	  trials,	  see	  Figure	  1.21.125–127	  





























Figure	   1.21	   Structures	   of	   KP1019	   and	   NMAI-­‐A,	   two	   Ru-­‐based	   drugs	   that	   have	  
reached	  phase	  II	  clinical	  trials.	  
	  
There	  are	  many	  other	  ruthenium	  complexes	  that	  have	  shown	  high	  activity	  in	  
cancer	  cell	   screening.	  Two	  types	  of	   ruthenium-­‐based	  complexes	   that	  have	  proved	  
to	  be	  particularly	  successful	  in	  cell	  studies	  are	  the	  RAPTA	  complexes	  from	  the	  Dyson	  
laboratory,128	  and	  another	  class	  of	   the	   the	  so	  called	   ‘piano	  stool’	   complexes	   from	  
the	   Sadler	   group.129	   Examples	   of	   these	   are	   shown	   in	   Figure	   1.22:	   RAPTA-­‐C,	   [(η6-­‐
para-­‐cymene)Ru(P-­‐1,3,5-­‐triaza-­‐7-­‐phospha-­‐tricyclo-­‐[3.3.1.1]decane))Cl2],	   and	  
complex	  A	   [(η6-­‐biphenyl)Ru(ethynediamine)Cl]+.	  Both	  of	   these	   types	  of	   complexes	  
are	  prone	  to	  hydrolysis	  and	  subsequently	  bind	  to	  DNA.130–132	  	  
New	   structures	   of	   complexes	   of	   the	   type	   developed	   by	   the	   Sadler	   group	  
allow	   not	   just	   for	   direct	   coordination	   of	   the	   complex	   to	  DNA,	   but	   also	   for	   ligand	  
intercalation	  and	  hydrogen	  bonding	  with	  the	  DNA.133	  As	  well	  as	  being	  important	  in	  





terms	  of	  hydrolysis,	  the	  monodentate	  leaving	  group	  of	  the	  ‘piano-­‐stool’	  complexes	  












Figure	  1.22	  Structures	  of	  active	  ruthenium	  complexes	  from	  the	  Sadler	  laboratory,	  A	  
[(η6-­‐biphenyl)Ru(ethlynediamine)Cl]+,	  and	  a	  complex	  from	  the	  Dyson	  laboratory,	  B	  
RATA-­‐C[(η6-­‐para-­‐cymene)Ru(P-­‐1,3,5-­‐triaza-­‐7-­‐phospha-­‐tricyclo-­‐[3.3.1.1]decane))Cl2].	  
	  
The	   chelating	   ligand	   of	   A	   has	   also	   been	   altered	   to	   include	   azopyridines,	  
increasing	  the	   lability	  of	  the	  arene	   ligand	  when	  compared	  to	  the	  ethylenediamine	  
analogue,131	  and	  even	  to	  O,O-­‐chelating	  ligands.135	  It	  was	  also	  found	  that	  increasing	  
the	   size	   of	   the	   arene	   ligand	   (e.g.	   to	   anthracene	  derivatives)	   has	   led	   to	   increasing	  
anticancer	  activity,	  this	  maybe	  due	  to	  increased	  DNA	  intercalation.	  
1.4.2	  Osmium	  and	  iridium	  complexes	  
Within	   the	   Sadler	   group	   the	   ‘piano	   stool’	   structure	   has	   been	   exploited	  
further	   to	   include	   osmium(II)	   arene	   and	   iridium(III)	   cyclopentadienyl	   complexes.	  
There	   are	   many	   similarities	   between	   osmium	   and	   ruthenium	   complexes,	   for	  
example	   altering	   the	   monodentate	   leaving	   group	   can	   have	   a	   similar	   effect	   on	  
complexes	   containing	   these	  metals.134	   However,	   some	   osmium-­‐based	   drugs	   have	  
been	  shown	  to	  be	  more	  potent	  in	  cell	   line	  testing	  than	  their	  ruthenium	  analogues	  





by	   an	   order	   of	   magnitude.136	   This	   may	   be	   ascribable	   to	   a	   difference	   in	   the	  
mechanism	   of	   action	   of	   the	   two	   drugs,	   likely	   due	   to	   their	   very	   different	   ligand	  
substitution	  kinetics.	  As	  well	   as	  binding	   to	  DNA,	  osmium	  complexes	   can	  generate	  
reactive	   oxygen	   species	   (ROS)	   that	   damage	   cells.137,138	   Transmission	   electron	  
microscopy	   studies	   found	   that	   osmium	  drugs	   induced	  mitochondrial	   swelling	   and	  
morphological	  changes	  in	  cancer	  cells,	  this	  observation	  suggests	  that	  mitochondrial	  
apoptotic	  pathways	  may	  be	   implicated	   in	  cell	  death.137	  Osmium	  arene	  drugs	  have	  
also	  been	  shown	  to	  be	  active	  in	  vivo	  with	  negligible	  toxicity.139	  
Iridium(III)	  ‘piano	  stool’	  complexes	  with	  N,N	  -­‐	  and	  C,N	  -­‐	  chelating	  ligands	  are	  
highly	   potent	   against	   cancer	   cells	   achieving	   sub-­‐micromolar	   activity.140	   The	  
cyclopentadienyl	   ligands,	   used	   instead	   of	   the	   arene	   ligands	   in	   the	   Ru	   and	   Os	  
complexes,	  have	  been	  shown	  to	  be	  important	  to	  hydrophobicity,	  DNA	  intercalation	  
and	   can	   also	   increase	   the	   lability	   of	   the	   monodentate	   leaving	   group.141	   Iridium	  
complexes,	   along	   with	   some	   ruthenium	   complexes,	   can	   possess	   catalytic	   activity	  
towards	  NADH	  which	  might	   affect	   the	   redox	  potential	   of	   a	   cell,	   possibly	   inducing	  
oxidative	  stress	  and	  causing	  cell	  death	  in	  this	  manner.142,143	  
	  
1.5	  Analytical	  techniques	  for	  the	  study	  of	  metal-­‐based	  drugs	  
In	  this	  section,	  the	  methods	  used	  here	  for	  studying	  metal-­‐based	  anticancer	  
drugs	  and	  their	  interactions	  with	  biomolecules	  are	  described.	  
	  
	  





1.5.1	  UV-­‐Visible	  spectroscopy	  
UV-­‐Visible	   spectroscopy	   is	   an	   optical	   technique	   that	   gives	   insight	   into	   the	  
electronic	   structure	   of	   a	   molecule.	   The	   molecule	   absorbs	   a	   photon	   of	   light,	  
promoting	  an	  electron	   from	   the	  ground	   state	   to	   an	  excited	   state.	   The	  amount	  of	  
energy	   absorbed	   is	   indicative	   of	   the	   separation	   of	   the	   two	   energy	   levels.	  Within	  
metal	  complexes	  there	  are	  three	  main	  types	  of	  these	  electronic	  transitions:	  	  
• Ligand	   field	   transitions,	   also	   known	   as	   metal	   centred	   transitions,	   are	  
excitations	  of	  electrons	  from	  one	  metal	  orbital	  to	  another	  metal	  orbital.	  
Examples	  are	  d-­‐d	  transitions	  which	  are	  relatively	  weak.	  
• Ligand-­‐to-­‐metal	  charge	  transfer	  or	  metal-­‐to-­‐ligand	  charge	  transfer	  refers	  
to	   transitions	   from	   ligand-­‐to-­‐metal	   or	   from	  metal-­‐to-­‐ligand.	   These	   are	  
usually	  much	  stronger	  absorption	  bands.	  
• Intra-­‐ligand	   transitions	   are	   those	   transitions	   that	   take	   place	   only	   from	  
one	  ligand	  orbital	  to	  another.	  
The	   highly	   absorbing	   properties	   of	   metal	   complexes	   and	   the	   ability	   to	   study	  
individual	   electronic	   transitions	   renders	   UV-­‐Vis	   absorption	   spectroscopy	   a	   very	  
useful	   tool	   for	  analysing	  metal	  complexes.	  Mackay	  et	  al.	  used	  these	  properties	   to	  
great	  effect	  whe	  studying	  the	  behaviour	  of	  photoactivatable	  Pt(IV)	  complexes,	  and	  
are	  able	  to	  monitor	  the	  dissociation	  of	  the	  azide	  ligands	  by	  following	  the	  intensity	  
of	  the	  LMCT	  band.109	  
The	   Beer-­‐Lambert	   law	   relates	   the	   absorption	   of	   a	   molecule	   to	   its	  
concentration,	  Equation	  1,	  where	  A	  is	  absorbance,	  I0	  and	  I	  are	  the	  intensities	  of	  the	  





incident	  and	  transmitted	  light,	  respectively,	  c	  is	  concentration,	  l	  is	  the	  pathlength	  of	  
the	  light,	  and	  ε is	  the	  molar	  absorptivity	  or	  extinction	  coefficient.	  This	  formula	  can	  
be	   used	   to	   determine	   the	   concentrations	   of	   species	   with	   known	   extinction	  
coefficients	  that	  would	  otherwise	  be	  difficult	  to	  measure,	  e.g.	  proteins	  and	  DNA.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1)	  
	  
1.5.2	  High-­‐performance	  liquid	  chromatography	  (HPLC)	  
High-­‐performance	   liquid	   chromatography	   forces	   solvent	   through	  a	   column	  
filled	   with	   extremely	   fine	   particles	   at	   high	   pressure,	   resulting	   in	   highly-­‐resolved	  
separations.144,145	  Liquid	  chromatography	  uses	  columns	  packed	  with	  small	  particles	  
to	  increase	  the	  rate	  of	  equilibration	  of	  the	  analyte	  between	  stationary	  and	  mobile	  
phases,	   and	   thereby	   increasing	   the	   efficiency	   of	   the	   separation.	   The	   term	  mobile	  
phase	   refers	   to	   the	   solvent	   passed	   through	   the	   HPLC	   system,	   and	   the	   term	  
stationary	  phase	   refers	   to	   the	   functionalised	  particles	  within	   the	   column	   that	   the	  
solvent	   passes	   over.	   The	   smaller	   the	   particles	   of	   the	   stationary	   phase,	   the	  more	  
efficient	   the	   column,	   the	   lower	   the	  detection	   limit	   and	   the	   faster	   the	   separation.	  
However,	   with	   decreasing	   particle	   size,	   resistance	   to	   the	   flow	   of	   solvent	   also	  
increases,	  causing	  the	  pressure	  to	  rise.	  Hence	  pumps	  and	  high-­‐pressure	  fittings	  are	  
required	  for	  the	  mobile	  phase	  to	  flow	  through	  an	  HPLC	  system.	  
The	   stationary	   phase	   support	   used	   in	   most	   HPLC	   columns	   is	   silica.	   The	  
particle	   sizes	   are	   typically	   3	   -­‐	   5	   μm	   in	   diameter,	   and	   are	   smaller	   for	   ultra-­‐high	  
pressure	  chromatography.	  Depending	  on	  the	  desired	  type	  of	  separation,	  these	  silica	  





particles	   can	   be	   functionalised	   with	   different	   groups	   to	   provide	   separation	   of	  
almost	  any	  type	  of	  analyte.	  These	  groups	  can	  be	  functionalised	  by	  chains	  of	  sugars	  
for	   chiral	   separation,	   or	   more	   commonly	   just	   carbon	   chains	   of	   various	   lengths,	  
depending	  on	  the	  size	  of	  the	  molecules	  in	  the	  sample	  (the	  larger	  the	  molecule,	  the	  
smaller	  the	  chain)	  for	  polarity-­‐based	  separations.	  
The	  majority	  of	  HPLC	  analysis	   is	  carried	  out	   in	  what	   is	  called	   the	   ‘reversed	  
phase’,	  in	  this	  case	  the	  particles	  are	  functionalised	  with	  hydrophobic	  groups,	  and	  a	  
hydrophilic	   solvent	   is	   used	   as	   themobile	   phase.	   This	   type	   of	   chromatography	   is	  
more	  popular	  since	  it	  can	  easily	  be	  applied	  to	  water-­‐soluble	  analytes,	  and	  typically	  
in	   more	   biologically-­‐relevant	   conditions.	   The	   opposite	   configuration	   is	   also	   used,	  
with	  a	  hydrophilic	  stationary	  phase	  and	  a	  hydrophobic	  mobile	  phase.	  This	  is	  useful	  
for	   the	   anaylsis	   of	   compounds	  with	   poor	  water	   solubility.	   An	   illustration	   of	   both	  









Figure	   1.23	  An	   illustration	  of	   stationary	   (SP)	   and	  mobile	   phases	   (MP)	   in	   reversed	  
and	  normal	  phase	  HPLC.	  
	  
Chromatography	   has	   been	   widely	   used	   in	   the	   study	   of	   metal	   complexes,	   from	  
characterisation	   and	   purification	   of	   the	   complexes,146–148	   monitoring	   reactions	   with	  





biomolecules,149,150	   analysis	   of	   enzymatic	   digestions	   of	   proteins	   and	   DNA,151,50	   and	   the	  
coupling	   of	   HPLC	   to	   mass	   spectrometry152	   or	   inductively-­‐coupled	   plasma	   mass	  
spectrometry	  (ICP-­‐MS)	  in	  order	  to	  characterise	  species	  and	  determine	  metal	  contents.153,154	  
	  
1.5.3	  Mass	  Spectrometry	  
Mass	  spectrometry	  (MS)	  is	  a	  technique	  used	  to	  measure	  the	  mass	  and	  give	  
insights	  into	  the	  structure	  of	  a	  given	  molecule.	  Molecules	  must	  be	  in	  the	  gas	  phase	  
for	  MS	   analysis	   and	   the	  must	   be	   ionised	   (either	   bofore	   or	   after	   entering	   the	   gas	  
phase).	  Usually	  an	  electric	   field	   is	  applied	   to	   the	  gaseous	   ions	   to	  accelerate	   them	  
and	  they	  are	  then	  separated	  by	  their	  mass	  to	  charge	  ratio	  (m/z).	  
There	   are	   many	   types	   of	   mass	   spectrometer	   arising	   from	   the	   different	  
combinations	  of	  ionisation	  and	  detection	  methods.	  Electron	  impact	  is	  a	  method	  of	  
ionisation	   for	   small	   volatile	   molecules	   that	   uses	   electrons	   to	   ‘knock	   off’	   other	  
electrons	   from	   the	  molecule	  of	   interest,	   creating	  a	  positively	   charged	   radical	   that	  
may	  undergo	  further	  transformations	   in	  the	  gas	  phase.	  Chemical	   ionisation	  uses	  a	  
reagent	   gas	   that	   is	   ionised	   and	   collided	  with	   the	   analyte	   transferring	   the	   charge.	  
Matrix-­‐assisted	  laser	  desorption	  (MALDI)	  uses	  laser	  light	  to	  vaporise	  the	  molecules	  
of	  the	  matrix	  containing	  the	  analyte.	  The	  matrix	  is	  designed	  to	  strongly	  absorb	  the	  
light	   of	   the	   laser,	   and	   it	   can	   then	   transfer	   its	   energy	   to	   the	   sample.	   A	   potential	  
difference	  is	  then	  applied	  to	  the	  plume	  of	  analyte	  and	  the	  sample	  becomes	  ionised.	  
This	  ionisation	  technique	  is	  much	  ‘softer’	  than	  those	  previously	  described,	  and	  can	  
be	  used	  for	  large	  molecules	  such	  as	  proteins.84,155	  





In	  the	  work	  carried	  out	  in	  this	  thesis,	  only	  electrospray	  ionisation	  (ESI)	  was	  
used.	  ESI	  is	  a	  very	  soft	  ionisation	  technique	  that	  requires	  a	  liquid	  sample	  input	  and	  
can	  be	  used	   for	   the	  analysis	  of	  small	   ions	  up	  to	   large	  proteins.	  Sample	  solution	   is	  
flowed	   through	   a	   capillary	   to	   the	   tip	  where	   a	   potential	   difference	   is	   applied.	   The	  
voltage	   applied	   partly	   determines	   the	   charge	   on	   the	   sample	   ions.	   The	   solution	  
forms	  charged	  droplets	  from	  which,	  with	  the	  aid	  of	  the	  sheath	  gas	  (typically	  N2),	  the	  
solvent	  molecules	  are	  evaporated.	  As	  the	  droplets	  shrink,	  the	  desolvation	  becomes	  
more	  rapid	  due	  to	  Coulombic	  forces	  that	  eventually	  overcome	  the	  cohesive	  forces	  
and	  the	  analyte	   is	  released	  from	  the	  droplet	  solvent-­‐free.155	  Figure	  1.24	  shows	  an	  
illustration	  of	  the	  process.	  
	  
Figure	  1.24	  An	  illustration	  of	  the	  electrospray	  ionisation	  process.156	  
	  
As	  mentioned	   above	   different	  methods	   of	   ionisation	   can	   be	   coupled	  with	  
different	  mass	  analysers,	  and	  either	  used	  on	  their	  own	  or	  in	  combination	  with	  each	  
other.	  The	  following	  mass	  analysers	  were	  used	  to	  obtain	  data	  in	  this	  thesis.	  	  
One	   of	   the	   simplest	   mass	   analysers	   is	   a	   quadrupole.	   It	   consists	   of	   four	  
parallel	   rods	   to	   which	   a	   constant	   voltage	   and	   an	   oscillating	   radio	   frequency	   are	  





applied	  to	  opposite	  pairs	  of	  rods.	  Ions	  pass	  through	  the	  rods	  and	  their	  direction	  of	  
travel	  is	  controlled	  by	  the	  frequencies	  applied	  to	  the	  rods.	  Hence,	  certain	  ions	  may	  
be	  excluded,	  depending	  on	  their	  m/z	  values.	  
Time-­‐of-­‐flight	   (TOF)	   analysers,	   as	   the	  name	   suggests,	   separate	   ions	  by	   the	  
time	   taken	   for	   them	   to	   travel	   through	   a	   high	   vacuum	   drift	   region	   within	   the	  
analyser	   called	   the	   drift	   region.	   Ions	   leave	   the	   ionisation	   chamber,	   and	   several	  
thousands	  of	   times	   a	   second	   a	   voltage	   is	   applied	   adjacent	   to	   the	   sample	   stream,	  
sending	  pulses	  of	  ions	  of	  the	  same	  kinetic	  energy	  into	  the	  drift	  region.	  The	  ions	  are	  
then	   separated	   by	   their	   mass-­‐to-­‐charge	   ratios.	   To	   improve	   the	   resolution,	   more	  
advanced	  instruments	  use	  a	  reflectron;	  this	  is	  a	  class	  of	  ion	  mirror	  that	  consists	  of	  
electrodes	   with	   progressively	   higher	   charges	   applied	   to	   them.	   This,	   in	   effect,	  
doubles	  the	  drift	  region	  and	  the	  resolving	  power	  of	  the	  analyser	  as	  well	  as	  focusing	  
ions	  of	  the	  same	  m/z.	  
An	   ion-­‐tap	  analyser	  shares	  some	  similarities	  with	   the	  quadrupole	  analyser.	  
Radio	  frequencies	  and	  applied	  voltages	  are	  used	  to	  select	   the	   ions.	  They	  are	  then	  
‘trapped’	  within	  the	  analyser	  and	  can	  accumulate	  before	  they	  are	  expelled	  towards	  
the	  detector.	  
Tandem	   mass	   spectrometry	   (MS/MS)	   is	   another	   technique	   used	   in	   the	  
course	   of	   this	   work.	   This	   term	   can	   be	   used	   to	   describe	   a	   number	   of	   ion	  
fragmentation	  techniques,	  but	  in	  this	  case	  it	  refers	  to	  collision-­‐induced	  dissociation	  
(CID).	   For	   this	   process	   an	   ion	   of	   interest	   in	   selected	   and	   isolated,	   often	   using	   a	  
quadrupole	   or	   an	   ion	   trap.	   An	   inert	   gas	   (in	   this	   case	   N2)	   is	   then	   introduced	   and	  
collisions	  with	  the	  gas	  fragment	  the	  ions.	  	  





In	   terms	   of	   application	   to	   the	   study	   of	   metal	   complexes,	   high-­‐resolution	  
mass	  spectrometry	  has	  been	  used	   for	   the	  characterisation	  of	  complexes,	   to	  study	  
their	   interaction	   with	   small	   biomolecules	   such	   as	   GSH,157	   their	   interactions	   with	  
proteins,158,159	  and	  their	  interactions	  with	  DNA.160–164	  
	  
Aims	  of	  this	  work	  
In	   order	   to	   understand	   the	   mechanisms	   of	   action	   of	   metallodrugs,	   it	   is	  
important	  to	  develop	  new	  methods	  for	  their	  characterisation,	  and	  in	  particular	  their	  
speciation	   in	   solution.	   It	   is	   not	  only	   important	   to	   identify	   target	   sites,	  but	   also	   to	  
determine	   the	  number	  and	   types	  of	   ligands	  which	  are	  bound	   to	   the	  metal	   at	   the	  
target	  site,	  and	  hence	  to	  determine	  how	  the	  initial	  ligands	  in	  the	  metallodrugs	  are	  
involved	  in	  activation	  and/or	  target	  reconition.	  
	  
The	  specific	  aims	  were	  as	  follows.	  
1. To	   use	   HPLC	   to	   characterise	   the	   lipophilicity	   of	   a	   series	   of	  
photoactivatable	   Pt(IV)	   anticancer	   complexes	   for	   which	   partition	  
coefficients	  could	  not	  readily	  be	  determined	  by	  conventional	  octanol-­‐water	  
shake	   flask	   methods,	   and	   to	   attempt	   to	   correlate	   their	   lipophilicity	   with	  
cancer	  cell	  uptake	  and	  biological	  activity.	  
2. To	  explore	  the	  use	  of	  chiral	  HPLC	  columns	  to	  separate	  enantiomers	  
of	  organometallic	  anticancer	  complexes,	  especially	  Ru(II)	  and	  Os(II)	  arenes,	  
and	   cyclopentadienyl	   Ir(III)	   complexes.	   Such	   separation	   is	   important	   for	  





biological	   testing	   and	   target	   site	   recognition,	   which	   can	   show	   a	   strong	  
dependence	  of	  the	  chirality	  of	  drugs.	  In	  particular,	  the	  aim	  was	  to	  examine	  
the	  stability	  of	  separated	  enantiomers	  and	  complexes	  with	  subtle	  difference	  
in	  structure	  such	  as	  facial	  chirality.	  
3. To	   explore	   the	   use	   of	   new	   methods	   involving	   the	   coupling	   of	  
photonic	  crystal	  fibres	  with	  high-­‐resolution	  mass	  spectrometry	  that	  may	  be	  
more	  efficient	  both	  in	  terms	  of	  the	  volume	  of	  analyte	  required	  (nanolitres),	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In	  this	  Chapter,	  ten	  photoactivatable	  platinum(IV)	  diazido	  complexes	  of	  the	  
general	   formula	   trans,trans,trans-­‐[Pt(N3)2(OH)2(R)(R’)]	   are	   discussed.	   The	  
lipophilicity	  of	  each	  complex	  is	  compared	  to	  its	   intracellular	  accumulation	  and	  IC50	  
values	   in	   A2780	   human	   ovarian	   cancer	   cells.	   The	   DNA	   binding	   of	   complex	  
trans,trans,trans-­‐[Pt(N3)2(OH)2(pyridine)2]	   is	   investigated	   by	   means	   of	   mass	  
spectrometry	  and	  chromatography.	  
	  
2.1	  Introduction	  	  
2.1.1	  Platinum-­‐based	  anticancer	  drugs	  	  
As	  discussed	  in	  Chapter	  1,	  platinum-­‐based	  drugs	  have	  a	  long	  and	  successful	  
history	   in	   anticancer	   therapy,	   first	   gaining	   FDA	   approval	   in	   1978.1	   Despite	   their	  
success	  they	  do	  suffer	  from	  two	  major	  drawbacks,	  namely	  severe	  side	  effects	  and	  
both	   intrinsic	   as	   well	   as	   acquired	   resistance	   of	   certain	   types	   of	   cancers.	   To	  
overcome	   these	   problems,	   new	   generations	   of	   platinum	   based	   drugs	   have	  
emerged.	  	  
In	  the	  Sadler	  group	  a	  new	  generation	  of	  potential	  platinum	  drugs	  are	  under	  
development	   that	   could	   overcome	   the	   problems	   of	   traditional	   platinum-­‐based	  
therapies,	  whilst	  retaining	  and	  even	  improving	  their	  efficacies.2	  The	  approach	  taken	  
utilises	   a	   Pt(IV)	   prodrug,	   a	   strategy	   that	   has	   been	   widely	   explored	   and	   has	   seen	  
Pt(IV)-­‐based	  complexes	  reach	  clinical	  trials.3,4	  These	  Pt(IV)	  prodrugs	  are	  reduced	  by	  
intracellular	  species	  to	  form	  a	  cytotoxic	  Pt(II)	  complex	  that	  has	  a	  similar	  mechanism	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of	   action	   to	   that	   of	   established	   platinum-­‐based	   agents.	   The	   method	   of	   Pt(IV)	  
reduction	  utilised	  by	   the	  Sadler	  group	   is	   light	  activation.	  This	  enables	  both	  spatial	  
and	   temporal	   resolution	   of	   the	   treatment,	   allowing	   only	   tumour	   tissue	   to	   be	  
targeted	  and	  hence,	  reducing	  any	  potentially	  harmful	  side	  effects	  in	  healthy	  cells.	  
Light	  activation	  is	  already	  in	  the	  clinic	  in	  the	  form	  of	  photodynamic	  therapy	  
(PDT).	   This	   treatment	   uses	   long	   wavelength	   light	   (600	   −	   850	   nm)	   to	   achieve	  
activation	   of	   the	   photosensitiser	   within	   the	   tumour.5,6	   This	   therapy	   is	   discussed	  
more	  fully	  in	  Section	  1.3	  of	  Chapter	  1.	  
2.1.2	  Platinum-­‐based	  anticancer	  drugs	  and	  their	  interaction	  with	  DNA	  
The	   DNA	   binding	   of	   platinum-­‐based	   drugs	   is	   key	   to	   their	   activity,	   and	  
therefore	  is	  an	  important	  area	  of	  study.	  The	  DNA	  damage	  induced	  by	  the	  platinum	  
drug	  is	  believed	  to	  attract	  intracellular	  proteins	  and	  cause	  the	  binding	  of	  the	  HMG1	  
region	  of	  proteins,	  triggering	  a	  signalling	  cascade	  that	  leads	  to	  apoptosis.	  	  
Mass	  spectrometry	  is	  a	  highly	  sensitive	  analytical	  technique.	  It	  is	  capable	  of	  
using	  very	  small	  sample	  volumes	  and	  low	  concentrations,	  allowing	  the	  observation	  
of	   species	   undetectable	   by	   other	   methods.	   Mass	   spectrometry	   has	   been	   widely	  
used	  in	  the	  past	  to	  study	  drug-­‐DNA	  interactions,	  including	  metal-­‐based	  drugs	  such	  
as	  cisplatin,	  and	  has	  proven	  to	  be	  very	  effective	  in	  determining	  the	  site	  of	  binding	  
and	  the	  structure	  of	  the	  adduct.7–9	  	  
To	   determine	   the	   binding	   site	   of	   the	   drug,	   tandem	   mass	   spectrometry	  
(MS/MS)	   is	   often	   used	   to	   fragment	   the	   DNA	   strand.	   These	   fragmentations	   are	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dependent	   upon	   whether	   the	   MS	   is	   in	   the	   positive	   or	   the	   negative	   mode,	   the	  
ionisation	  method,	   e.g.	   ESI	   and	  MALDI,	   and	   the	   type	  of	   fragmentation	  employed,	  
e.g.	  collision	  induced	  dissociation	  (CID).	  The	  nomenclature	  for	  the	  cleavages	  of	  the	  
oligonucleotide,	   shown	   in	   Figure	   2.1,	   is	   analogous	   to	   that	   widely	   used	   for	   the	  
fragmentation	   of	   peptide	   chains.10	   There	   are	   four	   possible	   cleavages	   of	   the	  
phosphate	  backbone,	   fragments	  containing	   the	  5’	   terminus	  of	   the	  oligonucleotide	  
are	   labelled	   a,	   b,	   c	   and	   d	   depending	   upon	   the	   position	   of	   the	   cleavage,	  with	   the	  
corresponding	   fragments	   w,	   x,	   y,	   and	   z	   containing	   the	   3’	   end	   of	   the	   strand.	   The	  
number	   of	   the	   fragment	   indicates	   how	   many	   bases	   from	   the	   terminus	   that	   the	  
cleavage	  occurred	  at.	  	  
	  
Figure	   2.1	  Nomenclature	   of	   oligonuclotide	   fragments	   caused	   by	   cleavage	   of	   the	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Complexes	   1-­‐10,	   8X	   and	   8Y	   were	   synthesised	   according	   to	   literature	  
procedures	  and	  characterised	  by	   1H	  NMR	  and	  elemental	  analysis.2,11–14	  The	  purity	  
and	  the	  24-­‐hour	  stability	  under	   low	  lighting	  conditions	  were	  determined	  by	  HPLC.	  
The	  purity	  of	  the	  complexes	  was	  determined	  as	  >	  96%	  for	  complexes	  1-­‐8,	  86%	  for	  9	  
and	  89%	  for	  10.	  The	  decrease	  in	  complex	  stability	  over	  24	  hours	  varied	  from	  ≤	  5%	  
decomposition	  for	  1,2,5,6	  and	  8,	  5-­‐10%	  for	  4	  and	  10,	  and	  15-­‐17%	  for	  3,	  7	  and	  9	  as	  
determined	  by	  chromatogram	  peak	  areas	  (see	  Appendix	  II).	  	  
HPLC	   grade	   methanol	   and	   water	   for	   HPLC	   mobile	   phase	   were	   purchased	  
from	   Fisher	   Scientific.	   Trifluoracetic	   acid	   (TFA),	   spectrophotometric	   grade	   (99+%),	  
was	  purchased	  from	  Sigma-­‐Aldrich.	  Unless	  otherwise	  stated,	  all	  of	  the	  water	  used	  
was	   doubly	   deionised	   water	   (DDW,	   with	   the	   exception	   of	   that	   used	   for	   HPLC),	  
purified	  using	  a	  Multipore	  Milli	  Q	  and	  a	  USF	  Elga	  UHQ	  water	  deioniser.	  Omix	  pipette	  
tips	   for	  micro	  extraction	  were	  purchased	  from	  Varian	   Inc.	  Amicon	  Stirred	  Cell	  and	  
regenerated	   cellulose	   ultrafiltration	  membranes	   (25	  mm	  diameter,	   1	   kDa	   cut-­‐off)	  
were	  purchased	  from	  Millipore.	  
Oligonucleotides.	   All	   oligonucleotides	   were	   purchased	   from	   DNA	  
Technology	  A/S	  (Denmark),	  with	  sodium	  as	  the	  counter	  ion,	  and	  were	  purified	  twice	  
by	   reversed-­‐phase	   high	   performance	   liquid	   chromatography	   (RP-­‐HPLC).	   All	   of	   the	  
oligonucleotides	  used	  in	  these	  experiments	  were	  subject	  to	  in-­‐house	  quality	  control	  
checks.	  Quantification	  of	   these	  agents	  was	  carried	  out	  using	  UV-­‐Vis	   spectroscopy,	  
Chapter	  2	  -­‐	  Chapter	  2	  The	  interaction	  of	  photoactivatable	  Pt(IV)	  complexes	  with	  





recording	  the	  absorbance	  at	  260	  nm	  of	  a	  dilution	  of	  the	  stock	  sample	  and	  using	  the	  
Beer-­‐Lambert	   law	   to	   calculate	   the	   concentration	   of	   the	   original	   solution.	   The	  
extinction	   coefficients	  were	   calculated	  with	   software	  using	  base	   composition	   and	  
nearest	   neighbour	   models:15	   oilgo	   1	   ε260	   nm	   =	   145,100	   M-­‐1cm-­‐1,	   oligo2	   ε260	   nm	   =	  
149800	  M-­‐1cm-­‐1,	  and	  oligo	  3	  ε260	  nm	  =	  143,000	  M-­‐1cm-­‐1.	  Mass	  spectrometry	  and	  HPLC	  




2.2.2.1	  Cellular	  uptake	  of	  Pt(IV)-­‐diazido	  complexes	  and	  platinum	  content	  
determination.	  
All	  of	  the	  work	  related	  to	  the	  culturing	  of	  cells,	  platinum	  accumulation	  studies	  and	  
platinum	  detection	  by	  ICP-­‐MS	  was	  carried	  out	  by	  Dr	  Ana	  Pizarro.	  
2.2.2.1.1	  Cell	  Culture	  
The	  A2780	  ovarian	  cancer	  cell	  line	  was	  obtained	  from	  the	  ECACC	  (European	  
Collection	  of	  Animal	  Cell	  Culture,	  Salisbury,	  UK).	  The	  cells	  were	  maintained	  in	  RPMI	  
1640	  media,	  which	  was	  supplemented	  with	  10%	  foetal	  calf	  serum,	  1%	  L-­‐glutamine,	  
and	   1%	   penicillin/streptomycin.	   All	   cells	   were	   grown	   at	   310	   K	   in	   a	   humidified	  
atmosphere	  containing	  5%	  CO2.	  
	  
	  
Chapter	  2	  -­‐	  Chapter	  2	  The	  interaction	  of	  photoactivatable	  Pt(IV)	  complexes	  with	  





2.2.2.1.2	  Platinum	  Accumulation	  in	  A2780	  Human	  Ovarian	  Carcinoma	  Cells	  	  
A2780	  cells	  were	  plated	  at	  a	  density	  of	  5x106	  cells/100	  mm	  Petri	  dish	  in	  10	  
mL	   of	   culture	   medium	   (three	   dishes	   were	   prepared	   per	   compound	   tested,	   and	  
three	  untreated	  control	  dishes).	  After	  24	  h	  incubation,	  cells	  were	  treated	  with	  the	  
Pt(IV)	   complexes	   and	   cisplatin	   for	   1	   h	   in	   the	   dark.	   Solutions	   of	   the	   platinum	  
compounds	   (100	  µM)	  were	   prepared	   in	   0.9%	   (w/v)	   saline	   and	   fresh	  media	   (1:10)	  
containing	   1%	   (v/v)	   DMSO.	   After	   1	   h	   of	   drug	   exposure	   at	   310	   K	   on	   a	   5%	   CO2	  
incubator,	   the	   drug-­‐containing	   medium	   was	   removed,	   and	   the	   cell	   monolayers	  
were	   washed	   with	   warm	   PBS	   twice,	   trypsinised,	   harvested	   and	   counted	   using	   a	  
haemocytometer	  in	  the	  dark.	  The	  cells	  were	  centrifuged,	  quickly	  washed	  with	  cold	  
PBS,	   and	   the	   cell	   pellets	   were	   stored	   at	   253	   K	   for	   determination	   of	   total	   cell	  
accumulation	  (the	  net	  effect	  of	  uptake	  and	  efflux)	  of	  platinum	  in	  the	  dark.	  The	  cell	  
pellets	  were	  digested	  in	  freshly	  distilled	  72%	  (w/v)	  HNO3	  in	  Wheaton	  V-­‐Vials	  with	  a	  
PTFE-­‐faced	   rubber-­‐lined	   cap	   (Sigma-­‐Aldrich)	   for	   16	   h	   at	   373	   K.	   After	   they	   were	  
cooled,	  the	  samples	  were	  diluted	  with	  doubly	  dionised	  water	  (DDW)	  to	  a	  maximum	  
final	   concentration	   of	   7.2%	   (w/v)	   HNO3	   (suitable	   for	   ICP-­‐MS	   analysis)	   prior	   to	  
quantification	   of	   195Pt.	   The	   standard	   deviations	   are	   based	   on	   experiments	  
performed	  in	  triplicate.	  
	  
2.2.2.1.3	   Inductively	   Coupled	   Plasma	   Mass	   Spectrometry	   (ICP-­‐MS)	  
Instrumentation	  and	  Calibration	  
All	  ICP-­‐MS	  analyses	  were	  carried	  out	  on	  an	  Agilent	  Technologies	  7500	  series	  
ICP-­‐MS	   instrument	   (California,	   USA).	   The	   solvent	   used	   for	   ICP-­‐MS	   analysis	   was	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doubly	  deionized	  water	  (DDW).	  The	  Platinum	  Standard	  for	  ICP	  (Fluka,	  1000	  mg/L	  in	  
5%	   (w/v)	   HCl)	   was	   diluted	   with	   7.2%	   HNO3	   (diluted	   with	   DDW	   from	   72%	   (w/v)	  
HNO3,	   doubly	   distilled	   on-­‐site)	   to	   freshly	   prepare	   calibrants	   at	   concentrations	  
ranging	  from	  200	  to	  0.1	  ppb.	  The	  ICP-­‐MS	  instrument	  was	  set	  to	  detect	  195Pt	  with	  a	  
detection	   limit	  of	  6.5	  ppt	  using	  no-­‐gas	  mode.	  The	  forward	  power	  was	  set	  to	  1550	  
W,	  argon	   flow	  was	  15	   L/min,	   and	   the	  auxiliary	  gas	   flow	  was	  0.9	   L/min,	  with	   166Er	  
used	  and	  the	  internal	  standard.	  
2.2.2.2	  UV-­‐Vis	  Spectroscopy	  
All	  UV-­‐Vis	   electronic	   absorption	   spectra	  were	  performed	  on	   a	  Varian	  Cary	  
300	  UV-­‐Vis	  spectrophotometer	  with	  a	  temperature	  control	  block	  using	  1	  cm	  path-­‐
length	   cuvettes.	   All	   spectra	   were	   baseline	   corrected	   using	   pure	   solvent	   as	   a	  
background.	  Data	  were	  processed	  using	  Microsoft	  Office	  Excel.	  
2.2.2.3	  Light	  Sources	  
Photoactivation	   of	   Pt(IV)	   complexes	   was	   conducted	   using	   a	   LZC-­‐ICH2	  
photoreactor	  (Luzchem	  Reseach	  Inc)	  with	  a	  temperature	  controller	  set	  at	  310	  K	  and	  
fitted	  with	  LZC	  420	  lamps	  (Luzchem	  Research	  Inc.,	  λmax	  =	  420	  nm).	  
2.2.2.4	  Chromatography	  
Conditions	   for	   the	   lipophilicity	   studies	   to	   determine	   both	   purity	   and	  
retention	   time	   determinations	   of	   Pt(IV)-­‐diazido	   complexes	   were	   as	   follows.	   All	  
experiments	  were	  carried	  out	  on	  the	  Agilent	  1200	  system	  using	  an	  Agilent	  Zorbax	  
eclipse	  plus	  C18	  column	  (5	  μm	  particle	  size,	  4.6	  x	  250	  mm)	  column.	  Solvent	  A	  was	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H2O	  containing	  0.1%	  TFA	  (v/v);	  Solvent	  B,	  MeOH	  containing	  0.1%	  TFA	  (v/v);	  with	  a	  
flow-­‐rate	  of	  1.00	  mL/min.	  The	  solvent	  gradient	  began	  at	  0%	  B	  rising	  to	  30%	  B	  over	  
30	  minutes.	  All	  injections	  were	  50	  μL	  of	  100	  μM	  solutions	  of	  each	  complex	  in	  DDW.	  
All	   solutions	   were	   prepared	   with	   minimal	   exposure	   to	   light.	   The	   column	   was	  
cleansed	  after	  each	  run	  with	  a	  high	  percentage	  of	  organic	  solvent,	  the	  column	  was	  
then	  allowed	  to	  equilibrate	  to	  the	  starting	  conditions.	  The	  wavelength	  of	  detection	  
was	  set	  at	  254	  nm.	  
HPLC	   studies	   of	   Pt-­‐oligonucleotide	   interactions	   were	   carried	   out	   on	   an	  
Agilent	   Technologies	   1100	   system	   with	   a	   Rheodyne	   7725i	   manual	   injector	   fitted	  
with	  a	  100	  μL	  loop	  and	  a	  variable	  wavelength	  UV	  detector.	  The	  mobile	  phases	  for	  all	  
analyses	   were:	   solvent	   A,	   H2O	   10	   mM	   NH4OAc;	   solvent,	   B	   acetonitrile	   10	   mM	  
NH4OAc.	   All	   chromatograms	   were	   processed	   using	   ChemStation	   and	   Microsoft	  
Office	  Excel.	  
All	   oligonucleotide	   purity	   tests	   were	   carried	   out	   on	   a	   Zorbax	   eclipse	   C18	  
strong-­‐bond	  250	  x	  4.6	  mm	  column,	  with	  a	  particle	  size	  of	  5	  µm	  with	  300	  Å	  pores,	  a	  
flow	  rate	  of	  1.00	  mL/min,	  wavelength	  of	  detection	  260	  nm	  and	  50	  µL	  injections.	  The	  
gradients	  used	  were	  either	  0	  −	  30	  %	  B	  over	  30	  min,	  or	  0	  −	  60	  %	  B	  over	  60	  min,	  and	  
the	  column	  oven	  was	  set	  to	  either	  35°C	  or	  40°C.	  	  
Separations	  involving	  the	  single-­‐strand	  oligonucleotide	  were	  carried	  out	  on	  
a	  Hichrom	  Ace	  C8	  250	  x	  4.6	  mm	  column,	  with	  a	  particle	   size	  of	  5	  µm	  with	  300	  Å	  
pores.	  The	  solvent	  gradient	  was	  isocratic	  for	  the	  first	  15	  min	  at	  7	  %	  B,	  increased	  to	  
80	   %	   B	   between	   15	   and	   21	   min,	   with	   a	   flow	   rate	   of	   1	   mL/min.	   The	   gradient	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remained	   isocratic	  at	  80	  %	  until	  30	  min	   into	   the	   run,	   then	  decreased	   to	  7	  %	  B	  by	  
30.5	  min,	  where	  it	  remained	  until	  the	  end	  of	  the	  run	  at	  37	  min,	  for	  the	  column	  to	  
equilibrate	   back	   to	   the	   starting	   conditions.	   The	   flow	   rate	   was	   1.00	   mL/min,	  
injections	   were	   of	   50	   µL,	   the	   column	   oven	   was	   at	   55°C	   and	   the	   wavelength	   of	  
detection	  was	  set	  at	  260	  nm.	  
2.2.2.5	  Mass	  spectrometry	  
Mass	   spectrometry	   was	   carried	   out	   on	   a	   Bruker	   HCT	   Ultra	   ion	   trap	  
instrument	   in	   both	   positive	   and	   negative	   modes.	   The	   sample	   flow	   rate	   was	   240	  
μL/h,	  and	  scan	  ranges	  varied	  from	  50	  −	  1000	  m/z	  to	  500	  –	  3000	  m/z.	  The	  solvent	  
used,	   cone	   voltage	   and	   source	   temperature	   varied	   depending	   on	   the	   sample	  
anaysed.	  
Most	  of	  the	  mass	  spectrometric	  data	  was	  high	  resolution	  mass	  spectrometry	  
(HR-­‐MS),	  and	  was	  carried	  out	  on	  a	  Bruker	  MaXis	  mass	  spectrometer.	  DNA	  samples	  
were	  analysed	  in	  the	  negative	  mode	  (sample	  flow	  rate	  100	  µL/h)	  Mass	  spectrometry	  
work	  with	  the	  oligonucleotides	  was	  carried	  out	  in	  the	  negative	  mode	  (290	  −	  5000	  m/z	  
scan	   range),	   capillary	   4000	  V,	   end	   plate	   offset	   −500	  V,	   dry	   gas	   4.0	   L/min,	   dry	   heater	  
180°C,	   nebuliser	   0.4	   bar.	   The	   acquisition	   parameters	   for	   spectra	   obtained	   in	   the	  
positive	  mode	  are	  as	  follows:	  scan	  range	  50	  −	  3000	  m/z,	  set	  capillary	  3000	  V,	  end	  
plate	  off-­‐set	  −500	  V,	  nebuliser	  pressure	  0.4	  bar,	  dry	  heater	  180	  °C,	  and	  dry	  gas	  4.0	  
L/min.	   All	   data	   were	   acquired	   and	   processed	   with	   Bruker	   MicroTOF	   control	   Bruker	  
Compas	  DataAnalysis	  (version	  4.0)	  and	  OriginPro8.1.	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All	  oligonucleotide	  samples	  analysed	  by	  MS	  were	  desalted	  to	  remove	  peaks	  
due	   to	   sodium	  and	  potassium	  adducts,	   as	  well	   as	   improving	   signal	   intensity.	   Two	  
different	  desalting	  methods	  were	  employed.	  The	  first	  method	  was	  to	  desalt	  using	  
an	  Amicon	  Stirred	  Cell	  under	  N2	  gas	  (70	  bar)	  using	  ultrafiltration	  membranes	  with	  a	  
1	   kDa	   cut	   off.	   The	   sample	   volume	  was	   first	   reduced	   from	  400	  µL	   to	   50	  µL	  whilst	  
stirring,	   and	  was	   then	  washed	  with	   two	  aliquots	  of	   200	  µL	  of	  DDW.	  The	   samples	  
were	  then	  diluted	  1	   in	  2	   in	  40	  mM	  NH4OAc	   in	  MeOH.	  The	  second	  method	  was	  to	  
use	  Omix	  micro	  extraction	  C18	  pipette	   tips,	   typically	  used	   to	  desalt	  peptides.	  The	  
manufacturer’s	  protocol	  was	  followed,	  eluting	  the	  sample	  in	  20	  mM	  NH4OAc	  (Sigma	  
Aldrich,	  99.99%)	  and	  80:20	  MeOH/H2O	  (v/v).	  	  
 
2.3	  Results	  
The	   complexes	   studied	   in	   this	   work	   are	   platinum(IV)-­‐diazido	   ones	   of	   the	  
general	   formula	   trans,trans,trans-­‐[Pt(N3)2(OH)2(R)(R’)],	   where	   R	   and	   R’	   are	   NH3,	  
methylamine,	  ethylamine,	  pyridine,	  2-­‐picoline,	  3-­‐picoline	  or	  thiazole.	  The	  structures	  
of	   the	   10	   complexes	   and	   that	   of	   cisplatin,	   the	   standard	   metal-­‐based	   anticancer	  
drug,	  are	  shown	  in	  Figure	  2.2.	  All	  of	  the	  following	  work	  was	  carried	  out	  under	  low-­‐
light	  conditions	  unless	  stated	  otherwise.	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Figure	  2.2	  Structures	  of	  the	  Pt(IV)	  diazido	  complexes	  studied	  here	  and	  that	  of	  
cisplatin.	  
	  
2.3.1	   Correlation	   between	   Lipophilicity	   and	   Cellular	   Accumulation	   of	   Platinum	  
Complexes	  
2.3.1.1	  Lipophilicity	  
The	   lippophilicity	   of	   the	   complexes	   1 −	   10	   was	   initially	   studied	   using	   the	  
shake	  flask	  octanol/water	  partition	  method.16	  However,	  this	  method	  proved	  to	  be	  
ineffective	  due	  to	  the	  very	  high	  hydrophilicity	  of	  the	  compounds.	  Instead,	  the	  time	  
taken	  for	  the	  complexes	  to	  elute	  from	  a	  reversed	  phase	  (RP)	  HPLC	  column	  was	  used	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as	  a	  measure	  or	  their	  lipophilicity	  for	  the	  purposes	  of	  comparison.	  This	  method	  also	  
measures	   the	   partition	   between	   hydrophilic	   (mobile	   phase)	   and	   hydrophobic	  
(stationary	  phase)	  phases,	  with	  the	  resulting	  retention	  time	  being	   intrinsic	   to	  that	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Figure	  2.3	  Retention	  times	  (tR)	  of	  complexes	  1-­‐10	  on	  a	  RP	  HPLC	  column.	  Solvent	  A	  
was	  H2O	  0.1%	  TFA;	  solvent	  B,	  MeOH	  0.1%	  TFA;	  with	  a	  flow	  rate	  of	  1.00	  mL/min.	  The	  
solvent	  gradient	  began	  at	  0%	  B	  rising	  to	  30%	  B	  over	  30	  minutes.	  Solutions	  for	  the	  
complexes	  were	  100	  μM,	  and	  a	  50	  μL	  aliquot	  of	  each	  solution	  was	  injected	  onto	  the	  
column.	  The	  general	  structure	  of	  the	  complexes	  and	  the	  different	   ligands	  are	  also	  
shown.	  Error	  bars	  are	  the	  standard	  deviation	  of	  two	  independent	  measurements.	  
	  
Some	  trends	  observed	  are	  expected,	  for	  example	  complexes	  1,	  4	  and	  8.	  This	  
series	   shows	  an	   increase	   in	   retention	   times	  and	   therefore	   in	   lipophilicity	  with	   the	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sequential	   substitution	  of	  NH3	  groups	   for	  more	  hydrophobic	  pyridine	   (py)	   ligands.	  
The	  series	  of	  complexes	  4-­‐6,	   in	  which	  the	  py	  R’	   ligand	  has	  a	  methyl	  substituent	  at	  
two	   different	   positions	   (2-­‐picolino	   and	   4-­‐picolino)	   increasing	   both	   the	  
hydrophobicity	  and	  the	  tR.	  These	  complexes	  also	  fit	  into	  a	  series	  with	  complex	  1.	  
Complexes	   2	   and	   7,	   which	   contain	   methylamine	   ligands,	   have	   retention	  
times	   that	   sit	   ‘out	   of	   series’.	   Complexes	  1	 −	 3	   form	  a	   series	   of	   compounds	   that	  
have	  an	   increasing	   carbon	   chain	   (from	  1	   to	  3),	  while	   the	   retention	   time	  of	  3	   (3.0	  
min)	  is	  longer	  than	  that	  of	  1	  (2.7	  min),	  as	  expected	  due	  to	  the	  increased	  lipophilicity	  
of	   the	   ethylamine	   ligand	   compared	   to	   the	   -­‐NH3	   one.	   Compound	   2	   has	   a	   much	  
higher	  retention	  time	  than	  that	  of	  3	  (8.1	  min),	  and	  even	  higher	  than	  that	  of	  complex	  
4	  (6.7	  min),	  which	  has	  a	  more	  hydrophobic	  py	  ligand.	  Conversely,	  the	  retention	  time	  
of	   complex	   7	   is	   shorter	   than	   expected	   in	   the	   series	   4,	   7	   and	   8.	   All	   of	   these	  
complexes	  have	  a	  py	  R’	  group	  and	  the	  R	  group	  increases	  in	  hydrophobicity	  from	  4	  
to	  8.	  The	  retention	  time	  of	  7	   (3.9	  min)	   is	   less	  than	  that	  of	  4	   (6.7	  min)	  and	  8	   (14.5	  
min).	  
The	  complex	  with	  a	  methylamine	  ligand	  that	  has	  a	  retention	  time	  that	  follows	  the	  
predicted	  series	  is	  complex	  10	  (6.1	  min).	  This	  compound	  is	  more	  hydrophobic	  than	  
the	   amino	   complex	   9	   (5.1	   min).	   The	   two	   compounds	   9	   and	   10	   with	   thiazole	   R’	  
ligands	  have	  shorter	  tRs	  values	  than	  those	  with	  py	  R’	  groups,	  with	  the	  exception	  of	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2.3.1.2	  Platinum	  Accumulation	  in	  A2780	  Cells	  
The	  cellular	  accumulation	  studies	  in	  this	  section	  were	  carried	  out	  by	  Dr	  Ana	  
Pizarro	  as	  were	  the	  measurements	  determining	  cellular	  Pt	  content.	  The	  conditions	  
for	  the	  cellular	  accumulation	  tests	  were	  designed	  to	  mimic	  those	  used	  to	  determine	  
the	   IC50	   values	   of	   the	   complexes.11	   The	   human	   ovarian	   A2780	   cancer	   cells	   were	  
exposed	   to	   100	   μM	   solutions	   of	   the	   drugs	   for	   1.00	   h	   in	   the	   dark.	   The	   platinum-­‐
based	  anticancer	  drug	  cisplatin	  was	   included	  as	  a	  positive	  control.	  The	   results	   for	  
the	  cellular	  uptake	  are	  shown	  in	  terms	  of	  ng	  of	  platinum	  per	  million	  cells.	  This	  was	  
determined	  by	  acidic	  digestion	  of	  the	  collected	  cells	  and	  the	  determination	  of	  their	  
platinum	   content	   by	   ICP-­‐MS.	   The	   results	   are	   shown	   in	   the	   form	  of	   a	   bar	   chart	   in	  
Figure	  2.4.	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Figure	  2.4	  Cellular	  uptake	  of	  Pt(IV)	  diazido	  anticancer	  complexes	  (100	  μM	  solutions)	  
in	   the	  dark	  and	   the	  established	  metal-­‐based	  anticancer	  drug	  cisplatin.	  The	   results	  
are	  represented	  in	  terms	  of	  ng	  of	  Pt	  accumulated	  per	  million	  cancer	  cells.	  
	  
Complexes	  1	  −	  3	  are	  taken	  up	  into	  the	  cells	  following	  the	  same	  trend	  as	  that	  
hydrophobicity,	  as	  determined	  by	  HPLC.	  Complexes	  4,	  5	  and	  6	  also	  follow	  the	  same	  
trend	  as	  their	  lipophilicity,	  but	  their	  uptake	  is	  less	  than	  that	  of	  compound	  1.	  Overall,	  
the	  compounds	  with	  a	  py	  or	  thiazole	  group	  have	  a	  lower	  cellular	  accumulation	  than	  
those	  complexes	  without	  an	  aromatic	   ligand.	  The	  exceptions	  are	  complexes	  8	  and	  
10,	   which	   are	   also	   the	   compounds	   with	   the	   highest	   cellular	   accumulation	   of	  
platinum.	  The	  lack	  of	  correlation	  between	  tR	  and	  cellular	  accumulation	  of	  platinum	  
over	  the	  whole	  series	  is	  summarised	  in	  Figure	  2.5.	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Figure	  2.5	  Plot	  of	  the	  HPLC	  retention	  times	  of	  compounds	  1	  −	  10	  and	  their	  cellular	  
accumulation	  over	  1	  h	  of	  drug	  exposure	  to	  A2680	  human	  ovarian	  carcinoma	  cells	  
(ng	  of	  platinum/	  million	  cells).	  The	  trendline	  is	  incuded	  to	  show	  a	  lack	  of	  correlation	  
between	  IC50	  value	  and	  cellular	  accumulation	  of	  platinum	  (shown	  by	  the	  low	  
correlation	  coefficient,	  R2	  value	  of	  0.0531).	  
	  
The	  relationship	  between	  the	  cellular	  accumulation	  in	  the	  dark	  and	  the	  IC50	  
values,	  when	  irradiated	  with	  365	  nm	  light,	  of	  complexes	  1-­‐10	  and	  cisplatin	  (CDDP)	  is	  
shown	  in	  Figure	  2.6.	  Complexes	  1,	  2,	  3,	  8	  and	  10	  support	  the	  hypothesis	  that	  higher	  
drug	  accumulation	   leads	   to	  greater	  potency.	  However,	   compounds	  6,	  7	   and	  9	   are	  
very	  active	   (<	  6	  μM)	  with	   low	  cellular	  accumulation	   (<	  5	  μM).	  This	   illustrates	   that	  
many	  other	  factors,	   including	  quantum	  yield	  of	  the	  compound	  and	  the	  potency	  of	  
the	   products	   of	   the	   photoreaction,	   are	   important	   for	   the	   efficacy	   of	   a	  
photoactivatable	   drug.	   A	   summary	   of	   the	   chemical	   biological	   properties	   of	  
complexes	  1-­‐10	  is	  shown	  in	  Table	  2.1.	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Figure	  2.6	  IC50	  for	  A2780	  cancer	  cells	  after	  1	  h	  drug	  exposure	  (in	  the	  dark)	  and	  then	  
irradiated	   for	  1.00	  h	  with	  365	  nm,	   in	  A2780	  cancer	  cells	  of	  complexes	  1	  −	  10	  and	  
cisplatin	   (CDDP)	   compared	   to	   the	   cellular	   accumulation	   of	   the	   complexes	   (ng	   of	  
platinum/million	   cells).	   The	   trendline	   is	   incuded	   to	   show	   a	   lack	   of	   correlation	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Table	  2.1	  Summary	  of	  the	  lipohilicity,	  cellular	  accumulation,	  IC50	  (365	  nm	  irradiated)	  
and	   IC50	   (dark).	   IC50	   values	   obtained	   by	   Dr	   Julie	   Woods	   of	   Ninewells	   Hospital,	  
University	  of	  Dundee.13,11,14	  Retention	   times	  are	  an	  average	  of	  2	  measurements	  ±	  
the	  standard	  deviation.	  
Complex	   tR/min	  
Pt	  accumulation	  in	  
A2780	  ng	  Pt/106	  cells	  
IC50	  irradiated	  
with	  365	  nm	  
light/μM	  
IC50	  in	  the	  
dark/μM	  
1	   2.7	  ±	  0.0	   5.4	   99.2	   >	  287.9	  
2	   8.1	  ±	  0.0	   14.1	   39.8	   >	  276.8	  
3	   3.0	  ±	  0.07	   7.4	   58.4	   >	  266.3	  
4	   6.7	  ±	  0.21	   2.0	   1.9	   >	  224.4	  
5	   14.2	  ±	  0.14	   3.8	   51.0	   >	  236.3	  
6	   15.8	  ±	  0.07	   3.9	   2.6	   26.8	  
7	   3.9	  ±	  0.0	   4.0	   2.3	   >	  236.3	  
8	   14.5	  ±	  0.14	   19.9	   1.1	   212.3	  
9	   5.1	  ±	  0.07	   2.7	   5.5	   186.9	  
10	   6.1	  ±	  0.07	   14.5	   3.2	   >	  232.9	  
CDDP	   NT	   8.1	   151.3	   152	  
	  
2.3.2	  Study	  of	  photoactivatable	  Pt(IV)	  diazido	  complex	  interaction	  with	  
oligonucleotides	  by	  chromatography	  
The	   most	   active	   Pt(IV)	   dazido	   complex	   studied	   in	   the	   previous	   section	  
against	  A2780	   cancer	   cell	   lines	  was	   compound	  8	   (t,t,t-­‐[Pt(N3)2(OH)2(py)2).	  As	  DNA	  
binding	  is	  thought	  to	  be	  the	  mechanism	  of	  action	  of	  Pt-­‐based	  drugs	  currently	  in	  the	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clinic,17	   the	   interaction	   of	   the	  most	   promising	   drug	   candidate	   from	   the	   previous	  
series	   of	   10	   compounds	   (complex	   8)	   with	   short	   single	   strand	   oligonucleotides	   is	  
studied	  in	  this	  section	  of	  the	  chapter.	  	  
2.3.2.1	   Interaction	   of	   t,t,t-­‐[Pt(N3)2(OH)2(py)2)	   with	   oligonucleotide	  
d’(ATACATGCTACATA)	  
A	  single	  strand	  oligonucleotide	  of	  sequence	  d’(ATACATGCTACATA),	  oligo	  1,	  
was	   purchased	   from	   DNA	   Technologies	   Europe	   A/S.	   This	   sequence	   contains	   one	  
guanine	   residue,	   the	   preferred	   binding	   site	   for	   platinum-­‐based	   drugs.18	   The	  
oligonucleotide	  was	   twice	  RP-­‐HPLC	  purified	  and	  with	  Na+	   as	   the	   counter	   ion.	   The	  
oligonucleotide	   was	   quantified	   using	   UV-­‐Vis	   absorption	   at	   260	   nm	   using	   a	  
calculated	  extinction	  coefficient.15	  An	  example	  of	  the	  UV-­‐Vis	  spectrum	  of	  oligo	  1	  is	  
shown	  in	  Figure	  2.7.	  The	  purity	  of	  the	  oligonucleotide	  used	  was	  confirmed	  by	  HPLC	  
(data	  not	  shown).	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Figure	   2.7	   UV-­‐Vis	   spectrum	   of	   d'(ATACATGCTACATA),	   oligo	   1,	   in	   water	   used	   to	  
determine	  the	  concentration	  of	  the	  oligonucleotide	  stock	  solution	  (ε260nm	  =	  145100	  
M-­‐1cm-­‐1).	  	  
	  
The	   light	   source	   used	   to	   activate	   complex	   8	   in	   the	   presence	   of	   the	  
oligonucleotide	  was	  a	  temperature-­‐controlled	  photoreactor	  (Luzchem	  Reseach	  Inc).	  
The	  arrangement	  of	  the	  bulbs	  within	  the	  photoreactor	  is	  shown	  in	  Figure	  2.8.	  Each	  
bulb	  was	   labelled	  with	   its	   corresponding	  position	   in	   the	  photoreactor	   so	   that	   the	  
irradiation	  of	  each	  sample	  remained	  the	  same	  for	  all	  experiments.	  The	  temperature	  
of	   the	   photoreactor	   was	   set	   at	   37°C,	   to	   mimic	   biological	   conditions,	   for	   all	  
experiments.	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Figure	   2.8	   Top:	   photoreactor	   used	   for	   the	   sample	   irradiations	   in	   this	   chapter,	  
bottom:	  schematic	  diagram	  of	  the	  bulb	  layout	  within	  the	  photoreactor.	  
	  
A	  HPLC	  method	  was	  developed	  and	  optimised	   for	   the	   separation	  of	   single	  
strand	  oligonucleotides	  from	  platinated	  oligonucleotides	  (Appendix	  III).	  The	  method	  
was	  used	  to	  analyse	  the	  following	  reaction.	  A	  solution	  of	  complex	  8	   (500	  μM)	  and	  
oligo	  1	  (250	  μM)	  in	  H2O	  was	  irradiated	  for	  a	  2	  h	  period	  with	  aliquots	  taken	  every	  30	  
min.	  Figure	  2.9	  shows	  the	  chromatograms	  of	  the	  aliquots	  taken	  before	   irradiation	  
and	   after	   30	   min	   of	   irradiation	   with	   365	   nm	   light.	   Chromatogram	   A,	   a	   1	   in	   10	  
dilution	  (in	  water)	  of	  the	  solution	  in	  the	  dark	  2.00	  min	  after	  solution	  mixing	  in	  the	  
dark,	   shows	   3	   peaks,	   the	   first	   peak	   (tR	   3.9	   min)	   corresponding	   to	   the	  
oligonucleotide.	  This	  was	  confirmed	  by	  analysing	  an	   injection	  of	   just	  oligo	  1	  using	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the	   same	   gradient.	   The	   following	   peaks	   (tR	   4.6	   min	   and	   tR	   5.1	   min)	   may	   be	  
attributable	   to	   a	   folding	   of	   the	   oligonucleotide	   or	   a	   short-­‐lived	   platinum-­‐
oligonucleotide	   adduct.	   It	   was	   not	   possible	   to	   characterise	   this	   species	   (nor	   to	  
determine	   whether	   it	   contained	   platinum)	   due	   to	   its	   very	   low	   concentration.	   In	  
chromatogram	  B	  (after	  30	  min	  of	  irradiation	  with	  365	  nm	  light)	  a	  new	  peak,	  (tR	  19.7	  

















































Figure	  2.9	  A	  solution	  of	  8	   (500	  μM)	  and	  oligo	  1,	  d'(ATACATGCTACATA),	   (250	  μM):	  
chromatogram	  A	  is	  a	  1	  in	  10	  dilution	  (in	  water)	  of	  the	  solution	  after	  2	  min	  of	  mixing	  
in	  the	  dark;	  chromatogram	  B	   is	  a	  1	   in	  10	  dilution	  (in	  H2O)	  of	  the	  solution	  after	  30	  
min	  of	   irradiation	  with	   365	  nm	  at	   37°C.	   Separation	   gradient	  was	   isocratic	   for	   the	  
first	  15	  min	  at	  7%	  B	  (v/v),	  increased	  to	  80%	  B	  (v/v)	  between	  15	  and	  21	  min,	  with	  a	  
flow	   rate	   of	   1.00	   mL/min,	   column	   oven	   temperature	   55°C.	   Solvent	   A,	   10	   mM	  
NH4OAc	  H2O;	  solvent	  B,	  10	  mM	  NH4OAc	  acetonitrile;	  wavelength	  of	  detection	  260	  
nm.	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The	  percentage	  of	  the	  integrated	  peak	  areas	  assigned	  as	  Pt-­‐oligonucleotide	  
adduct	  over	  the	  course	  of	  the	  2.0	  h	  irradiation	  period	  is	  shown	  in	  Figure	  2.10.	  After	  
30	  min	  the	  maximum	  amount	  of	  platinum	   is	  bound	  to	   the	  DNA	  and	  then	  reduces	  
slightly	   over	   the	   next	   90	   min.	   It	   is	   within	   the	   error	   of	   the	   experiment	   that	   this	  
reduction	   is	   not	   significant,	   and	   the	   maximum	   level	   of	   the	   platinated	  
oligonucleotide	  is	  reached	  before	  30	  min	  and	  remains	  constant	  thereafter.	  




















Figure	   2.10	   The	   percentage	   of	   the	   peak	   area	   corresponding	   to	   the	   Pt-­‐
oligonucleotide	  adduct	  (tR	  19.7	  min)	  against	  the	  time	  of	  sample	  irradiation	  (complex	  
8,	   500	   μM	   and	   oligo	   1,	   250	   μM)	   with	   365	   nm	   light	   at	   37°C.	   Error	   bars	   are	   the	  
standard	  deviation	  of	  5	  manual	  peak	  integrations	  of	  3	  independent	  experiments.	  
	  
2.3.2.2	  Sequence	  selectivity	  of	  Pt(IV)	  diazido	  complex	  oligonucleotide	  binding	  
The	  sequence	  selectivity	  for	  complex	  8,	   (t,t,t-­‐[Pt(N3)2(OH)2(py)2),	  binding	  to	  
single	   strand	   DNA	   was	   explored	   using	   three	   different	   oligonucleotides,	   each	   14	  
bases	  in	  length.	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The	  sequences	  are	  as	  follows:	  	  
oligo	  1	  d’(ATACATGCTACATA)	  	  
oligo	  2	  d’(ATACATGGTACATA)	  	  
oligo	  3	  d’(ATACGTGCTACATA)	  	  
The	  same	  irradiation	  procedure	  as	  stated	  for	  oligo	  1	  in	  Section	  2.3.2	  was	  applied	  to	  
oligo	   2	   and	   3.	   Chromatograms	   of	  8	   (500	   μM)	   and	   oligo	   2	   (250	   μM)	   in	  water	   are	  
shown	  in	  Figure	  2.11.	  Analysis	  of	  the	  solution	  in	  the	  dark,	  with	  2.0	  min	  after	  mixing,	  
shown	   in	   chromatogram	   A	   indicates	   the	   presence	   of	   unreacted	   oligonucleotide	  
(peak	  1	   tR	   3.86	  min)	  and	  another	   species,	  possibly	  a	   folded	   strand,	   (peak	  2	   tR	   5.1	  
min).	  In	  chromatogram	  B,	  the	  solution	  irradiated	  with	  365	  nm	  for	  30	  min,	  contains	  a	  
third	  peak	  attributable	  to	  a	  Pt-­‐oligonucleotide	  adduct	  at	  19.7	  min.	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Figure	  2.11	  A	  solution	  of	  8	  (500	  μM)	  and	  oligo	  2	  (250	  μM)	  in	  water.	  Chromatogram	  
A:	  a	  1	  in	  10	  dilution	  of	  the	  solution	  after	  2	  min	  mixing	  in	  the	  dark.	  Chromatogram	  B:	  
a	   1	   in	  10	  dilution	  of	   the	   solution	  after	   30	  min	  of	   irradiation	  with	  365	  nm	   light	   at	  
37°C.	  Separation	  gradient	  was	  isocratic	  for	  the	  first	  15	  min	  at	  7%	  B	  (v/v),	  increased	  
to	  80%	  B	   (v/v)	  between	  15	  and	  21	  min,	  with	  a	   flow	   rate	  of	  1.00	  mL/min,	   column	  
oven	  temperature	  55°C.	  Solvent	  A,	  10	  mM	  NH4OAc	  H2O;	  solvent	  B,	  10	  mM	  NH4OAc	  
acetonitrile;	  wavelength	  of	  detection	  260	  nm.	  
	  
The	   same	   protocol	  was	   also	   applied	   to	   oligo	   3,	   with	   the	   results	   shown	   in	  
Figure	   2.12.	   The	   peak	   assigned	   as	   the	   oligonucleotide	   (tR	   3.9	  min)	   can	   clearly	   be	  
seen	  in	  the	  chromatogram	  of	  the	  solution	  in	  the	  dark	  (A).	  After	  irradiation	  a	  peak	  is	  
observed	  at	  19.67	  min	  that	  is	  attributed	  to	  platinated	  oligonucleotide.	  This	  peak	  is	  
Chapter	  2	  -­‐	  Chapter	  2	  The	  interaction	  of	  photoactivatable	  Pt(IV)	  complexes	  with	  





of	  a	  similar	  intensity	  to	  that	  of	  the	  platinated	  oligo	  1	  after	  30	  min	  of	  irradiation,	  but	  












































Figure	  2.12	  A	  solution	  of	  8	  (500	  μM)	  and	  oligo	  3	  (250	  μM)	  in	  H2O.	  Chromatogram	  A:	  
a	  1	  in	  10	  dilution	  of	  the	  solution	  after	  2	  min	  mixing	  in	  the	  dark.	  Chromatogram	  B:	  a	  
1	  in	  10	  dilution	  of	  the	  solution	  after	  30	  min	  of	  irradiation	  with	  365	  nm	  light	  at	  37°C.	  
Separation	  gradient	  was	  isocratic	  for	  the	  first	  15	  min	  at	  7%	  B	  (v/v),	  increased	  to	  80%	  
B	   (v/v)	   between	   15	   and	   21	   min,	   with	   a	   flow	   rate	   of	   1.00	   mL/min,	   column	   oven	  
temperature	   55°C.	   Solvent	   A,	   10	   mM	   NH4OAc	   H2O;	   solvent	   B,	   10	   mM	   NH4OAc	  
acetonitrile;	  wavelength	  of	  detection	  260	  nm.	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The	  rates	  of	  platination	  of	  the	  three	  oligonucleotides	  are	  compared	  in	  Figure	  
2.13.	   After	   30	   min	   of	   irradiation	   with	   365	   nm	   UVA,	   the	   maximum	   level	   of	  
platination	   was	   attained	   or	   had	   almost	   been	   reached,	   regardless	   of	   the	  
oligonucleotide	   sequence.	   The	   percentage	   peak	   area	   attributed	   to	   the	   platinated	  
oligonucleotide	   after	   120	   min	   of	   irradiation	   with	   365	   nm	   UVA	   for	   each	   of	   the	  
strands	  follows	  the	  following	  trend:	  oligo	  1	  >oligo	  3	  >oligo	  2,	  see	  Table	  2.2.	  There	  is	  
very	   little	   difference	  between	   the	  percentage	  peak	   areas	   attributed	   to	  platinated	  
DNA	  for	  oligo	  1	  and	  3.	  The	  percentage	  peak	  areas	  of	  platinated	  oligonucleotide	  for	  
oligo	  2	  is	  almost	  a	  third	  less	  than	  that	  for	  the	  other	  strands,	  suggesting	  that	  oligo	  2	  
offers	  less	  favourable	  binding	  sites.	  
























Figure	  2.13	  The	  percentage	  of	  the	  peak	  area	  within	  the	  chromatogram	  attributed	  to	  
the	   three	   platinated	   oligonucleotides	   and	   how	   this	   changes	  when	   irradiated	  with	  
365	  nm	  light.	  Values	  are	  averaged	  over	  a	  minimum	  of	  2	  experiments,	  with	  5	  manual	  
integrations	   taken	   for	  each	  experiment	   (error	  bars	  are	   the	   standard	  deviations	  of	  
these	  values).	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Table	   2.2	   The	   percentage	   peak	   area	   attributable	   to	   platinated	   oligonuclotide	   for	  
oligo	   	   1,	   d’(ATACATGCTACATA),	   oligo	   2,	   d’(ATACATGGTACATA),	   and	   oligo	   3,	  
d’(ATACGTGCTACATA)	   at	   time	   0	   and	   120	   min	   of	   irradiation.	   Error	   bars	   are	   the	  
standard	   deviations	   of	   a	   minimum	   of	   2	   independent	   expeiments,	   each	  manually	  
intergrated	  5	  times.	  
Time	  of	  irradiation	  
(365	  nm)	  /	  min	  
Oligo	  1	  
%	  peak	  area	  of	  
platinated	  DNA	  
Oligo	  2	  
%	  peak	  area	  of	  
platinated	  DNA	  
Oligo	  3	  
%	  peak	  area	  of	  
platinated	  DNA	  
0	   3.52	  (±	  2.10)	   0	  (±	  0.0)	   4.44	  (±	  0.47)	  
120	   33.92	  (±	  2.94)	   20.88	  (±	  5.70)	   31.70	  (±	  6.49)	  
	  
2.3.2.3	  Wavelength	  of	  activation	  of	  Pt(IV)	  diazido	  complexes	  
Longer	   wavelength	   light	   is	   preferred	   for	   in	   vivo	   drug	   activation,	   as	   it	  
penetrates	   further	   into	   tissue.19,20	   Complex	  8	   can	  be	   activated	  by	  wavelengths	   of	  
light	  as	   long	  as	  green	   light.13	  To	   investigate	   if	  a	  different	  wavelength	  of	  activation	  
produces	   a	   change	   in	   the	  DNA	   adduct	   formed	  by	  8	   and	   oligo	   1,	   a	   set	   of	   420	   nm	  
bulbs	  was	  fitted	  in	  the	  photoreactor	  (in	  the	  same	  arrangement	  as	  shown	  in	  Figure	  
2.8).	  	  The	  same	  protocol	  as	  in	  Section	  2.3.2.1	  was	  then	  carried	  out	  using	  this	  longer	  
wavelength	   of	   light.	   Figure	   2.14	   (chromatogram	   A)	   shows	   the	   solution	   of	   8	   (500	  
μM)	   and	   oligo	   1,	   d’(ATACATGCTACATA),	   (250	   μM)	   2	  min	   after	  mixing	   in	   the	   dark	  
(and	  diluted	  1	  in	  10	  in	  water).	  Three	  peaks	  can	  be	  observed	  in	  this	  chromatogram:	  1	  
is	  attributable	  to	  oligo	  1	  (tR	  3.9	  min),	  the	  second	  	  (2	  tR	  4.5	  min)	  and	  third	  (3	  tR	  5.1	  
min)	  to	  folded	  forms	  of	  the	  oligonucleotide.	  After	  the	  solution	  had	  been	  irradiated	  
for	  30	  min	  with	  420	  nm	  light	  (chromatogram	  B,	  Figure	  2.14)	  a	  new	  peak	  (4)	  at	  19.7	  
min	   is	   detected.	   This	   is	   the	   same	   retention	   time	   as	   the	   peak	   assigned	   as	   the	  
platinated	  oligo	  1	  when	  a	  similar	  solution	  was	  irradiated	  with	  365	  nm	  UVA,	  Fig	  2.9.	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Figure	  2.14	  A	  solution	  of	  8	  (500	  μM)	  and	  oligo	  1	  (250	  μM)	  in	  H2O.	  Chromatogram	  A:	  
a	  1	  in	  10	  dilution	  of	  the	  solution	  after	  2	  min	  mixing	  in	  the	  dark.	  Chromatogram	  B:	  a	  
1	  in	  10	  dilution	  of	  the	  solution	  after	  30	  min	  of	  irradiation	  with	  420	  nm	  light	  at	  37°C.	  
Separation	  gradient	  was	  isocratic	  for	  the	  first	  15	  min	  at	  7%	  B	  (v/v),	  increased	  to	  80%	  
B	   (v/v)	   between	   15	   and	   21	   min,	   with	   a	   flow	   rate	   of	   1.00	   mL/min,	   column	   oven	  
temperature	   55°C.	   Solvent	   A,	   10	   mM	   NH4OAc	   H2O;	   solvent	   B,	   10	   mM	   NH4OAc	  
acetonitrile;	  wavelength	  of	  absorption	  260	  nm.	  
	  
The	  platination	  of	  oligo	  1	  in	  the	  presence	  of	  8	  irradiated	  with	  either	  365	  nm	  
or	   420	   nm	   light	   over	   a	   period	   of	   2	   h	   are	   compared	   in	   Figure	   2.15.	   The	   solution	  
irradiated	   with	   365	   nm	   light	   reaches	   a	   maximum	   amount	   of	   oligonucleotide	  
platination	   after	   30	   min	   of	   irradiation.	   The	   solution	   irradiated	   with	   the	   longer	  
wavelength	  of	  420	  nm	  light	  takes	  60	  min	  to	  achieve	  the	  same	  level	  of	  platination.	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Figure	   2.15	  Graph	   of	   the	   percentage	   of	   the	   peak	   area	  within	   the	   chromatogram	  
attributed	  to	  the	  platinated	  oligonucleotide	  and	  how	  this	  percentage	  changes	  with	  
irradiation	  with	  365	  nm	  and	  420	  nm	  light	  over	  a	  period	  of	  2	  h.	  Values	  are	  averaged	  
over	   a	   minimum	   of	   2	   experiments,	   with	   5	   manual	   integrations	   taken	   for	   each	  
experiment	  (error	  bars	  are	  the	  standard	  deviations	  of	  these	  values).	  
	  
2.3.3	  Photoactivatable	  Pt(IV)	  diazido	  complex	  interaction	  with	  an	  oligonucleotide	  
by	  mass	  spectrometry	  
2.3.3.1	  Interaction	  of	  trans,trans,trans-­‐[Pt(N3)2(OH)2(py)2]	  and	  oligo	  1	  
The	   chromatography-­‐based	   studies	   of	   Section	   2.3.2	   suggest	   that	   the	  
irradiation	   of	   8	   (t,t,t-­‐[Pt(N3)2(OH)2(py)2])	   in	   the	   presence	   of	   an	   oligonucleotide	  
generates	  a	  platinum	  species	  that	  binds	  to	  the	  DNA.	  Mass	  spectrometry	  was	  used	  
to	  characterise	  this	  new	  adduct	  once	  it	  was	  bound	  to	  the	  oligonucleotide.	  Initially,	  a	  
de-­‐salting	  protocol	  was	  developed	  as	  the	  excess	  salt	  bound	  to	  the	  oligonucleotide	  
in	  solution	  could	  potentially	  damage	  the	  mass	  spectrometer,	  if	  it	  was	  sprayed	  into	  
the	  instrument,	  e.g.	  block	  the	  skimmer	  cone.	  Salt	  adducts	  of	  the	  DNA	  would	  also	  be	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detected	  and	  could	  potentially	  overlap	  with	  species	  of	  interest	  in	  the	  resulting	  mass	  
spectrum.	  An	  Amicon	  stirred	  cell	  with	  1	  kDa	  cut-­‐off	  ultrafiltration	  membrane	  was	  
used,	  as	  outlined	  in	  Section	  2.2.1.7,	  in	  order	  to	  de-­‐salt	  the	  oligonucleotide	  samples.	  
The	  spectrum	  of	  an	  8	  μM	  solution	  of	  desalted	  oligo	  1,	  d’(ATACATGCTACATA),	  in	  40	  
mM	  NH4OAc	  80%	  MeOH/20%	  H2O	  in	  the	  negative-­‐ion	  mode	  is	  shown	  in	  Figure	  2.16;	  
the	  -­‐4	  at	  1056.179	  m/z	  (predicted	  1056.184	  m/z)	  and	  -­‐3	  at	  1408.574	  m/z	  (predicted	  
1408.581	   m/z)	   charge	   states	   were	   observed.	   Throughout	   this	   work	   the	   fully	  
protonated	   form	  of	  an	  oligonucleotide	  will	  be	   referred	   to	  as	  M,	   i.e.	   the	   -­‐4	   charge	  
state	  of	  oligo	  1	  has	  9	  additional	  protons.	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Figure	  2.16	  High	  resolution	  mass	  spectrum	  of	  oligo	  1	  (8	  μM)	  in	  40	  mM	  NH4OAc	  80%	  
MeOH/20%	  H2O	  (v/v)	  in	  the	  negative	  ion	  mode.	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Analogous	   experiments	   to	   those	   analysed	   by	   chromatography	   in	   section	  
2.3.2	   were	   carried	   out	   and	   the	   resulting	   solutions	   investigated	   by	   mass	  
spectrometry.	   The	   spectrum	   of	   8	   (250	   μM)	   irradiated	   with	   365	   nm	   light	   in	   the	  
presence	  of	  oligo	  1	   (250	  μM),	   following	  de-­‐salting,	   is	  shown	   in	  Figure	  2.17.	  The	   -­‐3	  
(1408.913	  m/z)	   and	   -­‐4	   (1056.439	  m/z)	   charge	   states	   of	   oligo	   1	  were	   detected,	   as	  
well	   as	   the	   -­‐3	  at	  1525.601	  m/z	   (1525.592	  m/z)	   and	   -­‐4	  at	  1143.946	  m/z	   (1143.943	  
m/z)	  charge	  states	  of	  another	  species.	  The	  isotopic	  pattern	  of	  these	  peaks	  suggest	  
that	  they	  contain	  platinum,	  and	  the	  m/z	  values	  would	  suggest	  that	  the	  new	  species	  
is	  [oligo	  1	  +	  [Pt(py)2]].	  This	  is	  believed	  to	  be	  the	  Pt-­‐oligonucleotide	  adduct	  observed	  
after	  irradiation	  with	  365	  nm	  light	  at	  19.67	  min	  in	  Chromatogram	  B,	  Figure	  2.12.	  
























Figure	  2.17	  A	  solution	  of	  8	  (250	  μM)	  and	  oligo	  1	  (250	  μM)	  irradiated	  with	  365	  nm	  
light	  for	  30	  min.	  High	  resolution	  mass	  spectrum	  of	  the	  desalted	  solution,	  final	  oligo	  
concentration	   approx.	   8	   μM,	   in	   40	   mM	   NH4OAc	   80%	   MeOH/20%	   H2O	   in	   the	  
negative	  ion	  mode.	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The	  chromatographic	  data	   in	  Section	  2.3.2	  suggest	  only	  a	  difference	   in	  the	  
rate	   of	   Pt-­‐oligonucleotide	   adduct	   formation	   and	   not	   in	   the	   type	   of	   DNA	   lesion	  
formed	   when	   the	   wavelength	   of	   activation	   of	   8	   is	   changed.	   To	   confirm	   this,	   a	  
solution	  of	  8	  (250	  μM)	  was	  irradiated	  with	  420	  nm	  light	  for	  60	  min	  in	  the	  presence	  
of	   oligo	   1	   (250	   μM).	   This	   solution	   was	   then	   de-­‐salted	   and	   the	   mass	   spectrum	  
recorded,	  see	  Fig.2.18.	  The	  -­‐3	  and	  -­‐4	  charge	  states	  of	  oligo	  1	  and	  [oligo	  1	  +	  [Pt(py)2]]	  
were	  again	  observed	  as	  shown	  in	  Figure	  2.17.	  























Figure	  2.18	  A	  solution	  of	  8	  (250	  μM)	  and	  oligo	  1	  (250	  μM)	  irradiated	  with	  420	  nm	  
light	  for	  60	  min.	  High	  resolution	  mass	  spectrum	  of	  the	  desalted	  solution,	  final	  oligo	  
concentration	  approx.	  8	  μM,	  in	  40	  mM	  NH4OAc	  80%	  MeOH	  20%	  H2O	  in	  the	  negative	  
ion	  mode.	  
	  
The	   effect	   of	   using	   a	   1:1	   molar	   ratio	   of	   8	   to	   oligo	   1	   in	   the	   irradiation	  
experiments	  studied	  by	  mass	  spectrometry	  (instead	  of	  the	  2:1	  molar	  ratio	  used	   in	  
Chapter	  2	  -­‐	  Chapter	  2	  The	  interaction	  of	  photoactivatable	  Pt(IV)	  complexes	  with	  





the	  chromatographic	  experiments)	  was	  explored	  by	  analysing	  a	  solution	  with	  a	  2:1	  
ratio	  by	  mass	  spectrometry.	  A	  solution	  of	  8	   (500	  μM)	  was	   irradiated	  with	  420	  nm	  
light	   for	   60	   min	   in	   the	   presence	   of	   oligo	   1	   (250	   μM)	   and	   de-­‐salted.	   The	   mass	  
spectrum	  of	   this	   solution	   is	   shown	   in	   Figure	  2.19.	   In	   addition	   to	   the	   -­‐3	   (1408.574	  
m/z)	  and	  -­‐4	  (1056.179	  m/z)	  charge	  states	  of	  oligo	  1,	  and	  the	  same	  charge	  states	  of	  
[oligo	   1	   +	   [Pt(py)2]]	   (1525.601	  m/z	   and	   1143.456	  m/z,	   respectively),	   a	   set	   of	   low	  
intensity	  peaks,	  also	  with	   -­‐3	  at	   (1642.556	  m/z)	   (1642.604	  m/z)	  and	   -­‐4	  at	  1231.667	  
m/z	  (1231.701	  m/z)	  charge	  states,	  assigned	  as	  [oligo	  1	  +	  2[Pt(py)2]],	  was	  observed.	  

























Figure	  2.19	  A	  solution	  of	  8	  (500	  μM)	  and	  oligo	  1	  (250	  μM)	  irradiated	  with	  420	  nm	  
light	  for	  60	  min.	  High	  resolution	  mass	  spectrum	  of	  the	  desalted	  solution,	  final	  oligo	  
concentration	   approx.	   8	   μM,	   in	   40	   mM	   NH4OAc	   80%	   MeOH/20%	   H2O	   in	   the	  
negative	  ion	  mode.	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2.3.3.2	  Platinum	  oligonucleotide	  interaction	  monitored	  by	  mass	  spectrometry	  –	  
15N	  labelled	  complexes	  
In	  the	  previous	  section	  the	  platinum	  adduct	  formed	  after	  photoactivation	  of	  
8	   (t,t,t-­‐[Pt(N3)2(OH)2(py)2)	   in	   the	   presence	   of	   oligo	   1,	   d’(ATACATGCTACATA),	   was	  
characterised	  as	  [oligo	  1	  +	  [Pt(py)2].	  Figure	  2.20	  shows	  the	  fit	  of	  the	  deconvoluted	  
observed	  peak	  due	  to	  [oligo	  1	  +	  [Pt(py)2]	  to	  the	  predicted	  pattern	  (Bruker	  Daltonics	  
data	  analysis).	  To	  confirm	  the	  assignment	  in	  section	  2.3.3.1	  15N	  labelled	  complex	  8	  
was	  also	  photoactivated	  in	  the	  presence	  of	  oligo	  1.	  


























Figure	  2.20	  Deconvoluted	  spectra	  of	  (−)	  observed	  and	  (u)	  predicted	  peak	  patterns	  
of	  [M+[Pt(py)2]].	  
	  
An	   isotopically−labelled	   complex	   8,	   8X	   trans,trans,trans-­‐
[Pt(N3)2(OH)2(15Npy)2],	   (500	  μM)	   containing	   two	   15N	  atoms,	  one	   in	  each	  of	   the	  py	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ligands,	  was	  irradiated	  with	  420	  nm	  light	  in	  the	  presence	  of	  oilgo	  1	  (250	  μM).	  The	  
same	   protocol	   was	   carried	   out	   using	   complex	   8Y,	   trans,trans,trans-­‐
[Pt(15N3)2(OH)2(15Npy)2],	   	  compound	  8	  with	  an	  15N	   label	  on	  each	  of	  the	  py	   ligands,	  
and	  one	  15N	  atom	  on	  each	  of	  the	  azido	  ligands.	  The	  resulting	  deconvoluted	  spectra	  
of	  the	  de-­‐salted	  solutions,	  and	  of	  complex	  8	  with	  oligo	  1,	  are	  shown	  in	  Figure	  2.21.	  
When	  the	  strand	  was	  reacted	  with	  8X,	  the	  platinated	  oligonucleotide	  peak	  shifts	  by	  
2	  atomic	  mass	  units	  (see	  Fig.	  2.21	  spectra	  X	  and	  Z),	  indicating	  the	  presence	  of	  two	  
15N	  labelled	  atoms.	  The	  same	  reaction	  with	  the	  doubly-­‐labelled	  complex	  8Y	  gave	  an	  
identical	  spectrum	  to	  that	  of	   the	  singly-­‐labelled	  complex	   (Fig.	  2.21	  spectrum	  Y).	   It	  
can	   therefore	   be	   concluded	   that	   the	   azide	   ligands	   are	   no	   longer	   bound	   to	   the	  
platinum	  metal	  centre	  after	  the	  adduct	  is	  formed.	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Figure	   2.21	   Deconvoluted	   spectra	   of	   of	   the	   photoproducts	   of	   oligo	   1,	  
d’(ATACATGCTACATA),	   irradiated	   for	   60	   min	   in	   the	   presence	   of	   8X:	   t,t,t-­‐
[Pt(N3)2(OH)2(15Npy)2];	   8Y:	   t,t,t-­‐[Pt(15N3)2(OH)2(15Npy)2];	   and	   8:	   compound	   8,	   t,t,t-­‐
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The	  lipophilicity	  of	  a	  potential	  drug	  is	  an	  important	  property	  and	  can	  prove	  
useful	  in	  the	  selection	  of	  promising	  new	  candidates.	  Indeed	  a	  drug’s	  lipophilicity	  is	  
key	   to	   its	   pharmokinetics	   and	   its	   pharmaceutical	   properties.	   It	   can	  be	  used	  as	   an	  
indication	  of	  how	  well	  a	  drug	  can	  pass	  through	  the	  cell	  membrane,	  and	  hence	  this	  
can	   influence	   its	   activity	   in	   vivo.	   The	   hydrophobicity	   of	   a	   drug	   is	   thought	   to	   be	  
crucial	   for	   its	   adsorption,	   distribution,	  metabolism	   and	   excretion	   in	   patients.	   It	   is	  
one	  of	  only	  four	  fundamental	  properties	  listed	  in	  Lipinski’s	  rules	  for	  an	  ideal	  organic	  
drug	  molecule,21	  and	  although	  they	  were	  not	  intended	  for	  inorganic	  drugs	  they	  can	  
be	  applied	  to	  their	  design.	  Lipinski’s	   ‘rules	  of	  five’	  states	  that	  an	  orally-­‐active	  drug	  
should	  have	  a	  Log	  P	  value	  of	  less	  than	  5	  (later	  revised	  to	  between	  -­‐0.4	  and	  5.6).22	  	  
Typically	   the	   shake-­‐flask	   method	   is	   used	   to	   determine	   the	   octanol/water	  
partition	   factor	   Log	   P.	   Use	   of	   triplicates	   of	   triplicate	  measurements	   by	   the	   shake	  
flask	   method,	   using	   ICP-­‐MS	   for	   platinum	   detection,	   did	   not	   produce	   a	   single	  
reproducible	  value	  and	  hence	  the	  method	  was	  abandoned	   in	   favour	  of	  measuring	  
relative	  hydrophobicities	  by	  HPLC.	  Chromatography	  is	  often	  used	  to	  investigate	  the	  
lipophilicity	  of	  compounds	  using	  octanol	  and	  water	  as	  the	  mobile	  phase,23	  or	  more	  
commonly	   determining	   the	   retention	   times	   in	   RP-­‐HPLC24–27.	   This	   involves	  
ddetermining	  the	  relative	  hydrophobicity	  of	  the	  compounds	  by	  a	  chromatographic	  
method,	  and	  the	  retention	  times	  of	  a	  range	  of	  compounds	  with	  known	  Log	  P	  values.	  
The	  k’	  value	  of	  each	  compound	  is	  then	  calculated	  according	  to	  equation	  1,	  where	  tR	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is	  the	  retention	  time	  of	  the	  compound	  and	  t0	   is	  the	  dead	  time	  of	  the	  system.	  The	  
value	  of	  	  k’	  can	  then	  be	  input	  into	  equation	  2,24	  where	  a	  and	  b	  are	  constants,	  and	  by	  
plotting	  the	  known	  Log	  P	  values,	  against	  the	   log	  of	  their	  k’	  values	  a,	  and	  b	  can	  be	  
determined,	  and	  the	  unknown	  Log	  P	  values	  calculated.	  
	  
	  
Unfortunately,	  this	  method	  requires	  a	  range	  of	  calibrants	  that	  have	  a	  similar	  range	  
of	   Log	   P	   values	   to	   those	   under	   investigation.	   As	   noted	   above,	   it	   has	   not	   been	  
possible	   to	   determine	   Log	  P	   values	   for	   such	  hydrophilic	   platinum	  complexes.	   The	  
Log	  P	  value	  of	  cisplatin	  has	  been	  determined	  as	  −2.19,	  but	  Hambley	  et	  al.	   it	  found	  
to	  be	  as	   low	  as	   -­‐2.53,	  an	  average	  of	  all	  of	   the	   reported	  values	   is	  −2.32.28–32	   Since	  
complexes	   1-­‐10,	   of	   the	   general	   formula	   trans,trans,trans-­‐[Pt(N3)2(OH)2(R)(R’)],	  
contain	   two	   hydroxido	   ligands,	   it	   is	   expected	   that	   they	   would	   be	   even	   more	  
hydrophilic	  than	  cisplatin.	  Complex	  4,	  t,t,t-­‐[Pt(N3)2(OH)2(py)(NH3),	  for	  example,	  has	  
a	   solubility	   of	   50	   mM	   in	   H2O.11	   As	   it	   was	   not	   possible	   to	   obtain	   a	   range	   of	  
compounds	  with	  known	  Log	  P	  values	  similar	  to	  those	  predicted	  for	  complexes	  1	  −	  
10,	  only	  relative	  comparisons	  between	  the	  complexes	  can	  be	  made.	  
Assumptions	   about	   the	   lipophilicity	   of	   a	   given	   compound	   based	   on	   the	  
properties	  of	  a	  set	  of	  ligands,	  in	  this	  case	  the	  literature	  Log	  P	  values	  of	  R	  and	  R’	  (see	  
Table	   2.3),	   were	   not	   in	   agreement	   with	   the	   data	   obtained;	   for	   example,	   the	  
methylamine-­‐containing	   complex	   2,	   t,t,t-­‐[Pt(N3)2(OH)2(NH3)(NH2CH3)],	   is	   more	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lipophilic	   than	   complex	   7,	   t,t,t-­‐[Pt(N3)2(OH)2(NH2CH3)(py)].	   Compounds	   1	   (t,t,t-­‐
[Pt(N3)2(OH)2(NH3)2]),	   2	   and	   3	   (t,t,t-­‐[Pt(N3)2(OH)2(NH3)(NH2CH2CH3)])	   comprise	   a	  
series	  of	  increasingly	  hydrophobic	  compounds	  on	  consideration	  of	  to	  the	  R’	  ligands.	  
However,	  2	  had	  the	  highest	  retention	  time	  of	  the	  series	  (tR	  =8.1	  min),	  see	  Fig	  2.3,	  
higher	  than	  that	  of	  complex	  4	  (tR	  =6.7	  min),	  where	  R’	  =	  py.	  In	  the	  case	  of	  compound	  
7,	  in	  the	  series	  4,	  7,	  8,	  t,t,t-­‐[Pt(N3)2(OH)2(NH2CH3)(py)],	  where	  the	  R	  group	  increases	  
in	  hydrophobicity	  from	  4	  (tR	  =6.7	  min)	  to	  8	  (tR	  =14.5	  min),	  the	  retention	  time	  of	  7	  (tR	  
=3.9	   min)	   is	   much	   shorter	   than	   expected.	   The	   unusual	   behaviour	   of	   these	   two	  
complexes	  cannot	  be	  attributed	  to	  the	  methylamine	  ligand	  alone,	  as	  compound	  10,	  
t,t,t-­‐[Pt(N3)2(OH)2(NH2CH3)(thiazole)],	  has	  a	  retention	  time	  that	  follows	  a	  lipophilitic	  
trend	  with	  complex	  9,	  t,t,t-­‐[Pt(N3)2(OH)2(NH3)(thiazole)].	  
	  
Table	  2.3	  Literature	  Log	  P	  values	  for	  the	  R	  and	  R'	  ligands	  of	  complexes	  1	  −	  10,	  *	  
indicates	  a	  predicted	  value.	  	  
Ligand	   Log	  P	  
NH3	   -­‐1.3833	  
NH2CH3	   -­‐0.5734	  
NH2CH2CH3	   -­‐0.1334	  
py	   0.6534	  
2-­‐pic	   1.19±0.19*35	  
4-­‐pic	   1.2233	  
tz	   0.44±0.29*36	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There	   are	   some	   theoretical	   trends	   in	   lipophilicity,	   based	   on	   the	   values	   in	  
Table	   2.3,	   that	   are	  borne	  out	  by	  data	   acquired.	   For	   example,	  with	   the	   sequential	  
substitution	  of	  NH3	  groups	  by	  more	  hydrophobic	  pyridine	  (py)	  ligands	  in	  the	  series	  
1,	   t,t,t-­‐[Pt(N3)2(OH)2(NH3)2]	   (tR	  =	  2.7),	  4,	   t,t,t-­‐[Pt(N3)2(OH)2(NH3)(py)],	   (tR	  =6.7	  min),	  
8,	  t,t,t-­‐[Pt(N3)2(OH)2(py)2],	  (tR	  =14.5	  min)	  leads	  to	  increased	  retention	  times.	  This	  is	  
also	  true	  of	  the	  series	  4-­‐6	  in	  which	  the	  py	  R’	  ligand	  has	  a	  methyl	  substituent	  added	  
at	   two	   different	   positions	   (2-­‐picoline,	   complex	   5,	   and	   4-­‐picoline,	   complex	   6).	  
However,	   this	   series,	   whilst	   in	   agreement	   with	   the	   retention	   time	   of	   1,	   has	   an	  
unexpectedly	  high	  tR	  value,	  5	  (14.2	  min)	  	  
These	   results	   suggest	   that	   the	   overall	   lipophilicity	   of	   a	   metal	   complex	   is	  
affected	   by	   more	   than	   just	   the	   properties	   of	   the	   individual	   ligands.	   Indeed,	  
attempts	  to	  predict	  the	  lipophilicity	  of	  Pt(IV)	  compounds	  by	  computational	  methods	  
have	   had	   to	   take	   this	   into	   account.	   Oldfield	   et	   al.	   developed	   a	   quantitative	  
structure-­‐property	   relationship	   (QSPR)	   for	   platinum	   complexes	   based	   on	   density	  
functional	   theory	   (DFT)	  calculations,	  and	  reported	   literature	  Log	  P	  values.31,32	  This	  
proved	  much	  more	  effective	  than	  relying	  upon	  predictions	  made	  using	  values	  based	  
on	   the	   ligand	   properties	   alone,	   consistent	   with	   the	   discrepancies	   in	   the	   data	  
reported	  here.	  Gramatica	  et	  al.	   report	   a	   similar	   approach	   to	  modelling	  QSPRs	   for	  
platinum	   based	   complexes,	   where	   a	   lipophilic	   descriptor	   and	   an	   electronic	  
descriptor	  are	  used	  to	  predict	  the	  lipophilicity	  of	  the	  whole	  compound.37	  This	  type	  
of	   method	   has	   been	   refined	   by	   Ermondi	   et	   al.	   to	   include	   VolSurf	   descriptors	  
(descriptors	   based	   on	   3D	   molecular	   fields)	   for	   improving	   the	   accuracy	   of	   the	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predictions.38	   This	   new	   QSPR	   model	   shows	   the	   importance,	   not	   just	   of	   the	  
lipophilicity	   of	   the	   substituent	   parts	   of	   the	   molecule,	   but	   also	   of	   its	   size	   and	  
hydrophobic	   interactions,	   specifically,	   that	   ligand	   orientation	   and	   subsequent	  
surface	   exposure	   to	   solvent	   are	   very	   important	   in	   determining	   the	   overall	  
lipophilicity	  of	  the	  complex.	  This	  supports	  data	  reported	  in	  Section	  2.3.1.1	  and	  the	  
findings	  that	  the	  lipophilicity	  cannot	  be	  predicted	  merely	  by	  ligand	  structure	  alone	  
and	  the	  solvation	  of	  the	  molecule	  must	  be	  considered.	  
The	   findings	   of	  Oldfield31,32	   and	   Ermondi38	   go	   some	  way	   to	   explaining	   the	  
anomalous	   results	   observed	   in	   Section	   2.3.1.1,	   but	   there	   are	   other	   factors	   to	  
consider.	   The	   partitioning	   of	   a	   complex	   between	   the	   mobile	   and	   stationary	  
chromatographic	  phases	  is	  a	  pH	  dependent	  process.	  This	  phenomenon	  was	  used	  by	  
Wiczling	  et	  al.	  to	  develop	  an	  HPLC-­‐based	  approach	  to	  deriving	  Log	  P	  and	  pKa	  values	  
of	  drugs	  by	  altering	  the	  pH	  value	  of	  the	  mobile	  phase.39	  The	  experiments	  reported	  
in	  this	  chapter	  used	  a	  mobile	  phase	  containing	  an	  ion-­‐pairing	  agent	  to	  ensure	  that	  
any	   charged	   species	   could	   be	   detected	   according	   to	   their	   hydrophobicity.	   In	   this	  
case	  the	  ion-­‐pairing	  agent	  used	  was	  trifluoroaceatic	  acid	  (TFA),	  which	  reduced	  the	  
pH	  of	  the	  mobile	  phase	  to	  1.7.	  Ronconi	  et	  al.	  found	  that	  for	  complexes	  of	  the	  type	  
([Pt(N3)2(OH)2(R)(R’)]),	   the	  pKa	   for	   the	  deprotonation	  of	   the	   first	  hydroxyl	  group	   is	  
around	  pH	  3,	  for	  example	  for	  complex	  1	  the	  pKa	  value	  is	  3.42	  ±	 0.01.40	  Alteration	  of	  
the	   am(m)ine	   ligands	   in	   the	   trans,trans,cis-­‐[Pt(N3)2(OH)2(R)(R’)]	   isomer	   had	   little	  
effect	   on	   the	   pKa	   of	   the	   hydroxyl	   group.	   Hence,	   all	   of	   the	   complexes	   should	   be	  
protonated	  in	  the	  aqueous	  mobile	  phase	  at	  pH	  1.7.	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The	  use	  of	  an	   ion-­‐pairing	  agent,	  combined	  with	  the	   low	  pH	  value	   indicates	  
that	  the	  complexes	  are	  protonated	  in	  the	  mobile	  phase	  and	  associated	  with	  the	  ion	  
pairing	  agent,	  i.e.	  the	  surface	  presented	  to	  the	  solvent	  molecules	  and	  the	  stationary	  
phase	  may	  be	  different	  from	  that	  of	  the	  complex	  alone.	  As	  previously	  discussed,	  the	  
interaction	  of	  a	  complex	  with	  solvent	  can	  have	  a	  significant	  effect	  on	  its	  retention	  
time	   and	   perceived	   lipophilicity.	   This	   suggests	   that	   the	   relative	   hydrophobicities	  
measured	  are	  of	  the	  TFA-­‐associated	  molecules	  not	  of	  complexes	  1	  −	  10.	  However,	  it	  
was	  necessary	  to	  include	  the	  TFA	  to	  allow	  for	  the	  separation	  and	  detection	  of	  any	  
charged	   Pt(II)	   impurities,	   and	   also	   to	   prevent	   peak	   broadening.	   This	   problem	  
associated	  with	  measuring	  lipophilicities	  by	  HPLC	  again	  highlights	  the	  fact	  that	  there	  
are	   many	   factors	   that	   contribute	   to	   a	   compound’s	   lipophilicity,	   and	   it	   is	   not	  
determined	  by	  the	  properties	  of	  the	  ligands	  alone.	  
2.4.2	  Platinum	  Accumulation	  in	  A2780	  Cells	  
It	   has	   previously	   been	   reported	   that,	   as	   is	   the	   case	  with	  many	   drugs,	   the	  
lipophilicity	   of	   Pt(IV)	   drugs	   has	   a	   positive	   correlation	   with	   their	   cellular	  
accumulation.30,41	   In	   the	  case	  of	   the	  complexes	   investigated	  by	  Oldfield	  et	  al,	   this	  
relationship	  showed	  a	  dramatic	  increase	  in	  uptake	  for	  complexes	  with	  positive	  Log	  
P	  values.31	  The	  reported	  higher	  Log	  P	  values	  were	  achieved	  by	  modifying	  the	  axial	  
ligands,	   and	   hence,	   increasing	   their	   hydrophobicity.	   The	   work	   in	   this	   chapter	  
compares	   the	   relative	   lipophilicity	   of	   ten	  Pt(IV)	   diazido	   complexes,	   of	   the	   general	  
formula	   trans,trans,trans-­‐[Pt(N3)2(OH)2(R)(R’)],	   with	   their	   cellular	   accumulation	  
after	   1	   h	   of	   exposure	   to	   100	   μM	   drug	   solutions	   in	   the	   dark.	   Data	   presented	   in	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Figures	   2.4	   and	   2.5	   show	   no	   correlation	   between	   the	   relative	   lipophilicity	   of	   the	  
complexes	  and	  their	  cellular	  accumulation	  across	  the	  series	  1	  −	  10.	  However,	  there	  
are	  some	  sub-­‐series	  that	  do	  exhibit	  the	  expected	  relationship:	  complexes	  1	  −	  3,	  and	  
complexes	  9	  and	  10.	  Of	  these	  two	  sub	  series	  9	  and	  10	  also	  followed	  the	  predicted	  
pattern	  of	  relative	  lipophilicity.	  The	  trend	  in	  cellular	  accumulation	  for	  complexes	  1	  −	  
3	   followed	   the	   same,	   if	   unexpected,	   pattern	   as	   that	   of	   their	   relative	   lipophilicity.	  
However,	  the	  cellular	  uptake	  of	  the	  sub-­‐series	  4	  −	  6	  shows	  a	  slightly	  different	  trend	  
to	  that	  of	  their	  lipophilicities.	  The	  cellular	  accumulation	  of	  5	  (3.8	  ng	  Pt	  /	  106	  cells),	  
and	  6	  (3.9	  ng	  Pt	  /	  106	  cells)	  is	  slightly	  higher	  than	  that	  of	  4	  (2.0	  ng	  Pt	  /	  106	  cells)	  and	  
there	  is	  a	  much	  smaller	  difference	  between	  their	  retention	  times,	  4	  (tR	  =	  6.7	  min),	  5	  
(tR	  =	  14.2	  min),	  6	   (tR	  =	  15.8	  min).	  The	  sub-­‐series	  1,	  4,	  and	  8,	  contains	  the	  complex	  
accumulated	   the	  most	   in	   the	   cells,	   complex	  8,	   t,t,t-­‐[Pt(N3)2(OH)2(py)2],	  which	   also	  
has	  the	  longest	  retention	  time	  of	  the	  t	  (tR	  =	  14.5	  min)	  and	  so	  follows	  the	  expected	  
lipophilic	   trend.	   Of	   the	   other	   complexes	   in	   the	   sub-­‐series	   (complexes	   1	   and	   4),	  
complex	   1	   also	   seems	   to	   exhibit	   a	   correlation	   between	   lipophilicity	   and	   cellular	  
accumulation,	   but	   complex	   4	   shows	   only	   a	   poor	   uptake	   (2.0	   ng	   /	   106	   cells),	   the	  
lowest	  of	  all	  ten	  compounds	  investigated.	  	  
There	  is	  a	  lack	  of	  correlation	  between	  the	  lipophilicity	  of	  complexes	  1-­‐10,	  as	  
determined	   by	   their	   chromatographic	   retention	   time,	   and	   their	   cellular	  
accumulation	   in	   A2780	   cancer	   cells.	   A	   correlation	   between	   these	   two	   properties,	  
along	  with	   linear	  uptake,	  non-­‐saturable	  uptake	  kinetics,	  and	  a	   lack	  of	  competitive	  
uptake	   inhibition	  by	  analogues,	  are	   indicative	  of	  passive	  diffusion.42,43	  Platinum(II)	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complexes	  have	  already	  been	  reported	  as	  entering	  cells	  by	  active	  transport	  via	  the	  
copper	  transporter	  CTR1	  and	  organic	  cation	  transporters	  1	  and	  2.44–48	  Active	  efflux	  
of	   cisplatin	   by	   the	   copper	   efflux	   transporters	   ATP7A	   and	   ATP7B,	   or	   efflux	   of	   Pt-­‐
glutathione	   conjugates	   by	   the	  GS-­‐X	   efflux	   transporters,	   has	   also	   been	   reported.42	  
Therefore	   it	  may	   be	   possible	   for	   these	   Pt(IV)	   diazido	   complexes	   to	   enter	   cells	   by	  
similar	  means.	  
This	   particular	   class	   of	   Pt(IV)	   diazido	   complex	   is	   highly	   water	   soluble,	  
typically	   in	   the	   tens	   of	   milimolar	   range,	   and	   yet	   4	   out	   of	   10	   of	   the	   series	   are	  
accumulated	  to	  a	  similar	  or	   to	  a	  higher	   level	   than	  the	  established	  platinum-­‐based	  
drug	  cisplatin,	  see	  Table	  2.1.	  The	  lack	  of	  correlation	  between	  their	  lipophilicity	  and	  
cellular	   accumulation	   suggests	   that	   theses	  Pt(IV)	  diazido	   complexes	  enter	   cells	  by	  
more	  than	  passive	  diffusion	  alone.	  It	  is	  also	  possible	  that	  the	  Pt(IV)	  complexes	  have	  
been	  reduced	  before	  they	  enter	  the	  cell,	  explaining	  the	  lack	  of	  correlation.	  The	  cell	  
culture	  medium	  used	  in	  the	  drug	  accumulation	  experiments	  (RPMI)	  contains	  amino	  
acids	  and,	  phosphate	  in	   large	  excess	  (when	  compared	  to	  the	  platinum	  complexes)	  
that	   are	   capable	   of	   reducing	   the	   complexes.	   The	   –OH	   axial	   ligands	   employed	   do	  
increase	  the	  stability	  of	  Pt(IV)	  complexes,	  as	  shown	  by	  Hambley	  et	  al.49	  This	  along	  
with	  the	  short	  exposure	  time	  used	   in	  the	  experiments	  minimises	  the	   likelihood	  of	  
reduction	  taking	  place	  but	  may	  not	  prevent	  it	  entirely.	  The	  new	  Pt(II)	  species	  then	  
may	  react	  further	  with	  species	  in	  the	  media.	  
The	  relationship	  between	  the	  cellular	  accumulation	  of	  complexes	  1	  −	  10	  and	  
their	  antiproliferative	  activity	  in	  A2780	  cancer	  cells,	  after	  activation	  for	  1	  h	  with	  365	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nm	   UVA,	   is	   summarised	   in	   Figure	   2.6.	   There	   is	   no	   correlation	   across	   the	   whole	  
series	   between	   the	   two,	   but	   this	   could	   arise	   for	   several	   reasons.	   The	   complexes	  
under	  investigation	  are	  prodrugs	  that	  must	  be	  photoactivated	  to	  become	  effective.	  
Therefore,	   the	   quantum	   yield	   (the	   amount	   of	   complex	   converted	   per	   photon	   of	  
energy	   absorbed)	   is	   a	   key	   factor	   in	   generating	   enough	   of	   the	   active	   species	   to	  
achieve	   cell	   death.	   The	   efficacy	   of	   established	   platinum-­‐based	   drugs	   such	   as	  
cisplatin	  is	  attributed	  to	  the	  activation	  of	  apoptotic	  pathways	  by	  the	  binding	  of	  DNA	  
repair	  proteins	  to	  lesions	  formed	  on	  DNA	  by	  the	  metal	  complex.	  The	  nature	  of	  the	  
lesion	   formed	   by	   different	   platinum	   complexes	   is	   thought	   to	   be	   responsible	   for	  
their	   differences	   in	   their	   activities.52–55	   It	   is	   worth	   noting	   that	   the	   most	   active	  
complex,	   8,	   had	   the	   highest	   level	   of	   cellular	   accumulation,	   the	   highest	   relative	  
lipophilicity	  (see	  Table	  2.1)	  and	  has	  a	  quantum	  yield	  of	  0.105	  at	  365	  nm	  (for	  a	  3.00	  
mM	  solution).13	  All	  of	  these	  factors	  may	  contribute	  to	  the	  increased	  potency	  of	  this	  
complex.	  
As	  a	  class	  of	  compound	  these	  potential	  anticancer	  drugs	  have	  been	  shown	  
to	  be	  highly	  active	  when	  irradiated	  with	  365	  nm	  UVA	  in	  A2780	  cancer	  cells,	  in	  some	  
cases	   (complexes	   6-­‐10)	   more	   than	   an	   order	   of	   magnitude	   more	   active	   than	  
cisplatin.	  They	  are	  highly	  active,	  even	  with	  the	  very	  short	  1.00	  h	  drug	  exposure	  time	  
and	  1	  h	  irradiation	  time.	  Only	  two	  compounds,	  6	  (IC50	  =	  26.8	  µM)	  and	  9	  (IC50	  =	  186.9	  
µM),	   exhibit	   any	   significant	   dark	   toxicity,	   and	   only	   one	   of	   these	   two	   (6)	   is	   more	  
active	   in	   the	  dark	  cisplatin	   (IC50	  =	  152	  µM).	  All	  other	  compounds	  have	  a	  dark	   IC50	  
value	  higher	  than	  210	  µM,	  greater	  than	  the	  concentration	  range	  used.	  These	  data	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highlight	   the	   temporal	   and	   spatial	   targeting	  offered	  by	   this	   exciting	   class	  of	  drug.	  
Further	  investigation	  of	  their	  behaviour	  once	  they	  have	  entered	  the	  cell	  is	  required	  
to	  gain	  more	  insight	  into	  the	  mechanism	  of	  action	  of	  these	  drugs.	  
2.4.3	  Study	  of	  photoactivatable	  Pt(IV)	  diazido	  complex	  interaction	  with	  
oligonucleotides	  by	  chromatography	  
The	   very	   low	   IC50	   of	   photoactivated	   complex	   8,	   t,t,t-­‐
[Pt(N3)2(OH)2(NH2CH3)(py)]	  in	  cancer	  cells,	  along	  with	  its	  high	  cellular	  accumulation	  
and	   relative	   lipophilicity	   make	   it	   an	   interesting	   candidate	   for	   study.	   As	   much	   is	  
already	   known	   about	   the	   most	   of	   the	   factors	   affecting	   the	   efficacy	   of	   this	  
photoactivatable	  drug,	  such	  as	  the	  quantum	  yield,	  the	  DNA	  adducts	  formed	  by	  the	  
complex	   upon	   activation	   with	   light	   was	   investigated.	   Some	   studies	   involving	   the	  
interaction	  of	  8	  with	  calf	  thymus	  DNA	  have	  been	  reported,56	  suggesting	  that	  after	  
photactivation	   8	   binds	   to	   DNA	   16	   times	   more	   than	   cisplatin	   and	   forms	   lesions	  
distinctly	  different	  to	  that	  of	  those	  formed	  by	  transplatin	  and	  cisplatin.	  In	  the	  study	  
reported	   here,	   short	   single	   strand	   oligonucleotides	   were	   selected	   for	   analysis	   by	  
mass	   spectrometry	   in	   order	   to	   replicate	   the	   increased	   concentration	   of	   single	  
stranded	  DNA	  in	  the	  rapidly	  proliferating	  cancer	  cells.	  
Chromatography	  is	  an	  analytical	  technique	  that	  has	  been	  used	  to	  study	  the	  
interaction	  of	  metal-­‐based	  drugs	  with	  DNA.	  The	  early	  work	  of	  Eastman	  followed	  the	  
reaction	   of	   cisplatin	   with	   deoxyribonucleosides	   by	   HPLC	   and	   1H	   NMR.57	   More	  
common	   metal-­‐based	   drugs	   are	   reacted	   with	   calf	   thymus	   DNA,	   enzymatically	  
digested	  and	  the	  resulting	  mixture	   is	  analysed	  by	  HPLC.58–61,17	  The	  use	  of	  controls	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and	  reactions	  of	  the	  drug	  with	  individual	  nucleotides	  allowed	  for	  the	  identification	  
and	  quantification	  of	  the	  adducts	  formed	  with	  calf	  thymus	  DNA	  or	  cellular	  DNA.	  In	  
this	  study,	  undigested	  DNA	  was	  used	  as	  only	  short	  strands	  were	  reacted	  with	   the	  
drug.	  An	  HPLC	  method	  was	  developed	  specifically	  for	  the	  separation	  of	  short-­‐strand	  
oligonucleotides,	  and	  those	  with	  platinum	  adducts	  bound	  to	  them.	  
Complex	   8	   (500	   μM)	  was	   irradiated	  with	   365	   nm	  UVA	   in	   the	   presence	   of	  
d’(ATACATGCTACATA),	  oligo	  1,	  (250	  μM)	  in	  water	  at	  37°C	  for	  2.00	  h.	  Aliquots	  were	  
taken	   every	   30	   min	   and	   analysed	   by	   HPLC.	   Time	   points	   at	   0	   and	   30	   min	   of	  
irradiation	   are	   shown	   in	   Figure	   2.9.	   After	   30	  min	   of	   irradiation,	   a	   new	   peak	  was	  
detected	  at	  19.7	  min,	  assigned	  as	  a	  platinated	  strand	  oligo	  1.	  There	  appears	  to	  be	  
only	  one	  new	  species	  generated	  by	  the	  photoactivation	  of	  8	  in	  the	  presence	  of	  oligo	  
1.	  However,	  due	  to	  the	  steep	  solvent	  gradient	  at	  this	  point	  of	  the	  HPLC	  method,	  it	  is	  
possible	   that	   more	   than	   one	   species	   may	   be	   contained	   within	   one	   peak	   of	   the	  
chromatogram.	   In	   the	  case	  of	  cisplatin	   it	   is	  known	  that	   there	  are	  several	   types	  of	  
Pt(II)-­‐DNA	   adducts	   formed,	   1,2-­‐d(GpG),	   1,2-­‐d(ApG),	   and	   1,3-­‐d(GpNpG).62,63	   The	  
second	   generation	   platinum	   drug	   carboplatin	   displays	   a	   similar	   DNA-­‐binding	  
profile,64	  as	  does	  oxaliplatin.65,54,66	  The	  efficacy	  of	  all	  three	  drugs	  is	  reliant	  upon	  the	  
1,2-­‐d(GpG)	  adducts.	  There	  is	  a	  smaller	  peak	  at	  5.1	  min	  possibly	  due	  to	  a	  folding	  of	  
the	   oligonucleotide,	   the	   DNA	   folding	   prediction	   programme	   mfold	   predicts	   the	  
formation	  of	  a	  hairpin	  at	  37°C,	  and	  0.5	  mM	  Na+	  see	  Figure	  2.22,67	  as	  the	  retention	  
time	  is	  very	  similar	  to	  that	  of	  oligo	  1	  and	  is	  also	  present	  in	  the	  chromatogram	  of	  the	  
solution	  on	  the	  dark.	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Figure	   2.22	   Structure	   of	   the	   hairpin	   formed	   by	   oligo	   1,	   d’(ATACATGCTACATA),	   at	  
37°C,	  0.5	  mM	  Na+.67	  
	  
2.4.4	  Sequence	  selectivity	  of	  Pt(IV)	  diazido	  complex	  oligonucleotide	  binding	  
The	   binding	   of	   8	   to	   three	   different	   oligonucleotide	   sequences	   was	  
compared.	  The	  sequences	  of	  the	  strands	  are:	  
oligo	  1	  d’(ATACATGCTACATA)	  	  
oligo	  2	  d’(ATACATGGTACATA)	  	  
oligo	  3	  d’(ATACGTGCTACATA)	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Each	  strand	  offers	  the	  possibility	  of	  the	  formation	  of	  several	  bis-­‐	  and	  mono-­‐adducts	  
of	  Pt	  complexes.	  Oligo	  1	  would	  allow	  the	  Pt(II)	  photoactivated	  form	  of	  complex	  8	  to	  
create	   mono-­‐adducts,	   likely	   at	   N7	   of	   guanine	   and	   N7	   or	   N1	   of	   adenine,	   1,3-­‐
d(ApNpG)	   bis-­‐adducts.	   All	   of	   these	   adducts	   could	   still	   be	   formed	   when	   8	   is	  
irradiated	  in	  the	  presence	  of	  oligo	  2,	  with	  the	  additional	  possibility	  of	  forming	  a	  1,2-­‐
d(GpG)	  bis-­‐adduct	  (the	  type	  of	  adduct	  responsible	  for	  the	  antiproliferative	  activity	  
of	  cisplatin).	  Photoactivation	  of	  8	  in	  the	  presence	  of	  oligo	  3	  can,	  once	  again,	  lead	  to	  
the	  formation	  of	  the	  same	  type	  of	  adducts	  that	  could	  be	  formed	  with	  oligo	  1,	  with	  
the	  addition	  of	  a	  1,3-­‐d(GpNpG)	  bis-­‐adduct.	  
The	  three	  oligonucleotides	  (250	  μM)	  were	  reacted	  with	  complex	  8	  (500	  μM)	  
and	  oligo	  2	  (250	  μM)	  in	  water	  was	  then	  irradiated	  with	  365	  nm	  UVA	  for	  2.00	  h,	  with	  
aliquots	  taken	  every	  30	  min.	  The	  results	  for	  oligo	  1,	  oligo	  2	  and	  oligo	  3	  are	  shown	  in	  
Figures	  2.9,	  2.10	  and	  2.11	  respectively.	  All	  of	  the	  solutions,	  when	  equilibrated	  in	  the	  
dark	  for	  2	  min	  after	  mixing,	  showed	  no	  reaction	  with	  8.	  The	  chromatograms	  of	  the	  
solutions	   irradiated	   with	   365	   nm	   for	   30	  min,	   labelled	   as	   chromatogram	   B	   in	   the	  
figures,	   contains	   a	   peak	   at	   19.7	   min	   attributable	   to	   a	   Pt-­‐oligonucleotide	   adduct.	  
Comparing	   the	   rates	  of	  platination	  of	   the	   three	  oligonucleotides,	   see	  Figure	  2.13,	  
the	  percentage	  peak	  area	  attributed	   to	   the	  platinated	  oligonucleotide	   follows	   the	  
trend:	  oligo	  1	  >oligo	  3	  >oligo	  2.	  	  
The	   fact	   that	   binding	   of	   the	   photoactivated	   form	   of	   8	   to	   oligo	   2	   is	  
disfavoured	  supports	  the	  findings	  of	  Pracharova	  et	  al.	  that	  the	  DNA	  lesions	  of	  8	  are	  
different	   to	   those	   formed	   by	   cisplatin,	   since	   oligo	   contains	   the	   classical	   cisplatin	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1,2(GpG)	  DNA	  binding	   site.56	   Small	  differences	   in	   the	  bend	   induced	   in	   the	  double	  
helix	   of	   DNA	   by	   the	   1,2-­‐d(GpG)	   lesion	   caused	   by	   oxaliplatin,	   are	   3°	   −	 4°	   less	  
compared	   to	   that	   of	   cisplatin,68	   is	   thought	   to	   be	   responsible	   for	   oxaliplatin’s	  
increased	   potency	   in	   colorectal	   cancer	   cells,	   previously	   not	   treatable	   with	  
cisplatin.69	   However,	   the	   interaction	   of	   the	   multinuclear	   platinum-­‐base	   drug	  
BBR3464	   of	   Farrell	   et	   al.	   with	   DNA	   gives	   rise	   to	   a	   unique	   binding	   mode.70	   The	  
mechanism	   of	   these	  multinuclear	   drugs	   involves	   the	   induction	   of	   cell	   autophagy,	  
before	   the	   activation	   of	   apoptotic	   pathways	   in	   order	   to	   achieve	   cell	   death;71	   this	  
may	  give	  rise	  to	  their	  activity	  in	  cisplatin-­‐resistant	  cell	  lines.	  
Prachova	   et	   al.,	   reported	   that	   8	   forms	   a	   1,3-­‐d(GpNpG)	   bis-­‐adduct.	   The	  
findings	   of	   this	   study	   that	   binding	   to	   oligos	   1	   and	   3	   both	   containing	   either	   1,3-­‐
d(ApNpG)	   or	   1,3-­‐d(GpNpG)	   binding	  modes	   supports	   their	   findings.	   The	   increased	  
steric	  bulk	  of	   the	  py	   ligands	  of	  8	   (compared	   to	   the	  NH3	   ligands	  of	  cisplatin)	   could	  
cause	  the	  1,2-­‐d(GpG)	  adduct	  to	  be	  disfavoured.	  It	  is	  also	  widely	  reported	  that	  other	  
platinum	   complexes	   of	   trans-­‐configuration	   form	   1,3-­‐bisadducts.72	   Computational	  
and	  theoretical	  studies	  by	  Tai	  et	  al.	  indicates	  that	  the	  reaction	  of	  duplex	  DNA	  with	  
photoactivated	  8	  may	  lead	  to	  GG	  interstrand	  crosslinks,	  and	  there	  is	  some	  evidence	  
that	  GC	  interstrand	  crosslinks	  may	  be	  formed.73,74,14	  The	  unusual	  binding	  mode	  of	  8	  
to	  DNA	  indicates	  that	  the	  mechanism	  of	  action	  of	  this	  drug	  is	  different	  from	  that	  of	  
conventional	   platinum-­‐based	  drugs,	   offering	   a	  new	   spectrum	  of	   activity	   in	   cancer	  
cells.	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2.4.5	  The	  effects	  of	  altering	  the	  wavelength	  of	  activation	  on	  the	  binding	  of	  Pt(IV)	  
diazido	  complexes	  to	  a	  series	  of	  oligonucleotides	  
The	   activation	   of	   light-­‐sensitive	   drugs	   within	   tissue	   is	   optimal	   if	   the	  
compound	  can	  be	  activated	  by	  wavelengths	  within	  the	  therapeutic	  window	  of	  600	  -­‐	  
850	  nm.75	  This	  is	  because	  longer	  wavelengths	  of	  light	  penetrate	  further	  into	  tissue	  
up	   to	   the	   point	   that	   coloured	   proteins	   such	   as	   haemoglobin	   begin	   to	   absorb	   the	  
longer	  wavelengths.	  Various	  constituent	  amino	  acids,	  small	  molecules	  and	  lipids	  etc	  
absorb	  the	  shorter	  wavelengths	  of	  light.19	  It	  has	  been	  shown	  that	  complex	  8	  can	  be	  
activated	  not	  just	  by	  UVA	  but	  by	  wavelengths	  as	  long	  as	  green	  light.13	  The	  effect	  of	  
altering	   the	  wavelength	  of	   activation	  of	  8	   from	  365	  nm	   to	   420	  nm	  on	  binding	   to	  
oligo	  1	  was	  investigated	  in	  Section	  2.3.2.	  
For	  both	  wavelengths	  of	   irradiation,	  a	  solution	  of	  complex	  8	   (500	  μM)	  and	  
oligo	  1	  (250	  μM)	  in	  water	  was	  irradiated	  for	  a	  2	  h	  period	  with	  aliquots	  taken	  every	  
30	  min.	  Chromatogram	  B	  (Fig.	  2.9)	  shows	  the	  appearance	  of	  a	  new	  peak	  at	  19.7	  min	  
after	   30	   min	   of	   irradiation	   with	   365	   nm	   light,	   assigned	   as	   a	   Pt-­‐oligonucleotide	  
adduct.	  After	  irradiation	  for	  30	  min	  with	  420	  nm	  light,	  chromatogram	  B	  Figure	  2.14,	  
again	  a	  peak	  at	  19.7	  min	  was	  detected.	  	  
When	  comparing	  the	  two	  wavelengths	  of	  activation	  the	  solution	   irradiated	  
with	   365	   nm	   reaches	   a	  maximum	   amount	   of	   oligonucleotide	   platination	   after	   30	  
min	  of	   irradiation,	  whereas	  the	  solution	  irradiated	  with	  420	  nm	  light	  takes	  90	  min	  
to	  achieve	  the	  same	  levels	  of	  platination.	  This	  would	  seem	  to	  be	  the	  only	  notable	  
difference	  between	  the	  two	  solutions.	  This	  agrees	  with	  the	  findings	  of	  Prachova	  et	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al.,56	   who	   found	   little	   difference	   when	   comparing	   365	   nm	   and	   420	   nm	   light	  
activation	  of	  8	  in	  transcription-­‐mapping	  experiments	  using	  plasmid	  DNA.	  This	  work	  
also	  gives	  some	  insight	  into	  the	  low	  overall	  amount	  of	  oligonucleotide	  platination	  of	  
8	  observed	  in	  this	  study.	  The	  experiments	  of	  Prachova	  et	  al	  followed	  the	  reaction	  of	  
8	  with	   calf	   thymus	  DNA	  over	   a	   24	   h	   period	  using	   thiourea	   to	   trap	  mono-­‐adducts	  
shows	   that	   the	   concentration	   of	   bis-­‐adducts	   formed	   is	   initially	   very	   low,	   and	  
increases	  during	  the	  first	  10	  h.	  The	  rapid	  analysis	  of	  the	  samples	  in	  this	  investigation	  
may	   indicate	   that	   these	   chromatographic	   studies	   did	   not	   detect	   similar	   levels	   to	  
those	  observed	  in	  biological	  assays.56,13	  
2.4.6	  Photoactivatable	  Pt(IV)	  diazido	  complex	  interaction	  with	  an	  oligonucleotide	  
by	  mass	  spectrometry	  
It	  was	  established	  by	  chromatographic	  methods	   in	  Section	  2.3.2	   that	  upon	  
photoactivation	  of	  8	   in	  the	  presence	  of	  an	  oligonucleotide	  a	  new	  species,	  thought	  
to	  be	  a	  platinated	  oligonucleotide,	  is	  formed.	  To	  identify	  the	  platinum-­‐DNA	  adduct	  
formed	   by	   8	   after	   irradiation,	   mass	   spectrometric	   methods	   were	   employed.	  
Solutions	  of	  8	  and	  oligo	  1	  in	  a	  1	  to	  1	  molar	  ratio	  were	  irradiated	  with	  365	  nm	  and	  
420	   nm	   light.	   Both	   solutions	   (Figures	   2.18	   and	   2.19)	   were	   analysed	   by	   mass	  
spectrometry	  and	  were	  found	  to	  contain	  unreacted	  oligo	  1	  and	  [oligo	  1	  +	  [Pt(py)2]].	  
Where	   two	  equivalents	  of	  8	  were	  used	   the	   species	   [oligo	  1	  +	  2[Pt(py)2]]	  was	  also	  
detected.	  The	  nature	  of	  the	  remaining	   ligands	  bound	  to	  the	  platinum	  centre	  after	  
adduct	   formation	  was	   confirmed	   by	   the	   use	   of	   15N	   labelled	   versions	   of	  8,	   Figure	  
2.21.	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From	  the	  MS	  data	  and	  the	  four	  coordinate	  square-­‐planar	  binding	  nature	  of	  
Pt(II),	  we	  can	  deduce	  that	  there	  are	  two	  pyridines	  coordinated	  to	  the	  metal	  centre	  
and	   binding	   to	   a	   DNA	   base	   accounts	   for	   another	   coordination	   site,	   leaving	   one	  
binding	  site	  unaccounted	  for.	  One	  possibility	  is	  that	  a	  mono-­‐adduct	  is	  formed	  and	  a	  
solvent	   molecule	   that	   is	   lost	   during	   the	   ionisation	   process	   could	   occupy	   the	  
remaining	  platinum(II)	   coordination	   site.	  Alternatively,	   the	  platinum	  could	  bind	   to	  
the	   oligonucleotide	   at	   two	   points,	   e.g.	   through	   the	  N7	   of	   guanine	   and	   the	  N3	   of	  
cytosine	  as	  noted	  in	  the	  interstrand	  crosslinks	  of	  trans-­‐Pt(II)	  complexes.52-­‐56	  The	  low	  
relative	  intensity	  of	  the	  [oligo	  1	  +	  [Pt(py)2]]	  species,	  -­‐3	  charge	  state	  (1525.601	  m/z)	  
and	   -­‐4	   (1143.456	  m/z),	   revealed	   that	  although	   individual	  peaks	   could	  be	   isolated,	  
the	  fragments	  of	  the	  oligonucleotide	  could	  not	  be	  detected	  above	  the	  background	  	  
noise	  of	  the	  instrument.	  The	  use	  of	  very	  low	  collision	  energies	  (1-­‐2	  eV),	  in	  an	  attept	  
to	   try	   to	   maintain	   peak	   intensity	   was	   not	   effective.	   This	   shows	   that	   it	   was	   not	  
possible	   to	   locate	   the	   platinum	   binding	   site	   by	   utilising	   the	   protein-­‐like	  
fragmentation	   of	   oligonucleotides8,76,7	   undergoing	   CID,	   although	   this	   has	   been	  
achieved	  with	  metal-­‐based	  drugs	  and	  oligonucleotides	  before	  by	  Groessl	  et	  al.	  and	  
others.76–79	  	  
If	   the	  adduct	  formed	   is	  a	  bis-­‐adduct	  with	  two	  pyridine	   ligands,	   it	  would	  be	  
consistent	  with	  previous	  MS	  and	  NMR	  studies	  of	  5	  with	  GMP	  after	  irradiation	  at	  420	  
nm.5	  However,	  unlike	  the	  reaction	  with	  GMP,	  no	  azide-­‐containing	  mono-­‐adduct	  and	  
no	  Pt(IV)	  species	  were	  observed.	  This	  may	  be	  due	  to	  the	  fact	  that	  these	  are	  short-­‐
lived	   species,	   with	   a	   lifetime	   of	   less	   than	   10	   h,	   and	   the	   relatively	   long	   overnight	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sample	   preparation	   for	   the	   oligonucleotide	   MS	   required	   me	   to	   desalt	   the	  
oligonucleotide	  indicates	  that	  they	  have	  decomposed	  or	  converted	  into	  bis-­‐adducts	  
by	  the	  time	  that	  the	  analysis	  took	  place.56	  
The	   DNA	   adducts	   formed	   by	   platinum	   complexes	   are	   believed	   to	   be	   the	  
reason	  for	  their	  anticancer	  efficacy.	  Platinum(IV)	  diazido	  complexes	  of	  the	  formula	  
structure	   t,t,t-­‐[Pt(N3)2(OH)2(R)(R’)]	   are	   no	   exception	   to	   this,	   but	   they	   have	   an	  
additional	   facet	   to	   their	   toxicity.	   Recently	   Butler	   et	   al.	   found	   that	   upon	  
photoactivation,	   8	   releases	   azide	   radicals	   that	   contribute	   to	   the	   induction	   of	   cell	  
death.80	   It	   was	   found	   that	   the	   radicals	   could	   be	   quenched	   by	   the	   amino	   acid	   L-­‐
tryptophan,	  a	  molecule	  in	  lower	  concentrations	  in	  some	  patients	  with	  breast	  cancer	  
when	  compared	   to	   those	  of	  healthy	   controls.81	   This	   additional	   affect	  of	   the	  azide	  
radicals	  may	  go	  some	  way	  to	  explaining	  the	  unusual	  method	  of	  cell	  death	  induced	  
by	   8	   after	   irradiation.	   The	   cells	   do	   not	   experience	   apoptosis,	   as	   is	   the	   case	  with	  
cisplatin-­‐induced	  cell	  death,	  but	  autophagy	  was	  implied	  via	  biological	  assays.82	  
	  
2.5	  Conclusions	  
The	   relative	   lipophilicity	   a	   series	   of	   ten	   platinum(IV)	   diazido	   complexes	   of	  
general	   formula	   t,t,t-­‐[Pt(N3)2(OH)2(R)(R’)]	   was	   determined	   by	   HPLC.	   The	   trend	   in	  
observed	  lipophilicity	  was	  different	  to	  the	  expected	  trend	  when	  considering	  just	  the	  
lipophilicity	   of	   the	   R	   and	   R’	   ligands.	   These	   observed	   lipophilicities	   were	   then	  
compared	   to	   the	   accumulation	   of	   compounds	   1	   −	   10	   in	   A2780	   human	   ovarian	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carcinoma	  cells.	  There	  appears	   to	  be	  no	  overall	   trend	  relating	  hydrophobicity	  and	  
cellular	  accumulation	  of	  these	  complexes.	  In	  turn,	  their	  potency	  in	  cancer	  cells	  (as	  
IC50	   values)	   has	   no	   obvious	   relationship	   with	   the	   cellular	   accumulation	   of	   the	  
complexes.	  It	  seems	  likely	  that	  because	  other	  factors,	  such	  as	  the	  quantum	  yield	  of	  
the	   complex,	   and	   the	   type	   of	   DNA	   lesion	   formed	   after	   photoactivation,	   have	   a	  
greater	  influence	  over	  the	  efficacy	  of	  this	  class	  of	  drug.	  
The	   DNA-­‐binding	   properties	   of	   one	   of	   these	   complexes,	   8	   t,t,t-­‐
[Pt(N3)2(OH)2(py)2],	   was	   investigated	   by	   HPLC	   and	   mass	   spectrometry.	   Upon	  
irradiation	  with	  UVA	  light	  in	  the	  presence	  of	  a	  single	  strand	  oligonucleotide,	  oligo	  1	  
d’(ATACATGCTACATA),	   a	   new	   species	   was	   created.	   When	   the	   sequence	   of	   the	  
oligonucleotide	  was	  changed	  to	  include	  the	  1,2-­‐d(GpG)	  binding	  mode,	  the	  amount	  
of	  platinum	  bound	  	  to	  the	  DNA	  reduced	  by	  one	  third.	  Levels	  of	  DNA	  platination	  for	  
oligo	  3,	  d’(ATACGTGCTACATA)	  were	  similar	  to	  that	  of	  oligo	  1.	  
The	  adduct	  formed	  by	  8	  upon	  photoactivation	  in	  the	  presence	  of	  oligo	  1	  was	  
characterised	   by	  mass	   spectrometry,	   and	   the	   species	  was	   found	   to	   be	   [oligo	   1	   +	  
[Pt(py)2]].	  	  This	  was	  confirmed	  by	  the	  photoactivation	  of	  15N	  labelled	  versions	  of	  8,	  
t,t,t-­‐[Pt(N3)2(OH)2(15Npy)2]	   (8X)	   and	   t,t,t-­‐[Pt(15N3)2(OH)2(15Npy)2]	   (8Y),	   in	   the	  
presence	   of	   oligo	   1.	   By	   both	   mass	   spectrometry	   and	   chromatography	   the	  
wavelength	   of	   activation	   of	   8	   was	   found	   to	   have	   no	   affect	   on	   the	   DNA	   adduct	  
formed,	  but	   the	   shorter	  wavelength	  of	   light	   caused	  more	   rapid	  platination	  of	   the	  
strand.	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These	  studies	  indicate	  that	  Pt(IV)	  diazido	  complexes	  are	  a	  highly	  potent	  class	  
of	  new	  anticancer	  drug	  with	  complicated	  structure-­‐activity	  relationships.	  They	  offer	  
many	  advantages	  when	  compared	  to	  conventional	  platinum-­‐based	  treatments.	  The	  
light	  activation	  offers	  spatial	  and	  temporal	  resolution	  of	  cancer	  therapy,	  as	  well	  as	  a	  
new	  spectrum	  of	  activity	  and	  an	  extra	  potency	  attributed	   to	   the	   release	  of	  highly	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3.1	  Introduction	  	  
As	   outlined	   in	   Chapter	   1,	   the	   efficacy	   of	   the	   platinum-­‐based	   anticancer	  
drugs	   currently	   in	   the	   clinic	   is	   attributed	   to	   their	   interactions	  with	   DNA.1,2,3	   New	  
generation	  drugs	  may	  also	  target	  DNA,4,5	  but	  can	  also	  be	  multi-­‐targeted,	  activating	  
cellular	   pathways	   by	   means	   of,	   e.g.,	   protein	   binding.6,7	   Drugs	   can	   interact	   with	  
various	   molecules	   before	   reaching	   the	   intra	   cellular	   target.	   Some	   of	   these	   are	  
proteins	   involved	   in	   cellular	   uptake,	   or	   efflux,	   or	   in	   side	   reactions	   that	   are	  
responsible	  for	  deactivation	  of	  the	  drug	  or	  can	  cause	  unwanted	  side	  effects.	  When	  
considering	   these	   interactions,	   it	   must	   be	   remembered	   that	   the	   human	   body	  
contains	   many	   chiral	   molecules:	   L-­‐amino	   acids,	   D-­‐sugars	   and	   even	   secondary	  
structures	  such	  asα-­‐helices	  in	  proteins	  the	  right-­‐handed	  twist	  of	  the	  double	  helix	  in	  
B-­‐DNA,	  and	  the	  left-­‐handed	  twist	  of	  Z-­‐DNA.	  Therefore	  if	  a	  potential	  new	  drug	  is	  also	  
chiral,	   then	   the	   ‘handedness’	   of	   this	   molecule	   is	   crucial	   for	   its	   cellular	   uptake,	  
transport,	  metabolism,	  interaction	  with	  DNA	  and	  proteins.8	  	  
There	   are	   many	   examples	   in	   the	   literature	   of	   chiral	   drugs,	   the	   different	  
enantiomers	  of	  which	  have	  varying	  effects	  on	  the	  human	  body.	  As	  recorded	  in	  the	  
1992	  statement	  on	  the	  development	  of	  new	  stereoisomeric	  drugs	  by	  the	  FDA,	  there	  
are	  categories	  in	  which	  chiral	  drugs	  can	  be	  placed.9	  The	  first	  comprises	  of	  drugs	  for	  
which	   both	   enantiomers	   give	   the	   desired	   effect	   e.g.	   ibuprofen	   and	   β-­‐lactam	  
antibiotics.	  The	  second	  are	  where	  one	  enantiomer	  has	   the	  desired	  effect	  and	   the	  
other	   is	   inactive	   e.g.	   propranolol.	   The	   third	   category	   comprises	   of	   drugs	   with	  
enantiomers	  that	  have	  differing	  activities.	  These	  potential	  differences	  in	  the	  activity	  




of	  enantiomers	  has	  led	  the	  FDA	  and	  other	  regulatory	  bodies	  to	  require	  the	  testing	  
of	  individual	  isomers	  before	  a	  drug	  can	  be	  licensed.	  	  
There	   are	   several	   means	   of	   achieving	   optically	   pure	   enantiomers:	   by	  
crystallisation,	   by	   using	   an	   optically	   pure	   second	   molecule	   to	   form	   pairs	   of	  
diastereomers,	   and	   by	   using	   stereo-­‐selective	   syntheses.	   For	   example	   Kilpin	   et	   al.	  
(2013)	  used	  optically	  pure	   ligands	   to	   synthesise	   the	   two	  different	  enantiomers	  of	  
organometallic	   ruthenium(II)	   compounds,	   and	   compared	   their	   antiproliferative	  
activity	  in	  ovarian	  cancer	  cells.10	  The	  Smith	  laboratory	  uses	  stero-­‐selective	  synthesis	  
to	   create	   ferrocene-­‐	   and	   ruthenocence-­‐based	   complexes	   that	   have	   antimalarial	  
activity.11,12	  
This	   work	   is	   concerned	   with	   the	   separation	   of	   enantiomers	   by	   chiral	  
chromatography.	   The	   technique	   employed	   utilises	   high	   performance	   liquid	  
chromatography	   (HPLC)	   with	   columns	   containing	   a	   chiral	   stationary	   phase,	   with	  
which	  the	  different	  enantiomers	  will	  interact	  to	  a	  varying	  extent	  depending	  on	  their	  
stereochemistry,	   thus	   allowing	   the	   enantiomers	   to	   be	   separated.	   Indeed,	   the	  
stationary	   phases	   of	   these	   columns	   are	   often	   sugar	   based,	   utilising	   amylose	   and	  
functionalised	   supports.13-­‐15	   There	   have	   been	   previous	   successes	   in	   using	   these	  
stationary	  phases	  to	  separate	  the	  enantiomers	  of	  organometallic	  compounds.16–18	  	  
The	   complexes	   studied	   in	   this	   work	   have	   a	   ‘piano	   stool’	   structure	   of	   the	  
general	   formula	   shown	   in	   Fig	   3.1,	   where	   M	   is	   the	   metal	   centre,	   X	   is	   the	   halide	  
leaving	  group,	  A	  is	  the	  arene	  ligand	  and	  L-­‐L’	  is	  the	  bidentate	  ligand.	  This	  study	  will	  
encompass	  Ir-­‐,	  Os-­‐	  and	  Ru-­‐based	  organometallic	  complexes.	  These	  compounds	  also	  
exhibit	   different	   types	   of	   chirality.	   The	   Ir-­‐based	   complexes	   have	   chiral	   metal	  




centres,	   as	   do	   the	   Os-­‐based	   compounds.	   The	   ruthenium	   complexes	   fall	   into	   two	  
categories:	   those	   that	   have	   an	   asymmetric	   arene	   ligand	   and	   have	   facial	   chirality,	  
and	  those	  that	  have	  a	  chiral	  centre	  at	  the	  metal	  and	  on	  the	  bidentate	  ligand.	  
	  
Figure	  3.1	  General	  structure	  of	  the	  complexes	  studied.	  Where	  M	  is	  the	  metal,	  A	  is	  




All	   solvents	   used	   were	   HPLC-­‐grade	   and	   obtained	   from	   Fischer	   Scientific,	  
except	  for	  n-­‐heptane	  which	  was	  purchased	  from	  Sigma	  Aldrich.	  	  Trifluoroacetic	  acid	  
(TFA,	  99.99%,	  spectrophotometric	  grade)	  and	  diethylamine	  (DEA,	  99.5%,	  purified	  by	  
re-­‐distillation)	  were	   purchased	   from	   Sigma	   Aldrich,	   and	   triethylamine	   (TEA,	   HPLC	  
grade)	   was	   purchased	   from	   VWR.	   All	   of	   the	   metal	   complexes	   analysed	   were	  














3.2.2.1	  Sample	  preparation	  
All	  samples	  were	  dissolved	  in	  HPLC	  grade	  EtOH	  unless	  stated	  otherwise,	  and	  
filtered	   using	   0.45	   μm,	   4	  mm,	   PTFE,	   SUPELCO	   Iso-­‐Disc	   syringe	   filters	   if	   there	  was	  
sufficient	  sample	  volume.	  If	  there	  was	  a	  limited	  amount	  of	  sample,	  the	  solution	  was	  
centrifuged	  at	  14,000	  rpm,	  5°C	  for	  10	  min	  and	  the	  supernatant	  used	  for	  analysis.	  In	  
the	  case	  of	  the	  poorly	  soluble	  complexes	  12	  and	  13,	  1.00	  mL	  of	  EtOH	  was	  added	  to	  
1	   mg	   of	   each	   compound.	   These	   samples	   were	   then	   sonicated	   for	   5	   min	   and	  
vortexed	   for	   10	   min.	   The	   solutions	   were	   then	   centrifuged	   and	   the	   supernatant	  
filtered	  using	  0.45	  μm	  syringe	  filters	  and	  the	  filtrate	  used	  for	  analysis.	  
3.2.2.2	  HPLC	  	  
All	   of	   the	   following	  work	  was	   carried	   out	   on	   an	   Agilent	   1200	   series	   HPLC	  
system	  equipped	  with	   a	  binary	  pump,	   a	   variable	  wavelength	  detector	   (VWD)	  and	  
fitted	  with	  a	  100	  μL	  loop	  in	  normal	  phase.	  The	  columns	  used	  were	  a	  CHIRALPAK	  IA	  
column	   (250	   mm	   x	   4.6	   mm)	   with	   an	   isocratic	   gradient	   of	   heptane:ethylacetate	  
containing	   0.1%	   (v/v)	   diethylamine	   (DEA),	   flow-­‐rate	   1.00mL/min,	   wavelength	   of	  
detection	  260	  nm	  and	  a	  CHIRALPAK	  IC	  column	  (250	  mm	  x	  4.6	  mm)	  with	  an	  isocratic	  
gradient	   of	   heptane:ethanol	   0.5%	   triethylamine	   (TEA),	   0.3%	   trifluoroacetic	  
acid(TFA)	   (v/v),	   flow-­‐rate	   1.00mL/min,	   wavelength	   of	   detection	   300	   nm.	   Initial	  
method	  development	  for	  the	  separation	  of	  complexes	  11,	  [Ir(η5-­‐Cpxbph)(phenpy)Cl],	  
on	  CHIRALPAK	  IA	  and	  18,	  on	  CHIRALPAK	  IC	  was	  carried	  out	  by	  Chiral	  Technologies	  
Europe.	   The	   initial	   methods	   for	   11	   had	   to	   be	   further	   optimised.	   Data	   were	  




processed	  using	  ChemStation	  and	  Microsoft	  Excel.	  The	  resolution	  of	  the	  separations	  
was	  calculated	  using	  the	  formula	  RS	  =	  2(t1	  –	  t2)	  /	  (w1	  +w2),	  where	  t1	  is	  the	  retention	  
time	  of	  the	  first	  peak,	  t2	  of	  the	  second,	  w1	  is	  the	  width	  of	  the	  first	  peak,	  and	  w2	  that	  
of	  the	  second.	  
3.3	  Results	  
The	  organometallic	  complexes	  studied	  in	  this	  chapter	  are	  listed	  in	  Table	  3.1	  
below.	   They	   include	   different	   metals	   and	   display	   several	   types	   of	   chirality.	   The	  
separation	  of	   the	  enantiomers	  of	   the	  chiral	  anticancer	  complexes	  was	  carried	  out	  
using	   HPLC	   columns	   with	   two	   different	   stationary	   phases:	   CHIRALPAK	   IA	   and	  
CHIRALPAK	  IC,	  see	  Figure	  3.2.	  Of	  the	  two	  stationary	  phases	  used,	  CHIRALPAK	  IA	  was	  
selected	  for	  the	  separation	  of	  neutral	  complexes	  and	  CHIRALPAK	  IC,	  with	  its	  chloro	  
groups,	  was	   employed	   for	   positively	   charged	   complexes.	   Compounds	  11-­‐17	   were	  
analysed	  using	  CHIRALPAK	  IA	  and	  18-­‐24	  using	  CHIRALPAK	  IC.	  	  




Table	  3.1	  Summary	  of	  the	  structures	  of	  the	  complex	  studied	  in	  this	  work.	  
	  
	  











































































Figure	  3.2	  Structures	  of	  the	  stationary	  phases	  CHIRALPAK	  IA	  (top)	  and	  CHIRALPAK	  IC	  
(bottom).	  	  
	  
3.3.1.1	   Stationary	   phase	   CHIRALPAK	   IA,	   complex	   11	   and	   the	   stability	   of	   its	  
enantiomers	  
A	   method	   was	   developed	   to	   separate	   the	   enantiomers	   of	   compound	   11,	  
[Ir(η5-­‐Cpxbph)	  (phenpy)Cl],	  provided	  by	  Dr	  Zhe	  Lui	  see	  Figure	  3.3.	  A	  10	  μL	  injection	  of	  
a	  solution	  of	  1	  mg	  of	  11	  dissolved	  in	  1	  mL	  of	  EtOH	  (HPLC-­‐grade)	  was	  analysed	  with	  
an	   isocratic	  gradient	  of	  60:40	  heptane:ethylacetate	  0.1%	  DEA.	  The	  chromatogram	  
(Figure	  3.4,	  top)	  shows	  two	  well-­‐resolved	  (RS	  2.76)	  peaks,	  peak	  1	  tR	  at	  7.65	  min	  and	  
peak	  2	  tR	  9.97	  min.	  





Figure	  3.3	  Structures	  of	  complexes	  11,	  [Ir(η5-­‐Cpxbph)(phenpy)Cl],	  	  
12,	  [Ir(η5-­‐Cp*)(benzq)Cl],	  and	  13,	  [Ir(η5-­‐Cp*)(dfphpy)Cl].	  
	  
To	  establish	  whether	  the	  isolated	  purified	  single	  isomers	  will	  revert	  back	  to	  
a	  raecimic	  mixure	  or	  remain	  pure,	  the	  individual	  peaks	  were	  then	  collected	  during	  
the	  course	  of	  eight	  analyses	  (to	  obtain	  enough	  matrial	  for	  subsequent	  analysis).	  All	  
of	  the	  fractions	  containing	  peak	  1	  (tR	  7.65	  min,	  Fig	  3.3)	  were	  combined	  together	  and	  
evaporated	  to	  dryness	  on	  a	  vaccum	  line,	  and	  this	  procedure	  was	  repeated	  for	  the	  
second	  peak,	  peak	  2	  (tR	  9.97	  min).	  The	  solid	  samples	  of	  each	  individual	  isomer	  were	  
then	  re-­‐dissolved	  in	  100	  μL	  of	  EtOH,	  left	  in	  solution	  for	  2	  h	  at	  ambient	  temperature	  
and	   subjected	   to	   the	  original	   separatation	  protocol.	   The	   chromatograms	   for	  both	  




collected	   peaks,	   see	   Figure	   3.4	   (bottom),	   clearly	   show	   that	   both	   single	   peaks	  
transformed	  into	  two	  peaks,	  indicating	  a	  return	  to	  a	  raecmic	  mixture.	  
	  
	  
Figure	  3.4	  Top:	  chromatogram	  of	  a	  solution	  of	  11	  in	  EtOH,	  peak	  1	  tR	  7.65	  min,	  peak	  
2	  tR	  9.97	  min,	  RS	  2.76.	  Bottom:	  chromatograms	  of	  repeat	  collections	  of	  peaks	  1	  and	  
2	   of	  11	   also	   in	   EtOH.	   All	   separations	   carried	   out	   using	   an	   isocratic	   flow	   of	   60:40	  








3.3.1.2	  Stationary	  phase	  CHIRALPAK	  IA,	  complexes	  12-­‐17	  
The	   initial	   conditions	   used	   to	   separate	   the	   enantiomers	   of	   11	   provided	   a	  
starting	   point	   for	   all	   subsequent	   separations	   of	   neutral	   enantiomers.	   Hence,	  
solutions	   of	   12,	   [Ir(η5-­‐Cp*)(ben)Cl],	   and	   13,	   [Ir(η5-­‐Cp*)(dfphpy)Cl],	   (compounds	  
provided	   by	   Dr	   Zhe	   Lui)	   in	   EtOH	   were	   analysed	   under	   these	   conditions.	   The	  
solubility	  of	  both	  compounds	  in	  EtOH	  and	  the	  mobile	  phase	  is	  very	  poor,	  and	  it	  was	  
not	  possible	  to	  achieve	  a	  solution	  of	  1.0	  mg/mL	  for	  either	  of	  the	  complexes.	  In	  view	  
of	  the	  slightly	  better	  solubility	  of	  these	  molecules	  in	  EtOH	  when	  compared	  to	  that	  
in	  the	  mobile	  phase	  alone,	  a	  1.0	  mg/mL	  solution	  of	  each	  was	  made	  up	  in	  EtOH	  as	  
outlined	   in	   the	   experimental	   Section	   3.2.1.1.	   The	   resulting	   chromatograms	   are	  
shown	  in	  Figure	  3.5.	  





Figure	   3.5	   Top:	   chromatogram	   of	   the	   separation	   of	   the	   two	   enantiomers	   of	   12,	  
peak1	   tR	   12.33	  min,	   peak	   2	   tR	   18.61	  min,	   RS	   4.39.	  Bottom:	   chromatogram	   of	   the	  
separation	  of	   the	  enantiomers	  of	  13,	   peak	  1	   tR	   9.11	  min,	  peak	  2	   tR	   13.98	  min,	  RS	  
5.83.	  The	  conditions	  used	  for	  both	  analyses	  were	  isocratic	  of	  60:40	  heptane/EtOAc	  
0.1%	  DEA	  (v/v)	  on	  a	  CHIRALPAK	  IA	  4.6	  x	  250	  mm	  column.	  
	  
There	  is	  a	  peak	  in	  both	  chromatograms	  at	  around	  3.5	  min,	  corresponding	  to	  
the	  dead	  time	  of	  the	  instrument,	  and	  attributable	  to	  the	  EtOH	  used	  to	  dissolve	  the	  
sample	   is	   the	   solvent	   front.	   In	   the	   case	   of	   both	   of	   these	   complexes,	   the	   peaks	  
attributable	   to	   the	   separated	   enantiomers	   are	   very	   small,	   due	   to	   the	   low	  
concentration	  of	  the	  sample.	  Several	  other	  complexes	  similar	  in	  structure	  were	  also	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Figure	   3.6	   Structures	   of	   complexes	   14,	   [Ir(η5-­‐Cp*)(py,4-­‐(2fph))Cl],	   15,	   [Ir(η5-­‐
Cp*)(py,4-­‐(4fph))Cl],	   16,	   [Ir(η5-­‐Cp*)(py,4-­‐(4tfmph))Cl],	   and	   17,	   [Ir(η5-­‐
Cp*)(pycarboxphen)Cl].	  
	  
Complexes	  14-­‐17,	  provided	  by	  Adam	  Millett,	  have	  improved	  solubility	  when	  
compared	  to	  12	  and	  13.	  Solutions	  of	  1	  mg/mL	  of	  each	  compound	  were	  made	  using	  
the	  mobile	  phase	  as	  a	  solvent.	  This	  removes	  the	  large	  signal	  at	  3.5	  min	  ascribable	  to	  
ethanol	   observed	   in	   the	   previous	   chromatograms.	   The	   improved	   solubility	   also	  





















observe,	   Figure	   3.7.	   The	   chromatograms	   in	   Fig.	   3.7	   show	   clear	   resolution	   of	   the	  
enantiomers	  of	  14,	  15	  and,	  with	  a	  somewhat	  reduced	  resoltion,	  16.	  Previously,	  the	  
resolution	  of	  the	  separated	  enantiomers	  for	  complexes	  11,	  13	  and	  13	  has	  been	  such	  
that	  there	  is	  a	  difference	  of	  between	  8	  and	  3	  min.	  This	  is	  also	  true	  of	  complexes	  14	  
and	  15,	  but	  for	  complex	  16	  the	  difference	  in	  retention	  times	  is	  reduced	  to	  	  less	  than	  
a	  minute.	  
3.3.1.3	  Solution	  stability	  of	  the	  enantiomers	  of	  complex	  17	  
As	  with	  14,	  15	   and	  16,	   compound	  17	   displayed	   improved	   solubility	   and	   a	  
solution	   of	   1.0	   mg/mL	   was	   made	   up	   using	   the	   mobile	   phase	   as	   a	   solvent.	   In	  
biological	  testing	  complex	  17	  has	  shown	  great	  promise	  with	  an	  IC50	  value	  of	  4.4	  μM	  
in	  A2780	  human	  carcenoma	  cells	  (A.	  Millett,	   I.	  Romero-­‐Canelon,	  unpublished).	  For	  
this	  reason,	  the	  stability	  of	  its	  two	  enantiomers	  was	  tested	  in	  the	  same	  manner	  as	  
those	  of	  11.	  The	  two	  peaks,	  higlighted	  in	  red	  and	  blue	  in	  Fig.	  3.8,	  were	  individually	  
collected	   over	   the	   course	   of	   eight	   separations.	   The	   fractions	   for	   each	   separated	  
peak	  were	  then	  combined	  and	  evaporated	  to	  dryness	  under	  vaccum.	  The	  resulting	  
solid	  was	  re-­‐dissolved	  in	  100	  μL	  of	  mobile	  phase	  (60:40	  heptane/EtOAc	  0.1%	  DEA),	  
allowed	  to	  sit	  for	  3	  h	  in	  solution	  at	  approximately	  20°C,	  and	  analysed	  as	  described	  
above.	  The	  chromatograms	  in	  Figure	  3.8	  clearly	  show	  that	  the	  purified	  peaks	  of	  17	  
revert	  back	  to	  a	  mixture	  of	  enantiomers.	  The	  retention	  times	  of	  all	  of	  the	  peaks	  and	  
the	  resolutions	  of	  these	  separations	  performed	  on	  the	  stationary	  phase	  CHIRALPAK	  
IA	  are	  shown	  in	  Table	  3.2.	  
	  





Figure	  3.7	  Chromatograms	  of	  the	  chiral	  separation	  of	  the	  different	  enantiomers	  of	  
14	  (top),	  peak1	  tR	  8.79	  min,	  peak	  2	  tR	  11.42	  min,	  RS	  2.86,	  15	  	  (middle)	  ,	  peak1	  tR	  8.76	  
min,	  peak	  2	   tR	  11.94	  min,	  RS	  3.12,	  and	  16	   (bottom)	   ,	  peak1	  tR	  6.93	  min,	  peak	  2	   tR	  
7.50	  min,	  RS	  0.97.	  Separations	  of	  20	  μL	  injections	  (1.0	  mg/mL)	  were	  carried	  out	  on	  a	  
column	  CHIRALPAK	  IA	  4.6	  x	  250	  mm,	  isocratic	  60:40	  heptane/EtOAc	  0.1%	  DEA	  (v/v).	  
	  





Figure	  3.8	  Top:	  Chromatogram	  of	  the	  chiral	  separation	  of	  the	  enantiomers	  of	  17,	  RS	  
2.35,	   peak	   1	   in	   blue,	   tR	   8.98	   min,	   peak	   2	   in	   red,	   tR	   11.28	   min.	   Bottom:	  
chromatograms	  of	  the	  repeat	  collections	  of	  peak	  1	  (blue)	  and	  peak	  2	  (red)	  showing	  
conversion	  back	  to	  a	  mixture	  of	  enantiomers.	  Separation	  conditions	  were	  as	  follows	  
20	   μL	   injections,	   samples	   dissolved	   in	   mobile	   phase,	   carried	   out	   on	   a	   column	  









Table	  3.2	  Retention	  times	  (t1	  and	  t2)	  and	  resolution	  of	  peaks	  eluted	  from	  the	  
CHIRALPAK	  IA column.	  
Complex	   t1	  /	  min	   t2	  /	  min	   RS	  
11	   7.65	   9.97	   2.76	  
12	   12.33	   18.61	   4.39	  
13	   9.11	   13.98	   5.83	  
14	   8.79	   11.42	   2.86	  
15	   8.76	   11.94	   3.12	  
16	   6.93	   7.50	   0.97	  
17	   8.98	   11.28	   2.35	  
	  
3.3.2	  Stationary	  phase	  CHIRALPAK	  IC	  analysis	  of,	  complexes	  18-­‐24	  
Several	  charged	  chiral	  drugs	  synthsised	  within	  the	  Sadler	  group	  have	  shown	  
great	   promise	   in	   biological	   assays	   for	   their	   anticancer	   properties.19–22	   The	  
separation	  of	  the	  enantiomers	  of	  several	  of	  these	  compounds	  was	  performed	  on	  an	  
HPLC	   column	  with	   the	   stationary	   phase	   CHIRALPAK	   IC.	   Unlike	   the	   neural	   iridium	  
complexes	   previously	   described,	   these	   compounds	   are	   osmium-­‐	   and	   ruthenium-­‐
based.	  The	  osmium-­‐based	  complexes	  are	  shown	  in	  Fig.	  3.9,	  18	  [Os(η6-­‐p-­‐cym)(azpy-­‐
NMe2)I]+,	   19	   [Os(η6-­‐p-­‐cym)(azpy-­‐NMe2)Br]+,	   20	   [Os(η6-­‐bip)(azpy-­‐NMe2)I]+,	   and	   21	  
[Os(η6-­‐bip)(azpy-­‐f)I]+.	   These	   compounds	   are	   all	   very	   similar	   in	   structure	   to	   one	  
another,	   and	   their	   enantiomers	   were	   separated	   using	   the	   same	   conditions.	   	   The	  
compounds	  were	  provided	  by	  Russell	  Needham.	  





Figure	   3.9	   Structures	   of	   Os-­‐based	   complexes	   18	   [Os(η6-­‐p-­‐cym)(azpy-­‐NMe2)I]+,	   19	  
[Os(η6-­‐p-­‐cym)(azpy-­‐NMe2)Br]+,	   20	   [Os(η6-­‐bip)(azpy-­‐NMe2)I]+,	   and	   21	   [Os(η6-­‐
bip)(azpy-­‐f)I]+.	  
	  
3.3.2.1.	  Complexes	  18-­‐21:	  separation	  of	  enantiomers	  and	  stability	  of	  18	  
The	  enantiomers	  of	  complex	  18	  were	  separated	  using	  an	   isocratic	  gradient	  
of	   50:50	   heptane:ethanol	   0.5%	   TEA,	   0.3%	   TFA,	   flow	   rate	   1.00	   mL/min,	   on	   a	  
CHIRALPAK	  IC	  column.	  The	  injections	  of	  sample	  18,	  1.0	  mg/mL	  in	  EtOH,	  were	  25	  μL	  
in	  volume.	  The	  resolution	  of	  0.93	  is	  significantly	  less	  than	  that	  achieved	  in	  previous	  
experiments	  (complexes	  11-­‐15	  and	  17),	  but	  there	  are	  still	  two	  separate	  peaks,	  see	  
Figure	   3.10	   (top).	   Repeated	   collections	   of	   the	   individual	   peaks,	   as	   detailed	   in	  




Section	  3.3.1,	  were	   carried	  out.	   The	   chromatogram	   in	   Fig	   3.10	   clearly	   shows	   that	  
the	  two	  enantiomers	  are	  stable	  over	  4	  h	  in	  solution	  at	  approximately	  20°C.	  
	  
Figure	  3.10	  Top:	  Chromatogram	  of	   the	   separated	   isomers	  of	  18,	  RS	  0.93,	  bottom:	  
re-­‐injection	  of	  repeat	  collections	  of	  peak	  1	  (blue),	  tR	  9.05	  min,	  and	  peak	  2	  (orange),	  
tR	   10.15,	   of	   18.	   Separation	   conditions	   were	   the	   same	   for	   both	   analyses:	   25	   μL	  
injections	  of	  a	  1.0	  mg/mL	  solution	  of	  18,	  isocratic	  50:50	  heptane:ethanol	  cantaining	  
0.5%	  TEA	  and	  0.3%	  TFA	  (v/v),	  flow	  rate	  1.00	  mL/min,	  on	  a	  CHIRALPAK	  IC	  column.	  
Separations,	  carried	  out	  under	  the	  same	  conditions	  as	  those	  for	  complex	  18,	  
were	  carried	  out	  successfully	  for	  complexes	  19,	  20	  and	  21	  (RS	  1.08,	  1.34	  and	  0.87,	  
respectively).	  	  Separation	  of	  the	  enantiomers	  of	  each	  complex	  19	  and	  20	  can	  clearly	  
be	  observed	  in	  Figure	  3.11.	  However,	  the	  enantiomers	  of	  complex	  21	  are	  not	  full-­‐
resolved,	  and	  there	  appears	  to	  be	  a	  second	  set	  of	  peaks	  at	  ca.	  9	  min,	  3	  min	  after	  the	  
first	  set,	  possibly	  as	  a	  result	  of	  hydrolysis	  of	  the	  complex.	  	  





Figure	   3.11	   Separation	   of	   the	   enantiomers	   of	   19,	   peak1	   tR	   10.40	  min,	   peak	   2	   tR	  
12.02	  min,	  RS	  1.08,	  20,	  peak1	   tR	  17.43	  min,	  peak	  2	   tR	  20.52	  min,	  RS	  1.34,	   and	  21,	  
peak1	  tR	  6.20	  min,	  peak	  2	  tR	  6.72	  min,	  RS	  0.87,	  using	  25	  μL	  injections	  of	  a	  1.0	  mg/mL	  
solution	  of	  18,	  isocratic	  50:50	  heptane:ethanol	  containing	  0.5%	  TEA	  and	  0.3%	  TFA,	  










3.3.2.2	  Complexes	  22	  and	  23:	  separation	  of	  enantiomers	  and	  stability	  of	  23	  
As	  well	  as	  osmium-­‐based	  compounds,	  the	  enantiomers	  of	  some	  ruthenium-­‐
based	  compounds	  were	  also	  seperated.	  Complexes	  22,	   [Ru(η6-­‐flu)(en)Cl]+,	  and	  23,	  
[Ru(η6-­‐phent)(en)Cl]+,	  are	  shown	  in	  Figure	  3.12,	  they	  are	  Ru-­‐based	  compounds	  that	  
have	  facial	  chirality	  due	  to	  the	  unsymmetric	  aromatic	  ligands.	  The	  compounds	  were	  
provided	   by	   Dr	   Abraha	  Habtemariam.	   A	  method	  was	   developed	   that	   successfully	  
separated	  the	  enantiomers	  of	  both	  complexes:	  70:30	   isocratic	  of	  heptane:ethanol	  
containing	  0.5%	  TEA,	  and	  0.3%	  TFA	  (v/v),	  flow	  rate	  1.00	  mL/min,	  25	  μL	  injection	  of	  a	  
1.0	  mg/mL	  solution	   in	  EtOH,	  on	  a	  CHIRALPAK	  IC	  column.	  The	  results	  are	  shown	  in	  
Figures	  3.13	  and	  3.14.	  The	  bottom	  of	  Figure	  3.14	  also	  shows	  the	  chromatograms	  of	  
the	  individual	  collected	  enantiomers	  of	  23,	  as	  detailed	  in	  Section	  3.3.1.	  After	  5	  h	  in	  
solution	  at	  approximately	  20°C,	  the	  enantiomers	  appear	  stable.	  
	  
Figure	   3.12	   Structures	   of	   complexes	   22,	   [Ru(η6-flu)(en)Cl]+	   and	   23,	   [Ru(η6-
phent)(en)Cl]+.	  
	  





Figure	  3.13	  Chromatogram	  for	  the	  separation	  of	  the	  two	  enantiomers	  of	  22,	  peak	  1	  
tR	  7.80	  min,	  peak	  2	  tR	  8.43	  min,	  RS	  0.92,	  isocratic	  70:30	  heptane:ethanol	  containing	  























Figure	  3.14	  Top:	  Chromatogram	  for	  the	  separation	  of	  the	  two	  enantiomers	  of	  23,	  RS	  
0.98,	  using	  an	  isocratic	  gradient	  of	  70:30	  heptane:ethanol	  containing	  0.5%	  TEA,	  and	  
0.3%	   TFA	   (v/v),	   flow	   rate	   1.00	   mL/min,	   on	   a	   CHIRALPAK	   IC	   column.	   Bottom:	  
chromatograms	  of	  the	  collected	  peaks	  1	  (purple),	  peak1	  tR	  7.52	  min,	  and	  2	  (blue),	  
peak	  2	  tR	  8.27	  min,	  of	  23.	  
	  
3.3.2.3.	  Complex	  24:	  using	  a	  system	  that	  can	  be	  separated	  by	  other	  means	  
	  Compound	   24,	   [Ru(η6-­‐p-­‐cym)(Impy)I]+,	   contains	   two	   chiral	   centres,	   i.e.	  
there	   are	   four	   possible	   diastereomers	   of	   the	   compound.	   	   The	   four	   different	  
diastereomers	  can	  be	  separated	  by	  crystallisation.	   In	   this	  section	  complexes	  using	  




only	  one	  set	  of	  the	  diastereomers,	  those	  with	  the	  R-­‐configurated	  bidentate	   ligand	  
(separated	   by	   crystallisation)	   are	   studied,	   see	   Fig	   3.15.	   Both	   compounds	   were	  
provided	   by	   Dr	   MarÍa	   Xosé	   Romero	   Castro.	   The	   method	   of	   separation	   of	   the	  
diastereomers	  with	  differing	  chirality	  at	   the	  metal	   centre	  was	  an	   isocratic	   flow	  of	  
70:30	  heptane:ethanol	  containing	  0.5%	  TEA,	  and	  0.3%	  TFA,	  flow	  rate	  1.00	  mL/min,	  
25	  μL	   injection	  of	  a	  1.0	  mg/mL	  solution	   in	  EtOH,	  on	  a	  CHIRALPAK	   IC	  column.	  This	  
was	  not	  optimised	  for	  complex	  24,	  and	  the	  peaks	  are	  not	  fully	  resolved,	  Figure	  3.16	  
(bottom).	   The	   retention	   times	   of	   all	   of	   the	   peaks	   and	   the	   resolutions	   of	   the	  
separations	  carried	  out	  on	  the	  stationary	  phase	  CHIRALPAK	   IC	  are	  shown	   in	  Table	  
3.3.	   However,	   since	   the	   enantiomers	   can	   be	   separated	   via	   crystallisation,	   these	  
pure	   enantiomers	   were	   also	   analysed.	   From	   the	   chromatograms	   of	   the	  
diastereomers	  separated	  by	  crystallisation,	  used	  as	  controls	   to	  establish	   retention	  
times,	   (Fig.	   3.16,	   top),	   the	   two	   diastereomers	   of	   24	   can	   be	   distinguished.	  
Diastereomer	   24-­‐B	   shows	   a	   small	   amount	   of	   24-­‐A	   since	   it	   converts	   back	   to	   a	  
mixture	   of	   enantiomers	   over	   time	  when	   in	   solution.	   In	   solution,	   the	   enantiomers	  
are	   in	   the	   proportion	   of	   1:3	   for	   controls	   A	   and	   B.	   The	   intergrations	   of	   the	   peaks	  
agree	  with	  this.	  










Figure	  3.16	  Top:	  chromatograms	  of	  the	  diastereomers	  separated	  by	  crystallisation	  
24-­‐A,	  tR	  15.36	  min,	  and	  24-­‐B,	  tR	  16.43	  min.	  	  Bottom:	  chromatogram	  of	  a	  mixture	  of	  
the	  diastereomers	   in	   EtOH,	  RS	   0.64.	   separation	  was	   carried	  out	   using	   an	   isocratic	  
flow	  of	  70:30	  heptane:ethanol	  0.5%	  TEA,	  0.3%	  TFA,	   flow	  rate	  1.00	  mL/min,	  25	  μL	  
injection	  of	  a	  1.0	  mg/mL	  solution	  in	  EtOH,	  on	  a	  CHIRALPAK IC	  column.	  
24#B%
24#A%




Table	  3.3	  Retention	  times	  (t1	  and	  t2)	  and	  resolution	  of	  peaks	  eluted	  from	  the	  
CHIRALPAK column.	  
Complex	   t1	  /	  min	   t2	  /	  min	   RS	  
18	   9.05	   10.15	   0.93	  
19	   10.40	   12.02	   1.08	  
20	   17.43	   20.52	   1.34	  
21	   6.20	   6.72	   0.87	  
22	   7.80	   8.43	   0.92	  
23	   7.52	   8.27	   0.98	  




Chiral	   compounds	   can	   often	   be	   separated	   by	   crystallisation,	   using	   an	  
optically-­‐pure	   second	  molecule	   to	   form	   pairs	   of	   diastereomers.	   They	   can	   also	   be	  
made	   by	   using	   stereo-­‐selective	   syntheses.23	   They	   can	   be	   separated	   by	   capillary	  
electrophoresis	  usng	  micellar	  electrokinetic	  chromatography.24	  This	  work	  has	  been	  
concerned	   with	   separations	   achieved	   by	   chiral	   chromatography.	   Typically,	   this	  
involves	  sugar-­‐based,	  e.g.	  amylose,	  stationary	  phases,15,25,26	  but	  all	  chiral	  stationary	  
phases	  rely	  on	  the	  same	  basic	  principles	  to	  achieve	  enantiomeric	  separation.	  They	  
contain	   structural	   features	   like	   cavities	   and,	   as	   in	   the	   case	   of	   polysaccharides,	  
groves.	  The	  enantiomeric	  purity	  of	  the	  stationary	  phase	  means	  that	  these	  features	  
have	   a	   specific	   stereochemistry	   or	   ‘handedness’,	   which,	   in	   turn	   governs	   its	  
interactions	   with	   the	   different	   molecular	   configurations	   of	   the	   analyte.	   The	  
enantiomer	  with	  the	  better	  ‘fit’	  for	  the	  groove/cavity	  is	  retained	  on	  the	  column	  for	  




longer.	  Functionalisation	  of	  the	  sugars	  affects	  other	  types	  of	  interaction	  important	  
in	   the	   separation	   process,	   such	   as:	   hydrogen	   bonding,	   electrostatic	   forces,	   π-­‐π	  
stacking,	  and	   steric	  effects.27	   The	   solvent	  mixture	  and	   the	  mobile	  phase	  additives	  
used	   dictate	   the	   extent	   of	   interaction	   between	   the	   analyte	   and	   the	   stationary	  
phase.	   The	   long	   chains	   of	   sugars	   that	   make	   up	   the	   stationary	   phase	   are	  
functionalised	  with	  a	  range	  of	  different	  substituents	  in	  order	  to	  be	  able	  to	  separate	  
the	  enantiomers	  of	  a	  range	  of	  different	  molecules.28–30,13	  However,	  Further	  types	  of	  
stationary	  phase	  have	  proven	   to	  be	  useful	   for	   the	   separation	  of	   chiral	  molecules,	  
such	   as	   the	   glycopeptide	   antibiotic	   teicoplanin,31	   and	   even	   the	   use	   of	   metal	  
complexes	  such	  as	  the	  octahedral	  ruthenium(II)-­‐based	  ones	  used	  by	  Sun	  et	  al.32	  
Previously	   the	   chiral	   stationary	   phases	   (supplied	   by	   Chiral	   Technologies	  
Europe)	   used	   in	   this	   study	   have	   been	   used	   to	   separate	   various	   metal-­‐based	  
complexes,	   such	   as	   the	   ruthenium-­‐based	   half-­‐sandwich	   complexes	   of	  Meggers	   et	  
al.33	  These	  complexes	  were	  found	  to	  racemise	  up	  to	  2%	  after	  24	  h	  at	  approximately	  
20°C	   in	   DMSO.	   There	   are	   various	   factors	   that	   contribute	   to	   the	   conformational	  
lability	   at	   the	   metal	   centre	   of	   organometallic	   complexes,	   such	   as	   solvent,	  
temperature	  and	  the	  nature	  of	  the	   ligands.34–38	  Temperature	  can	  be	  an	   important	  
factor	  as	  shown	  in	  the	  1H	  NMR	  experiments	  carried	  out	  by	  Brunner	  et	  al.	  on	  Ru(II)	  
and	  Os(II)	  half-­‐sandwich	  complexes.	  They	  found	  that	  at	  low	  temperatures	  (193-­‐195	  
K),	   solutions	   prepared	   from	   enantiomerically-­‐pure	   crystals	   remain	   as	   such	   in	  
solution,	  but	  when	  the	  temperature	  increases	  (223-­‐294	  K),	  the	  concentration	  of	  the	  
other	  epimer	   increases.37	   It	  has	  also	  been	  shown	  that	  chelating	  bi-­‐dentate	   ligands	  
increase	  the	  stability	  of	  a	  complex	  when	  compared	  to	  mono-­‐dentate	  ligands	  
The	   stationary	   phase	   CHIRALPAK	   IA	   under	   the	   same	   chromatographic	  




protocol	  was	  shown	  to	  separate	  the	  enantiomers	  of	  a	  range	  of	  Ir-­‐based	  complexes,	  
differring	   only	   in	   the	   structure	   of	   the	   bi-­‐dentate	   ligand,	   but	   all	   are	   chiral	   at	   the	  
metal	   centre.	   This	   series	   of	   complexes	   has	   shown	   great	   potential	   in	   biological	  
assays.	  Complex	  11,	   [Ir(η5-­‐Cpxbph)(phenpy)Cl],	   is	  highly	  cytotoxic	  with	  an	   IC50	  value	  
of	   0.70	   μM	   in	   A2780	   human	   ovarian	   cancer	   cells.39	   Slight	   modifications	   to	   the	  
ligands	  of	  these	  complexes	  can	  produce	  large	  changes	  in	  retention	  times.	  When	  the	  
2-­‐phenylpyridne	   (2-­‐phenpy)	   ligand	   of	  11	   is	   switched	   to	   7,8-­‐benzoquinoline	   and	   a	  
less	   extended	   arene	   ligand	   (Cp*)	   is	   used,	   complex	   12,	   [Ir(η5-­‐Cp*)(benzq)Cl]	   is	  
formed.	  A	   less	  hydrophobic	  arene	   ligand	   is	  used	  and	  so	   the	   retention	   time	  of	   the	  
compound	   is	   increased;	   as	   with	   normal-­‐phase	   chromatography,	   the	   more	  
hydrophobic	  the	  complex,	  the	  quicker	  it	  will	  elute.	  The	  higher	  hydrophobicity	  of	  the	  
bi-­‐dentate	   ligand,	   unusually,	   results	   in	   the	   retention	   times	   of	   both	   peaks	   almost	  
doubling	  (9.97	  min	  to	  18.61	  min),	  as	  does	  the	  resolution	  (2.76	  min	  to	  4.39	  min),	  as	  
noted	  in	  Table	  4.2.	  	  
Complexes	  14,	   [Ir(η5-­‐Cp*)(py,4-­‐(2fph))Cl],	  and	  15,	   [Ir(η5-­‐Cp*)(py,4-­‐(4fph))Cl],	  
differ	  from	  11	  by	  a	  fluoro	  group	  on	  the	  phenyl	  ring,	  in	  the	  ortho	  position	  for	  14,	  and	  
the	  para	  position	  for	  15,	  and	  the	  changing	  of	  the	  arene	  ligand	  to	  Cp*.	  Once	  again,	  
substitution	   of	   Cpxbph	   for	   Cp*	   results	   in	   an	   increase	   in	   retention	   time.	   When	  
comparing	  the	  complexes	  14	  and	  15,	  the	  retention	  times	  of	  the	  two	  enantiomers	  of	  
these	   compounds	   are	   very	   similar.	   The	   enantiomers	   of	   15	   elute	   slightly	   further	  
apart	   than	   those	   of	   14,	   giving	   a	   resolution	   0.26	   higher.	   The	   complex	   with	   two	  
fluorine	   substituents	   on	   the	   bi-­‐dentate	   ligand	  13,	   [Ir(η5-­‐Cp*)(dfphpy)Cl],	   however,	  
has	  an	   increased	  retention	  time	  for	  both	  peaks,	   t1	  =	  9.11	  min	  and	  t2	  =	  13.98	  min;	  
along	   with	   a	   high	   resolution	   of	   the	   separation,	   RS	   =	   5.38.	   This	   suggests	   that	  




increasing	   the	   bulkiness	   of	   the	   bi-­‐dentate	   ligand	   increases	   the	   retention	   times	   of	  
both	  the	  species	  eluted,	  and	  also	  the	  resolution	  of	  the	  separation.	  However,	  this	  is	  
only	  true	  up	  to	  a	  point,	  and	  when	  a	  bulkier	  substituent	  is	  added	  to	  the	  bi-­‐dentate	  
ligand,	   as	   in	   complex	   16,	   [Ir(η5-­‐Cp*)(py,4-­‐(4tfmph))Cl],	   (RS	   =	   0.97),	   there	   is	   a	  
dramatic	   loss	   of	   resolution	  when	   compared	   to	   complex	  14,	   (RS	   =	   2.86),	   and	  even	  
greater	  still	  when	  compared	  to	  the	  other	  complex	  with	  a	  para	  substituted	  ring,	  15,	  
(RS	  =	  3.12).	  This	  is	  presumably	  attributable	  to	  steric	  hindrance	  caused	  by	  the	  larger	  
group	  on	  the	  phenyl	  ring	  a	  phenomenon	  which	  reduces	  interaction	  of	  the	  molecule	  
with	  the	  CHIRALPAK	  IA	  stationary	  phase.	  
	  All	  the	  complexes	  with	  a	  Cp*	  arene	  ligand	  experience	  the	  largest	  change	  in	  
retention	   time	   for	   the	   second	   enantiomer	   t2	   (when	   compared	   to	   11);	   this	   is	   the	  
dominant	   factor	   in	   any	   change	   of	   resolution.	   In	   the	   case	   of	   complex	   17,	   [Ir(η5-­‐
Cp*)(pycarboxphen)Cl],	   where	   the	   substitution	   is	   on	   the	   pyridine	   ring,	   both	  
retention	  times	  are	  shifted,	  causing	  the	  loss	  of	  resolution.	  The	  change	  in	  retention	  
times	   may	   also	   be	   due	   to	   the	   ligand	   altering	   the	   overall	   hydrophobicity	   of	   the	  
complex,	  a	  property	  which	  can	  also	  be	  crucial	  for	  the	  passive	  uptake	  of	  such	  drugs	  
into	  cells.40	   From	   literature	  values	  of	   Log	  P	  values	  of	   the	  octanol/water	  partitions	  
for	   similar	   iridium-­‐based	   complexes,41	   some	   observed	   trends	   could	   be	   related	   to	  
the	  work	  reported	  here.	  A	  series	  of	  complexes:	  [Ir(η5-­‐Cp*)(1,10-­‐phenanthroline)Cl]+,	  
[Ir(η5-­‐Cpxph)(1,10-­‐phenanthroline)Cl]+,	   and	   [Ir(η5-­‐Cpxbph)(1,10-­‐phenanthroline)Cl]+	  
have	   reported	   Log	   P	   values	   of	   -­‐0.82,	   0.48	   and	   1.11	   respectively.41	   This	   increasing	  
lipophilicity,	  conceivably	  attributable,	  to	  the	  extension	  of	  the	  arene	  ligand,	  was	  also	  
observed	  when	  comparing	  complex	  11	  with	  those	  containing	  the	  shorter	  Cp*	  ligand.	  
The	  unusual	  observation	  that	  increasing	  the	  hydrophobicity	  of	  the	  bi-­‐dentate	  ligand	  




increases	  the	  retention	  time	  of	  the	  complex	  for	  normal	  phase	  chromatography	  may	  
arise	   from	  the	  shape	  of	   the	  bi-­‐dentate	   ligand.	  As	   the	  measured	  hydrophobicity	  of	  
the	  complexes	  [Ir(η5-­‐Cpxph)(biphenyl)Cl]+,	  and	  [Ir(η5-­‐Cpxph)(1,10-­‐phenanthroline)Cl]+,	  
demonstrates	   an	   increase	   in	   Log	   P	   values	   from	   -­‐0.95	   to	   0.48.	   The	   shape	   of	   the	  
extended	   bi-­‐dentate	   ligand	   could	   give	   rise	   to	   increased	   interactions	   with	   the	  
functionalised	  sugars	  that	  comprise	  up	  the	  stationary	  phase.	  
The	  stationary	  phase	  CHIRALPAK	  IA	  has	  previously	  been	  shown	  to	  separate	  
the	   enantiomers	   of	   [tris(2-­‐phenylpyridine)	   iridium	   (III)]	   	   using	   an	   isocratic	   mix	   of	  
hexane/CHCl3/CH2Cl2	  (75:20:5).42	  Unlike	  the	  complexes	  analysed	  here,	  Chen	  et	  al.42	  
showed	   that	   the	   separated	   enantiomers	   of	   [tris(2-­‐phenylpyridine)iridium(III)]	   did	  
not	  undergo	   racemisation	  after	  purification.	  This	  may	  suggest	   that	   the	  octahedral	  
structure	   of	   the	   complexes	   studied	   by	   Chen	   et	   al.	   may	   be	  more	   stable	   than	   the	  
piano-­‐stool	  configuration	  of	  those	  investigated	  in	  this	  work.	  
In	  view	  of	  the	  wider	  range	  of	  charged	  anticancer	  organometallic	  complexes	  
available,	  a	  much	  broader	  range	  of	  structures	  could	  be	  compared.	  In	  the	  case	  of	  the	  
Os-­‐based	   complexes,	   the	   effect	   of	   changing	   the	   arene,	   the	   bi-­‐dentate	   ligand	   and	  
the	   halide	   leaving	   ligand,	   an	   alteration	   already	   shown	   to	   be	   significant	   in	   cellular	  
uptake	   for	  Ru-­‐based	  complexes,43	   can	  be	  explored.	  By	   replacing	   the	   iodido	   ligand	  
(18,	  [Os(η6-­‐p-­‐cym)(azpy-­‐NMe2)I]+)	  with	  bromido	  (19	  [Os(η6-­‐p-­‐cym)(azpy-­‐NMe2)Br]+),	  
the	   retention	   times	   of	   both	   peaks	   are	   longer	   and	   t2	   (the	   retention	   time	   of	   the	  
second	  peak	  to	  be	  eluted)	  even	  longer,	  thereby	  increasing	  the	  resolution.	  Extension	  
of	   the	   arene	   ligand	   from	   para-­‐cymene	   (18)	   to	   biphenyl	   (20,	   [Os(η6-­‐bip)(azpy-­‐
NMe2)I]+)	   leads	   to	   a	   large	   modification	   in	   the	   chromatograms	   of	   the	   Os-­‐based	  
complexes,	   the	   value	   t1	   changes	   by	   8.38	   min,	   that	   of	   t2	   by	   10.37	   min,	   and	   the	  




resolution	   increases	  by	  0.42.	  This	   is	  ascribable	   to	   the	   increased	  hydrophobicity	  of	  
the	  complex	  by	  adding	  an	  extra	  phenyl	  ring.	  However,	  the	  most	  dramatic	  shift	  is	  the	  
considerable	  reduction	  in	  retention	  times	  of	  both	  enantiomers	  when	  the	  bi-­‐dentate	  
ligand	  is	  changed	  from	  azpy-­‐NMe2	  (20)	  to	  azpy-­‐F	  (21,	  [Os(η6-­‐bip)(azpy-­‐f)I]+);	  indeed,	  
t1	  shortens	  by	  11.23	  min,	  and	  t2	  by	  13.8	  min.	  The	  chromatogram	  of	  20	  shows	  very	  
broad	  peaks	  over	  2	  min,	  and	  with	  the	  introduction	  of	  the	  new	  ligand	  the	  peaks	  for	  
21	  narrow	  to	  under	  one	  minute	  in	  width,	  resulting	  in	  only	  a	  small	  loss	  of	  resolution	  
(0.47).	  
Compounds	   with	   a	   ruthenium	   centre	   were	   also	   analysed.	   22,	   [Ru(η6-­‐
flu)(en)Cl]+,	  and	  23,	  [Ru(η6-­‐phent)(en)Cl],+	  	  which	  are	  facially	  chiral	  and	  only	  have	  a	  
small	  difference	  in	  their	  aromatic	  ligands	  from	  fluorene	  (22)	  to	  phenanthrene	  (23).	  
This	  is	  reflected	  in	  a	  maximum	  difference	  of	  0.28	  min	  between	  the	  retention	  times	  
of	  the	  enantiomers	  eluted	  first,	  and	  only	  a	  difference	  of	  0.06	  in	  the	  resolution	  of	  the	  
two	  chromatograms.	  Upon	  separation	  of	   the	   two	  enantiomers	  of	  22,	   they	  remain	  
stable	   in	  solution,	  Fig	  3.14.	  There	   is	  a	  small	  amount	  of	  contamination	  observed	   in	  
the	  chromatogram	  shown	  in	  Fig.	  3.14	  this	  is	  believed	  to	  be	  due	  to	  grease	  from	  the	  
vacuum	  line.	  This	  stability	  means	  that	   it	   is	  possible	  to	  scale	  up	  the	  separation	  and	  
collect	  enough	  of	  each	  purified	  enantiomer	  in	  order	  to	  carry	  out	  kinetic	  studies,	  cell	  
testing	   and	   further	   experiments	   required	   for	   potential	   new	   drugs	   that	   are	   chiral.	  
This	   is	   also	   the	   case	   for	   the	   Os-­‐based	   complex	   18,	   which	   has	   already	   shown	  
promising	  activity	  as	  a	  racemic	  mixture.19	  	  
Studies	   on	   the	   other	   Ru-­‐based	   complex	   investigated,	   24	   ([Ru(η6-­‐p-­‐
cym)(Impy)I]+),	  show	  that	  diasteriomers	  with	  two	  chiral	  centres,	  one	  of	  which	  is	  in	  
the	  R-­‐	  configuration,	  can	  be	  separated	  by	  chromatographic	  methods.	  Studies	  of	  the	  




stability	  of	  the	  separated	  enantiomers	  of	  the	  Os-­‐	  and	  Ru-­‐based	  complexes	  suggest	  




In	   conclusion,	   the	   enantiomers	   and	   diastereomers	   of	   several	  metal-­‐based	  
compounds	  were	  separated	  by	  chromatographic	  methods	  using	  CHIRALPAK	  IA	  and	  
CHIRALPAK	   IC	   columns.	   The	   stability	   of	   some	   of	   these	   enantiomers	   was	   also	  
assessed.	  All	  of	  the	   	  neutral	   Ir(Cp*)-­‐based	  complexes	  tested	  reverted	  to	  a	  racemic	  
mixture	  after	  a	  minimum	  of	  2	  h	  in	  solution	  at	  approximately	  20°C,	  however,	  the	  Ru-­‐	  
and	  Os-­‐based	  enantiomers	  maintained	  stability	  over	  2	  or	  more	  hours	  in	  ethanol	  at	  
approximately	  20°C.	  Separations	  of	  these	  enantiomers	  can,	  in	  the	  future,	  be	  scaled	  
up	  to	  obtain	  enough	  material	  for	  cell	  testing	  and	  further	  biological	  assays.	  
Small	   structural	   differences,	   such	   as	   changing	   the	   halide	   leaving	   group	  
(complexes	  11-­‐17),	  were	  found	  to	  have	  a	  substantial	  effect	  on	  the	  retention	  time	  of	  
the	   enantiomers	   and	   the	   resolution	   of	   the	   separation.	   Alteration	   of	   any	   of	   the	  
ligands	  of	  the	  complex	  was	  shown	  to	  give	  rise	  to	  change	  in	  retention	  times,	  but	  the	  
most	   dramatic	   changes	   were	   caused	   by	   the	   addition	   of	   either	   hydrophillic	   or	  
hydrophobic	   groups	   to	   the	   bi-­‐dentate	   ligand.	   In	   summary,	   these	   studies	   have	  
provided	   an	   important	   step	   towareds	   the	   preparation	   of	   chirally	   pure	  
organometallic	   complexes	   which	   can	   undergo	   clinical	   development.	   In	   prinicle,	  
biological	  assays	  can	  now	  be	  carried	  out	  using	  both	  the	  racemate	  and	  the	  individual	  




enantiomers	  of	  those	  compounds	  which	  are	  stable	  in	  solution,	  or	  only	  the	  racemate	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In	  this	  chapter	  the	  development	  of	  a	  new	  analytical	  technique	  that	  couples	  
mass	   spectrometry	   and	   photonic	   crystal	   fibres	   is	   reported.	   Initially	   the	   use	   of	  
different	  types	  of	  sample	  cell	  construction	  was	  explored	  and	  the	  system	  optimised.	  
The	  efficacy	  of	  the	  technique	  will	  then	  be	  assessed	  by	  using	  it	  to	  study	  a	  well	  known	  
photoreaction.	   The	   system	   was	   proven	   successful,	   and	   the	   technique	   was	   then	  
applied	   to	   a	   new	   system	   to	   gain	   insight	   into	   the	  mechanism	   of	   action	   of	   a	   new	  
potential	  phototherapy.	  
4.1	  Introduction	  
4.1.1	  Photoactivatable	  metal-­‐based	  drugs	  
Metal-­‐based	   anticancer	   drugs	   have	   had	   success	   in	   the	   clinic	   for	   over	   30	  
years,1	  and	  are	  used	  in	  the	  treatment	  of	  a	  wide	  range	  of	  cancers	  such	  as	  bladder,	  
head,	   neck,	   testicular	   and	   cervical.2	   However,	   as	   discussed	   in	   Chapter	   1	   many	  
cancers	  are	  intrinsically	  resistant	  to	  platinum-­‐based,	  others	  may	  develop	  resistance	  
over	   time	   and	   it	   can	   also	   cause	   multiple	   unwanted	   side	   effects	   such	   as	  
nephrotoxicity	   and	   ototoxicity.	   These	   problems	   have	   led	   to	   the	   use	   of	   new	  
strategies	  in	  the	  development	  of	  metal-­‐based	  drugs	  to	  reduce	  side-­‐effects	  and	  have	  
a	   different	   spectrum	   of	   activity	   to	   established	   platinum-­‐based	   treatments.	   This	  
quest	  for	  new,	  better,	  metal-­‐based	  treatments	  has	  led	  to	  exploration	  of	  the	  use	  of	  
different	   oxidation	   states	   of	   the	  metal	   centre,	   with	   the	   inclusion	   of	   more	   stable	  
Pt(IV)	  drugs	  to	  reduce	  unwanted	  side	  effects,	  and	  even	  the	  use	  of	  different	  metal	  
centres,	  such	  as	  ruthenium,	  osmium	  and	  iridium.	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Various	   methods	   have	   been	   employed	   to	   improve	   the	   targeting	   of	   these	  
exciting	   new	   drugs	   such	   as	   the	   attachment	   of	   cell-­‐penetrating	   peptides,3,4	   using	  
them	   to	   functionalise	   nanoparticles5	   	   and	   the	   inclusion	   of	   enzyme	   inhibitors	   to	  
block	  detoxification	  pathways6	  (these	  are	  discussed	  at	  greater	  length	  in	  Chapter	  1).	  
Another	  strategy	  to	  reduce	  unwanted	  side-­‐effects	  is	  to	  use	  a	  prodrug	  that	  can	  then	  
be	   activated	  once	   it	   has	   reached	   the	   tumour	   site.	   This	   can	  be	  performed	  using	   a	  
variety	   of	   techniques,	   one	   of	   which	   is	   photoactivation,	   where	   a	   prodrug	   is	  
converted	   into	   the	   active	   form	   of	   the	   drug	   using	   light.	   The	   Sadler	   group	   have	  
synthesised	  a	  range	  of	  promising	  potential	  light	  activated	  drugs	  using	  both	  platinum	  
and	   ruthenium.7-­‐8	   Light	   therapies	   are	   already	   in	   the	   clinic	   in	   the	   form	   of	  
photodynamic	   therapy	   (PDT).	   This	   therapy	   involves	   porphryin-­‐based	   drugs	   being	  
activated	  by	  600	  -­‐	  850	  nm	  light	  and	  generating	  reactive	  oxygen	  species	  that	  induce	  
cell	  death.	  	  
4.1.2	  Hyphenated	  mass	  spectrometry	  techniques	  
Mass	  spectrometry	  has	  long	  been	  used	  in	  conjunction	  with	  other	  analytical	  
techniques,	   such	   as	   gas	   chromatography	   and	   capillary	   electrophoresis.,9,10	   The	  
advent	   of	   electrospray	   ionisation	   in	   the	   field	   of	   mass	   spectrometry	   not	   only	  
increased	  the	  types	  of	  sample	  that	  could	  be	  analysed	  but	  also	  the	  ease	  with	  which	  a	  
range	   of	   techniques	   could	   be	   coupled	   with	   mass	   spectrometry.	   Liquid	  
chromatography-­‐mass	   spectrometry	   (LC-­‐MS)	   is	   used	   in	   laboratories	   all	   over	   the	  
world	  every	  day,	  and	  has	  been	  combined	  with	  other	  analytical	  methods	  to	  create	  
techniques	   such	   as	   LC-­‐ICP-­‐MS11	   and	   LC-­‐MS-­‐NMR,	   giving	   great	   insight	   into	   sample	  
composition	  and	  structures.	  Recent	  advances	  have	  led	  to	  the	  development	  of	  ultra-­‐
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high	   performance	   liquid	   chromatography-­‐mass	   spectrometry	   (UPLC-­‐MS),	  
dramatically	   shortening	   analysis	   times,	   and	   the	   inclusion	   of	   nano	   liquid	  
chromatography	   reducing	   sample	   and	   solvent	   volumes.	   The	   reduction	   in	   solvent	  
consumed	   and	   waste	   generated	   by	   these	   developments	   in	   the	   field	   of	  
chromatography	   not	   only	   reduces	   costs,	   but	   also	   minimises	   the	   environmental	  
impact	  of	  a	  given	  analysis.	  
The	  tendency	  towards	  miniaturisation,	  requiring	   less	  sample	  for	  essentially	  
the	   same	   analysis	   has	   led	   to	   the	   inclusion	  of	  microfluidics12	   into	   the	   field,	   and	   in	  
recent	   years	   lab-­‐on-­‐a-­‐chip	   approaches.13,14	   Emphasis	   has	   also	  been	  placed	  on	   the	  
speed	   of	   analysis	   and	   the	   possibility	   of	   online	  mass	   spectrometry	  measurements	  
like	   those	   used	   by	   Yu	   et	   al.	   to	  monitor	   protease-­‐catalysed	   reactions	   such	   as	   the	  
trypsinolysis	  of	   cytochrome	  c	   and	   for	  online	  quality	   control	   sampling	  of	   industrial	  
reactions.15	   The	   aim	   of	   this	   chapter	   is	   to	   bring	   together	   these	   elements	   of	   dual	  
analysis,	   reduced	   sample	   volumes,	   online	   sampling	   and	   the	   in	   situ	   irradiation	  
adaptations	   already	   embraced	   by	   some	   analytical	   techniques,	   e.g.	   NMR	   probes	  
fitted	  with	  lasers	  to	  study	  photochemical	  reactions	  in	  real	  time.	  
4.1.3	  Photonic	  crystal	  fibres	  
Photonic	   crystal	   fibres	   (PCFs)	   are	   a	   type	   of	   optical	   fibre	   with	   unusual	  
properties.16	   They	   typically	   consist	   of	   a	   core	   surrounded	   by	   a	   photonic	   crystal	  
cladding	  of	  very	  high-­‐grade	  silica	  glass.	  They	  are	  fabricated	  by	  arranging	  capillaries	  
and	  rods	  of	  high-­‐grade	  silica	  into	  the	  shape	  of	  the	  desired	  structure	  of	  the	  fibre.	  The	  
glass	   is	   then	   heated	   to	   extremely	   high	   temperatures	   (2000°C),	   and	   the	   silica	   is	  
stretched	  out	  using	  a	  drawing	  tower;	  the	  resulting	  fibre	  has	  a	  diameter	  of	  around	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40	  μm.	  These	  fibres	  exhibit	  characteristically	  low	  guidance	  and	  transmission	  losses	  
either	  by	  funnelling	  the	  light	  using	  a	  photonic	  bandgap,	  or	  a	  modified	  form	  of	  total	  
internal	   reflection.17,18	   The	   fibres	   can	   have	   either	   a	   solid	   or	   a	   hollow	   core	   (an	  
example	  of	  a	  hollow	  core	  fibre	  is	  show	  in	  Figure	  4.1).	  The	  immediate	  advantage	  of	  
these	   structures	   when	   considering	   the	   analysis	   of	   solutions	   are	   the	   gaps	   in	   the	  
cladding,	  and	  in	  some	  cases	  the	  core,	  i.e.	  those	  which	  allow	  liquids	  to	  pass	  through	  
the	   fibres.	   This	   work	  will	   be	   primarily	   concerned	  with	   the	   applications	   of	   hollow	  
core	  photonic	  crystal	  fibres	  (HC-­‐PCFs)	  
	  
Figure	  4.1	  Scanning	  electron	  micrograph	  of	  a	  cross-­‐section	  of	  a	  Kagomé	  hollow-­‐core	  
PCF.19	  	  
Previous	  uses	  of	  these	  fibres	  are	  discussed	  in	  Chapter	  1,	  Section	  1.3.1.	  In	  this	  
chapter	   PCFs	   are	   put	   to	   a	   new	   use,	   in	   combination	   with	   a	   high-­‐resolution	   mass	  
spectrometer	   using	   a	   coupling	   device,	   on	   a	   microfluidic	   scale	   to	   reduce	   analysis	  
times	   (microfluidics	   have	   been	   previously	   coupled	   to	   a	   mass	   spectrometer	   for	  
various	   applications20).	   This	   fusion	   of	   analyses	   aims	   to	   create	   a	   new	   analytical	  
technique	   that	   allows	   samples	   to	   be	   irradiated	   rapidly	   analysed	   and	   any	  
photoproducts	   characterised	   using	   minimal	   sample	   volume	   with	   low	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concentrations.	   It	  may	  also	  allow	  the	  detection	  of	  short-­‐lived	  species	   that	  are	  not	  
observed	  by	  standard	  methods.	  	  
	  
4.2	  Experimental	  
4.2.1	  Materials	  	  
All	   of	   the	  water	  used	  was	  doubly	  deionised	  water	   (DDW),	  purified	  using	  a	  
Multipore	   Milli	   Q	   and	   a	   USF	   Elga	   UHQ	   water	   deioniser.	   Coupling	   devices	   and	  
microfluidic	  mounts	  were	  constructed	  ‘in-­‐house’	  at	  the	  Max	  Plank	  institute	  of	  light	  
in	  Erlangen;	  the	  initial	  microfluidic	  sample	  cells	  were	  constructed	  by	  Grayme	  White	  
(Cambridge	   University).	   The	   microfluidic	   chips	   were	   purchased	   from	   the	  
microfluidic	   ChipShop	   and	   the	   flow	   meter	   from	   (SLG1430-­‐150)	   Sensirion.	   For	  
sample	  introduction,	  a	  500	  µL-­‐glass	  syringe	  from	  Hamilton	  was	  used,	  and	  a	  syringe	  
pump	   from	  kdScientific.	   Cyanocobalamin	   (99.99%)	  and	  aquacobalamin	  were	   from	  
Sigma-­‐Aldrich,	  as	  was	  the	  sodium	  nitroprusside	  (99.99%),	  5’-­‐GMP,	  as	  a	  sodium	  salt,	  
(99.99%)	  and	  L-­‐cysteine	  (99.99%).	  Both	  the	  5’-­‐AMP	  (99.99%)	  and	  glutathione	  (GSH)	  
(99.99%)	   were	   purchased	   from	   Acros	   Organics.	   The	  metal-­‐based	   drug	   complex	   8	  
(t,t,t-­‐[Pt(py)2(N3)2(OH)2])	  was	  synthesised	  according	  to	  literature	  methods,7	  24	  ([(p-­‐
cym)Ru(bpm)(py)][PF6]2)	  by	  Dr	  Soledad	  Betanzos-­‐Lara	  and	  25	  ([{(η6-­‐indan)RuCl}2(μ-­‐
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4.2.2	  Methods	  
5.2.2.1	  Sample	  preparation	  
All	  MS	  samples	  were	  filtered	  using	  NALGENE	  0.2	  μm	  polyethersulfone	  (PES)	  
filters	  and	  then	  centrifuged	  at	  14,000	  rpm,	  5°C	   for	  a	  period	  of	  10	  min.	  The	  pH	  of	  
samples	  was	  measured	  using	  a	  Mettler-­‐Toledo	  glass	  microelectrode	  connected	  to	  a	  
Martini	  instruments	  Mi150	  pH/temperature	  bench	  meter	  calibrated	  at	  pH	  values	  of	  
4,	  7	  and	  10	  using	  pH	  buffers	  from	  Mettler-­‐Toledo	  
4.2.2.2	  Mass	  spectrometry	  	  
Preliminary	   mass	   spectra,	   to	   test	   for	   interactions	   between	   8,	   t,t,t-­‐
[Pt(N3)2(OH)2(py)2],	   and	   the	   PCF	  were	   carried	   out	   on	   a	   Bruker	  HCT	  Ultra	   ion	   trap	  
mass	  spectrometry	  in	  the	  positive	  mode.	  Sample	  flow	  rate	  was	  240	  μL/h,	  with	  scan	  
ranges	   varied	   from	   50	   −	   1000	  m/z	   to	   500	   −	   3000	  m/z.	   The	   solvent	   used,	   cone	  
voltage	  and	  source	  temperature	  varied	  depending	  on	  the	  sample.	  All	  other	  spectra	  
were	   obtained	   on	   a	   Bruker	   MaXis	   high-­‐resolution	   mass	   spectrometer	   (HR-­‐MS).	  
Samples	  were	   introduced	   to	   the	  MS	   at	   a	   flow	   rate	   of	   100	   µL/h.	   	   The	   acquisition	  
parameters	  for	  spectra	  obtained	  in	  the	  positive	  ion	  mode	  are	  as	  follows:	  scan	  range	  
50	  −	  3000	  m/z,	  set	  capillary	  3000	  V,	  end	  plate	  off-­‐set	  −500	  V,	  nebuliser	  pressure	  0.4	  
bar,	  dry	  heater	  180	  °C,	  and	  dry	  gas	  4.0	  L/min.	  Negative	  ion	  spectra	  were	  obtained	  
using	   the	   same	   conditions	   as	   those	   in	   the	   positive	   ion	  mode	   except	   that	   the	   set	  
capillary	  was	  4000	  V	  and	  the	  ion	  polarity	  was	  set	  to	  negative.	  MS/MS	  experiments	  
were	  carried	  using	  the	  conditions	  detailed	  above	  with	  an	  isolation	  width	  of	  6	  m/z,	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and	   the	   collision	   energy	   varied	   depending	   on	   the	   sample.	   All	   spectra	   were	  
processed	  using	  Bruker	  Daltonics	  Analysis	  software	  and	  Origin	  Pro	  8.1.	  
4.2.2.3	  Light	  sources	  	  
The	  405	  nm	  laser	  used	  was	  purchased	  from	  Thorlabs,	  the	  488	  nm	  laser	  from	  
Toptica,	  and	  operated	  using	  Top	  Control	  software.	  
	  
4.3.	  Results	  
4.3.1	   Photonic	   crystal	   fibre	   mass	   spectrometry	   (PCF-­‐MS)	   system	   design	   and	  
development	  
As	  outlined	  in	  Chapter	  2,	  it	  is	  thought	  that	  there	  may	  be	  some	  DNA	  adducts	  
formed	   when	   complex	   8,	   ttt-­‐[Pt(py)2(N3)2(OH)2],	   is	   irradiated	   in	   the	   presence	   of	  
oligonucleotides,	   that	  are	  currently	  undetectable	  by	  conventional	  methods	  due	  to	  
the	   lengthy	  sample	  preparation.	  Reactions	  of	  8	  with	  5’-­‐GMP	  not	  only	  produce	  the	  
[Pt(py)2(5’-­‐GMP)2]	  adduct	  observed	  on	  oligonucleotides	   in	  Chapter	  2,	  but	  also	   the	  
monoazido	   adduct	   [Pt(py)2(N3)(5’-­‐GMP)].7	   These	   species	   are	   not	   detected	   by	  
conventional	  MS	  methods,	  an	  observation	  possibly	  ascribable	  to	  the	  time	  taken	  to	  
prepare	  the	  sample	  for	  analysis	  and	  the	  fact	  some	  platinum	  DNA	  adducts	  transform	  
over	   time.21	  With	   this	   in	  mind,	   a	   system	   incorporating	   the	   use	   of	   PCFs	  was	   been	  
designed	   to	   characterise	   short-­‐lived	   photoproducts	   that	   had	   not	   previously	   been	  
detected.	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4.3.1.1	  PCF-­‐MS	  system	  design	  and	  development:	  metallic	  coupling	  devices	  
For	  the	  purposes	  of	  this	  chapter,	  the	  term	  ‘direct	   infusion’	  will	  be	  used	  for	  
samples	  that	  have	  been	  directly	  injected	  into	  a	  mass	  spectrometer	  via	  PEEK	  tubing	  
using	   a	   syringe	   and	   syringe	   pump.	   This	   is	   a	   conventional	   method	   for	   the	  
introduction	  of	  samples	   into	  the	  mass	  spectrometer,	  and	  was	  used	  as	  a	  means	  of	  
producing	  a	  ‘standard’	  mass	  spectrum	  for	  comparison	  with	  those	  generated	  by	  the	  
PCF-­‐MS	   system.	   The	   vast	   majority	   of	   work	   in	   this	   chapter	   concerning	   fibre	  
fabrication,	   optical	   coupling,	   and	   the	   introduction	   of	   solutions	   to	   the	   PCFs	   was	  
carried	  out	  by	  Dr	  Sarah	  Unterkofler.	  My	  work	  was	  concerned	  with	  optimisation	  of	  
the	  microfluidic	   circuitry,	  achieving	   successful	   coupling	  of	   the	   system	  to	   the	  mass	  
spectrometer,	   carrying	   out	   control	   reactions	   by	   ‘conventional	   methods’	   for	  
comparison	  purposes	  and	  the	  selection	  of	  appropriate	  photoreactions	  for	  analysis.	  
It	   was	   first	   necessary	   to	   establish	   if	   there	  was	   any	   interaction	   between	   the	   bare	  
silica	   of	   the	   PCF	   and	   the	   metal	   complex	   that	   may	   affect	   the	   mass	   spectrum	  
observed.	   Preliminary	   experiments	   carried	   out	   on	   an	   ion-­‐trap	  mass	   spectrometer	  
indicated	   that	   there	  were	   no	  major	   differences	   between	   the	   spectra	   of	   a	   10	   μM	  
solution	  ofcomplex	  8	  in	  a	  50:50	  water/methanol	  solvent	  mix	  when	  flowed	  through	  
a	   PCF	   or	   PEEK	   tubing	   (both	   when	   in	   the	   dark	   and	   irradiated).	   These	   initial	  
experiments	  were	   then	   repeated	   on	   a	   high-­‐resolution	   instrument	   (Bruker	  MaXis)	  
using	  a	   solution	  of	  100	  μM	  solution	  of	  8	   in	  50:50	  DDW	  and	  acetonitrile,	  with	   the	  
addition	  of	  the	  steel	  coupling	  devices;	  see	  Figure	  4.2,	  to	  the	  PCF.	  The	  solvent	  was	  
changed	  to	  acetonitrile,	  since	  this	  produced	  a	  lower	  signal-­‐to-­‐noise	  ratio	  than	  that	  
of	  the	  water	  methanol	  mix.	  This	  inclusion	  of	  metallic	  coupling	  devices	  to	  allow	  the	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introduction	  of	  sample	  and	  light	  to	  the	  PCF	  (set-­‐up	  shown	  in	  Figure	  4.3)	  introduced	  
several	  new,	  unknown	  platinum	  containing	  species	  at	  579.2,	  750.2	  and	  857.2	  m/z,	  
see	  Figure	  4.4.	  MS/MS	  of	  the	  peak	  at	  750.2	  m/z	  shows	  fragments	  at	  383.1,	  411.1,	  
579.2	   and	   	   732.2	  m/z.	   The	   ions	   383.1	   and	   411.1	  m/z	   are	   also	   observed	   in	   the	  
spectrum	   of	   the	   direct	   infusion	   of	   8,	   Figure	   4.5.	   	   This	   would	   suggest	   that	   the	  
coupling	  devices	  have	  introduced	  a	  contaminant.	  
	  
Figure	  4.2	  An	  example	  of	  an	  initial	  metallic	  (steel)	  coupling	  device	  built	  in	  the	  Max	  
Plank	  Institute	  of	  Light,	  Erlangen	  used	  in	  the	  first	  PCF-­‐MS	  system	  (Figure	  4.3).	  
	  
	  
Figure	   4.3	   Schematic	   of	   a	   PCF	   sample	   injection	   system	  when	   coupled	   to	   405	   nm	  
laser	  light.	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For	  completeness	  of	  the	  comparison,	  the	  sample	  was	  then	  irradiated	  within	  
the	   system	   using	   405	   nm	   laser	   light.	   The	   photoactivation	   of	   8	   resulted	   in	   the	  
creation	   of	   several	   species	   that	  were	   also	   previously	   detected	   by	   direct	   infusion.	  
The	  molecular	  formulae	  of	  some	  of	  the	  ions	  was	  determined:	  382.0	  m/z	  PtC10H11N4,	  
430.0	  m/z	  PtC10H12O2N5,	  388.0	  m/z	  PtC10H13O2N2.	  A	  structure	  is	  proposed	  for	  one	  of	  
the	  photoproducts	   (388.0	  m/z):	   this	   is	  a	  Pt(III)	   ion.	   Indeed,	   the	  photoactivation	  of	  
Pt(IV)	   diazido	   complexes	   have	   previously	   been	   reported	   to	   generate	   this	   type	   of	  
species	   (see	  Figure	  4.6).22	   The	   intensity	  of	   the	  unknown	   species	  579.2,	   750.2	   and	  
857.2	  m/z	  decreases	  over	  the	  time	  of	   irradiation,	  Figure	  4.7.	  The	  system	  was	  then	  
cleaned	   by	   continual	   flushing	   with	   acetonitrile.	   Further	   new	   unknown	   platinum-­‐
containing	  peaks	  then	  appeared	  at	  382.0	  m/z	  and	  619.1	  m/z,	  Figure	  4.8.	  Even	  under	  
dark	  conditions,	  and	  a	  continual	  flow	  of	  clean	  solvent,	  these	  species	  remained.	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Figure	  4.4	  Top	  spectrum	  is	  of	  complex	  8,	  10	  μM	  in	  50:50	  methanol	  and	  DDW,	  in	  the	  
dark	   flowed	   through	  PEEK	   tubing	  only;	   the	  bottom	   spectrum	   is	   the	   complex,	   100	  
μM	   in	   50:50	   acetonitrile	   and	   DDW,	   flowed	   through	   the	   coupling	   device	   and	   PCF	  
system	   in	   the	   dark.	   Additional	   unknown	   peaks	   appear	   in	   this	   spectrum	   at	   579.2,	  
750.2	  and	  857.2	  m/z.	  The	  peak	  at	  388.1	  m/z	  is	  assigned	  as	  [Pt(III)(py)2(OH)2]+,	  494.1	  
m/z	  as	  [M	  +	  Na]+,	  and	  943.1	  m/z	  as	  [2M	  +	  H]+.	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Figure	  4.5	  MS/MS	  of	  750.2	  m/z	  peak	  ascribable	  to	  contamination	  introduced	  by	  the	  
coupling	  device,	  possibly	  from	  glue	  used	  in	  the	  construction.	  Peak	  isolation	  width	  of	  
6	  m/z	  collision	  energy	  15	  eV.	  Its	  isotopic	  pattern	  suggests	  the	  presence	  of	  Pt	  in	  the	  
ion,	   as	   would	   the	   smaller	   fragments	   383.1	   and	   411.1	   m/z	   also	   seen	   by	   direct	  
infusion.	  The	  loss	  of	  18	  m/z	  is	  attributed	  to	  the	  loss	  of	  H2O.	  
	  
The	  photostability	  of	  these	  contaminant	  peaks	  was	  then	  tested	  by	  switching	  
the	   laser	   back	   on.	   The	   post-­‐irradiation	   contaminants	   appear	   to	   be	   highly	  
photostable,	   and	   did	   not	   break	   down	   after	   28	   min	   of	   irradiation	   and	   constant	  
flushing	  with	  acetonitrile.	  The	  sample	  cells	  provided	  effective	  optical	  coupling	  from	  
the	   laser	   to	   the	   fibre,	  but	  also	   introduced	  contamination	  and	  have	   large	  pre-­‐	  and	  
post-­‐irradiation	  mixing	  volumes	  of	  60	  μL	  each.	  These	  large	  mixing	  volumes	  increase	  
the	  time	  of	  analysis,	  and	  the	  possibility	  of	  photoactivated	  species	   interacting	  with	  
each	   other	   and	   solvent	   molecules.	   An	   alternative	   method	   of	   sample	   and	   light	  
introduction	   was	   therefore	   deemed	   to	   be	   required.	   Preferably,	   the	   construction	  
would	  be	  of	  a	  less	  reactive	  material	  and	  the	  mixing	  volumes	  would	  be	  smaller	  whilst	  
retaining	  the	  optical	  properties	  of	  the	  sample	  cell.	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Figure	  4.7	  Irradiation	  of	  complex	  8	  (100	  μM)	  in	  acetonitrile	  over	  time	  (t	  =	  0,	  5,	  8.5	  
min),	   infused	   through	   the	   PCF-­‐MS	   system.	   Ions	   that	   reduced	   in	   intensity	   with	  
irradiation	   are	   highlighted	   in	   purple,	  whilst	   those	   that	   increase	   are	   highlighted	   in	  
orange.	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Figure	   4.8	   The	   initial	  mass	   spectrum	   of	   the	   instrument	   being	   flushed	  with	   HPLC-­‐
grade	  acetonitrile,	   showing	   the	  contamination	   from	  the	  metallic	  coupling	  devices,	  
after	   irradiation.	   Ions	   619.1	   and	   382.0	  m/z	   are	   photostable.	   A	   small	   amount	   of	  
943.1	  m/z,	  [2M	  +	  H]+	  was	  also	  detected.	  	  
	  
4.3.1.2	   PCF-­‐MS	   system	   design	   and	   development:	   plastic	   microfluidic	   coupling	  
devices	  
It	  was	  thought	  that	  the	   introduction	  of	  plastic	   (Teflon)	  microfluidic	  devices	  
would	  improve	  the	  system	  since	  they	  would	  have	  smaller	  mixing	  volumes	  than	  the	  
metallic	  coupling	  devices,	  reducing	  the	  analysis	  time,	  see	  Figure	  4.9.	  An	  additional	  
improvement	  was	   the	   drawing	   of	   a	   new	   photonic	   crystal	   fibre	   (Figure	   4.10)	   that	  
would	  guide	  the	  light	  better	  at	  405	  nm.	  The	  core	  of	  the	  fibre	  is	  smaller	  by	  5	  µm	  and	  
the	   cladding	   has	   been	   altered	   to	   better	   ‘trap’	   405	   nm	   light.	   When	   using	   the	  
microfluidic	  devices,	  the	  fibre	  had	  to	  be	  placed	  inside	  one	  of	  the	  three	  PEEK	  tubing	  
outlets	  (Figure	  4.9	  and	  Figure	  4.11);	  however,	  the	  inner	  diameter	  of	  the	  tubing	  was	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too	  small	  to	  fit	  the	  fibre	  and	  its	  protective	  cladding.	  To	  overcome	  this	  problem,	  the	  
cladding	  was	   removed	  with	  a	   razor	  blade,	   leaving	   the	   fibre	  exposed.	  Without	  any	  
cladding,	   the	   fibre	   is	   brittle	   and	   was	   prone	   to	   breakage	   when	   the	   ferrules	   are	  
tightened	  to	  create	  a	  closed	  system.	  
	   	  
Figure	   4.9	   Diagram	   of	   the	   microfluidic	   device	   used	   as	   an	   interface	   to	   introduce	  
sample	  solution	  and	  light	  into	  the	  PCF	  and	  allow	  for	  MS	  analysis.	  
	  
The	  microfulidics	  proved	  problematic	  when	   it	   came	   to	  guiding	   the	   light	   to	  
the	   PCF.	   Even	   in	   just	   an	   air-­‐filled	   system,	   it	   was	   not	   possible	   to	   guide	   the	   light	  
efficiently	   into	   the	  core	  of	   the	   fibre.	  This	  may	  have	  been	  due	   to	  breakages	   in	   the	  
section	   of	   the	   fibre	   with	   the	   cladding	   removed	   close	   to	   the	   coupling	   interface.	  
There	  also	  appeared	  to	  be	  imperfections	  in	  the	  glass	  coverslip	  where	  the	  light	  was	  
coupled	  to	  the	  device,	  possibly	  arising	  from	  the	  adhesive	  used	  in	  the	  construction	  
of	   the	   unit.	   The	   glue-­‐based	   construction	   also	   prevented	   the	   passage	   of	   organic	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microfluidic	   devices	   did	   not	   prove	   successful.	   It	   was	   then	   proposed	   that	   PVC	  
coupling	  devices,	  constructed	  using	  Teflon	  tape	  instead	  of	  glue,	  would	  be	  used.	  This	  
would	  result	  in	  a	  return	  to	  large	  pre-­‐	  and	  post-­‐irradiation	  mixing	  volumes.	  	  
	  
Figure	   4.10	   Cross-­‐section	   of	   the	   new	   Kagomé	   fibre	   with	   improved	   405	   nm	   light	  
guiding	  properties	  by	  changing	  the	  core	  size,	  the	  internal	  stucture	  of	  the	  fibre	  and	  
the	  cladding	  thickness	  (core	  approx.	  15	  μm).	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Figure	  4.11	  Schematic	  of	  the	  coupling	  of	  a	  microfluidic	  device	  into	  the	  system	  using	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4.3.1.3	  Design	  of	  PCF-­‐MS	  system:	  PVC	  coupling	  devices	  
The	  system	  previously	  described	   in	  Section	  4.3.1.2	  was	   further	  adapted	  by	  
the	  substitution	  of	  the	  microfluidic	  cells	  for	  new	  PVC	  pressure	  cells	  (Figure	  4.12).	  It	  
was	  hoped	   that	   they	  would	  aid	   the	   coupling	  of	   light	   into	   the	   fibre	  using	  optically	  
accessible	   windows	   constructed	   from	   a	   high-­‐grade	   glass	   and	   reduce	   the	  
contamination	  problems	  associated	  with	  past	  systems.	  	  
After	  focusing	  the	  laser	  light	  into	  the	  core	  of	  the	  fibre,	  the	  flow	  rate	  through	  
the	   system	  was	  measured	   in	   order	   to	   establish	   the	   rate	   required	   for	   the	   syringe	  
pump	  to	  reach	  the	  ideal	  flow	  into	  the	  mass	  spectrometer.	  The	  tubing	  was	  detached	  
from	   the	  MS	  at	   the	  end	  of	   the	   system.	  The	  volume	  of	   liquid	   that	   flowed	   through	  
over	   a	   15	   min	   period	   was	   collected	   in	   an	   Eppendorf	   tube	   and	   its	   volume	  
determined.	  This	   is	  a	  very	  crude	  approximation	  of	  the	  flow	  within	  the	  system,	  but	  
should	   be	   enough	   to	   obtain	   a	   spectrum	   of	   high	   enough	   intensity.	   In	   view	   of	   the	  
back-­‐pressure	  within	   the	   system	   the	   syringe	   pump	   had	   to	   be	   set	   to	   200	   µL/h	   to	  
achieve	  the	  desired	  100	  µL/h	  flow-­‐rate.	  The	  flow	  rate	  of	  the	  sample	  is	  an	  important	  
consideration	  when	  using	   ESI,	   since	   it	   affects	  both	   the	  desolvation	   and	   ionisation	  
processes.	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Figure	  4.12	  Picture	  of	  the	  new	  PVC	  coupling	  devices	  replacing	  the	  old	  microfluidic	  
ones.	  
	  
First	  0.2	  µm	  filtered	  DDW	  was	  flowed	  through	  the	  system,	  followed	  by	  the	  
calibrant,	   sodium	   formate.	  At	   this	   point	   it	  was	  established	   that	   the	   intrinsic	  dead	  
volume	  of	  the	  system	  was	  problematic	  for	  the	  low	  flow-­‐rate	  (100	  μL)	  of	  the	  system.	  
Although	  the	  volume	  of	  the	  fibre	  itself	  is	  very	  small	  (65	  nL	  in	  the	  core),	  the	  internal	  
volume	  of	  each	  PVC	  pressure	  cell	   is	  60	  µL,	   requiring	  over	  an	  hour	   to	   run	  solution	  
through	  the	  system.	  
A	   500	  µM	   solution	  of	  8,	   ttt-­‐[Pt(py)2(N3)2(OH)2],	   in	  DDW	  was	   then	  pumped	  
into	  the	  system.	  The	  set	  flow	  rate	  was	  increased	  from	  200	  μL	  to	  500	  μL	  to	  reduce	  
the	  dead	  time	  but	  this	  gave	  rise	  to	  the	  spray	  in	  to	  the	  MS	  taking	  longer	  to	  stabilise,	  
a	  phenomenon	  which	  increased	  the	  pressure	  within	  the	  system.	  
The	  first	  spectrum	  was	  obtained	  after	  1	  h,	  Fig.	  4.13.	  The	  sodium	  adduct	  of	  
the	   complex	   is	   clearly	   observed	   at	   494.1	  m/z,	   as	  well	   a	   dimer	   of	   the	   complex	   at	  
943.1	  m/z,	  and	  some	  fragment	  ions/photoproducts	  at	  388.1	  and	  412.1	  m/z.	  When	  
the	  PCF-­‐MS	  spectrum	  is	  compared	  to	  the	  spectrum	  of	  the	  complex	  directly	  infused	  
into	  the	  MS,	  both	  under	  dark	  conditions	  (Fig.	  4.14)	  and	  after	  irradiation	  at	  420	  nm	  
(Fig.	  4.15),	  significant	  differences	  were	  observed.  
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Figure	  4.13	  Mass	  spectrum	  of	  500	  µM	  complex	  8,	   ttt-­‐[Pt(py)2(N3)2(OH)2],	   in	  DDW,	  
irradiated	  with	  405	  nm	  laser	  light	  in	  the	  PCF-­‐MS	  system.	  Peak	  at	  388.1	  m/z	  assigned	  
as	  [Pt(py)2(OH)2]+,	  494.1	  m/z	  as	  [M	  +	  Na]+	  and	  943.1	  m/z	  as	  [2M	  +	  H]+.	  	  
	  
The	   directly	   infused	   sample	   in	   the	   dark,	   Figure	   4.14,	   contains	   a	   relatively	  
high	   abundance	   of	   the	   complex	   with	   a	   sodium	   ion	   and	   the	   fragment	  
ion/photoproduct	   388.0	   m/z	   [Pt(py)2(OH)2]+;	   a	   dimer	   of	   this	   complex	   is	   also	  
detected	   at	   943.1	  m/z.	   In	   the	   irradiated	   sample,	   Figure	   4.15	   there	   is	   a	   complete	  
absence	   of	   dimer	   formation	   and	   very	   low	   intensity	   of	   the	   peak	   assigned	   to	   the	  
complex	  with	  a	  sodium	  ion.	  This	  may	  indicate	  that	  the	  dimer	  is	  likely	  to	  be	  formed	  
during	   the	   ionisation	   process;	   as	   the	   droplet	   size	   shrinks	   and	   complex	   ions	   are	  
forced	   closer	   together.	   The	   dominant	   peak	   in	   the	   spectrum	   in	   Figure	   4.15	   is	   the	  
fragment	   ion/photoproduct	   [Pt(py)2(OH)2]+	   at	   388.0	   m/z,	   indicating	   that	  
photoreduction	  had	  taken	  place. 
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Comparison	   of	   the	   spectrum	   of	   the	   sample	   irradiated	   within	   the	   PCF-­‐MS	  
system	   (Figure	   4.13)	   with	   directly	   infused	   samples	   reveals	   similarities	   with	   the	  
spectrum	   of	  8	   in	   the	   dark	   (Figure	   4.14),	   such	   as	   the	   presence	   of	   dimer	   and	   high	  
proportions	  of	  the	  complex	  with	  a	  sodium	  ion.	  This	  suggests	  that	  the	  solution	  may	  
not	   have	   been	   fully	   irradiated.	   The	   PCF-­‐MS	   spectrum	   also	   contains	   a	   peak	   not	  
observed	  in	  either	  of	  the	  other	  two	  spectra	  at	  469.1	  m/z.	  From	  the	  isotopic	  pattern	  
of	  the	  peak,	  it	  is	  highly	  likely	  that	  the	  species	  contains	  platinum,	  but	  its	  structure	  is	  
as	  yet	  undetermined.	  Tentative	  assignment	  to	  a	  short-­‐lived	  species	  not	  detected	  by	  
direct	   infusion	   can	   be	   ruled	   out	   in	   view	   of	   the	   long	   period	   of	   time	   between	   the	  
sample	  being	  exposed	  to	  the	  laser	  light	  and	  acquisition	  of	  the	  PCF-­‐MS	  spectrum	  (1.0	  
h).	  	  
	  
Figure	   4.14	  Mass	   spectrum	   of	   a	   dark	   solution	   containing	   500	   μM	   of	   8	   in	   DDW	  
directly	  infused.	  Peaks	  at	  388.1	  m/z	  are	  assigned	  as	  [Pt(py)2(OH)2]+,	  494.1	  m/z	  as	  [M	  
+	  Na]+,	  and	  943.1	  m/z	  as	  [2M	  +	  H]+.	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Another	  reason	  for	  the	  PCF-­‐MS	  sample	  having	  greater	  similarity	  to	  the	  dark	  
directly	  infused	  sample	  is	  that	  during	  the	  time	  taken	  for	  the	  sample	  to	  flow	  through	  
the	  system,	  the	  light	  drifted	  from	  the	  core	  of	  the	  fibre	  as	  indicated	  by	  the	  post-­‐fibre	  
imaging	   camera	   (Fig.	   4.3).	   This	   could	  occur	   for	   several	   reasons;	   the	  generation	  of	  
small	   bubbles	   of	   N2	   gas	   from	   the	   photoreduction	   reaction;7	   the	   high	   flow-­‐rate	  
through	   the	   system	   could	   have	   placed	   it	   under	   strain	   causing	   movement	   of	   the	  
fibre,	  and	  also	  the	  limited	  ability	  of	  the	  fibre	  to	  guide	  light	  at	  405	  nm.	  
	  
Figure	  4.15	  Mass	  spectrum	  of	  the	  direct	  infusion	  of	  a	  500	  µM	  solution	  of	  8	  after	  30	  
min	  of	  irradiation	  at	  420	  nm	  in	  a	  photoreactor.	  Peaks	  at	  388.1	  m/z	  are	  assigned	  as	  
[Pt(py)2(OH)2]+	  and	  494.1	  m/z	  as	  [M	  +	  Na]+	  .	  	  
 
4.3.1.4	  Design	  of	  PCF-­‐MS	  system:	  microfluidic	  devices	  using	  ‘off-­‐the-­‐shelf’	  chips	  
To	  reduce	  drifting	  of	  the	  light	  out	  of	  the	  core,	  as	  described	  at	  the	  end	  of	  the	  
previous	  section,	   the	  set	  up	  was	  modified	  so	  that	  the	  sample	   is	   introduced	  at	  the	  
opposite	   end	   to	   which	   the	   light	   is	   coupled	   into	   the	   system.	   This	   is	   intended	   to	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reduce	  movement	  at	  the	  end	  of	  the	  fibre	  that	  the	  laser	  is	  focused	  into,	  preventing	  
the	   light	   from	   moving	   out	   of	   the	   core	   once	   focused.	   A	   flow	   meter	   was	   also	  
introduced	   to	   obtain	   accurate,	   online	  measurements	   of	   the	   flow-­‐rate,	   see	   Figure	  
5.16.	   	   The	   wavelength	   of	   laser	   light	   used	   was	   also	   changed	   to	   488	   nm	   for	   two	  
reasons:	  firstly,	  PCFs	  are	  better	  at	  guiding	  longer	  wavelengths	  of	  light,	  and	  secondly	  
this	   is	   a	   better	   wavelength	   for	  medical	   application,	   with	   a	   view	   to	   working	   with	  
photoactivatable	   anticancer	   complexes	   with	   potential	   for	   clinical	   use.	   A	   cross-­‐
section	  of	  this	  new	  fibre	  can	  be	  seen	  in	  Figure	  4.17.	  
	  
Figure	   4.16	   Schematic	   of	   the	   updated	   system,	   complete	   with	   flow-­‐meter	   and	  
microfluidics	   chips	   with	  mounts	   (Figure	   4.18).	   PEEK	   tubing	   in	   red,	   PCF	   in	   yellow,	  
light	  in	  blue,	  and	  the	  microfluidics	  are	  surrounded	  by	  a	  dashed	  line.	  
The	   connection	   of	   the	   fibre	   to	   the	   rest	   of	   the	   system	   was	   also	   modified.	  
Commercially	   available	   polymeric	   microfluidic	   chips	   consisting	   of	   16	   separate	   channels	  
were	  mounted	  onto	  a	   specially	  made	  metal	   frame.	  The	  PCF	  and	   the	  PEEK	   tubing	  were	  
connected	  to	  a	  single	  channel	  in	  each	  chip	  using	  HPLC	  PEEK	  fittings,	  and	  as	  with	  previous	  
systems	   the	   fiber	   ends	   remain	   optically-­‐accessible,	   see	   Figure	   4.18.	   	   These	   individual	  
channels	  have	  a	  volume	  less	  than	  400	  nL,	  and	  when	  combined	  with	  the	  volume	  of	  the	  PCF	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(average	   length	   25	   cm)	   gives	   a	   total	   volume	  of	   3.1	   μL	   (not	   including	   PEEK	   tubing),	   the	  
smallest	  volume	  of	  this	  system	  to	  date.	  
	  
	  
Figure	  4.17	  A	  cross	  section	  of	  the	  Kagomé	  fibre	  designed	  to	  guide	  488	  nm	  light;	  the	  
core	  size	  has	  been	  increased,	  as	  has	  the	  cladding.	  
	  
This	   system	   has	   the	   potential	   to	   give	   the	   quickest	   delivery	   of	   irradiated	  
sample	  to	  the	  mass	  spectrometer.	  The	  system	  was	  validated	  before	  any	  conclusions	  
were	  drawn	  from	  the	  data	   that	   it	  yielded.	  Previously	  complex	  8	  was	  used	   for	   this	  
purpose	  and	  signal	  intensity	  was	  a	  continual	  problem.	  This	  may	  be	  due	  to	  the	  fact	  
that	  this	  class	  of	  complex	  is	  neutral	  and	  usually	  detected	  by	  mass	  spectrometry	  as	  a	  
sodium	  or	  potassium	  adduct.23	  The	  bare	  silica	  walls	  of	  the	  PCF	  may	  be	  affecting	  the	  
process	   by	   which	   the	   complex	   acquires	   these	   ions,	   so	   that	   it	   may	   be	   detected.	  
Therefore,	  a	  new	  model	  photoreaction	  was	  required	  as	  a	  proof-­‐of-­‐concept	  means	  
of	  testing	  the	  efficacy	  of	  the	  system.	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Figure	  4.18	  Schematic	  of	  the	  microfluidic	  chip	  in	  its	  mount	  and	  how	  it	  is	  connected	  
to	  the	  rest	  of	  the	  system.	  Sample	  in	  dark	  blue,	  PEEK	  tubing	  in	  red	  and	  green,	  laser	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4.3.2	  Vitamin	  B12	  -­‐	  a	  model	  for	  PCF-­‐MS	  system	  validation	  in	  the	  positive-­‐ion	  mode	  
The	   photodissociation	   of	   vitamin	   B12,	   cyanocobalamin,	   has	   been	   the	   subject	   of	  
much	  research	  and	  involves	  the	  loss	  of	  the	  Co-­‐bound	  cyano	  group	  upon	  irradiation,	  and	  its	  
replacement	  with	  a	  water	  molecule	  to	  give	  aquacobalamin	  (Figure	  4.19).24,25,26	  This	  is	  a	  pH	  
dependent	   process	   and	   normally	   only	   occurs	   at	   high	   or	   low	   pH	   values.27,19	   As	   with	   the	  
previous	   experiments	   to	   validate	   the	   PCF-­‐MS	   system	   (in	   this	   case	   the	   system	   shown	   in	  
Section	  4.3.1.4),	   it	  must	  be	  compared	  with	  conventional	  methods.	   In	   this	  case,	  as	  well	  as	  
directly	   infusing	   sample	   solutions	   in	   the	   dark,	   an	   aliquot	   of	   the	   sample	   was	   placed	   in	   a	  
quartz	  cuvette	  and	  irradiated	  using	  a	  488	  nm	  laser	  set	  at	  the	  same	  power	  as	  for	  the	  PCF-­‐MS	  
experiments	   (5	  mW).	   For	   all	   future	   experiments,	   this	   is	   referred	   to	   as	   the	   ‘conventional	  
method	   of	   irradiation’.	   For	   the	   purpose	   of	   system	   validation	   in	   the	   positive-­‐ion	  mode,	   a	  
solution	  of	  cyanocobalamin	  at	  pH	  1	  and	  another	  at	  pH	  8	  were	   irradiated	  by	  conventional	  
and	  PCF-­‐MS	  methods	  for	  comparison.	  
	  
	  Figure	  4.19	  Photosubstitution	  of	  cyanocobalamin,	  [CNCbl],	  to	  give	  aquacolbalamin,	  
[H2OCbl]+.	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4.3.2.1	  Photoaquation	  of	  vitamin	  B12	  at	  pH	  1.7:	  conventional	  method	  
The	  photoaquation	  of	  cyanocobalamin	  has	  been	  shown	  to	  occur	  more	  rapidly	  at	  
llower	  pH.28	  A	  solution	  of	  100	  μM	  of	  cyanocobalamin	  (pH	  1.7)	  was	  directly	  infused	  into	  the	  
mass	  spectrometer	  under	  dark	  conditions.	  The	  resulting	  spectrum	  is	  shown	  in	  Figure	  4.20.	  
The	  most	  abundant	  ions	  in	  the	  spectrum	  are	  678.3	  m/z	  assigned	  as	  the	  doubly	  protonated	  
molecular	  ion	  ([CNCbl	  +	  2H]2+),	  and	  689.3	  m/z	  as	  a	  doubly-­‐charged	  sodium	  adduct	  ([CNCbl	  
+	  H	  +	  Na]2+).	  
	  
Figure	  4.20	  Spectrum	  of	  a	  100	  μM	  solution	  of	  vitamin	  B12	  in	  DDW	  at	  pH	  1.7	  in	  the	  
dark,	  directly	   infused,	   the	  peak	  at	  678.3	  m/z	  was	  assigned	  as	   [CNCbl	  +	  2H]2+,	  and	  
that	  at	  689.3	  m/z	  as	  [CNCbl	  +	  H	  +	  Na]2+.	  
	  
An	   aliquot	   taken	   from	   the	   same	  100	  μM	   stock	   solution	  was	   placed	   in	   a	   quartz	  
cuvette	   and	   irradiated	   with	   488	   nm	   laser	   light	   for	   10.00	   h.	   	   This	   solution	   was	   then	  
centrifuged	  for	  10	  min;	  and	  the	  supernatant	  was	  injected	  into	  the	  mass	  spectrometer.	  This	  
spectrum	  (Figure	  4.21)	  still	  contains	  the	  doubly	  protonated	  cyanocobalamin	  molecular	  ion	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following	   peaks	   appeared	   only	   in	   the	   spectrum	  of	   the	   irradiated	   solution:	   i.e.,	   those	   at	  
664.8	  m/z	  was	  assigned	  as	  the	  cyano	  free	  cobalamin	  species,	  [Cbl	  +	  H]2+,	  and	  673.8	  m/z	  as	  
aquacobalamin	   ([H2OCbl	   +	   H]2+)	   were	   observed	   showing	   that	   a	   photoreaction	   had	  
occurred.	  
	  
Figure	  4.21	  Spectrum	  of	  conventionally	  irradiated	  100	  μM	  solution	  of	  vitamin	  B12	  in	  
DDW	  (10	  h,	  488	  nm)	  at	  pH	  1.	  After	   irradiation	  the	  peaks	  at	  664.8	  m/z	  assigned	  as	  
[Cbl	  +	  H]2+,	  673.8	  m/z	  ([H2OCbl	  +	  H]2+),	  	  682.8	  m/z	  ([H2OCbl	  +	  H2O	  +	  H]2+)	  and	  693.8	  
m/z	  ([H2OCbl	  +	  H2O	  +	  Na]2+)	  were	  observed.	  
	  
4.3.2.2	  Photoaquation	  of	  vitamin	  B12	  at	  pH	  1.7:	  PCF-­‐MS	  system	  	  
The	  irradiation	  of	  vitamin	  B12	  was	  then	  repeated	  within	  the	  PCF-­‐MS	  system	  
by	  flowing	  a	  100	  μM	  aqueous	  solution	  of	  vitamin	  B12	  at	  pH	  1.7	  through	  the	  set-­‐up.	  A	  
signal	   was	   observed	   that	   was	   much	   more	   intense	   than	   anything	   achieved	   using	  
previous	  samples	  or	   systems.	  After	  15	  min,	   the	  signal	   intensity	  had	  stabilized	  and	  
reached	  a	  maximum	  value,	  	  at	  which	  point	  the	  spectrum	  of	  the	  solution	  in	  the	  dark	  
was	  recorded	  (Figure	  4.22	  (A)).	  The	  488	  nm	  laser	  was	  then	  switched	  on	  and	  after	  a	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assigned	  as	  [Cbl	  +	  H]2+,	  and	  [H2OCbl	  +	  H]2+	  (Figure	  4.22(B)),	  indicating	  the	  successful	  
photoconversion	  of	  cyanocobalamin	  to	  its	  aqua	  adduct.	  	  
	   	  
Figure	  4.22:	  Mass	  spectra	  of	  vitamin	  B12	  (100	  µM)	  in	  DDW	  at	  pH	  1.7,	  obtained	  using	  
the	  PCF-­‐MS	  system.	  (A)	  Spectrum	  of	  vitamin	  B12	  in	  the	  dark;	  the	  peak	  at	  678.3	  m/z	  
was	  assigned	  as	   [CNCbl	  +	  2H]2+	  and	  689.3	  m/z	  as	   [CNCbl	  +	  H	  +	  Na]2+.	   (B)	  After	  15	  
min	  of	   irradiation	  at	  488	  nm;	  the	  664.8	  m/z	  peak	  was	  assigned	  as	   [Cbl	  +	  H]2+,	  and	  
that	  at	  673.8	  m/z	  as	  [H2OCbl	  +	  H]2+.	  
	  
4.3.2.3	  Photoaquation	  of	  vitamin	  B12	  at	  pH	  7.9:	  conventional	  methods	  
As	   this	   is	   a	   pH	   dependent	   reaction	   and	   CNCbl	   is	   most	   stable	   to	  
photodecomposition	   between	   pH	   7	   and	   8,	   the	   cuvette	   and	   PCF-­‐MS	   comparisons	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were	  carried	  out	  within	  this	  pH	  range	  in	  order	  to	  investigate	  the	  possible	  superiority	  
of	  the	  continuous	  flow	  set-­‐up.	  The	  cuvette	  was	  again	  exposed	  to	  a	  minimum	  of	  10	  h	  
irradiation	  with	  488	  nm	  light,	  but	  in	  this	  case	  the	  solution	  of	  vitamin	  B12	  was	  at	  pH	  
7.9.	  In	  this	  case,	  there	  was	  no	  difference	  between	  the	  spectra	  of	  the	  sample	  in	  the	  
dark	  and	  that	  of	  the	  irradiated	  solution:	  an	  example	  is	  given	  in	  Figure	  4.23.	  At	  the	  
higher	  pH	  value,	  different	  ions	  are	  observed	  compared	  to	  the	  spectrum	  acquired	  for	  
the	   lower	  pH	  solution.	  A	   lower	  proportion	  of	  protonated	  species	   is	  detected,	  with	  
salt	   adducts	   such	   as	   sodium	   and	   potassium	   being	   more	   abundant.	   The	   peaks	   at	  
700.3	  m/z	   and	   734.3	  m/z	   were	   assigned	   as	   [CNCbl	   +	   2Na]2+	   and	   [CNCbl	   +	   2K	   +	  
2(H2O)]2+	  respectively.	  
	  
Figure	  4.23	  Mass	  spectrum	  from	  the	  direct	  infusion	  of	  100	  μM	  vitamin	  B12	  in	  DDW	  
at	  pH	  7.9.	  The	  peak	  at	  678.3	  m/z	  was	  assigned	  as	  [CNCbl	  +	  2H]2+,	  and	  those	  at	  689.3	  
m/z	  as	  [CNCbl	  +	  H	  +	  Na]2+,	  700.3	  m/z	  as	  [CNCbl	  +	  2Na]2+,	  and	  734.3	  m/z	  as	  [CNCbl	  +	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4.3.2.4	  Photoaquation	  of	  vitamin	  B12	  at	  pH	  7.9:	  PCF-­‐MS	  system	  	  
The	   same	   stock	   solution,	   at	   pH	   7.9	   was	   once	   again	   irradiated	   within	   the	  
fibre-­‐based	  system,	  and	  a	  similar	  spectrum	  of	  the	  solution	  in	  the	  dark	  was	  obtained,	  
see	  Figure	  4.24	  A.	  The	  laser	  was	  switched	  on,	  and	  after	  20	  min	  the	  spectrum	  shown	  
in	  Figure	  4.24	  B	  was	  recorded.	  Although	  not	  observed	  to	  the	  same	  extent	  as	  that	  at	  
pH	  1.7,	  a	  photoreaction	  is	  clearly	  observed	  here,	  and	  is	  attributable	  to	  the	  superior	  
irradiance	  achieved	  within	  the	  fibre.	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Figure	  4.	  24	  Spectra	  from	  the	  PCF-­‐MS	  system:	  	  100	  μM	  of	  vitamin	  B12	  in	  DDW	  at	  pH	  
7.9	  (A)	  the	  solution	  in	  the	  dark:	  peaks	  at	  689.3	  m/z	  were	  assigned	  as	  [CNCbl	  +	  H	  +	  
Na]2+,	  697.3	  m/z	  as	  [CNCbl	  +	  H	  +	  K]2+,	  700.3	  m/z	  as	  [CNCbl	  +	  2Na]2+,	  708.3	  m/z	  as	  
[CNCbl	   +	   Na	   +	   K]2+	   and	   716.2	   m/z	   [CNCbl	   +	   2K]2+).	   Spectrum	   (B)	   the	   solution	  
irradiated	  for	  20	  min:	  peak	  at	  664.8	  m/z	  assigned	  as	  [Cbl	  +	  H]2+,	  that	  at	  675.8	  m/z	  as	  
[Cbl	  +	  Na]2+,	  and	  that	  at	  683.8	  m/z	  as	  [Cbl	  +	  K]2+.	  
	  
4.3.3	  PCF-­‐MS	  system	  validation:	  Sodium	  nitroprusside	  -­‐	  a	  model	  reaction	  for	  
system	  validation	  in	  the	  negative-­‐ion	  mode	  
The	   potential	   of	   the	   PCF-­‐MS	   system	   to	   utilise	   the	   negative-­‐ion	  mode	  was	  
also	   explored	   using	   a	   well-­‐characterised	   system.	   Sodium	   nitroprusside	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Na2[Fe(CN)5NO]2H2O	  (SNP)	  is	  an	  iron-­‐based	  vasodilator	  used	  in	  the	  clinic	  (structure	  
shown	  in	  Figure	  4.25).29	  The	  action	  of	  the	  drug	   is	  ascribable	  to	  the	  release	  of	  NO	  
from	   the	   complex	   into	   the	   blood	   stream.	   This	   process	   can	   be	   accelerated	   by	  
exposure	   to	   light.30,31	   There	   is	   some	  evidence	   to	   suggest	   this	   input	  of	   energy	   can	  
also	  trigger	  the	  release	  of	  the	  remaining	  cyano	  groups.	  32,33,34	  
	   	  
Figure	  4.25	  The	  structure	  of	  sodium	  nitroprusside	  (SNP).	  
Since	   this	   compound	  has	  been	  studied	   for	  many	  years,	   its	  behaviour	  upon	  
ESI	   ionisation	   is	   well	   known.35	   Similar	   to	   the	   photoactivation	   of	   SNP,	   ionisation	  
causes	  the	  loss	  of	  the	  NO	   ligand	  followed	  by	  the	  loss	  of	  multiple	  CN-­‐	  ligands.35	  As	  
fragmentation	   and	   light	   activation	   give	   such	   similar	   results,	   determination	   of	  
photoactivation	   is	   dependent	   on	   the	   relative	   abundance	   of	   the	   fragment	   and	  
molecular	  ions.	  	  
As	  with	  the	  experiments	  performed	  for	  validation	  of	  the	  PCF-­‐MS	  system	  in	  
the	   positive	   mode	   (see	   Section	   4.2.2),	   the	   irradiation	   of	   SNP	   along	   with	   control	  
solutions	   in	  the	  dark	  was	  analysed	  using	  both	  conventional	  methods	  and	  the	  PCF-­‐
MS	  system	  for	  compartive	  purposes.	  From	  the	  spectrum	  of	  the	  compound	  directly	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ionisation	  process,	   the	  complex	  undergoes	  a	  significant	  amount	  of	   fragmentation.	  
The	  species	  at	  238.9	  m/z	  was	  assigned	  as	  [[Fe(CN)5(NO)]+Na]-­‐,	  and	  the	  peaks	  208.9	  
m/z	   as	   [[Fe(CN)5]+Na]-­‐,	   133.9	   m/z	   as	   [[Fe(CN)3]]-­‐	   and	   107.9	   m/z	   as	   [[Fe(CN)2]]-­‐.	  
When	  this	   ‘dark’	  spectrum	  is	  compared	  to	  one	  of	  the	  same	  solution	   irradiated	  for	  
several	   hours	   using	   488	   nm	   laser	   light,	   Figure	   4.27,	   there	   is	   little	   observable	  
difference	   between	   the	   peak	   intensities;	   the	   same	   was	   the	   case	   when	   the	  
experiment	  was	  carried	  out	  using	  the	  PCF-­‐MS	  system	  (results	  not	  shown).	  
	  
Figure	  4.26	  Mass	   spectrum	  of	   SNP,	   500	  μM	   in	  DDW,	  directly	   infused	   in	   the	  dark.	  
The	   peak	   at	   238.9	  m/z	   is	   assigned	   as	   [[Fe(CN)5(NO)]+Na]-­‐,	   that	   at	   208.9	  m/z	   as	  
[[Fe(CN)5]+Na]-­‐,	  133.9	  m/z	  as	  [[Fe(CN)3]]-­‐,	  and	  107.9	  m/z	  as	  [[Fe(CN)2]]-­‐.	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Figure	  4.27	  Mass	  spectrum	  of	  a	  500	  μM	  SNP	  solution	  in	  DDW	  irradiated	  for	  3.00	  h	  
with	   488	   nm	   light	   and	   directly	   infused.	   The	   peak	   at	   238.9	  m/z	   was	   assigned	   as	  
[[Fe(CN)5(NO)]+Na]-­‐,	   that	   at	   208.9	   m/z	   as	   [[Fe(CN)5]+Na]-­‐,	   that	   at	   133.9	   m/z	   as	  
[[Fe(CN)3]]-­‐	  and	  107.9	  m/z	  as	  [[Fe(CN)2]]-­‐.	  
	  
4.3.4	  PCF-­‐MS	  system	  application:	  photoactivation	  of	  ruthenium	  anticancer	  
complexes	  
The	  unification	  of	  PCFs	  and	  mass	  spectrometry	  has,	  in	  the	  previous	  sections	  
of	   this	   chapter,	   been	   shown	   to	   be	   superior	   to	   conventional	   methods	   of	   sample	  
irradiation	  and	  analysis	  in	  some	  cases.	  This	  technique	  can	  now	  be	  extended	  to	  the	  
study	   of	   photoactivatable	   ruthenium	   drugs.	   As	   shown	   in	   Section	   4.3.1.4	   Pt(IV)-­‐
diazido	  complexes	  are	  not	  good	  candidates	  for	  this	  system,	  in	  view	  of	  the	  fact	  that	  
they	   are	   neutral	   and	   often	   only	   detected	   as	   salt	   adducts.	   This	   produces	   mass	  
spectra	   from	   the	  PCF-­‐MS	   that	  differ	   greatly	   from	   those	  obtained	  by	   conventional	  
methods	  using	  similar	  conditions.	  Complex	  24	  is	  a	  doubly-­‐charged	  ruthenium-­‐based	  
compound,	  see	  Figure	  4.28,	  that	   loses	  a	  pyridine	  (py)	   ligand	  after	  being	   irradiated	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with	   light	   for	   several	   hours.36,8	   The	   fact	   that	  24	   is	   charged	   should	  mean	   that	   it	   is	  
easier	  to	  detect	  in	  the	  mass	  spectrometer	  than	  a	  neutral	  compound	  that	  has	  to	  pick	  
up	  a	  charge	  to	  be	  observed.	  The	  fact	  that	  24	  requires	  a	  longer	  period	  of	  irradiation	  
to	   be	   activated	   by	   conventional	   methods	   than	   8	   allows	   for	   a	   more	   interesting	  
comparison	   between	   the	   PCF-­‐MS	   system	   and	   conventional	   irradiation	   methods;	  
because	  of	  this,	  the	  organometallic	  arene	  complex	  24	  was	  selected.	  	  
	  
Figure	  4.28	  Structure	  of	  24,	  [Ru(η6-­‐p-­‐cym)(2,2ʹ′-­‐bipyrimidine)(py)]	  2+.	  
	  
As	   with	   the	   system	   validation	   experiments	   (Sections	   4.2.3	   and	   5.2.3),	  
conventional	  methods	  were	  used	  as	  a	  comparison	  to	  test	  the	  efficacy	  of	  the	  PCF-­‐MS	  
system,	  as	  well	  as	  to	  those	  in	  the	  reported	  literature.	   	  Controls	  of	  the	  solutions	   in	  
the	  dark	  were	  also	  analysed	  by	  both	  methods.	  
The	  direct	  infusion	  of	  a	  250	  μM	  solution	  of	  24	  in	  DDW	  in	  the	  dark	  results	  in	  
the	  spectrum	  shown	  in	  Figure	  4.29.	  The	  most	  abundant	  ion	  is	  197.0	  m/z,	  assigned	  
as	  [M	  −	  (py)]2+;	  other	  significant	  peaks	  are	  236.6	  m/z	   [M]2+	  and	  at	  618.1	  m/z	   [M	  +	  
(PF6)]+.	   	   The	   species	   at	   197.0	   m/z	   is	   what	   is	   expected	   to	   be	   produced	   upon	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irradiation	   of	   24	   and	   was	   also	   detected	   in	   the	   spectrum	   of	   the	   sample	   after	  
irradiation	   (Figure	   4.30),	   as	   were	   the	   previously	   noted	   peaks.	   There	   was	   little	  
observable	   difference	   before	   and	   after	   irradiation	   by	   conventional	  methods.	   The	  
reaction	   was	   also	   carried	   out	   in	   the	   PCF-­‐MS	   system,	   and	   the	   same	   result	   was	  
obtained.	  This	   lack	  of	  distinction	  between	   the	   spectra	  of	   the	   complex	   in	   the	  dark	  
and	  after	  irradiation	  made	  it	  a	  poor	  candidate	  for	  further	  investigation.	  
	  
Figure	  4.29	  Mass	  spectrum	  of	  a	  directly	  infused	  dark	  solution	  (250	  μM	  in	  DDW),	  of	  
complex	  24.	  Species	  at	  197.0	  m/z,	  assigned	  as	  [M	  −	  (py)]2+,	  236.6	  m/z	  [M]2+,	  and	  at	  
618.1	  m/z	  as	  [M	  +	  (PF6)]+.	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Figure	   4.30	  Mass	   spectrum	   of	   directly	   infused	   solution	   (250	   μM	   in	   DDW),	   of	   24,	  
irradiated	  with	  488	  nm	   light	   for	  16	  h.	   Species	  at	  197.0	  m/z,	   are	  assigned	  as	   [M	  −	  
(py)]2+,	  236.6	  m/z	  [M]2+,	  and	  at	  618.1	  m/z	  as	  [M	  +	  (PF6)]+.	  	  	  
	  
4.3.5	  PCF-­‐MS	  system	  application	  as	  a	  rapid	  microreactor	  screening	  technique	  to	  
gain	  insights	  into	  the	  mechanism	  of	  action	  of	  photoactivatable	  drugs	  
As	   outlined	   in	   Section	   4.3.4,	   charged	   photoactivatable	   ruthenium-­‐based	  
complexes	  have	  been	  shown	  to	  be	  good	  candidates	   for	  PCF-­‐MS,	  and	  after	   limited	  
success	   with	   complex	   24,	   the	   dinuclear	   complex	   25,	   [{(η6-­‐indan)RuCl}2(μ-­‐2,3-­‐
dpp)](PF6)2,	   see	   Figure	   4.31,	   was	   selected	   for	   this	   study.	   The	   photoactivation,	  
aquation	   and	   DNA	   binding	   properties	   of	   this	   compound	   have	   been	   previously	  
reported,37	  and	  provide	  a	  good	  comparison	  to	  the	  findings	  of	  this	  work.	  The	  aim	  of	  
this	   series	   of	   experiments	   was	   to	   use	   the	   PCF	   as	   a	   microreactor	   in	   order	   to	  
photoactivate	  25	  in	  the	  presence	  of	  a	  range	  of	  small	  biomolecules	  that	  are	  present	  
within	   the	   cell,	   or,	   alternatively,	   can	   act	   as	   a	   model	   for	   larger	   molecules,	   e.g.	  
nucleobases	  and	  DNA.	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Figure	  4.30	  The	  structure	  of	  25,	  [{(η6-­‐indan)RuCl}2(μ-­‐2,3-­‐dpp)](PF6)2.	  
	  
Upon	   irradiation,	   25	   loses	   an	   indan	   ligand	   and	   will	   bind	   with	   DNA;37	   the	  
complex	   can	   also	   undergo	   aquation	   when	   in	   aqueous	   solution.	   This	   may	   be	  
prevented	   by	   the	   presence	   of	   a	   high	   concentration	   of	   Cl-­‐	   ions.	   However,	   for	   the	  
PCF-­‐MS	   system,	   this	   approach	   is	   impractical,	   as	   the	   mass	   spectrometer	   will	   not	  
tolerate	  high	   levels	  of	   salt.	  As	   in	   the	  previous	   sections,	   there	  were	   controls	  using	  
conventional	   methods	   for	   each	   experiment,	   and	   dark	   controls	   using	   both	  
techniques.	  Since	  data	  from	  both	  the	  PCF-­‐MS	  and	  the	  conventional	  methods	  were	  
acquired	  over	  time	  in	  aqueous	  solution,	  they	  may	  be	  complicated	  by	  the	  aquation	  
of	  25.	  
The	   direct	   infusion	   controls	   (Figure	   4.31)	   indicate	   that	   the	   fragmentation	  
process	   for	   this	   molecule	   is	   different	   from	   that	   of	   its	   photodissociation	   and	  
aquation	  pathways.	  The	  main	  ions	  detected	  in	  the	  solution	  spectrum	  in	  the	  dark	  are	  
the	  doubly	  charged	  molecular	  ion	  at	  372.0	  m/z	  ([M]2+),	  a	  singly-­‐charged	  PF6−	  adduct	  
at	  888.96	  m/z	   ([M+(PF6)]+),	  and	  a	  singly	  charged	  fragment	   ion	  at	  489.01	  m/z	   ([(η6-­‐
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ion	  at	  363.51	  m/z	  and	  353.00	  m/z	  that	  are	  the	  result	  of	  aquation	  of	  25,	  and	  show	  
the	   loss	  of	  at	   least	  one	  Cl-­‐	   ion.	   In	  summary,	  when	  in	  the	  dark,	  the	  spectrum	  of	  25	  
will	  show	  the	  loss	  of	  chlorido	  ligands	  and	  may	  fragment	  into	  mononuclear	  species.	  
However,	  there	  is	  no	  loss	  of	  an	  indan	  ligand	  from	  the	  ruthenium	  centre	  (Figure	  4.32	  
A).	  
	  
Figure	  4.31	   (A)	  Direct	   infusion	  of	  dimer	  complex	  25	   in	   the	  dark,	  250	  μM	   in	  DDW:	  
peaks	  assigned	  372.0	  m/z	   as	   [M]2+,	  888.96	  m/z	   as	   [M+(PF6)]+	  and	   fragment	   ion	  at	  
489.01	  m/z	   ([(η6-­‐indan)RuCl(μ-­‐2,3-­‐dpp)]+).	   (B)	   Spectrum	   of	   25	   (250	   μM	   in	   DDW)	  
irradiated	   488	   nm	   for	   14	   h	   and	   the	   appearance	   of	   a	   peak	   at.276.99	  m/z	   as	   [(η6-­‐
indan)Ru2(μ-­‐2,3-­‐dpp)]2+.	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A	  250	  μM	  solution	  of	  25	  in	  DDW	  was	  irradiated	  with	  488	  nm	  light	  for	  14	  h,	  
and	   the	   resulting	   spectrum	   is	   shown	   in	   Figure	  4.32B.	   The	   intensities	  of	   the	  peaks	  
attributed	   to	   the	   aquation	   of	   25	   are	   higher	   in	   the	   spectrum	   of	   the	   irradiated	  
solution	  that	  that	  of	  the	  complex	  in	  the	  dark.	  There	  is	  also	  a	  much	  larger	  increase	  in	  
the	  intensity	  of	  the	  species	  at	  227.04	  m/z,	  assigned	  as	  [(η6-­‐indan)Ru(μ-­‐2,3-­‐dpp)]2+.	  
The	   major	   difference	   in	   the	   spectra	   acquired	   is	   the	   peak	   at	   276.99	  m/z	   that	   is	  
observed	   after	   irradiation,	   and	   is	   assigned	   as	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)]2+.	   This	   is	  
significant	  as	   it	  shows	  the	   loss	  of	  an	   indan	   ligand	  from	  25,	  and	  demonstrates	  that	  
there	  can	  be	  easily	  achievable	  determination	  of	  a	  successful	  photoreaction,	  as	  the	  
loss	  of	  this	  group	  is	  not	  observed	  under	  dark	  conditions.	  
The	  experiment	  was	  then	  repeated	  in	  the	  PCF-­‐MS	  system	  (Figure	  4.33),	  the	  
only	   differences	   observed	   being	   that	   species	   resulting	   from	   aquation,	   such	   as	  
363.51	  m/z,	   increase,	   but	   this	   is	   to	   be	   expected,	   as	   the	   compound	   has	   been	   in	  
solution	  for	  a	  longer	  period	  of	  time.	  There	  is	  a	  drop	  in	  overall	  intensity	  for	  the	  PCF-­‐
MS	  spectrum,	  which	  is	  to	  be	  expected	  when	  a	  reaction	  is	  transferred	  to	  the	  system,	  
as	  well	  as	  loss	  of	  intensity	  due	  to	  hydrolysis	  of	  the	  main	  peak	  species.	  The	  intensity	  
of	   the	   species	   [(η6-­‐indan)Ru(μ-­‐2,3-­‐dpp)]2+	   (227.04	  m/z)	   is	   higher	   for	   the	   sample	  
injected	  in	  the	  dark	   in	  PCF-­‐MS	  experiment	  than	  when	  directly	   infused	  in	  the	  dark.	  
Irradiation	   of	   the	   sample	   produces	   the	   same	   species	   as	   the	   control	   sample,	   and	  
again	  an	  increase	  in	  the	  peak	  at	  227.04	  m/z.	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Figure	  4.32	  PCF-­‐MS	  system	  mass	  spectra	  of	  25	   (250	  μM)	  in	  DDW:	  (A)	  spectrum	  of	  
the	   solution	   in	   the	   dark.	   Peaks	   assigned:	   372.0	   m/z	   as	   [M]2+,	   888.96	   m/z	   as	  
[M+(PF6)]+	  and	  fragment	  ion	  at	  489.01	  m/z	  as	  [(η6-­‐indan)RuCl(μ-­‐2,3-­‐dpp)]+;	  (B)	  after	  
15	   min	   of	   irradiation	   at	   488	   nm,	   a	   new	   peak	   at	   276.99	   m/z	   appears	   ([(η6-­‐
indan)Ru2(μ-­‐2,3-­‐dpp)]2+).	  
	  
Since	  metal-­‐based	  anticancer	  drugs	  that	  are	  currently	  in	  the	  clinic	  are	  known	  
to	   bind	   to	   DNA,38,39,40	   25	   was	   irradiated	   in	   the	   presence	   of	   two	   different	  
nucleobases,	   to	   model	   its	   interaction	   with	   oligonucleotides.	   Initially,	   two	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equivalents	   of	   5’-­‐GMP	   were	   added	   to	   an	   aqueous	   solution	   of	   25	   (500	   μM	  
nucleobase	   to	   250	  µM	  of	   complex).	   	   Spectra	   in	   the	   dark	  were	   obtained	   for	   both	  
PCF-­‐MS,	   and	   conventional	   experiments.	   The	   samples	   were	   irradiated:	   14h	   in	   a	  
cuvette	   for	   the	   conventional	   measurement,	   and	   15	   min	   in	   the	   PCF.	   Once	   again,	  
there	  was	  close	  agreement	  between	  the	  conventional	  method	  control	  and	  the	  PCF-­‐
MS	  experiment,	  the	  only	  differences	  being	  a	  drop	  in	  peak	  intensity	  for	  the	  PCF-­‐MS	  
experiments	   and	   the	   appearance	   of	   the	   species	   at	   658.6	  m/z	   in	   just	   the	   PCF-­‐MS	  
irradiated	  spectrum.	  
In	  both	  dark	  spectra,	  and	  as	  shown	  in	  Figure	  4.34,	  there	  is	  the	  appearance	  of	  
a	  new	  peak	  is	  apparent	  at	  517.6	  m/z	  ([{(η6-­‐indan)Ru}2(μ-­‐2,3-­‐dpp)	  +	  5’-­‐GMP]2+.	  This	  
would	   suggest	   that	  5’-­‐GMP	  binds	   to	  25	   in	   the	  dark,	  presumably	  after	  aquation	  of	  
the	   compound.	   This	   species	   would	   seem	   to	   be	   fragmented	   in	   the	   mass	  
spectrometer,	  giving	  rise	  to	  the	  singly-­‐charged	  ion	  at	  582.03	  m/z.	  Upon	  irradiation	  
by	  conventional	  and	  PCF-­‐MS	  methods,	  new	  peaks	  are	  observed	  at	  458.51	  m/z	  and	  
467.5	  2	  m/z	   that	  were	  assigned	  as	  [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  5’-­‐GMP]2+	  and	  [(η6-­‐
indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  5’-­‐GMP	  +	  H2O]2+	  respectively.	  These	  species	  are	  indicative	  of	  
post-­‐irradiation	   binding	   in	   view	   of	   the	   loss	   of	   an	   indan	   ring.	   This	   is	   further	  
supported	  by	  the	  presence	  of	  a	  small	  amount	  of	  a	  640.04	  m/z	  peak,	  corresponding	  
to	  a	  doubly	  charged	  species	  which	   is	  assigned	  as	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  2(5’-­‐
GMP)]2+,	   and	   at	   649.04	  m/z,	   assigned	   as	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	   +	   2(5’-­‐GMP)	   +	  
H2O]2+.	  The	  species	  at	  658.6	  m/z	  is	  only	  present	  in	  the	  PCF-­‐MS	  spectrum,	  and	  is	  of	  
relatively	   low	  intensity;	  this	   is	  assigned	  to	  [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  2(5’-­‐GMP)	  +	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H2O	  +	  2H+]2+.	  The	  binding	  of	  5'-­‐GMP	  that	  occurs	  after	  aquation	  of	  the	  complex	  also	  
increases	  in	  the	  post-­‐irradiation	  spectra.	  	  
	  
Figure	  4.33	  PCF-­‐MS	  of	  250	  μM	  25	  and	  500	  μM	  5'-­‐GMP	  in	  DDW.	  Spectrum	  (A)	  is	  the	  
dark	  solution	  peak	  at	  517.6	  m/z	  which	   is	  assigned	  as	   [{(η6-­‐indan)Ru}2(μ-­‐2,3-­‐dpp)	  +	  
5’-­‐GMP]2+,	  the	  species	  at	  582.03	  m/z	  [(η6-­‐indan)Ru	  +	  5’-­‐GMP]+	  and	  spectrum	  (B)	  is	  
after	  15	  min	  irradiation	  at	  488	  nm	  light;	  new	  peaks	  at	  640.04	  m/z	  and	  649.04	  m/z	  
are	  assigned	  as	  [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  2(5’-­‐GMP)]2+,	  and	  [(η6-­‐indan)Ru2(μ-­‐2,3-­‐
dpp)	  +	  2(5’-­‐GMP)	  +	  H2O]2+	  respectively.	  
	  
Complex	  25	  was	  then	  irradiated	  in	  the	  presence	  of	  5’-­‐AMP	  under	  the	  same	  
conditions	   as	   those	   previously	   stated	   for	   5’-­‐GMP	   (250	   μM	   25	   and	   500	   μM	  
nucleobase).	  In	  the	  dark,	  there	  appears	  to	  be	  no	  reaction	  between	  25	  and	  5’-­‐AMP,	  
see	  Figure	  4.35.	  After	  irradiation	  by	  both	  methods,	  a	  species	  appears	  at	  623.55	  m/z;	  
this	   species	   is	   assigned	   as	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	   +	   2(5’-­‐AMP)]2+.	   The	   low	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intensity	   of	   this	   peak	   in	   the	   PCF-­‐MS	   spectrum	   indicated	   that	   the	   signal-­‐to-­‐noise	  
ratio	  in	  this	  spectrum	  was	  too	  high	  to	  definitively	  assign	  the	  peak	  using	  these	  data	  
alone.	   However,	   the	   assignment	   was	   confirmed	   using	   the	   sample	   irradiated	   by	  
conventional	  methods.	  This	  is	  also	  the	  case	  for	  the	  peak	  at	  566.04	  m/z,	  assigned	  as	  
[(η6-­‐indan)Ru	  +	  (5’-­‐AMP)]+.	  
	  
Figure	  4.34	  PCF-­‐MS	  of	  250	  μM	  25	  and	  500	  μM	  5'AMP	  in	  DDW.	  Spectrum	  (A)	  is	  the	  
dark	  solution;	  a	  peak	  is	  detected	  at	  348.07	  m/z	  ([5’-­‐AMP	  +	  H]+),	  and	  spectrum	  (B)	  is	  
after	  15	  min	  irradiation	  at	  488	  nm:	  the	  new	  peak	  at	  566.04	  m/z	   is	  assigned	  as[(η6-­‐
indan)Ru	  +	  (5’-­‐AMP)]+.	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In	   order	   to	  mimic	   the	   interaction	   of	   25	   with	   intracellular	   proteins,	   it	   was	  
irradiated	  in	  the	  presence	  of	  the	  amino	  acid	  L-­‐cysteine.	  A	  ratio	  of	  2:1	  amino	  acid	  to	  
(500	  μM)	  complex	   (250	  μM)	  was	  used,	  and	  the	  sample	  was	   incubated	  at	  ambient	  
temperature	  for	  the	  at	  least	  the	  time	  that	  it	  took	  to	  irradiate	  the	  solutions	  by	  both	  
methods	  (30	  min	  for	  the	  PCF-­‐MS	  sample	  in	  the	  dark,	  and	  14	  h	  for	  the	  conventional	  
measurement).	  There	  would	  appear	  to	  be	  no	  reaction	  in	  the	  dark	  between	  25	  and	  
L-­‐cysteine,	   see	   Figure	   4.36.	   Upon	   irradiation	   by	   both	   conventional	   and	   PCF-­‐MS	  
methods,	  a	  series	  of	  peaks	  appear	  at	  337-­‐339	  m/z.	  These	  are	  doubly-­‐charged,	  and	  
from	   their	   isotopic	   pattern,	   contain	   more	   than	   one	   Ru	   atom.	   These	   species	   are	  
likely	  to	  be	  [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  (L-­‐Cys)]2+	  (338.49	  m/z),	  and	  [Ru2(μ-­‐2,3-­‐dpp)	  
+	  2(L-­‐Cys)]2+	  (339.99	  m/z).	  However,	  the	  low	  intensity	  of	  the	  signal	  and	  the	  overlap	  
means	  that	  this	  is	  difficult	  to	  determine	  in	  view	  of	  the	  high	  signal	  to	  noise	  ratio	  and	  
the	   complicated	   isotopic	   patterns	   of	   the	   species	   in	   question.	   Two	   other	  
photoproducts	  were	  also	  detected,	   and	  are	   shown	   in	   Figure	  4.36.	   These	  are	   [(η6-­‐
indan)Ru(μ-­‐2,3-­‐dpp)	   +	   (L-­‐Cys)]+	   (574.09	  m/z),	   and	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	   +	   2(L-­‐
Cys)]2+	  at	  396.52	  m/z.	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Figure	  4.35	  PCF-­‐MS	  of	  250	  μM	  25	  and	  500	  μM	  l-­‐Cys	  in	  DDW.	  Spectrum	  (A)	  is	  of	  the	  
solution	  in	  the	  dark	  and	  spectrum	  (B)	  is	  after	  15	  min	  irradiation	  at	  488	  nm	  light.	  The	  
peaks	   not	   observed	   before	   in	   spectrum	   B	   are	   assigned	   as	   396.52	   m/z,	   [(η6-­‐
indan)Ru2(μ-­‐2,3-­‐dpp)	   +	   2(L-­‐Cys)]2+	   and	   574.09	  m/z,	   [(η6-­‐indan)Ru(μ-­‐2,3-­‐dpp)	   +	   (L-­‐
Cys)]+.	  
	  
Reactions	  with	  the	  intracellular	  tripeptide	  glutathione	  were	  studied	  since	  it	  
an	   important	   mechanism	   of	   resistance	   to	   metal-­‐based	   drugs.41,42,43	   Complex	   25	  
(250	  μM)	  was	   irradiated	   in	   the	  presence	  of	   two	  equivalents	  of	  glutathione	   (GSH),	  
see	  Figure	  4.37,	  with	  the	  dark	  controls	  again	  incubated	  for	  at	  least	  the	  same	  length	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of	  time	  as	  the	  period	  of	  irradiation	  (30	  min	  for	  the	  PCF-­‐MS	  experiments,	  and	  14	  h	  
for	   the	   sample	   analysed	   conventionally).	   In	   the	   dark,	   there	   was	   a	   new	   species	  
generated	  at	  408.56	  m/z	  that	  contains	  one	  Ru	  atom,	  is	  doubly	  charged	  and	  would	  
appear	  to	  contain	  one	  molecule	  of	  GSH	  and	  a	  fragment	  of	  GSH	  bound	  with	  the	  loss	  
of	  an	   indan	  group,	  even	   in	   the	  dark	   (this	  peak	  decreased	  after	   irradiation).	   In	   the	  
irradiated	  spectrum,	  further	  new	  species	  were	  observed	  including	  430.52	  m/z	  that	  
was	   assigned	   as	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	   +	   GSH]2+,	   and	   526.06	   m/z	   as	   [(η6-­‐
indan)Ru	  +	  GSH]+.	  Species	  at	  ca.	  580	  and	  584	  m/z	  form	  a	  cluster	  of	  peaks	  in	  the	  PCF-­‐
MS	   spectrum,	   but	   in	   the	   conventionally	   irradiated	   spectrum	  only	   the	   584.06	  m/z	  
species,	  [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  2GSH]2+,	  was	  present.	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Figure	  4.36	  PCF-­‐MS	  of	  250	  μM	  25	  and	  500	  μM	  GSH	  in	  DDW.	  Spectrum	  (A)	   is	  from	  
the	   solution	   in	   the	   dark,	   with	   the	   peaks	   at	   208.09	  m/z	   assigned	   as	   [GSH	   +	   H]+,	  
615.17	  m/z	  as	  [2GSH	  +	  H]+.	  Spectrum	  (B)	  is	  after	  15	  min	  irradiation	  at	  488	  nm;	  peaks	  
at	  430.52	  m/z,	  526.06	  m/z	   and	  584.06	  m/z	   are	  attributed	   to	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐




4.4.1.	   Photonic	   crystal	   fibre	   mass	   spectrometry	   (PCF-­‐MS)	   system	   design	   and	  
development	  
Throughout	   the	   development	   of	   the	   PCF-­‐MS	   system,	   several	   different	  
coupling	  devices	  were	  used.	  The	  ideal	  coupling	  device	  would	  have	  a	  very	  small	  dead	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volume	  to	  allow	  for	  rapid	  analysis,	  and	  also	  to	  minimise	  the	  possibility	  of	  short-­‐lived	  
species	   reacting	  with	   each	   other	   or	   solvent	  molecules.	   Changes	   to	   these	   devices	  
were	   driven	   by	   the	   practicalities	   of	   the	   experiments	   involved	   and	   the	   problems	  
encountered.	  
4.4.1.1	  PCF-­‐MS	  system	  design	  and	  development:	  metallic	  coupling	  devices	  
Preliminary	   experiments	   involving	   flowing	   a	   sample	   of	   8	   through	   the	   PCF	  
and	   directly	   infusing	   it	   into	   the	   mass	   spectrometer	   (Section	   4.3.1)	   showed	   that	  
there	  was	  no	  difference	  between	  the	  resulting	  spectra.	  The	  inclusion	  of	  the	  metallic	  
coupling	  devices	  to	  gain	  the	  ability	  to	  introduce	  light	  and	  sample	  to	  the	  fibre	  led	  to	  
the	   appearance	   of	   new	   species	   in	   the	   mass	   specrtum	   of	   8,	   see	   Figure	   4.4.	   The	  
distincitve	   isotopic	   patterns	   of	   	   these	   new	   species	   suggests	   that	   they	   contain	  
platinum.	  MS/MS	  of	  the	  peak	  at	  750.2	  m/z	  shows	  fragments	  at	  383.1,	  411.1,	  579.2	  
and	   	   732.2	  m/z	   that	   all	   contain	   platinum.	   The	   ions	   383.1	   and	   411.1	  m/z	   are	   also	  
observed	   in	   the	   spectrum	  of	   the	  direct	   infusion	  of	  8,	   Figure	   4.5.	   The	  presence	  of	  
these	  expected	  species	  within	  the	  unknown	  ions,	  along	  with	  the	  isotopoic	  pattern	  
of	   the	   peaks,	   suggests	   that	   complex	   8	   forms	   some	   kind	   of	   adduct	   with	   a	   low	  
molecular	   weight	   contaminant	   introduced	   by	   the	   coupling	   device.	   However,	   the	  
contaminant	  could	  not	  be	  identified	  since	  it	  was	  not	  possible	  to	  isolate	  it.	  
4.4.1.2	   PCF-­‐MS	   system	   design	   and	   development:	   plastic	   microfluidic	   coupling	  
devices	  
The	   previous	   metallic	   coupling	   cells	   had	   a	   relatively	   large	   internal	   mixing	  
volume	  of	  60	  μL.	  The	  change	   in	  both	  the	  construction	  and	   internal	  volume	  of	   the	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coupling	  device	  to	  custom	  made	  teflon	  microfliidic	  devices	  was	  intended	  to	  improve	  
the	   speed	   of	   anaysis	   and	   remove	   the	   system	   contamination	   introduced	   by	   the	  
metallic	  devices.	  However,	   the	  PEEK	   tubing	   that	  was	  glued	   into	   the	  device	  at	   the	  
point	  of	  fabication	  has	  an	  inner	  diamenter	  that	  is	  too	  small	  to	  contain	  the	  PCF	  with	  
its	  cladding,	  see	  Figure	  4.9.	  As	  the	  fibre	  must	  reach	  the	  glass	  coverslip	  at	  the	  end	  of	  
the	   device	   in	   order	   to	   maximise	   the	   amount	   of	   light	   that	   enters	   the	   PCF,	   the	  
protective	   plastic	   coating	   had	   to	   be	   removed	   so	   that	   it	   could	   fit	   into	   this	   smaller	  
tubing.	   The	  glass	  was	   left	  exposed	  and	  brittle.	   It	  had	   to	  pass	   through	   two	   sets	  of	  
fingertight	   fittings	   (Figure	   4.11)	   and	   there	   were	   many	   problems	   with	   the	   fibre	  
breaking	  within	  the	  device.	  Consequently,	  many	  devices	  had	  to	  be	  employed,	  and	  
the	  quality	  of	  the	  glass	  coverlip	  seemed	  to	  vary	  greatly.	  The	  removal	  of	  the	  cladding	  
also	  lessened	  the	  ability	  of	  the	  PCF	  to	  guide	  the	  laser	  light	  along	  those	  sections	  of	  
the	  fibre,	  and	  therefore	   it	  was	  not	  possible	  to	  guide	  any	   light	   into	  the	  core	  of	  the	  
fibre.	  
4.4.1.3	  PCF-­‐MS	  system	  design	  and	  development:	  PVC	  coupling	  devices	  
The	   PVC	   coupling	   devices	   allowed	   the	   fibre	   to	   remain	   intact	   and	   be	   in	  
contact	  with	   high	   quality	   glass	  windows	   to	   act	   as	   an	   interface	   between	   the	   laser	  
light	  and	  the	  PCF,	  see	  Figure	  4.12.	  This	  feature	  allowed	  the	  light	  to	  be	  successfully	  
focused	   into	   the	   core	   of	   the	   fibre.	   The	   limiting	   feature	   of	   these	   coupling	   devices	  
was	  not	  their	   light	  guiding	  ability,	  but	  their	   internal	  volume	  of	  60	  μL.	  With	  a	  total	  
volume	  of	  120	  µL	  for	  the	  two	  devices	  alone,	  and	  a	  flow-­‐rate	  of	  100	  μL/h,	  a	  sample	  
took	   over	   an	   hour	   from	   the	   point	   of	   injection	   to	   reach	   the	   mass	   spectrometer.	  
Although	   the	   flow	   rate	   was	   later	   doubled,	   the	   time	   of	   analysis	   did	   not	   improve	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drastically	   as	   there	   was	   still	   the	   dead-­‐time	   of	   the	   instrument,	   also	   and	   the	   time	  
required	   for	   the	   electrospray	   to	   stabilise.	   It	   also	   became	   apparent	   that	   Pt(IV)-­‐
diazido	   complexes	   may	   not	   be	   the	   best	   compounds	   to	   test	   the	   efficacy	   of	   the	  
system.	  
As	   promising	   new	   photoactivatable	   drug	   candidates,	   it	   was	   believed	   that	  
this	   class	   of	   compound	  would	   be	   ideal	   for	   study	   by	   PCF-­‐MS.44,45	   Some	  previously	  
reported	   photoproducts	   of	   complex	   8	   were	   detected	   by	   PCF-­‐MS,	   such	   as	  
[Pt(py)2(OH)(H2O)]+,	   but	   the	   spectra	   varied	   greatly	   from	   those	   obtained	   by	  
conventional	  direct	  infusion.7	  This	  may	  be	  attributable	  to	  the	  intrinsic	  properties	  of	  
this	  particular	   type	  of	   complex,	   [Pt(py)2(N3)2(OH)2],	  being	  a	  neutral	   species	   that	   is	  
difficult	   to	   ionise,	   and	   is	   typically	   detected	   as	   a	   fragment	   of	   a	   salt	   adduct.23	   The	  
difficulty	  in	  ionising	  these	  complexes	  results	   in	  decreased	  signal	   intensity,	  which	  is	  
further	   exacerbated	   by	   the	   intrinsic	   loss	   of	   signal	   caused	   by	   the	   PCF-­‐MS	   system.	  
This	   problem	  may	   not	   have	   been	   appreciated	   during	   preliminary	   experiments	   as	  
they	  were	  performed	  on	  an	  instrument	  requiring	  a	  much	  higher	  flow	  rate	  (240	  μL/h	  
compared	  to	  100	  μL/h	  when	  using	  the	  MaXis),	  minimising	  any	  interaction	  with	  the	  
PCF.	  
4.4.1.4	   PCF-­‐MS	   system	  design	   and	  development:	  microfluidic	   devices	   using	   ‘off-­‐
the-­‐shelf’	  chips	  
To	   reduce	   the	   volume	   of	   the	   system,	   commercially	   available	   microfluidic	  
chips	  were	  used	  as	  coupling	  devices	  in	  combination	  with	  PEEK	  fittings	  and	  custom-­‐
made	  mounts.	   The	   system	   volume	  was	   reduced	   to	   3.1	   μL,	   40	   times	   smaller	   than	  
that	  required	  when	  either	  the	  metallic	  or	  Teflon	  devices	  were	  used	  (both	  volumes	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do	  not	  include	  the	  PEEEK	  tubing).	  The	  wavelength	  of	  light	  used	  was	  lengthened,	  and	  
because	  of	  this	   the	  structure	  of	  the	  fibre	  was	  also	  altered.	  The	  change	  to	  488	  nm	  
light	   was	   due	   to	   the	   improved	   light-­‐guiding	   properties	   of	   PCFs	   at	   longer	  
wavelengths,	   as	   well	   as	   achieving	   activation	   of	   8	   at	   longer,	   more	   desirable	  
wavelengths.	  Complex	  8	  has	  also	  previously	  been	  shown	  to	  be	  activated	  at	   longer	  
wavelengths.7	   In	   this	   case,	   the	   longer	   the	  wavelength	  of	   activation	   the	  better,	   as	  
the	  light	  will	  penetrate	  deeper	  into	  the	  tissue	  when	  administered	  in	  the	  clinic.	  
4.4.2	  PCF-­‐MS	  system	  validation:	  vitamin	  B12	  -­‐	  a	  model	  reaction	  for	  system	  
validation	  in	  the	  positive	  mode	  
The	   photoaquation	   of	   vitamin	   B12	   is	   a	  well-­‐characterised	   process	   that	   has	  
been	  widely	  reported	  in	  the	  literature,24,19,27	  making	  it	  an	  ideal	  reaction	  to	  test	  this	  
novel	   system.	   	   The	   problems	   such	   as	   poor	   signal	   intensity	   and	   alterations	   in	   the	  
mass	  spectra	  encountered	  with	  the	  use	  of	  Pt(IV)-­‐diazido	  complexes	  were	  overcome	  
by	   the	   use	   of	   a	   charged	   complex.	   The	   higher	   powers	   achieved	   within	   the	   core	  
compared	  to	  conventional	  methods	  drastically	  reduce	  the	  time	  required	  to	  induce	  
photoactivation	  of	  an	  acidic	  solution	  of	  vitamin	  B12	  from	  10	  h	  to	  15	  min.	  Comparing	  
these	  two	  approaches	  to	  the	  irradiation	  of	  vitamin	  B12	  in	  terms	  of	  the	  light	  dosage	  
received	  by	   the	   sample,	   the	   input	  power	   in	   the	   fibre	  experiment	  of	  P0HC-­‐PCF	  =	  2.35	  
mW	  is	  sufficient	  for	  photoconversion.	  In	  the	  case	  of	  the	  conventional	  experiment,	  a	  
doubled	   input	   power	   of	   P0cuv	  =	   4.5	   mW	   still	   results	   in	   the	   intensity	   within	   the	  
cuvette	  being	  5	  orders	  of	  magnitude	  lower	  in	  comparison	  to	  in	  the	  fibre	  (I0cuv	  =	  40	  
mW/cm2,	   I0HC-­‐PCF	  =	  700	  W/cm2).	  This	   is	  the	  reason	  for	  the	  conventional	  experiment	  
taking	  over	  10	  hours	  and	  still	  not	  reaching	  completion.	  In	  terms	  of	  sample	  volume	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consumed,	   the	   PCF-­‐MS	   approach	   is	   more	   advantageous	   than	   the	   conventional	  
methods	   since	   it	   only	   requires	   25	   μL	   (volume	   required	   to	   carry	   out	   a	   15	   min	  
analysis)	  of	  sample	  in	  comparison	  to	  at	  least	  600	  μL	  using	  a	  cuvette,	  a	  reduction	  of	  
more	  than	  20	  times.	  
Sample	   volumes	   were	   also	   reduced	   from	   600	   μL	   to	   25	   μL.	   The	   increased	  
light	   power	   even	   makes	   it	   possible	   to	   photoactivate	   a	   neutral	   solution	   of	  
cyanocobalamin,	  which	   cannot	   be	   achieved	   by	   conventional	  methods	   (with	   16	   of	  
irradiation)	   with	   less	   than	   30	   min	   of	   irradiation.	   The	   product	   of	   this	   reaction,	  
aquacobalamin	   is	   only	   detected	   in	   small	   amounts.	   However,	   this	   is	   due	   to	   the	  
stability	  of	  aquacobalamin,	  which	  even	  when	  directly	  infused	  in	  its	  pure	  form,	  very	  
little	  of	  the	  molecular	  ion	  is	  detected,	  the	  dominant	  peak	  is	  cobalamin	  as	  noted	  in	  
the	   irradiated	   PCF-­‐MS	   spectra.	   There	   is	   also	   a	   small	   amount	   of	   cyancobalamin	  
present	   in	   the	   PCF-­‐MS	   irradiated	   spectrum.	   This	   may	   be	   due	   to	   incomplete	  
photoreaction	   of	   the	   starting	   material,	   but	   is	   more	   likely	   due	   to	   dilution	   of	   the	  
sample	   irradiated	   within	   the	   core	   by	   the	   dark	   solution	   that	   passed	   through	   the	  
cladding	  holes.	  	  
4.4.3	  PCF-­‐MS	  system	  validation:	  Sodium	  nitroprusside	  -­‐	  a	  model	  reaction	  for	  
system	  validation	  in	  the	  negative	  mode	  
Having	   proven	   the	   efficacy	   of	   the	   system	   in	   the	   positive-­‐mode,	   its	  
performance	  was	   also	   tested	   in	   the	   negative-­‐mode	   using	   the	   vasodilator	   sodium	  
nitroprusside.	  Once	  again	  high	  signal	  intensity	  was	  achieved	  and	  the	  spectra	  closely	  
resembled	   those	   reported	   in	   the	   literature	   with	   the	   complex	   first	   losing	   NO	  
followed	  by	  sequential	  loss	  of	  the	  CN-­‐	  ligands.35	  Unfortunately,	  there	  was	  a	  lack	  of	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distinction	  between	  dark	  and	  irradiated	  spectra.	  It	  was	  also	  not	  possible	  to	  observe	  
this	   difference	   in	   the	  PCF-­‐MS	   system.	   This	   could	  possibly	   be	  because	  even	   in	   the	  
low	  levels	  of	  light	  present	  during	  sample	  preparation	  and	  injection,	  activation	  of	  the	  
complex	  was	  induced.	  It	  could	  also	  just	  be	  possible	  that	  the	  fragmentation	  pathway	  
of	  the	  complex	  in	  a	  mass	  spectrometer	  is	  very	  similar	  to	  its	  photactivation	  pathway.	  
However,	   it	   has	   still	   been	   proven	   in	   principle	   that	   the	   system	   can	   work	   in	   the	  
negative-­‐ion	  mode.	  	  
4.4.4	  PCF-­‐MS	  system	  application:	  photoactivation	  of	  ruthenium	  potential	  
anticancer	  complexes	  
As	  the	  system	  incorporating	  the	   ‘off-­‐the-­‐shelf’	  chips	  was	  shown	  to	  work	   in	  
positive-­‐ion	  mode,	  it	  could	  be	  applied	  to	  the	  study	  of	  new	  potential	  drugs	  such	  as	  
24.	   This	  particular	   compound	   is	   charged,	   resulting	   in	   a	  high	   signal	   intensity	  being	  
detected,	   and	   produces	   fewer	   fragments	   than	   the	   Pt(IV)	   predecessors.	  
Unfortunately,	   similarly	   to	   the	   case	   of	   SNP,	   the	   compound	   is	   highly	   fragmented	  
upon	  ionisation	  in	  a	  similar	  manner	  to	  the	  effects	  of	  irradiation,	  resulting	  in	  the	  loss	  
of	   the	   pyridine	   ligand	   The	   peak	   intensity	   did	   not	   change	   significantly	   between	  
spectra	   recorded	   in	   the	  dark	   and	   that	  of	   the	   complex	  once	   irradiated.	   Therefore,	  
this	  could	  not	  be	  employed	  as	  an	  indicator	  of	  activation	  of	  the	  complex.	  In	  view	  of	  
this	   ambiguity,	   it	   could	   not	   be	   determined	   whether	   or	   not	   photoactivation	   had	  
occurred.	   The	   reaction	   yielded	   the	   same	   results	  when	   carried	   out	   in	   the	   PCF-­‐MS	  
system.	  Although	  the	  use	  of	  24	  for	  the	  purposes	  of	  monitoring	  a	  photoreaction	  was	  
not	  successful,	  it	  has	  demonstrated	  that	  a	  metal-­‐based	  drug	  can	  be	  flowed	  through	  
the	  PCF-­‐MS	  system,	  achieving	  a	  high	  enough	  signal,	  facilitating	  MS/MS	  analysis.	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4.4.5	  PCF-­‐MS	  system	  application:	  PCF-­‐MS	  as	  a	  rapid	  microreactor	  screening	  
technique	  to	  gain	  insights	  into	  the	  mechanism	  of	  action	  of	  photoactivatable	  drugs	  
The	   complex	   25,	   [{(η6-­‐indan)RuCl}2(μ-­‐2,3-­‐dpp)](PF6)2,	   was	   proposed	   as	  
another	   candidate	   for	   investigation	   by	   PCF-­‐MS,	   as	   it	   is	   another	   photoactivatable	  
positively	   charged	   metal-­‐based	   drug.	   	   None	   of	   the	   previously	   encountered	  
problems	   such	   as	   low	   signal	   intensity	   or	   ambiguous	   complex	   fragmentation	  were	  
apparent	  when	  carrying	  out	  the	  controls	  using	  conventional	  methods.	  The	  PCF-­‐MS	  
spectra	  and	  controls	  based	  on	  conventional	  methods	  showed	  no	  differences	  other	  
than	   a	   small	   reduction	   in	   intensity	   for	   the	   PCF-­‐MS	   spectra.	   All	   of	   the	   detected	  
species	   were	   the	   same	   by	   both	   methods.	   The	   time	   taken	   for	   the	   sample	   to	   be	  
irradiated	  and	   the	   total	   sample	  volume	  was	  greatly	   reduced	  by	  using	   the	  PCF-­‐MS	  
method,	  from	  16	  h	  to	  15	  min.	  Upon	  irradiation	  of	  25,	  by	  both	  methods,	  there	  was	  
an	   increase	   in	   the	   species	   at	   227.04	  m/z	   assigned	   as	   [(η6-­‐indan)Ru(μ-­‐2,3-­‐dpp)]2+,	  
suggesting	  that	  exposure	  to	  light	  may	  result	  in	  the	  compound	  fragmenting	  in	  other	  
ways	   as	   opposed	   to	   simple	   loss	   of	   the	   indan	   group.	   The	   further	   reactions	   with	  
biological	  substrates	  will	  help	  to	  determine	  if	  this	  is	  the	  case	  
Having	   established	   the	   suitability	   of	   the	   PCF-­‐MS	   system	   to	   study	   the	  
irradiation	  of	  25,	  a	  short	  series	  of	  experiments	  using	  a	  range	  of	  small	  molecules	  to	  
act	  as	  models	  for	  larger	  species	  present	  within	  cells	  was	  performed	  in	  order	  to	  gain	  
insight	  into	  its	  intracellular	  behaviour.	  In	  the	  presence	  of	  the	  nucleobase	  5‘-­‐GMP,	  a	  
favoured	  binding	  site	  for	  other	  metal-­‐based	  drugs,40,39	  25	  undergoes	  aquation	  and	  
forms	   a	   mono-­‐adduct.	   This	   is	   supported	   by	   the	   findings	   of	   Magennis	   et	   al.	   who	  
reported	  DNA	  binding	  of	  25	   in	  the	  dark.37	  When	  25	  was	  irradiated	  in	  the	  presence	  
	   Chapter	  4	  –	  Photonic	  crystal	  fibre	  mass	  spectrometry	   	  
	  
	   208	  
of	  5’-­‐GMP,	  new	  5’-­‐GMP	  adducts	  were	  detected.	  The	  binding	  of	  5'-­‐GMP	  that	  occurs	  
after	   aquation	   of	   the	   complex	   also	   increases	   in	   the	   post-­‐irradiation	   spectra.	   This	  
may	  arise	  from	  the	  concentration	  of	  the	  aqua	  adduct	  increasing	  over	  the	  time	  taken	  
for	  the	  spectra	  to	  be	  acquired,	  or	  for	  the	  irradiation	  to	  be	  completed,	  depending	  on	  
the	  method	  of	  analysis.	  
Similarly,	   when	   photoactivated	   in	   the	   presence	   of	   5’-­‐AMP,	   adducts	   of	   5’-­‐
AMP	  were	   also	   detected	   but	   the	   peaks	   attributed	   to	   these	   are	   less	   intense	   than	  
those	  due	  to	  5’GMP	  adducts.	  Magennis	  et	  al.	  also	  report	  an	  increase	  in	  DNA	  binding	  
upon	  irradiation.37	  There	  is	  some	  binding	  with	  amino	  acids	  such	  as	  cysteine,	  but	  this	  
binding	   occurs	   to	   a	   lesser	   extent	   than	  with	   nucleotides.	   This	   is	   supported	   by	   the	  
findings	   of	   Wang	   et	   al.	   who	   reported	   that	   the	   complex	   [(η6-­‐biphenyl)RuCl(en)]+	  
reacts	  slowly	  with	  L-­‐cysteine	  in	  aqueous	  solution.46	  The	  complex	  does	  bind	  to	  other	  
sulfur-­‐containing	   species,	   as	   the	   detection	   of	   the	   species	   peaks	   at	   430.52	  m/z,	  
526.06	  m/z	  and	  584.06	  m/z	  (attributed	  to	  [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	  +	  GSH]2+,	  [(η6-­‐
indan)Ru	   +	   GSH]+	   and	   [(η6-­‐indan)Ru2(μ-­‐2,3-­‐dpp)	   +	   2GSH]2+	   respectively)	   indicates	  
that	   it	   binds	   to	   GSH	   upon	   photoactivation.	   The	   presence	   of	   these	   species	  would	  
suggest	  the	  photoactivation	  of	  25	  and	  subsequent	  binding	  of	  GSH.	  This	  may	  be	  the	  
reason	   for	   the	   high	   IC50	   value	   of	   the	   complex	   as	   GSH	   binding	   is	   a	   well-­‐known	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4.5	  Conclusions	  
In	   conclusion,	   a	   new	   technique	   for	   the	   rapid	   irradiation	   and	   analysis	   of	  
photoactivatable	  metal	   complexes	  has	  been	  developed.	  The	  design	  of	   the	   system	  
evolved	  greatly	  over	  the	  course	  of	  the	  work.	  The	  internal	  volume	  of	  the	  sample	  cells	  
used	   to	   introduce	   liquid	   and	   light	  was	   decreased	   from	  60	  μL	   to	   360	   nL.	   This	   is	   a	  
dramatic	   reduction	   in	   pre-­‐	   and	   post-­‐irradiation	   mixing	   within	   the	   system.	   The	  
wavelength	  of	  light	  was	  also	  altered	  from	  405	  nm	  to	  488	  nm,	  and	  along	  with	  it	  the	  
structure	  of	  the	  fiber	  used,	  to	  allow	  photoactivation	  at	  a	  slightly	  longer	  wavelength.	  	  
The	   system	   was	   then	   validated	   in	   the	   positive-­‐ion	   mode	   using	   a	   known	  
photoreaction,	   the	   photoaquation	   of	   cyanocobalamin,	   and	   the	   results	   were	  
compared	  to	  those	  generated	  using	  conventional	  techniques.	  There	  appeared	  to	  be	  
very	   little	  difference	  between	  the	  PCF-­‐MS	  spectra	  and	  that	  of	  those	  from	  samples	  
irradiated	  using	  conventional	  methods.	  There	  is	  however,	  a	  noticeable	  drop	  in	  peak	  
intensity	   when	   working	   with	   the	   PCF-­‐MS	   system	   compared	   to	   conventional	  
methods.	   This	   may	   prove	   problematic	   in	   the	   case	   of	   identifying	   photoproducts	  
generated	  by	  the	  system.	  Although	  the	  system	  was	  not	  properly	  validated	  using	  the	  
vasodilator	   sodium	   nitroprusside,	   the	   data	   suggest	   that	   the	   methods	   should	   be	  
applicable	  to	  the	  negative	  modes.	  The	  system	  did	  not	  generate	  any	  artefacts	  and	  a	  
high	   signal	   intensity	   was	   observed	   in	   the	   negative-­‐ion	   mode.	   The	   system	   in	   its	  
current	   state	  has	  many	  advantages	  over	   conventional	  methods	  as	   it	   requires	   less	  
than	  one	  twentieth	  of	  the	  sample	  and	  can	  irradiate	  samples	  forty	  times	  faster	  due	  
to	  the	  high	  light	  powers	  achieved	  in	  the	  fibre	  core.	  However,	  the	  deadtime	  of	  the	  
system	  is	  currently	  preventing	  truly	  rapid	  sample	  analysis.	  As	  although	  irradiation	  of	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the	  sample	  should	  only	  take	  a	  matter	  of	  seconds	  the	  species	  are	  not	  detected	  for	  15	  
min.	  	  	  
This	   new	   technique	   was	   subsequently	   used	   to	   gain	   insight	   into	   the	  
mechanism	   of	   action	   of	   the	   photoactivatable	   ruthenium-­‐based	   drug	   25,	   [{(η6-­‐
indan)RuCl}2(μ-­‐2,3-­‐dpp)](PF6)2.	  A	  series	  of	  models	  for	  intracellular	  components	  was	  
used	  to	  predict	  how	  the	  complex	  might	  behave	  in	  cells	  (5’-­‐GMP,	  5’-­‐AMP,	  L-­‐Cys	  and	  
GSH).	  The	  complex	  was	  found	  to	  bind	  to	  nucleobases	   in	  the	  dark	  and	  this	  binding	  
increased	  upon	   irradiation.	  Compound	  25	  was	  also	   found	   to	  bind	  more	   to	  5’GMP	  
than	  5’AMP.	  These	  findings	  are	  consistent	  with	  the	  work	  of	  Magennis	  et	  al,	  carried	  
out	  using	  conventional	  methods.37	  The	  metal-­‐based	  drug	  25	  also	  binds	  strongly	  to	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Chapter	  5	  	  



















In	  the	  course	  of	  this	  work	  analytical	  techniques,	  primarily	  high	  performance	  
liquid	  chromatography	   (HPLC)	  and	  mass	  spectrometry	   (MS),	  have	  been	  applied	   to	  
study	  various	  properties	  of	  metal-­‐based	  anticancer	  drugs.	  In	  Chapter	  2	  the	  study	  of	  
the	   intracellular	   accumulation	   of	   a	   new	   generation	   of	   platinum-­‐based	   drugs	   is	  
reported.	  The	  relative	  lipophilicity	  of	  a	  series	  of	  10	  platinum(IV)	  diazido	  complexes	  
of	   the	   general	   formula	   trans,trans,trans-­‐[Pt(N3)2(OH)2(R)(R’)]	   (where	   R	   and	   R’	   are	  
NH3,	   methylamine,	   ethylamine,	   pyridine,	   2-­‐picoline,	   3-­‐picoline	   or	   thiazole)	   was	  
determined	  by	  HPLC.	  The	  trend	  predicted	  based	  on	  the	  lipophilicity	  of	  the	  R	  and	  R’	  
ligands	   did	   not	   correlate	  with	   the	   observed	   lipophilicities.	   These	   observed	   values	  
were	   then	   compared	   to	   the	   platinum	  accumulation	   of	   compounds	  1-­‐10	   in	  A2780	  
human	   ovarian	   carcinoma	   cells.	   There	   appeared	   to	   be	   no	   overall	   trend	   relating	  
hydrophobicity	  to	  the	  cellular	  accumulation	  of	  these	  complexes.	  Furthermore,	  the	  
potency	  of	  these	  complexes	  in	  cancer	  cells	  (in	  the	  form	  of	  IC50	  values)	  also	  has	  no	  
obvious	   relationship	   to	   their	   cellular	   accumulation.	   These	   studies	   suggest	   that	  
active	  transport	  inside	  the	  cells	  is	  partly	  the	  cause.	  However,	  it	  is	  thought	  that	  other	  
factors,	   such	   as	   the	   quantum	   yield	   of	   the	   complex,	   and	   the	   type	   of	   DNA	   adduct	  
formed	  by	  the	  photoactivated	  species	  have	  a	  greater	  influence	  over	  the	  efficacy	  of	  
this	  class	  of	  drug.	  Amino	  acids	  and	  reducing	  agents	  present	   in	  the	  cell	  media	  may	  
have	  also	  reacted	  with	  the	  Pt(IV)	  diazido	  complexes	  in	  the	  dark,	  forming	  new	  Pt(II)	  
species.	   This	  would	   explain	   the	   lack	   of	   correlation	   between	   the	   observed	   activity	  
and	  the	  properties	  of	  the	  Pt(IV)	  complexes.	  
One	  of	  these	  complexes,	  8	  trans,trans,trans-­‐[Pt(N3)2(OH)2(py)2]	  (where	  py	  is	  
pyridine),	   was	   selected	   for	   further	   investigation	   in	   view	   of	   its	   low	   IC50	   value	   and	  





high	  relative	  lipophilicity	  and	  cellular	  accumulation.	   Irradiation	  of	  8	  with	  UVA	  light	  
in	  the	  presence	  of	  a	  single	  strand	  oligonucleotide,	  oligo	  1	  d’(ATACATGCTACATA),	  led	  
to	  a	  new	  species	  being	  detected	  by	  chromatography.	  Changing	  the	  oligonucleotide	  
to	  d’(ATACGTGCTACATA),	  oligo	  3,	  gave	  similar	  results	  to	  those	  obtained	  using	  oligo	  
1.	  However,	  the	  amount	  of	  platinum	  bound	  to	  the	  DNA	  reduced	  by	  one	  third	  when	  
the	  sequence	  of	  the	  oligonucleotide	  was	  changed	  to	  include	  the	  possibility	  of	  a	  1,2-­‐
d(GpG)	  binding	  mode.	  	  
The	  {Pt(py)2}2+	  adduct	  formed	  by	  8	  upon	  photoactivation	  in	  the	  presence	  of	  
oligo	  1	  was	  characterised	  by	  mass	  spectrometry.	  The	  species	  was	  assigned	  as	  {oligo	  
1	  +	  [Pt(py)2]}	  and	  15N	  labelled	  versions	  of	  8,	  t,t,t-­‐[Pt(N3)2(OH)2(15Npy)2]	  (8X)	  and	  t,t,t-­‐
[Pt(15N3)2(OH)2(15Npy)2]	   (8Y),	   were	   photoactivated	   in	   the	   presence	   of	   oligo	   1	   to	  
confirm	  the	   formation	  of	   this	   species.	  Changing	   the	  wavelength	  of	  activation	  of	  8	  
from	  365	  nm	   to	  420	  nm	  was	   found	   to	   cause	  decrease	   the	   rate	  platination	  of	   the	  
oligonucleotide	   upon	   irradiation	   of	   8.	   Studies	   by	   both	   mass	   spectrometry	   and	  
chromatography	   show	   that	   changing	   the	   wavelength	   of	   activation	   was	   found	   to	  
have	  no	  affect	  on	  the	  type	  of	  DNA	  adduct	  formed.	  	  
In	   Chapter	   3,	   normal-­‐phase	   chiral	   HPLC	   was	   used	   to	   separate	   the	  
enantiomers	   and	   diastereomers	   of	   a	   series	   of	   ruthenium,	   osmium	   and	   iridium	  
organometallic	   anticancer	   complexes.	   Columns	   containing	   the	   amylose-­‐	   and	  
cellulose-­‐based	   stationary	   phases	   CHIRALPAK	   IA	   and	   CHIRALPAK	   IC	   were	   used.	  
Methods	  were	  developed	  and	  optimised	  through	  out	  the	  course	  of	  this	  work.	  The	  
stability	  in	  solution	  of	  some	  of	  these	  separated	  enantiomers	  was	  investigated.	  All	  of	  
the	  neutral	  Ir(III)pentamethylcyclopendadiene-­‐based	  complexes	  tested	  reverted	  to	  





a	  racemic	  mixture	  after	  a	  minimum	  of	  2	  h	  in	  ethanol	  at	  room	  temperature,	  but	  the	  
Ru-­‐	   and	   Os-­‐based	   enantiomers	   maintained	   stability	   under	   the	   same	   conditions.	  
Small	  changes	  in	  each	  of	  the	  ligands	  (i.e.,	  halide	  leaving	  group,	  bidentate	  ligand	  and	  
arene)	  resulted	  in	  changes	  to	  the	  retention	  times	  of	  the	  species	  eluted	  and	  hence,	  
resolution	  of	   the	   separation.	  Changing	   the	  hydrophobicity	  of	   the	  bidentate	   ligand	  
resulted	  in	  the	  largest	  changes	  of	  retention	  times.	  	  
In	  Chapter	  4,	  the	  development	  and	  validation	  ofphotonic	  crystel	  fibre	  mass	  
spectrometry	   as	   a	   novel	   technique	   for	   the	   rapid	   irradiation	   and	   analysis	   of	  
photoactivateable	  drugs	  is	  reported.	  The	  internal	  volume	  of	  the	  sample	  cells	  used	  in	  
the	  system	  was	  reduced	  from	  60	  μL	  to	  360	  nL	  over	  the	  course	  of	  the	  investigation.	  
The	  photonic	  crystal	  fibre	  (PCF)	  used	  was	  improved	  in	  order	  to	  guide	  488	  nm	  light.	  
The	  system	  was	  then	  validated	  in	  the	  positive	  mode	  using	  a	  known	  photoreaction,	  
the	   photoaquation	   of	   cyanocobalamin,	   and	   the	   results	   were	   compared	   to	   those	  
generated	   using	   conventional	   techniques.	   The	   spectra	   obtained	   using	   the	   PCF	  
system	   differ	   only	   slightly	   from	   those	   obtained	   by	   the	   conventional	  method,	   the	  
main	   difference	   being	   the	   drop	   in	   signal	   intensity	   when	   using	   the	   PCF	   system.	  
Comparing	   this	  new	  method	   to	  conventional	   techniques,	   sample	   irradiation	   times	  
are	  reduced	  from	  8	  h	  to	  15	  min	  and	  sample	  volumes	  are	  reduced	  by	  20	  times.	  
The	  system	  was	   then	  used	   to	  study	   the	  photoactivation	  of	   the	   ruthenium-­‐
based	  drug	  26,	  [{(η6-­‐indan)RuCl}2(μ-­‐2,3-­‐dpp)](PF6)2	  (where	  (μ-­‐2,3-­‐dpp)	  is	  (2,3-­‐bis(2-­‐
pyridyl)pyrazine)).	  A	  series	  of	  small	  molecules	  was	  used	  as	  models	  for	  intracellular	  
components	  to	  gain	  insight	  into	  how	  the	  complex	  might	  behave	  in	  cells	  (5’-­‐GMP,	  5’-­‐
AMP,	  L-­‐Cys	  and	  GSH).	  The	  findings	  agree	  with	  the	  work	  of	  Magennis	  et	  al.,	  carried	  





out	  using	  conventional	  methods.	  Complex	  26	  was	  found	  to	  bind	  to	  nucleobases	  in	  
the	   dark,	   binding	   increased	   upon	   irradiation	   with	   5’GMP,	   and	   this	   was	   favoured	  
over	  5’AMP	  binding.1	  After	  irradiation	  complex	  26	  was	  also	  found	  to	  bind	  strongly	  
to	  GSH,	  a	  known	  deactivation	  pathway	  of	  metal-­‐based	  drugs.2,3	  
5.2	  Future	  work	  
Future	   studies	   of	   the	   intracellular	   behaviour	   of	   platinum(IV)-­‐diazido	  
complexes	   of	   the	   general	   formula	   trans,trans,trans-­‐[Pt(N3)2(OH)2(R)(R’)]	   could	   be	  
extended	  to	  include	  a	  wider	  range	  of	  complexes	  to	  build	  a	  greater	  understanding	  of	  
structure-­‐activity	  relationships.	  Other	  properties	  of	  the	  complexes	  already	  included	  
in	   the	  study	  should	  also	  be	  determined,	   such	  as	   the	  quantum	  yield	  and	   the	  DNA-­‐
binding	   properties.	   The	   use	   of	   HPLC	   retention	   times	   as	   a	   measure	   of	   relative	  
hydrophobicity	  may	  prove	  useful	  for	  the	  comparison	  of	  other	  hydrophilic	  series	  of	  
compounds.	  
Investigations	   of	   the	   nature	   of	   the	  DNA	   adduct	   formed	  by	  8	   have	   already	  
been	  shown	  in	  Chapter	  2	  of	  this	  work.	  However,	  work	  is	  already	  under	  way	  to	  study	  
it	   further	   using	   other	   techniques.	   Single	   molecule	   Förster	   resonance	   energy	  
transfer,	   also	   known	   as	   single	   molecule	   fluorescence	   resonance	   energy	   transfer,	  
describes	   the	   energy	   transfer	   between	   two	   chromophores,	   one	   donor	   and	   one	  
acceptor.	  The	  energy	  is	  not	  transferred	  by	  fluorescence,	  but	  rather	  by	  non-­‐radiative	  
transfer.	  This	  transfer	  can	  take	  place	  over	  distances	  of	  1	  -­‐	  10	  nm,4,5	  and	  can	  be	  used	  
to	   determine	   the	   relative	   distances	   between	   the	   donor	   and	   acceptor	  
choromophores,	  and	  hence	  the	  bend	  induced	  by	  the	  platinum	  adduct.	  SM-­‐FRET	  has	  
previously	   been	   used	   to	   study	   structural	   features	   of	   DNA,	   and	   drug-­‐induced	  





changes	  to	  DNA,6–8	  including	  the	  study	  of	  the	  interaction	  of	  the	  high	  mobility	  group	  
domain	  that	  is	  present	  in	  some	  transcription	  factors	  with	  cisplatin-­‐modified	  DNA.9	  	  
A	  unique	  system	  combining	  multiparameter	  fluorescence	  detection	  of	  single	  
molecules	   combined	  with	  molecular	  dynamics	   simulations	  has	  been	  pioneered	  by	  
the	  Magennis	   group	   at	   The	  University	   of	  Manchester.10	   In	   collaboration	  with	   the	  
Magennis	   group,	   the	   bending	   induced	   in	   a	   30-­‐mer	   duplex	   of	   DNA	   by	   8	   can	   be	  
investigated.	   Initially,	   the	   duplex	   bend	   caused	   by	   the	   1,2-­‐d(GpG)	   cisplatin	   adduct	  
can	  be	  investigated	  since	  this	  is	  a	  well-­‐characterised	  adduct.	  A	  duplex	  which	  can	  be	  
used	   in	   this	   study	   is	   shown	  below	   (Figure	   5.1):	   the	   acceptor	   chromophore	   is	   Cy5	  








Figure	  5.1	   The	  sequence	  of	   the	  30-­‐mer	  duplex	   investigated	   in	   this	   report	  and	   the	  
structures	  of	  the	  dyes	  used	  for	  SM-­‐FRET	  studies.	  
The	   various	   stages	  which	   are	  outlined	   in	   Figure	   5.2	   below,	   beginning	  with	  
the	  initial	  step	  of	  platinating	  oligo	  4	  (the	  unlabelled	  strand),	  followed	  by	  purification	  
of	  the	  platinated	  strand,	  annealing	  with	  the	  labelled	  oligo	  5,	  and	  the	  final	  SM-­‐FRET	  
analysis.	  If	  the	  resulting	  value	  of	  the	  cisplatin-­‐induced	  DNA	  bend	  angle	  is	  consistent	  





with	  the	  literature	  reported	  values,	  then	  the	  technique	  can	  be	  applied	  to	  new,	  less	  























Figure	  5.2	  Outline	  of	  the	  overall	  SM-­‐FRET	  experiment	  broken	  down	  into	  individual	  
stages:	  the	  first	  and	  second	  stages	  in	  future	  work	  to	  be	  carried	  out	  at	  the	  University	  
of	  Warwick	  and	  the	  third	  and	  fourth	  stages	  by	  our	  collaborators	  in	  Manchester.	  
	  
Regarding	   the	  chiral	   separation	  of	  organometallic	  drugs,	   those	  separations	  
shown	   to	   be	   sucessful	   in	   Chapter	   3	   and	   the	   isolation	   of	   stable	   separated	  
enantiomers	  can	  be	  scalled	  up.	  This	  will	  allow	  for	  enough	  of	  the	  each	  isomer	  to	  be	  
collected	  for	  biological	  assays	  to	  be	  carried	  out.	  In	  this	  manner	  the	  efficacy	  of	  each	  
isomer	   can	   be	   assessed	   individually,	   allowing	   for	   further	   develpoment	   of	   the	  
selected	  anticancer	  drug.	  





The	   photonic	   crystal	   fibre	   (PCF)	   system	   detailed	   in	   chapter	   4	   has	   shown	  
great	  potential	  .	  It	  can	  now	  be	  used	  as	  a	  method	  to	  screen	  photoactivatable	  drugs	  
for	   insights	   into	   their	  mechanism	  of	  action.	  Biological	   assays	  of	   complex	  26	   ([{(η6-­‐
indan)RuCl}2(μ-­‐2,3-­‐dpp)]2+)	  should	  be	  carried	  out	  to	  see	  if	  predictions	  made	  using	  the	  
PCF	  system	  screening	  are	  correct.	  Within	  the	  system	  itself,	  the	  deadtime	  has	  been	  
minimised	  by	  reducing	  the	  length	  of	  tubing	  connecting	  the	  various	  components.	  To	  
reduce	  what	  appears	   to	  be	  an	   intrinsic	  deadtime	  of	  15	  min	   in	   this	   system,	   it	  may	  
prove	  useful	   to	  develop	  or	  adapt	   the	  electrospray	   ionisation	  device	   to	  better	   suit	  
the	  flow-­‐rates	  and	  pressures	  of	  the	  PCF	  system;	  since	  nano-­‐flow	  technologies	  have	  
already	  been	   reported	  as	   sucessfully	   coupled	   to	  mss	   spectrometers,	   this	  problem	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Appendix	  III	  
Appendix	  III	  part	  A:	  desalting	  methods	  
In	  this	  thesis	  two	  methods	  of	  desalting	  are	  used,	  and	  they	  are	  compared	  in	  
this	  section.	  The	  methods	  used	  were:	  Omix	  pipette	  tips,	  that	  uses	  the	  adherence	  of	  
the	  oligonucleotide	  to	  C18	  to	  remove	  salt,	  and	  an	  Amicon	  stirred	  cell,	  employing	  a	  1	  
kDa	   cut	   off	   filter	   disc.	   The	   two	   devices	   are	   shown	   below	   in	   Figure	   III-­‐A.	   The	  
recoveries	   of	   oligonucleotide	   from	   the	   devices,	   as	   well	   as	   the	   amount	   of	   salt	  
adducts	  detected	  via	  mass	  spectrometry,	  were	  compared.	  
	  
Figure	  III-­‐A	  Left,	  Omix	  pipette	  tips,	  and	  right,	  the	  Amicon	  stirred	  cell.	  
	  
The	   Omix	   pipette	   tips	   use	   a	   series	   of	   buffers	   and	   solutions	   to	   allow	  
adherence	   of	   the	   oligonucleotide	   to	   the	   C18	   within	   the	   tip,	   and	   its	   subsequent	  
removal.	  This	  can	  be	  repeated	  for	  multiple	  ‘cycles’	  (up	  to	  10	  times,	  according	  to	  the	  
manufacturer)	   to	   increase	   sample	   recovery,	   in	   this	   comparison	  3	   cycles	   are	  used.	  
The	   tips	   are	   recommended	   for	   use	   with	   peptides,	   and	   the	   manufacturer	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recommends	   that	   the	   sample	   is	   acidified	   and	   that	   the	   tips	   are	   prepared	   for	   use	  
using	  trifluoroaceatic	  acid	  (TFA)	  buffer.	  The	  UV-­‐Visable	  spectra	  in	  Figure	  III-­‐B	  show	  a	  
4%	  recovery	  of	  the	  oligonucleotide	  (ATACATGCTACATA)	  by	  this	  method.	  	  
	  
Figure	   III-­‐B	   Top:	   initial	   concentration	   of	   200	   μm,	   bottom:	   oligonucleotide	  
concentration	   of	   8	   μm	   eluted	   after	   a	   total	   of	   3	   cycles.	   Total	   recovery	   of	  
oligonucleotide	  by	  this	  method	  was	  4%.	  
	  
The	  poor	   recovery	   from	  the	  manufacturers	  protocol	   led	  me	   to	  change	   the	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mM	   solution	   of	   NH4OAc.	   The	   sample	   was	   no	   longer	   acidified	   before	   desalting,	  
rather	   it	   is	  diluted	  1	   in	  2	   in	  a	  solution	  of	  80	  mM	  NH4OAc.	  Ammonium	  acetate	  has	  
the	  advantage	  of	  not	  only	  being	  less	  damaging	  to	  the	  mass	  spectrometer	  than	  TFA,	  
but	  it	  also	  still	  displaces	  the	  Na+	  and	  K+	  ions	  associated	  with	  the	  oligonucleotide	  and	  
will	   disassociate	   during	   the	   ionisation	   process.	   This	   ion-­‐pairing	   also	   allows	   for	  
interaction	   with	   the	   non-­‐polar	   C18	   and	   adherence	   to	   its	   surface.	   This	   change	   of	  
solvents	  improved	  recovery	  by	  5	  times,	  giving	  an	  overall	  oligonucleotide	  recovery	  of	  
20%	  for	  this	  method	  of	  desalting	  (Figure	  III-­‐C).	  
	  
Figure	   III-­‐C	   Top:	   initial	   concentration	   (200	   μm),	   bottom:	   after	   3	   cycles	   using	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The	  other	  desalting	  method	  used	  in	  this	  thesis	  was	  the	  Amicon	  stirred	  cell,	  
fitted	  with	  a	  1kDa	  cut-­‐off	  filter	  disc.	  This	  device	  uses	  the	  filter	  disc	  to	  retain	  the	  14	  
base-­‐long	  oligonucleotide,	  whilst	   the	   excess	   salt	   in	   solution	   is	   forced	   through	   the	  
membrane	  by	  nitrogen	  gas	  as	  the	  sample	   is	  slowly	  stirred.	  Using	  this	  method,	  the	  
sample	   can	  be	  washed	   to	   remove	   salts	   associated	  with	   the	  oligonucleotide.	  After	  
this	   ammonium	   acetate	   is	   added	   to	   help	   displace	   Na+	   and	   K+	   ions.	   The	   recovery	  
from	  this	  method	  was	   found	   to	  be	  67%	  after	  one	  wash	  and	  24%	  overall	   recovery	  
after	  2	  washes,	  see	  Figure	  III-­‐D.	  This	  device	  can	  also	  be	  used	  to	  concentrate	  more	  
dilute	  samples	  for	  analysis.	  
The	  resulting	  mass	  spectra	  of	  these	  solutions	  are	  shown	  in	  Figure	  III-­‐E.	  The	  
samples	  desalted	  using	  the	  Amicon	  stirred	  cell	  contain	  fewer	  salt	  adducts	  than	  the	  
sample	   desalted	   using	   the	  Omix	   tips.	   The	   number	   of	  washes	   that	   the	   stirred	   cell	  
sample	  undergoes	  also	  decreases	  the	  number	  of	  salt	  adducts	  detected.	  Other	  ways	  
to	  improve	  the	  mass	  spectra	  of	  oligonucleotides	  are	  to	  leave	  the	  sample	  overnight	  
in	   ammonium	   acetate	   and	   to	   use	   up	   to	   50%	   isopropanol	   as	   the	   solvent	   used	   to	  
spray	   the	   sample.	   The	  Amicon	   stirred	   cell	  method	  was	   then	  used	   to	   obtain	   high-­‐
resolution	   mass	   spectrometry	   data	   for	   this	   thesis,	   allowing	   for	   the	   accurate	  
determination	   of	   new	   platinum-­‐DNA	   adducts.	   The	   Omix	   tips	   were	   used	   in	  
conjunction	   with	   an	   ion-­‐trap	   mass	   spectrometer	   to	   determine	   if	   they	   were	   the	  
correct	  molecular	  weight	  during	  the	  oligonucleotide	  quality	  control	  process.	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Figure	   III-­‐D	   Oligonucleotide	   recovery	   from	   the	   Amicon	   stirred	   cell	   desalting	  
method.	  Top:	  initial	  concentration	  (200	  μm),	  middle:	  recovery	  after	  first	  wash	  (167	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Figure	  III-­‐E	  Mass	  spectra	  of	  the	  oligonucleotide	  (ATACATGCTACATA)	  desalted	  using:	  
1	  Omix	  pipette	  tips,	  2	  an	  Amicon	  stirred	  cell	  with	  1	  kDa	  filter	  and	  one	  sample	  wash,	  
3	  using	  the	  Amicon	  stirred	  cell	  and	  washing	  the	  sample	  twice.	  
	  
Appendix	  III	  part	  B:	  method	  optimisation	  of	  the	  separation	  of	  free	  oligonucleotide	  
from	  oligonucleotide	  with	  platinum	  adducts.	  
The	  analysis	  of	  the	  photoactivation	  of	  complex	  8	  (t,t,t-­‐[Pt(N3)2(OH)2(py)2)	  in	  
the	  presence	  of	  an	  oligonucleotide	  by	  chromatography	  required	  the	  development	  
of	  a	  separation	  method.	  This	  began	  with	  the	  selection	  of	  the	  column	  and	  the	  mobile	  
phase	  used.	  A	  longer	  column,	  250	  mm	  rather	  than	  150	  mm,	  to	  increase	  the	  number	  
of	   theoretical	   plates,	  was	   chosen.	   The	   increased	  number	  of	   theoretical	   plates	   (N)	  
results	  an	   increase	   in	   the	  resolving	  power	  of	   the	  column	  (Equation	  1),	  where	  N	   is	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the	   number	   of	   plates,	   α	   is	   the	   separation	   factor	   (α	   =	   k2/k1),	   kav	   is	   the	   average	  
retention	  factor	  (kav	  =	  (k1	  +	  k2)/2,	  and	  RS	  is	  the	  peak	  resolution.1	  
N = !(!!!)!!!    ∙   !!!!"!!"    ∙ R!                              (1)1 
The	  type	  of	  chromatography	  was	  reversed	  phase,	  as	  a	  hydrophilic	  mobile	  phase	  is	  
more	  biologically	  relevant	  and	  offers	  the	  best	  solubility	  for	  DNA.	  	  This	  requires	  the	  
use	  of	  a	  hydrophobic	  stationary	  phase.	  The	  stationary	  phases	  used	  for	  the	  work	  in	  
this	   thesis	  are	   silica-­‐based	  and	  are	   functionalised	  with	  carbon	  chains	   (C8	  and	  C18	  
respectively).	   To	   allow	   the	   long	   oligonucleotides	   to	   interact	   with	   the	   stationary	  
phase,	  particles	  with	  a	  larger	  pore	  size	  (300	  Å)	  were	  used.	  
Reversed	   phase	   chromatography	   does;	   however,	   pose	   a	   problem	   as	   the	  
separation	   of	   analytes	   is	   reliant	   upon	   the	   interaction	   on	   the	   charged	  
oligonucleotides	   with	   the	   non-­‐ionic	   hydrophobic	   stationary	   phase.	   To	   overcome	  
this	   an	   ion-­‐pairing	   agent	   can	   be	   added	   to	   the	  mobile	   phase,	  which	  will	   associate	  
with	  the	  oligonucleotide,	  creating	  a	  neutral	  species,	  and	  allow	  interaction	  with	  the	  
stationary	   phase.	   Common	   ion-­‐pairing	   agents	   for	   DNA	   chromatography	   are	  
triethyammonium	   acetate	   (TEAA)	   and	   ammonium	   acetate.	   There	   are	   many	  
examples	   of	   NH4OAc	   containing	   mobile	   phase	   being	   used	   to	   analyses	   Pt-­‐DNA	  
interactions	   by	   chromatography.2–4	   This	   along	   with	   the	   ‘sticky’	   nature	   of	   TEAA,	  
meaning	  that	  it	  is	  more	  difficult	  to	  flush	  out	  of	  instruments,	  mean	  that	  NH4OAc	  was	  
selected	   as	   the	   ion-­‐pairing	   agent.	   The	   concentration	   of	   the	   addative	   is	   also	  
important,	  as	  was	  highlighted	  by	  A.	  Eastman	  (1986).5	  He	  observed	  a	  separation	  of	  
two	   formerly	   unresolved	   peaks	   by	   lowering	   the	   concentration	   of	   ammonium	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acetate	   from	   0.1	   M	   to	   0.02	   M.	   The	   salt	   interacts	   with	   the	   oligonucleotide,	  
sharpening	   peaks,	   reducing	   retention	   times.	   At	   lower	   concentrations	   of	   cation,	  
adducts	  elute	   later	  and	  produce	  broader	  peaks	  but	  previously	  unresolved	   species	  
can	   be	   separated.	   As	   a	   result	   of	   this	   a	   concentration	   of	   10	  mM	  NH4OAC	   in	   both	  
solvents	   was	   chosen.	   The	   pH	   of	   the	   mobile	   phases	   was	   also	   lowered	   to	   5.5	   to	  
improve	   peak	   sharpness	   by	   increasing	   likelihood	   of	   phosphate	   backbone	  
protonation.	  	  
The	   wavelength	   of	   detection	   used	   (260	   nm)	   was	   selected,	   as	   this	   is	   the	  
wavelength	   at	   which	   the	   extinction	   coefficient	   of	   DNA	   is	   the	   highest.	   The	  
instrument	   used	   had	   a	   fault	   with	   the	   column	   thermostat	   fault,	   resulting	   in	   the	  
ability	   to	   only	   heat	   the	   column	   and	   not	   the	   eluent	   entering	   it	   as	   well.	   This	   has	  
resulted	  in	  the	  reporting	  of	  higher	  temperatures	  that	  one	  would	  normally	  use	  in	  the	  
HPLC	   of	   oligonucleotides,	   as	   the	   solution	   had	   to	   be	   heated	   through	   the	   column	  
rather	  that	  directly.	  The	  flow	  rate	  used	  throughout	  the	  method	  development	  was	  
1.00	  mL/min.	  
A	  solvent	  gradient	  was	  required	  to	  separate	  the	  unreacted	  oligonucleotide	  
from	  that	  with	  a	  platinum	  species	  bound.	  Initially	  separations	  were	  carried	  out	  on	  a	  
Zorbax	  eclipse	  C18	  strong-­‐bond	  25	  x	  4.6	  mm	  5	  µm	  particle	  size	  with	  a	  300	  Å	  pore	  
size.	  The	  development	  of	  the	  method	  began	  using	  a	  simple	  0	  –	  80	  %	  B	  (v/v)	  over	  80	  
min	  gradient	  (80/80	  gradient).	  This	  is	  a	  useful	  starting	  point	  for	  the	  development	  of	  
new	  methods	  as	  for	  every	  minute	  of	  the	  method	  the	  percentage	  of	  B	   is	   increased	  
by	  1	  %.	  So	  it	  is	  easy	  to	  isolate	  points	  of	  interest	  in	  the	  gradient	  and	  adapt	  them.	  The	  
resulting	  chromatogram	  is	  no	  shown	  here.	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The	  early	  elution	  of	  the	  unresolved	  peaks	  using	  the	  80/80	  gradient	  indicated	  
that	   they	  elute	  with	  only	  a	   small	  proportion	  of	  acetonitrile	  present	   in	   the	  solvent	  
mix.	  The	  starting	  percentage	  of	  acetonitrile	  was	  set	  to	  just	  below	  that	  at	  which	  the	  
unreacted	  oligonucleotide	  is	  eluted	  and	  then	  kept	  isocratic	  for	  some	  time	  and	  then	  
gradually	   increased.	  This	  was	  done	  with	  the	  aim	  of	  separating	  the	  unreacted	  DNA	  
from	   the	   slightly	  more	  hydrophobic	   platinated	  DNA.	   The	  height	   and	   steepness	   of	  
this	  gradient	  was	  refined	  to	  achieve	  the	  best	  possible	  separation	  conditions	  on	  this	  
column.	  Both	  the	  gradient	  and	  the	  resulting	  chromatogram	  are	  shown	  in	  Figure	  III-­‐
F.	   	   The	   solvent	   was	   isocratic	   for	   the	   first	   15	  min	   at	   6	   %	   B,	   increased	   to	   15	   %	   B	  
between	   15	   and	   18	   min,	   with	   a	   flow	   rate	   of	   1	   mL/min.	   The	   gradient	   remained	  
isocratic	   at	   15	  %	  until	   30	  min	   into	   the	   run,	   then	   increased	   to	   80	  %	  B	   by	   31	  min,	  
where	   it	   remained	   until	   the	   end	   of	   the	   run	   at	   35	   min.	   For	   this	   separation	   the	  
column	  oven	  was	  to	  35°C.	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Figure	   III-­‐F	   Top:	   solvent	   gradient	   used	   for	   separation,	   bottom:	   chromatogram	   of	  
oligonucleotide	   d’(ATACATGCTACATA)	   irradiated	   in	   the	   presence	   of	  
[Pt(N3)2(OH)2(py)2]2+	   for	   5	   h	   at	   37°C	   with	   420	   nm.	   Separated	   using	   the	   above	  
gradient	  A:	  NH4OAc	  10	  mM	  H2O,	  B:	  NH4OAc	  10	  mM	  ACN),	  flow	  rate	  1.00	  mL	  /	  min,	  
wavelength	  of	  detection	  260	  nm.	  
	  
The	  Gradient	  shown	  in	  Figure	  III-­‐F	  gives	  a	  better	  separation	  that	  the	  80/80	  
gradient	  but	  still	  not	  complete	  resolution.	  The	  other	  options	  to	  improve	  resolution	  
were:	  to	  change	  the	  stationary	  phase	  for	  one	  functionalised	  with	  a	  shorter	  carbon	  
chain,	   e.g.	   C8;	   or	   to	   change	   the	   mobile	   phase.	   Increasing	   the	   concentration	   of	  
ammonium	  acetate	  would	  increase	  ion	  suppression,	  sharpening	  peaks	  but	  reducing	  
resolution.	  As	   such	   this	  would	  not	  be	  a	  useful	   strategy.	  The	   same	  can	  be	   said	   for	  
decreasing	   the	   concentration	   as	   it	   is	   already	   quite	   low	   and	   reducing	   the	   ion	  
suppression	   and	   causing	   the	   already	   quite	   broad	   peaks	   to	   broaden	   further.	   The	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increase	   the	   interaction	   of	   the	   analyte	   with	   the	   stationary	   phase	   and	   improve	  
separation.	  	  
An	  80/80	  gradient	  was	  then	  run	  using	  a	  C8	  column,	  shown	  in	  Figure	  III-­‐G.	  A	  
peak	  due	  to	  the	  unreacted	  oligonucleotide	  is	  observed	  and	  a	  shoulder	  attributable	  
to	  the	  oligonucleotide	  with	  the	  adduct	  formed	  by	  photoactivated	  8.	  
	  
Figure	   III-­‐G	   Chromatogram	   of	   the	   oligonucleotide	  
d’(TATCATAAATAAATGGTATATTTTATAACT)	   incubated	   with	   [Pt(NH3)2(H2O)2]2+	  
separated	  using	  a	  gradient	  from	  0	  –	  80	  %B;	  A:	  NH4OAc	  10	  mM	  H2O,	  B:	  NH4OAc	  10	  
mM	   ACN),	   flow	   rate	   1.00	   mL	   /	   min,	   wavelength	   of	   detection	   260	   nm,	   column	  
thermostat	  35°C.	  
	  
A	   new	   gradient	   was	   then	   used	   to	   try	   to	   separate	   the	   shoulder	   from	   the	  
peak,	  similar	  to	  that	  shown	  in	  Figure	  III-­‐F.	  This	  gradient	  is	  shown	  in	  Figure	  II-­‐H,	  and	  
begins	  at	  6%	  B	  remaining	  isocratic	  for	  some	  time.	  After	  which,	  B	  is	  increased	  by	  9	  %	  
over	   3	   min	   with	   the	   intention	   of	   separating	   the	   two.	   The	   peaks	   appear	   to	   be	  
resolved	  but	  there	  is	  another	  shoulder	  on	  the	  peak	  at	  around	  19	  min	  that	  is	  may	  be	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Figure	  III-­‐H	  Top:	  gradient	  used	  for	  the	  separation	  shown	  below:	  chromatogram	  of	  
oligonucleotide	   d’(ATACATGCTACATA)	   irradiated	   in	   the	   presence	   of	  
[Pt(N3)2(OH)2(py)2]2+	   for	   60	  min	   at	   37°C	  with	   420	   nm.	   Separated	   using	   the	   above	  
gradient	  A:	  NH4OAc	  10	  mM	  H2O,	  B:	  NH4OAc	  10	  mM	  ACN),	  flow	  rate	  1.00	  mL	  /	  min,	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The	  method	  was	  then	  altered	  many	  times	  to	  optimise	  this	  separation	  as	  far	  
as	   possible,	   again	   adjusting	   the	   length	   of	   the	   isocratic	   period	   and	   the	   slope	   and	  
extent	   of	   the	   gradient	   that	   followed.	   The	   temperature	   of	   the	   column	   thermostat	  
was	  also	   increased	   to	   reduce	   the	  possibility	  of	  oligonucleotide	   folding,	  and	  hence	  
improving	   the	   separation.	   The	   resulting	   optimised	   gradient	   is	   show	   in	   Figure	   III-­‐I	  
and	  is	  the	  method	  outlined	  in	  Chapter	  2,	  Section	  2.2.2.4.	  However,	  there	  was	  not	  a	  
very	   efficient	   transfer	   of	   heat	   to	   the	   analyte	   (as	   outlined	   previously	   in	   this	  
appendix)	   and	   this	   may	   be	   the	   reason	   for	   the	   folded	   oligonucleotide	   structures	  
observed	  in	  Chapter	  2.	  
	  
Figure	  1III-­‐I	  Top:	  gradient	  used	  for	  the	  separation	  shown	  below:	  chromatogram	  of	  
oligonucleotide	   d’(ATACATGCTACATA)	   irradiated	   in	   the	   presence	   of	  
[Pt(N3)2(OH)2(py)2]2+	   for	   60	  min	   at	   37°C	  with	   420	   nm.	   Separated	   using	   the	   above	  
gradient	  A:	  NH4OAc	  10	  mM	  H2O,	  B:	  NH4OAc	  10	  mM	  ACN),	  flow	  rate	  1.00	  mL	  /	  min,	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Appendix	  III	  part	  C:	  oligonucleotide	  quality	  control	  (QC)	  procedure	  
The	   following	  are	   the	  quality	  control	  procedures	  carried	  out	   for	  all	  of	   the	  custom	  
oligonucleotides	  detailed	  in	  this	  thesis.	  
Quantisation	  
UV-­‐Vis	  spectroscopy	  
Using	   the	   Beer-­‐Lambert	   law	   and	   a	   calculated	   molar	   absorption	   coefficient	   from	  
Tataurov	   et	   al.6	   the	   concentration	   of	   a	   solution	   of	   an	   oligonucleotide	   can	   be	  
calculated.	  Here	  is	  an	  example	  of	  the	  dilution	  steps	  required	  to	  obtain	  a	  good	  UV-­‐
Visible	  spectrum	  for	  a	  5	  µM	  oligonucleotide	  synthesis	  in	  1	  mL	  DDW:	  
Total	  1	  in	  400	  dilution.	  
1	  in	  10	  dilution	  of	  stock	  	  
	  
1	  in	  10	  dilution	  of	  previous	  stock	  dilution	  
	  
1	  in	  4	  dilution	  of	  previous	  solution	  (UV-­‐Vis	  sample,	  ca.	  5	  µM)	  
Purity	  tests	  
HPLC	  
Using	   the	  Agilent	  1100	   series	  HPLC	  with	  a	  Rheodyne	  7725i	  manual	   injector	   fitted	  
with	  a	  100	  μL	  loop	  and	  a	  variable	  wavelength	  UV	  detector.	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Mobile	  phase	   for	  all	  analyses:	   solvent	  A,	  H2O	  10	  mM	  NH4OAc	   (pH	  5.5);	   solvent,	  B	  
ACN	  10	  mM	  NH4OAc.	  
Column	  PJS	  54	  (Zorbax	  eclipse	  C18	  strong-­‐bond	  25	  x	  4.6	  mm	  5	  µm	  particle	  size	  with	  
a	  300	  Å	  pore)	  
Method	  folder:	  RM_2011	  	  
Method	  file:	  3030	  
Flow	  rate	  1	  mL/min	  
Wavelength	  of	  absorption	  is	  260	  nm	  
Gradient:	  0	  -­‐	  30	  %	  B	  over	  30	  min	  
Column	  oven	  temperature	  40	  °C	  
Sample:	  
45	  µL	  injections	  of	  a	  ~	  1	  in	  150	  dilution	  of	  the	  stock	  (ca.	  16	  µM)	  
Molecular	  mass	  confirmation	  	  
Mass	  Spectrometry	  
Analysis	  using	  the	  HCT	  Ultra	  (ion-­‐trap)	  
Sample	  preparation	  
Perform	  a	  1	  in	  10	  dilution	  of	  stock	  (ca.	  250	  µM)	  for	  a	  total	  volume	  of	  50	  µL	  (ca.	  25	  
µM).	  This	  solution	   is	   then	  diluted	  1	   in	  2	   in	  at	   least	  80	  mM	  NH4OAc	  to	  give	  a	  total	  
volume	  of	  100	  µL	  (ca.	  12.5	  µM).	  This	  solution	  then	  undergoes	  5	  cycles	  of	  Omix	  tip	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desalting	   (adapted)	   protocol,	   eluting	   20	   µL	   each	   round.	   The	   resulting	   solution	   is	  
then	  directly	  infused	  in	  to	  the	  MS	  without	  any	  further	  dilution.	  
Adapted	  Omix	  protocol	  (1	  cycle)	  
1.	  Aspirate	  100	  µL	  of	  50:50	  ACN	  H2O	  and	  discard,	  repeat.	  
2.	  Aspirate	  100	  µL	  of	  40	  mM	  NH4OAc	  (in	  H2O)	  and	  discard,	  repeat.	  
3.	  Aspirate	  100	  µL	  of	  sample	  and	  expel,	  repeat	  4-­‐5	  times.	  
4.	  Change	  pipetting	  volume	  to	  10	  µL.	  
5.	  Aspirate	  10	  µL	  of	  40	  mM	  NH4OAc	  (60:40	  MeOH/H2O).	  
6.	  Dispense	  sample	  for	  analysis.	  
7.	  Repeat	  steps	  2	  –	  6	  for	  another	  4	  cycles.	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